100-BRADYCARIA-INDUCING-DRUGS.html


***interaction***
drug1
class name: BRADYCARIA INDUCING DRUGS
class code: C0N0S0
drug2
class name: OTHER BRADYCARIA INDUCING DRUGS
class code: C0N0S0
Risk of excessive bradycardia (addition of the effects)
severity: Take into account

***interaction***
drug1
class name: BRADYCARIA INDUCING DRUGS
class code: C0N0S0
drug2
drug name: FINGOLIMOD
rxNorm: 1012892
atc: L04AA27
Increase of the bradycardia inducing effects which can have fatal consequences. The beta-blocking agents are even more at risk since they inhibit the adrenergic compensation mechanisms
severity: Not recommended
Clinical monitoring and sustained EKG during the 24 hours following the first dose.

***interaction***
drug1
class name: BRADYCARIA INDUCING DRUGS
class code: C0N0S0
drug2
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG during the administration of these together.
101-BRENTUXIMAB.html


***interaction***
drug1
drug name: BRENTUXIMAB 
rxNorm: 1147320
more atc: L01XC12
drug2
drug name: BLEOMYCIN 
rxNorm: 1622
atc: L01DC01
Risk of increase of pulmonary toxicity
severity: CONTRAINDICATION

***interaction***
drug1
drug name: BRENTUXIMAB 
rxNorm: 1147320
more atc: L01XC12
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the concentrations of the active metabolite of the brentuximab, with risk of neutropenia
severity: Take into account
102-BUPRENORPHINE.html


***interaction***
drug1
drug name: BUPRENORPHINE
rxNorm: 1819
more atc: N02AE01
more atc: N07BC01
drug2
drug name: ATAZANAVIR
rxNorm: 343047
atc: J05AE08
Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor 
severity: Take into account

***interaction***
drug1
drug name: BUPRENORPHINE
rxNorm: 1819
more atc: N02AE01
more atc: N07BC01
drug2
class name: BENZODIAZEPINES AND RELATED
class code: N05-001
With the buprenorphine used in opioid replacement therapy: increased risk of respiratory depression which could be fatal.
severity: Take into account
Evaluate carefully the risk/benefits relationship of administering these substances together. Inform the patient of the necessity of adhering to the prescribed dosages.

***interaction***
drug1
drug name: BUPRENORPHINE
rxNorm: 1819
more atc: N02AE01
more atc: N07BC01
drug2
drug name: FOSAMPRENAVIR
rxNorm: 358262
atc: J05AE07
Risk of increase or of decrease of the effects of the A to take into account buprenorphine [sic], simultaneously by inhibition and acceleration of its metabolism by the protease inhibitor. 
severity: Take into account

***interaction***
drug1
drug name: BUPRENORPHINE
rxNorm: 1819
more atc: N02AE01
more atc: N07BC01
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor
severity: Take into account

***interaction***
drug1
drug name: BUPRENORPHINE
rxNorm: 1819
more atc: N02AE01
more atc: N07BC01
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.

***interaction***
drug1
drug name: BUPRENORPHINE
rxNorm: 1819
more atc: N02AE01
more atc: N07BC01
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.
103-BUPROPION.html


***interaction***
drug1
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
drug2
drug name: CLOMIPRAMINE
rxNorm: 2597
atc: N06AA04
Risk of increase of the undesirable effects of the cloripramine due to decrease of its hepatic metabolism by the bupropion
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the clomipramine during the treatment with the bupropion.

***interaction***
drug1
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
drug2
drug name: DESIPRAMINE
rxNorm: 3247
atc: N06AA01
Risk of increase of the undesirable effects of the desipramine due to decrease of its hepatic metabolism by the bupropion
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the desipramine during the treatment with the bupropion.

***interaction***
drug1
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
drug2
drug name: FLECAINIDE
rxNorm: 4441
atc: C01BC04
Risk of increase of the undesirable effects of the flecainide due to decrease of its hepatic metabolism by the bupropion
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the bupropion.

***interaction***
drug1
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
drug2
class name: MAOI-B 
class code: N04BD0-001
Risk of hypertensive crises
severity: CONTRAINDICATION

***interaction***
drug1
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
drug2
drug name: MEQUITAZINE
rxNorm: 29528
atc: R06AD07
Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor
severity: Not recommended

***interaction***
drug1
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
drug2
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion

***interaction***
drug1
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
drug2
drug name: NORTRIPTYLINE
rxNorm: 7531
atc: N06AA10
Risk of increase of the undesirable effects of the nortriptyline due to decrease of its hepatic metabolism by the bupropion
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the nortriptyline during the treatment with the bupropion.

***interaction***
drug1
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
drug2
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
Risk of increase of the undesirable effects of the propafenone due to decrease of its hepatic metabolism by the bupropion
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the bupropion.

***interaction***
drug1
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
drug2
drug name: TAMOXIFEN
rxNorm: 10324
atc: L02BA01
Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine [sic]
severity: Not recommended

***interaction***
drug1
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
drug2
drug name: TRAMADOL
rxNorm: 10689
atc: N02AX02
Increase of the plasma concentrations of the tramadol due to decrease of its hepatic metabolism by the bupropion. In addition, risk of convulsions due to addition of the effects of the two medications
severity: Take into account

***interaction***
drug1
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
drug2
drug name: VEMURAFENIB
rxNorm: 1147220
atc: L01XE15
Risk of decrease of the concentrations of the bupropion, with increase of its active metabolite and increased toxicity
severity: Take into account
104-BUSPIRONE.html


***interaction***
drug1
drug name: BUSPIRONE
rxNorm: 1827
atc: N05BE01
drug2
drug name: DIAZEPAM
rxNorm: 3322
atc: N05BA01
Risk of increase of the undesirable effects of the buspirone
severity: Take into account

***interaction***
drug1
drug name: BUSPIRONE
rxNorm: 1827
atc: N05BE01
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the diltiazem, with increase of its undesirable effects
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the buspirone if necessary.

***interaction***
drug1
drug name: BUSPIRONE
rxNorm: 1827
atc: N05BE01
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: D10AF52
more atc: J01FA01
more atc: S01AA17
Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation
severity: Not recommended

***interaction***
drug1
drug name: BUSPIRONE
rxNorm: 1827
atc: N05BE01
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation
severity: Not recommended

***interaction***
drug1
drug name: BUSPIRONE
rxNorm: 1827
atc: N05BE01
drug2
Drug with no codes: GRAPEFRUIT (JUICE AND FRUIT)
Rick of increase of the undesirable effects of the buspirone due to decrease of its metabolism by the grapefruit
severity: Take into account

***interaction***
drug1
drug name: BUSPIRONE
rxNorm: 1827
atc: N05BE01
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the buspirone during the treatment with rifampicin and after it is stopped.

***interaction***
drug1
drug name: BUSPIRONE
rxNorm: 1827
atc: N05BE01
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the verapamil, with increase of its undesirable effects.
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the buspirone if necessary.
105-BUSULFAN.html


***interaction***
drug1
drug name: BUSULFAN
rxNorm: 1828
atc: L01AB01
drug2
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
Risk of increase of the toxicity of the busulfan due to decrease of its clearance by the deferasirox
severity: Take into account

***interaction***
drug1
drug name: BUSULFAN
rxNorm: 1828
atc: L01AB01
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
With the busulfan in large doses: doubling of the concentrations of busulfan by the itraconazole
severity: Not recommended

***interaction***
drug1
drug name: BUSULFAN
rxNorm: 1828
atc: L01AB01
drug2
drug name: METRONIDAZOLE
rxNorm: 6922
more atc: A02BD08
more atc: A02BD03
more atc: A02BD02
more atc: A01AB17
more atc: D06BX01
more atc: G01AF01
more atc: J01XD01
more atc: P01AB01
more atc: A02BD01
With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole
severity: Not recommended
106-CABAZITAXEL.html


***interaction***
drug1
drug name: CABAZITAXEL
rxNorm: 996051
atc: L01CD04
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Decrease of the concentrations of the cytotoxic by increase of its metabolism by the inducer, with risk of lower effectiveness
severity: Take into account

***interaction***
drug1
drug name: CABAZITAXEL
rxNorm: 996051
atc: L01CD04
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the undesirable dose dependent effects of the cabazitaxel due to inhibition of its metabolism by the enzymatic inducer
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the cabazitaxel during the treatment with the enzymatic inhibitor.
107-CAFFEINE.html


***interaction***
drug1
drug name: CAFFEINE 
rxNorm: 1886
more atc: N06BC01
more atc: V04CG30
drug2
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism
severity: Take into account

***interaction***
drug1
drug name: CAFFEINE 
rxNorm: 1886
more atc: N06BC01
more atc: V04CG30
drug2
drug name: DIPYRIDAMOLE
rxNorm: 3521
atc: B01AC07
With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the caffeine
severity: Precaution for use
Interrupt a caffeine based treatment at least 5 days before myocardial perfusion imaging with the dipyridamole and avoid consumption of coffee, tea, chocolate, or cola during the 24 hours that precede the test.

***interaction***
drug1
drug name: CAFFEINE 
rxNorm: 1886
more atc: N06BC01
more atc: V04CG30
drug2
drug name: ENOXACIN
rxNorm: 3925
atc: J01MA04
Increase of the plasma concentrations of caffeine, which can lead to agitation and hallucinations, due to decrease of its hepatic metabolism
severity: Not recommended

***interaction***
drug1
drug name: CAFFEINE 
rxNorm: 1886
more atc: N06BC01
more atc: V04CG30
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
In case of sudden discontinuation of consumption of coffee or of medications containing caffeine, risk of increase of the plasma concentrations of lithium
severity: Take into account

***interaction***
drug1
drug name: CAFFEINE 
rxNorm: 1886
more atc: N06BC01
more atc: V04CG30
drug2
drug name: MEXILETINE
rxNorm: 6926
atc: C01BB02
Increase of the plasma concentrations of caffeine, due to inhibition of its hepatic metabolism by the mexiletine
severity: Take into account

***interaction***
drug1
drug name: CAFFEINE 
rxNorm: 1886
more atc: N06BC01
more atc: V04CG30
drug2
drug name: NORFLOXACINE
rxNorm: 7517
more atc: J01MA06
more atc: S01AE02
Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine
severity: Take into account

***interaction***
drug1
drug name: CAFFEINE 
rxNorm: 1886
more atc: N06BC01
more atc: V04CG30
drug2
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
Possible increase of the plasma concentrations of the caffeine, with risk of overdose, due to inhibition of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of caffeine.
108-CALCITONIN.html


***interaction***
drug1
drug name: CALCITONIN
rxNorm: 36118
more atc: H05BA
more atc: H05BA03
more atc: H05BA02
more atc: H05BA01
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together.
109-CALCIUM.html


***interaction***
drug1
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
drug2
class name: BISPHOSPHONATES
class code: M05B-001
For the calcium salts administered via oral route: decrease of the digestive absorption of the bisphosphonates
severity: Precaution for use
Take calcium salts and antacids at a different time from the bisphosphonates (from 30 minutes minimum to more than 2 hours apart, if possible, depending on the bisphosphonate). 

***interaction***
drug1
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
drug2
class name: TETRACYCLINE ANTIBIOTICS
class code: J01AA
Decrease of the digestive absorption of the tetracycline antibiotics
severity: Precaution for use
Take the calcium salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).

***interaction***
drug1
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Risk of serious arrhythmias, even lethal ones, with the calcium salts administered by IV route. 
severity: Contraindication
-with the calcium salts via IV, except for parenteral supplementation

***interaction***
drug1
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
drug2
class name: THIAZIDE DIURETICS AND RELATED
class code: C03-003
Risk of hypercalcemia due to decrease of the urinary elimination of the calcium. 
severity: Take into account

***interaction***
drug1
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
drug2
drug name: ESTRAMUSTINE
rxNorm: 4089
atc: L01XX11
Decrease of the digestive absorption of the estramustine
severity: Precaution for use
Take the calcium salts at a different time from the estramustine (more than 2 hours apart, if possible).

***interaction***
drug1
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
drug2
drug name: IRON
rxNorm: 1431589
atc: B03A
With the iron salts by oral route: decrease of the digestive absorption of the iron salts
severity: Precaution for use
Take the iron salts at a different time from meals and in the absence of calcium.

***interaction***
drug1
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
drug2
class name: THYROID HORMONES
class code: H03AA
Decrease of the absorption of the thyroid hormones
severity: Precaution for use
Take the calcium salts at a different time from the thyroid hormones (more than 2 hours apart, if possible).

***interaction***
drug1
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
drug2
drug name: STRONTIUM
rxNorm: 81638
atc: M05BX03
With the calcium salts administered by oral route: decrease of the digestive absorption of the strontium
severity: Precaution for use
Take the strontium at a different time from the calcium salts (more than two hours apart, if possible).

***interaction***
drug1
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
drug2
drug name: ZINC
rxNorm: 
more atc: A12CB
Decrease of the digestive absorption of the zinc by the calcium 
severity: Precaution for use
Take the calcium salts at a different time from the zinc (more than 2 hours apart, if possible).
10-FUSIDIC-ACID.html


***interaction***
drug1
drug name: FUSIDIC ACID
rxNorm: 4608
more atc: D06AX01
more atc: D09AA02
more atc: J01XC01
more atc: S01AA13
drug2
class name: HMG-COA REDUCTASE INHIBITORS (STATINS)
class code: C10AA
Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type.
severity: CONTRAINDICATION
Stop the treatment with the HMG-COA Reductase Inhibitor before starting a treatment with fusidic acid or use another antibiotic.

***interaction***
drug1
drug name: FUSIDIC ACID
rxNorm: 4608
more atc: D06AX01
more atc: D09AA02
more atc: J01XC01
more atc: S01AA13
drug2
class name: OMBITASVIR + PARITAPEVIR
class code: OMPA
Increase of the plasma concentrations of the fusidic acid due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir
severity: CONTRAINDICATION
110-CANAKINUMAB.html


***interaction***
drug1
drug name: CANAKINUMAB
rxNorm: 853491
atc: L04AC08
drug2
class name: ANTI-TNF ALPHA
class code: 4ABO
Risk of increase of serious infections
severity: Not recommended
111-CARBAMAZEPINE.html


***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: ACETAZOLAMIDE
rxNorm: 167
atc: S01EC01
Increase of the plasma concentrations of carbamazepine with signs of overdose.
severity: Precaution for use
Clinical monitoring, and, if needed, testing of the plasma concentrations of carbamazepine and possible reduction of its dosage

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
With the cimetidine used in doses greater than or equal to 800 mg/day: at the beginning of treatment, increase of the plasma concentrations of carbamazepine due to inhibition of its hepatic metabolism by the cimetidine 
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the carbamazepine, especially during the first days of treatment with the cimetidine 

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the carbamazepine.

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: CLONAZEPAM
rxNorm: 2598
atc: N03AE01
Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of the clonazepam due to increase of its hepatic metabolism by the carbamazepine
severity: Precaution for use
Clinincal monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: CLOZAPINE
rxNorm: 2626
atc: N05AH02
Risk of increase of the serious hematological effects 
severity: Not recommended

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: DANAZOL
rxNorm: 3102
atc: G03XA01
Increase of the plasma concentrations of carbamazepine, with signs of overdose
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the carbamazepine.

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Increase of the plasma concentrations of carbamazepine and decrease of the digoxinemia
severity: Precaution for use
Exercise caution in the interpretation of the plasma concentrations.

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
class name: POTASSIUM LOWERING DIURETICS
class code: C03
Risk of symptomatic hyponatremia
severity: Precaution for use
Clinical and biological monitoring. If possible, use another class of diuretics.

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism
severity: Not recommended

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: ETHOSUXIMIDE
rxNorm: 4135
atc: N03AD51
Decrease of the plasma concentrations of ethosuximide
severity: Precaution for use
Clinical monitoring, plasma dosage of the ethosuximide and possible increase of its dosage.

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: FELBAMATE
rxNorm: 24812
atc: N03AX10
Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of felbamate due to increase of its hepatic metabolism by the carbamazepine
severity: Precaution for use
Clinical monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants.

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
atc: J02AC01
For doses of fluconazole >=200 mg per day: possible increase of the undesirable effects of the carbamazepine
severity: Precaution for use
Adjust the dosage of carbamazepine, during the antifungal treatmentand after it is stopped.

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: FLUOXETINE
rxNorm: 4493
more atc: N06AB03
more atc: N06CA03
Increase of the plasma concentrations of carbamazepine with signs of overdose
severity: Precaution for use
Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped. 

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
Increase of the plasma concentrations of carbamazepine with signs of overdose
severity: Precaution for use
Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped.

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism
severity: Not recommended

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
Increase of the plasma concentrations of carbamazepine with signs of overdose, due to decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and. if needed, plasma dosage and possible reduction of the dosage of the carbamazepine.

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: LAMOTRIGINE
rxNorm: 28439
atc: N03AX09
Risk of increase of the neurological effects (vertigo, ataxia, diplopia) of the carbamazepine when the lamotrigine is introduced
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the carbamazepine. 

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Risk of neurotoxicity manifesting as disorders of the cerebellum, confusion, drowsiness, ataxia. These disorders are reversible when the treatment with the lithium is stopped.
severity: Not recommended

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: ST JOHN'S WORT
rxNorm: 258326
Risk of decrease of the plasma concentrations and of the effectiveness of the carbamazepine
severity: Not recommended

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: NINTEDANIB
rxNorm: 1592737
more atc: L01XE31
Decrease of the plasma concentrations of nintedanib due to decrease of its absorption by the carbamazepine
severity: Precaution for use
Clinical monitoring during the administration of these substances together.

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: OLANZAPINE
rxNorm: 61381
more atc: N05AH03
Risk of decrease of the plasma concentrations of the olanzapine and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the carbamazepine
severity: Precaution for use
Clinical monitoring, and if needed, adjustment of the dosage of the olanzapine.

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
Drug with no codes: GRAPEFRUIT (JUICE AND FRUIT)
Increase of the plasma concentrations of carbamazepine, with risk of overdose, due to inhibition of its metabolism by the grapefruit
severity: Not recommended

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: PAROXETINE
rxNorm: 32937
atc: N06AB05
Increase of the plasma concentrations of carbamazepine with signs of overdose
severity: Precaution for use
Clinical monitoring, testing of the plasma concentrations of carbamazepine and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped.

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
Progressive decrease of the plasma concentrations of carbamazepine and of its active metabolite without apparent modification of its anticonvulsive effectiveness
severity: Take into account
Use prudence with respect to the interpretation of the plasma concentrations.

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Reciprocal reduction of the plasma concentrations (increase of the metabolism without apparent modification of the anticonvulsive effectiveness)
severity: Take into account
Use prudence in the interpretation of the plasma concentrations. 

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring, testing of the plasma concentrations, and adjustment of the dosage of the carbamazepine during the treatment with the refampicin and after it is stopped.

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: RISPERIDONE
rxNorm: 35636
atc: N05AX08
Risk of decrease of the active fraction of the risperidone and of its therapeutic effectiveness due to increase of its hepatic metabolism by the carbamazepine
severity: Precaution for use
Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone.

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism
severity: Not recommended

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
drug name: TOPIRAMATE
rxNorm: 38404
atc: N03AX11
Decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the carbamazepine
severity: Precaution for use
Clinical monitoring, and if needed, adjustment of the dosage of the topiramate during the treatment with the carbamazepine and after it is stopped. 

***interaction***
drug1
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
drug2
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
Increase of the plasma concentrations of the active metabolite of the carbamazepine with signs of overdose. In addition, decrease of the plasma concentrations of valproic acid due to increase of its hepatic metabolism by the carbamazepine
severity: Precaution for use
Clinical monitoring, plasma dosages, and adjustment of the dosage of the two anticonvulsants.
112-CARMUSTINE.html


***interaction***
drug1
drug name: CARMUSTINE
rxNorm: 2105
atc: L01AD01
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the carmustine) 
severity: Not recommended
113-CARVEDILOL.html


***interaction***
drug1
drug name: CARVEDILOL
rxNorm: 20352
atc: C07AG02
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the carvedilol, which can be dangerous in the case of treatment for heart failure due to decrease of its hepatic metabolism by the cimetidine
severity: CONTRAINDICATION
Use another gastric H2 receptor antagonist.

***interaction***
drug1
drug name: CARVEDILOL
rxNorm: 20352
atc: C07AG02
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Regular clinical monitoring and adjustment of the dosage of the carvedilol during the treatment with the rifampicin. When the rifampicin is stopped, risk of large increase of the plasma concentrations of carvedilol imposing a reduction of the dosage and strict clinical monitoring.
114-CALCIUM-POLYSTYRENE-SULFONATE.html


***interaction***
drug1
drug name: CALCIUM POLYSTYRENE SULFONATE
rxNorm: 47630
drug2
drug name: SORBITOL
rxNorm: 9945
more atc: A06AD18
more atc: A06AG07
more atc: B05CX02
more atc: V04CC01
With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal
severity: CONTRAINDICATION
115-SODIUM-POLYSTYRENE-SULFONATE.html


***interaction***
drug1
drug name: SODIUM POLYSTYRENE SULFONATE
rxNorm: 56512
drug2
drug name: SORBITOL
rxNorm: 9945
more atc: A06AD18
more atc: A06AG07
more atc: B05CX02
more atc: V04CC01
With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal
severity: Not recommended
116-CEFALOTIN.html


***interaction***
drug1
drug name: CEFALOTIN
rxNorm: 2236
atc: J01DB03
drug2
class name: AMINOGLYCOSIDES
class code: J01GB-001
Increase of the nephrotoxicity of the aminoglycosides by the cefalotin is under discussion
severity: Precaution for use
Monitoring of renal function.
117-CEFAMANDOLE.html


***interaction***
drug1
drug name: CEFAMANDOLE
rxNorm: 2178
atc: J01DC03
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.
118-CEFOPERAZONE.html


***interaction***
drug1
drug name: CEFOPERAZONE
rxNorm: 2184
atc: J01DD12
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.
119-CEFOTETAN.html


***interaction***
drug1
drug name: CEFOTETAN
rxNorm: 2187
atc: J01DC05
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.
11-NICOTINIC-ACID.html


***interaction***
drug1
drug name: NICOTINIC ACID
rxNorm: 446722
drug2
Drug with no codes: ALCOHOL (DRINK OR INGREDIENT)
Risk of rash, redness, and heat linked to an increase of the vasodilator effect 
severity: Take into account
120-CEFTRIAXONE.html


***interaction***
drug1
drug name: CEFTRIAXONE
rxNorm: 2193
more atc: J01DD04
more atc: J01DD54
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped.
121-CHLORDIAZEPOXIDE.html


***interaction***
drug1
drug name: CHLORDIAZEPOXIDE
rxNorm: 2356
atc: N05BA02
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
With the cimetidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness
severity: Precaution for use
Warn patients of the increase of risk when driving an automobile or using machinery.
122-CHLOROQUINE.html


***interaction***
drug1
drug name: CHLOROQUINE
rxNorm: 2393
atc: P01BA01
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Risk of increase of the blood concentrations of ciclosporin and of the creatinemia
severity: Precaution for use
Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after the chloroquine is stopped. 

***interaction***
drug1
drug name: CHLOROQUINE
rxNorm: 2393
atc: P01BA01
drug2
drug name: CIMETIDINE
rxNorm: 2541
more atc: A02BA01
more atc: A02BA51
Slowing of the elimination of the chloroquine and risk of overdose
severity: Take into account

***interaction***
drug1
drug name: CHLOROQUINE
rxNorm: 2393
atc: P01BA01
drug2
class name: THYROID HORMONES
class code: H03AA
Risk of clinical hypothyroidism in patients taking thyroid hormones in substitution therapy
severity: Precaution for use
Monitoring of serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped.
123-CHLORPROMAZINE.html


***interaction***
drug1
drug name: CHLORPROMAZINE
rxNorm: 2403
atc: N05AA01
drug2
drug name: INSULIN
rxNorm: 
more atc: 5856
With strong doses (100 mg per day of chlorpromazine): elevation of glycemia (decrease of the freeing of insulin)
severity: Precaution for use
Inform the patient and reinforce self monitoring of blood glucose. Possible adjustment of the dosage of the insulin during the treatment with the neuroleptic and after it is stopped.

***interaction***
drug1
drug name: CHLORPROMAZINE
rxNorm: 2403
atc: N05AA01
drug2
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
With strong doses (100 mg per day of chlorpromazine): elevation of glycemia (decrease of the freeing of insulin)
severity: Precaution for use
Inform the patient and reinforce self monitoring of blood glucose. Possible adjustment of the dosage of the neuroleptic during the treatment and after it is stopped. 
124-CICLOSPORIN.html


***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: URSODEOXYCHOLIC ACID
rxNorm: 
more atc: A05AA02
Risk of variation of the blood concentrations of ciclosporin 
severity: Take into account

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
Increase of the plasma concentrations of afatinib due to increase of its absorption by the ciclosporin
severity: Precaution for use
It is recommended that the ciclosporin be administered as far from the afatinib as possible, preferably at an interval of 6 to 12 hours away from the administration of the dose of afatinib. 

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: ALISKIREN
rxNorm: 325646
atc: C09XA02
Increase by nearly 5 times of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects. 
severity: CONTRAINDICATION

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: AMBRISENTAN
rxNorm: 358274
atc: C02KX02
Doubling of the concentrations of ambrisentan, with increase of the vasodilator effect (severe headaches )
severity: Take into account

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
class name: AMINOGLYCOSIDES
class code: J01GB-001
Larger increase of the creatinemia than with ciclosporin alone, with increase of the nephrotoxic risk 
severity: Take into account

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Increase of the blood concentrations of ciclosporin, due to decrease of its hepatic metabolism, with risk of nephrotoxic effects


severity: Not recommended
Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage of the ciclosporin during the treatment with the amiodarone

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: AMPHOTERICIN B 
rxNorm: 732
more atc: A01AB04
more atc: A07AA07
more atc: G01AA03
more atc: J02AA01
With the amphotericin B administered by IV route: greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances)
severity: Take into account

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
class name: SOMATOSTATIN ANALOGS
class code: H01CB0-001
With the ciclosporin administered orally:

reduction of the blood concentrations of ciclosporin (decrease of its intestinal absorption).


severity: Precaution for use
Increase of the doses of ciclosporin according to testing of the plasma concentrations and reduction of the dosage after the treatment with the somatostatin analog is stopped

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Risk of addition of the nephrotoxic effects, especially with older patients.


severity: Precaution for use
Monitor renal function at the beginning of the treatment with the NSAI.

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the intestinal absorption of the cholesterol lowering medication)
severity: Precaution for use
Do not exceed the dosage of 10mg/day of atorvastatin. If the therapeutic objective is not reached at that dosage, use another statin not affected by this type of interaction.

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: AZITHROMYCIN 
rxNorm: 18631
more atc: J01FA10
Risk of increase of the blood concentrations of ciclosporin and of the creatinemia
severity: Precaution for use
Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the two substances together and after the macrolide is stopped

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
Large decrease of the blood concentrations of the ciclosporin and increase of the plasma concentrations of bosentan
severity: CONTRAINDICATION

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: CHLOROQUINE
rxNorm: 2393
atc: P01BA01
Risk of increase of the blood concentrations of ciclosporin and of the creatinemia
severity: Precaution for use
Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after the chloroquine is stopped. 

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin
severity: Take into account

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: CLINDAMYCIN
rxNorm: 2582
more atc: D10AF01
more atc: G01AA10
more atc: J01FF01
more atc: D10AF51
Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity
severity: Precaution for use
Reinforce testing of the blood dosages of ciclosporin and possible increase of its dosage.

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
Risk of addition of the undesirable neuromuscular effects and increase of the toxicity of the colchicine with risk of overdose due to inhibition of its elimination by the ciclosporin, especially in cases of pre-existing renal insufficiency
severity: Not recommended

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
Increase by more than double of the plasma concentrations of dabigatran, with increase of the risk of bleeding
severity: CONTRAINDICATION

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: DANAZOL
rxNorm: 3102
atc: G03XA01
Increase of the blood concentrations of ciclosporin due to inhibition of its hepatic metabolism
severity: Precaution for use
Blood concentration dosage of ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
class name: POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)
severity: Not recommended

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
class name: POTASSIUM LOWERING DIURETICS
class code: C03
Risk of increase of the creatinemia without modification of the blood concentrations of ciclosporin, even in the absence of fluid depletion. Also risk of hyperuricemia and of complications such as gout
severity: Tale into account

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: ERIBULINE
rxNorm: 1045453
atc: L01XX41
Increase of the plasma concentrations of eribuline by the ciclosporin
severity: Not recommended

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: EVEROLIMUS
rxNorm: 141704
atc: L04AA18
Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together 
severity: Precaution for use
Blood concentration dosage of the everolimus, possibly adjustment of the dosage, and testing of the renal function during the administration of the two together and after it is stopped. 

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: EZETIMIBE
rxNorm: 341248
more atc: C10BA05
more atc: C10AX09
more atc: C10BA02
For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin
severity: Not recommended

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: FENOFIBRATE
rxNorm: 8703
more atc: C10AB05
more atc: C10BA03
more atc: C10BA04
Risk of increase of the nephrotoxicity of the ciclosporin
severity: Precaution for use
Clinical and biological monitoring of the renal function during and after the administration of the two medications together. 

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: FIDAXOMICIN
rxNorm: 1111103
atc: A07AA12
Increase of the plasma concentrations of the fidaxomicin. 
severity: Not recommended

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
Risk of increase of the blood concentrations of ciclosporin and of the creatinemia
severity: Precaution for use
Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of these medications together and after the macrolide is stopped.

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: LERCANIDIPINE
rxNorm: 135056
more atc: C09BB02
more atc: C08CA13
Moderate increase of the blood concentrations of the immunosuppressant and larger increase of the concentrations of the lercanidipine
severity: Precaution for use
Separate the administration of the two medications. Blood concentration dosage of the immunosuppressant, and adjustment if necessary of its dosage during the administration of the medications together and after it is stopped.

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications
severity: Precaution for use
Blood concentration dosage of ciclosporin and of methotrexate. Adjustment of the dosage if necessary during the administration of the two together and after it is stopped.

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: METHYLPREDNISOLONE
rxNorm: 6902
more atc: D07AA01
more atc: D10AA02
more atc: H02AB04
more atc: D07CA02
more atc: S01CA08
more atc: H02BX01
With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin
severity: Take into account

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: MIDECAMYCIN
rxNorm: 30005
atc: J01FA05
Risk of increase of the blood concentrations of ciclosporin and of the creatinemia
severity: Precaution for use
Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after the macrolide is stopped. 

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: MODAFINIL
rxNorm: 30125
atc: N06BA07
Risk of decrease of the blood concentrations and of the effectiveness of the immunosuppressant
severity: Not recommended

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: NIFEDIPINE
rxNorm: 7417
atc: C08CA05
Risk of addition of undesirable effects of the gum disorders type.
severity: Not recommended
Use another dihydropyridine.

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: NINTEDANIB
rxNorm: 1592737
more atc: L01XE31
Increase of the plasma concentrations of the nintedanib due to increase of its absorption by the ciclosporin
severity: Precaution for use
Clinical monitoring during the administration of there substances together. 

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
Decrease of the blood concentrations of ciclosporin due to decrease of its intestinal absorption, with risk of loss of the immunosuppressive activity
severity: Not recommended
Take the orlistat at a different time form the ciclosporin (at least 3 hours apart). Reinforce testing of blood dosages of the ciclosporin, especially at the beginning of the administration of the medications together, and at the time of a possible increase in the dosage of the orlistat.

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: PITAVASTATIN
rxNorm: 861634
atc: C10AA08
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the pitavastatin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: POTASSIUM
rxNorm: 8588
atc: A12BA
Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)
severity: Not recommended
Avoid the administration of these two substances together unless there is pre-existing hypokalemia.

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: PREDNISOLONE
rxNorm: 8638
more atc: A07EA01
more atc: C05AA04
more atc: D07AA03
more atc: D07XA02
more atc: H02AB06
more atc: R01AD02
more atc: S01BA04
more atc: S01CB02
more atc: S02BA03
more atc: S03BA02
more atc: D07CA03
more atc: S01CA02
more atc: S02CA01
more atc: S03CA02
more atc: D07BA01
more atc: S01BB02
more atc: V03AB05
Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)
severity: Take into account

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: REPAGLINIDE
rxNorm: 73044
atc: A10BX02
Increase of more than double of the concentrations of the repaglinide due to increase of its absorption
severity: Not recommended

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: ROSUVASTATIN
rxNorm: 301542
atc: C10AA07
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the rosuvastatin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: ROXITHROMYCIN
rxNorm: 9478
atc: J01FA06
Risk of increase of the blood concentrations of ciclosporin and of the creatinemia
severity: Precaution for use
Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped. 

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolosis type due to decrease of the metabolism of the simvastatin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: SIROLIMUS
rxNorm: 35302
atc: L04AA10
Increase of the blood concentrations of sirolimus by the ciclosporin. The nephrotoxicity of the ciclosporin is also increased when the two medications are administered together
severity: Precaution for use
It is recommended that the sirolimus be administered 4 hours after the cyclosporine. Testing of the renal function, during the administration of the two medications together and after it is stopped.

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: SULFINPYRAZONE
rxNorm: 10205
atc: M04AB02
Decrease of the blood concentrations of ciclosporin due to increase of its metabolism by the sulfinpyrazone
severity: Precaution for use
Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with sulfinpyrazone and after it is stopped.

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: TENEFOVIR ALAFENAMIDE
rxNorm: 1721603
Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption
severity: Precaution for use
In case of administration with the ciclosporin, the dose of tenofovir alafenamide must be limited to 10 mg per day. 

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: TERBINAFINE
rxNorm: 37801
atc: D01BA02
Decrease of the blood concentrations of ciclosporin
severity: Precaution for use
Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with terbinafine and after it is stopped. 

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: TICLOPIDINE
rxNorm: 10594
atc: B01AC05
Decrease of the blood concentrations of ciclosporin
severity: Precaution for use
Increase of the dosage of the ciclosporin according to testing of the blood concentrations. Reduction of the dosage when the ticlodipine is stopped. 

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: TRIMETHOPRIM
rxNorm: 10829
atc: J01EA01
With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporin

With the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity
severity: Take into account

***interaction***
drug1
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders
severity: Precaution for use
Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
125-CIMETIDINE.html


***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
drug name: ALFENTANIL
rxNorm: 480
atc: N01AH02
With the cimetidine used in doses greater than or equal to 800mg/day: increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism
severity: Precaution for use
Adjust the dosage of the alfentanil when administered with the cimetidine.

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cimetidine and a week after it is stopped. 

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
With the cimetidine used in doses greater than or equal to 800 mg/day: at the beginning of treatment, increase of the plasma concentrations of carbamazepine due to inhibition of its hepatic metabolism by the cimetidine 
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the carbamazepine, especially during the first days of treatment with the cimetidine

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
drug name: CARMUSTINE
rxNorm: 2105
atc: L01AD01
With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the carmustine)
severity: Not recommended

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
drug name: CARVEDILOL
rxNorm: 20352
atc: C07AG02
With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the carvedilol, which can be dangerous in the case of treatment for heart failure due to decrease of its hepatic metabolism by the cimetidine
severity: CONTRAINDICATION
Use another H2 receptor antagonist.

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
drug name: CHLORDIAZEPOXIDE
rxNorm: 2356
atc: N05BA02
With the cemitidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness
severity: Precaution for use
Warn patients of the increase of risk when driving an automobile or using machinery.

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
drug name: CHLOROQUINE
rxNorm: 2393
atc: P01BA01
Slowing of the elimination of the chloroquine and risk of overdose
severity: Take into account

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin
severity: Take into account

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
drug name: DIAZEPAM
rxNorm: 3322
atc: N05BA01
With the cimetidine used in doses greater than or equal to 800 mg/day: increased risk of drowsiness
severity: Precaution for use
Warn the patient of the increase of risk when driving an automobile or using machinery. 

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
drug name: LIDOCAINE
rxNorm: 6387
more atc: C01BB01
more atc: C05AD01
more atc: D04AB01
more atc: N01BB02
more atc: R02AD02
more atc: S01HA07
more atc: S02DA01
With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)
severity: Precaution for use
Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
drug name: LOMUSTINE
rxNorm: 6466
atc: L01AD02
With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the lomustine)
severity: Not recommended

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
drug name: METHADONE
rxNorm: 6813
atc: N07BC02
Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.
severity: Precaution for use
Strengthen clinical and electrocardiographic monitoring; if needed, adjustment of the dosage of the methadone during the treatment with the cimetidine and after it is stopped. 

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the cimetidine

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
drug name: MOCLOBEMIDE
rxNorm: 30121
atc: N06AG02
With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the moclobemide, due to decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring with possible adjustment of the dosage of moclobemide

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
drug name: NIFEDIPINE
rxNorm: 7417
atc: C08CA05
With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine
severity: Precaution for use
Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. 

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of phenytoin with possibility of appearance of the usual signs of overdose
severity: Not recommended
If administering the substances together cannot be avoided, strict clinical monitoring, plasma concentration dosages of the phenytoin, and possible adjustment of its dosage during the treatment with the cimetidine and after it is stopped.

***interaction***
drug1
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia. If there is reason for it, adjustment of the theophylline during the treatment with the cimetidine and after it is stopped. 
126-CINACALCET.html


***interaction***
drug1
drug name: CINACALCET
rxNorm: 407990
atc: H05BX01
drug2
drug name: DEXTROMETHORPHAN
rxNorm: 3289
atc: R05DA09
Very large increase of the plasma concentrations of dextromethorphan with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet
severity: CONTRAINDICATION

***interaction***
drug1
drug name: CINACALCET
rxNorm: 407990
atc: H05BX01
drug2
drug name: FLECAINIDE
rxNorm: 4441
atc: C01BC04
Increase of the plasma concentrations of flecanaide with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the flecainide during the treatment with cinacalcet.

***interaction***
drug1
drug name: CINACALCET
rxNorm: 407990
atc: H05BX01
drug2
drug name: MEQUITAZINE
rxNorm: 29528
atc: R06AD07
Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor
severity: Not recommended

***interaction***
drug1
drug name: CINACALCET
rxNorm: 407990
atc: H05BX01
drug2
drug name: METOPROLOL
rxNorm: 6918
atc: C07AB02
Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with cinacalcet.

***interaction***
drug1
drug name: CINACALCET
rxNorm: 407990
atc: H05BX01
drug2
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
Increase of the plasma concentrations of propafenone with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the propafenone during the treatment with cinacalcet.

***interaction***
drug1
drug name: CINACALCET
rxNorm: 407990
atc: H05BX01
drug2
drug name: VORTIOXETINE
rxNorm: 1455099
atc: N06AX26
Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the cinacalcet and after it is stopped. 
127-CIPROFLOXACIN.html


***interaction***
drug1
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
drug2
drug name: AGOMELATINE
rxNorm: 306718
atc: N06AX22
Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects. 
severity: Not recommended

***interaction***
drug1
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
drug2
drug name: CAFFEINE 
rxNorm: 1886
more atc: N06BC01
more atc: V04CG3
Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism
severity: Take into account

***interaction***
drug1
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
drug2
drug name: CLOZAPINE
rxNorm: 2626
atc: N05AH02
Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the clozapine during the treatment with the ciprofloxacin and after it is stopped. 

***interaction***
drug1
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
drug2
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA0
more atc: L04AX03
Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin
severity: Not recommended

***interaction***
drug1
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Variation, possibly large, of the concentrations of phenytoin in the case of treatment with ciprofloxacin
severity: Precaution for use
Clinical monitoring and testing of the plasma concentrations of the anticonvulsant during the treatment with ciprofloxacin and after it is stopped.

***interaction***
drug1
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
drug2
drug name: ROPINIROLE
rxNorm: 72302
atc: N04BC04
Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the ropinirole during the treatment with the ciprofloxacin and after it is stopped. 

***interaction***
drug1
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
drug2
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrythmias, especially of torsades de pointes. 
severity: Precaution for use
Clinical monitoring and EKG during the administration of these substances together. 

***interaction***
drug1
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia 
128-CITRATES.html


***interaction***
drug1
class name: CITRATES
class code: V09HX
drug2
class name: ALUMINUM (SALTS)
class code: A02AD0-001
Risk of facilitation of systemic uptake of the aluminum, especially in case of altered renal function. 
severity: Precaution for use
Take the aluminum based gastrointestinal medications at a different time (more than 2 hours apart if possible) from the citrates, including natural citrates (citrus fruit juices). 
129-CLADRIBINE.html


***interaction***
drug1
drug name: CLADRIBINE
rxNorm: 44157
atc: L01BB04
drug2
drug name: LAMIVUDINE
rxNorm: 68244
atc: J05AF05
Risk of decrease of the effectiveness of the cladribine by the lamivudine
severity: Not recommended
12-URSODEOXYCHOLIC-ACID.html


***interaction***
drug1
drug name: URSODEOXYCHOLIC ACID
rxNorm: 
more atc: A05AA02
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Risk of variation of blood concentrations of ciclosporin
severity: Take into account
130-CLARITHROMYCIN.html


***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: ATAZANAVIR
rxNorm: 343047
atc: J05AE08
Increase of the plasma concentrations of clarithyromycin and inhibition of the formation of its active metabolite
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these together.

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent
severity: Precaution for use
Use weaker doses of the cholesterol lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the carbamazepine.

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushings syndrome
severity: Take into account

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Increase of the digoxinemia due to increase of its absorption
severity: Precaution for use
Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with clarithromycin and after it is stopped. 

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: EBASTINE
rxNorm: 23796
atc: R06AX22
Increased risk of ventricular arrhythmias in predisposed subjects (congenital long QT syndrome)
severity: Not recommended

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: ERIBULINE
rxNorm: 1045453
atc: L01XX41
Increase of the plasma concentrations of eribuline by the clarithromycin.
severity: Not recommended

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: ETRAVIRINE
rxNorm: 475969
atc: J05AG04
In the treatment of infections with Mycobacterium avium complex, risk of decrease of the effectiveness of the clarithromycin due to increase of its hepatic metabolism by the etravirine
severity: Take into account

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: FIDAXOMICIN
rxNorm: 1111103
atc: A07AA12
Increase of the plasma concentrations of the fidaxomicin
severity: Not recommended

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: GLIBENCLAMIDE
rxNorm: 4815
atc: A10BB01
Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic
severity: Precaution for use
Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin. 

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: GLIMEPIRIDE
rxNorm: 25789
atc: A10BD06
Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. 
severity: Precaution for use
Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin 

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism
severity: Not recommended
If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage. 

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of treatment. 

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: LINEZOLIDE
rxNorm: 190376
atc: J01XX08
Risk of increase of the undesirable effects of the linezolide by the clarithromycin due to increase of its absorption
severity: Take into account

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: LUMEFANTRINE
rxNorm: 847728
atc: P01BF01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended
If this is possible, interrupt the medication tending to induce torsades de pointes. If administering these medications together cannot be avoided, testing of the QT before hand and EKG monitoring. 

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: MIZOLASTINE
rxNorm: 61455
atc: R06AX25
Risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: PRAVASTATIN
rxNorm: 42463
atc: C10AA03
Increase of the plasma concentration of the pravastatin by the clarithromycin
severity: Precaution for use
Clinical and biological monitoring during the treatment with the antibiotic

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: REPAGLINIDE
rxNorm: 73044
atc: A10BX02
Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide
severity: Precaution for use
Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the hypoglycemic agent during the treatment with the clarithromycin.

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the two medications together.

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and risk of lower effectiveness of the clarithromycin, especially with the HIV patient, due to increase of its hepatic metabolism by the rifampacin
severity: Precaution for use
Regular clinical and biological monitoring.

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (contentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent
severity: CONTRAINDICATION

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrhythmias, especially of torsades de points
severity: Precaution for use
Clinical monitoring and EKG during the administration of these medications together. 

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetic
severity: Precaution for use
Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Risk of increase of the theophyllinemia, particularly with children
severity: Take into account

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
Increase of the concentrations of venlafaxine with risk of overdose
severity: Take into account

***interaction***
drug1
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
drug2
class name: VINCA ALKALOIDS
class code: L01CA
Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin.
severity: Precaution for use
Strict clinical and biological monitoring. Possibly, use another antibiotic. 
131-CLINDAMYCIN.html


***interaction***
drug1
drug name: CLINDAMYCIN
rxNorm: 2582
more atc: D10AF01
more atc: G01AA10
more atc: J01FF01
more atc: D10AF51
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage. 
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the clindamycin and after it is stopped. 

***interaction***
drug1
drug name: CLINDAMYCIN
rxNorm: 2582
more atc: D10AF01
more atc: G01AA10
more atc: J01FF01
more atc: D10AF51
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity
severity: Precaution for use
Reinforced testing of the blood dosages of ciclosporin and possible increase of its dosage.

***interaction***
drug1
drug name: CLINDAMYCIN
rxNorm: 2582
more atc: D10AF01
more atc: G01AA10
more atc: J01FF01
more atc: D10AF51
drug2
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
more atc: L04AD02
Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity
severity: Precaution for use
Reinforced testing of the blood dosages of tacrolimus and possible increase of its dosage.
132-CLOBAZAM.html


***interaction***
drug1
drug name: CLOBAZAM
rxNorm: 21241
atc: N05BA09
drug2
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
Increase of the plasma concentrations of these anticonvulsants, with risk of overdose, due to inhibition of their hepatic metabolism
severity: Precaution for use
Clinical monitoring, plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol and possible adjustment of the dosage of the anticonvulsant taken with it as well.
133-CLOMIPRAMINE.html


***interaction***
drug1
drug name: CLOMIPRAMINE
rxNorm: 2597
atc: N06AA04
drug2
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
Risk of increase of the undesirable effects of the clomipramine due to decrease of its hepatic metabolism by the bupropion
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the clomipramine during the treatment with the bupropion. 
134-CLONAZEPAM.html


***interaction***
drug1
drug name: CLONAZEPAM
rxNorm: 2598
atc: N03AE01
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of the clonazepam due to increase of its hepatic metabolism by the carbamazepine
severity: Precaution for use
Clinical monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants
135-CLONIDINE.html


***interaction***
drug1
drug name: CLONIDINE
rxNorm: 2599
more atc: C02AC01
more atc: N02CX02
more atc: S01EA04
drug2
class name: TRICYCLIC ANTIDEPRESSANTS
class code: N06AA-001
Described for desipramine, imipramine:

inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)
severity: Not recommended

***interaction***
drug1
drug name: CLONIDINE
rxNorm: 2599
more atc: C02AC01
more atc: N02CX02
more atc: S01EA04
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)
severity: Take into account

***interaction***
drug1
drug name: CLONIDINE
rxNorm: 2599
more atc: C02AC01
more atc: N02CX02
more atc: S01EA04
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)
severity: Take into account

***interaction***
drug1
drug name: CLONIDINE
rxNorm: 2599
more atc: C02AC01
more atc: N02CX02
more atc: S01EA04
drug2
drug name: YOHIMBINE
rxNorm: 220982
atc: G04BE04
Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors
severity: Not recommended
136-CLOPIDOGREL.html


***interaction***
drug1
drug name: CLOPIDOGREL
rxNorm: 32968
atc: B01AC04
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
Increase of the risk of hemorrhage due to addition of the platelet antiagregation action


severity: Not recommended
-aside from validated indications for this combination of drugs in acute coronary syndromes. 

***interaction***
drug1
drug name: CLOPIDOGREL
rxNorm: 32968
atc: B01AC04
drug2
drug name: PACLITAXEL
rxNorm: 56946
atc: L01CD01
Increase of the concentrations of the paclitaxel by the clopidogrel, with risk of increase of the undesirable effects.
severity: Take into account

***interaction***
drug1
drug name: CLOPIDOGREL
rxNorm: 32968
atc: B01AC04
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)
severity: Precaution for use
Clinical monitoring and testing of the plasma concentrations of phenytoin.

***interaction***
drug1
drug name: CLOPIDOGREL
rxNorm: 32968
atc: B01AC04
drug2
drug name: REPAGLINIDE
rxNorm: 73044
atc: A10BX02
Increase of the concentrations of the repaglinide by the clopidogrel, with risk of increase of the undesirable effects.
severity: Take into account
137-CLOZAPINE.html


***interaction***
drug1
drug name: CLOZAPINE
rxNorm: 2626
atc: N05AH02
drug2
class name: BENZODIAZEPINES AND RELATED
class code: N05-001
Accrued risk of drop in blood pressure with respiratory and/or cardiac arrest.
severity: Take into account

***interaction***
drug1
drug name: CLOZAPINE
rxNorm: 2626
atc: N05AH02
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Risk of increase of the serious hematological effects 
severity: Not recommended

***interaction***
drug1
drug name: CLOZAPINE
rxNorm: 2626
atc: N05AH02
drug2
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the clozapine during the treatment with the ciprofloxacin and after it is stopped. 

***interaction***
drug1
drug name: CLOZAPINE
rxNorm: 2626
atc: N05AH02
drug2
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
Increase of the plasma concentrations of clozapine with signs of overdose
severity: Precaution for use
Increased clinical monitoring; if needed, adjustment of the dosage of the clozapine during the treatment with the fluvoxamine and after it is stopped.

***interaction***
drug1
drug name: CLOZAPINE
rxNorm: 2626
atc: N05AH02
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)
severity: Precaution for use
Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the phenytoin.

***interaction***
drug1
drug name: CLOZAPINE
rxNorm: 2626
atc: N05AH02
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)
severity: Precaution for use
Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the rifampicin.
138-COBICISTAT.html


***interaction***
drug1
drug name: COBICISTAT
rxNorm: 1306284
more atc: V03AX03
more atc: J05AR09
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Risk of increase of the undesirable effects of the amiodarone due to decrease of its metabolism by the cobicistat
severity: CONTRAINDICATION

***interaction***
drug1
drug name: COBICISTAT
rxNorm: 1306284
more atc: V03AX03
more atc: J05AR09
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Risk of decrease of the effectiveness of the cobicistat due to the increase of its metabolism by the inducer
severity: CONTRAINDICATION

***interaction***
drug1
drug name: COBICISTAT
rxNorm: 1306284
more atc: V03AX03
more atc: J05AR09
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the plasma concentratons of the cobicistat or of the inhibitor of CYP3A4
severity: Take into account
To know the risks and levels of severity of each interaction, consult the specific authorization for sale to the public ("Authorisation de la Mise sur le Marche" a French document) of each medication.

***interaction***
drug1
drug name: COBICISTAT
rxNorm: 1306284
more atc: V03AX03
more atc: J05AR09
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Risk of increase of the concentrations of itraconazole by the cobicistat
severity: Precaution for use
Clinical monitoring during the administration of these medications together. Large doses of itraconazole (>200 mg per day) are not recommended. 

***interaction***
drug1
drug name: COBICISTAT
rxNorm: 1306284
more atc: V03AX03
more atc: J05AR09
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer
severity: CONTRAINDICATION

***interaction***
drug1
drug name: COBICISTAT
rxNorm: 1306284
more atc: V03AX03
more atc: J05AR09
drug2
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat
severity: CONTRAINDICATION

***interaction***
drug1
drug name: COBICISTAT
rxNorm: 1306284
more atc: V03AX03
more atc: J05AR09
drug2
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
Very large increase of the metabolite of the rifabutin, with risk of increase of its toxicity (uveitis, neutropenia). Furthermore, possible decrease of the concentrations of cobicistat
severity: Precaution for use
Adjustment of the dosage of the rifabutin (in principle, reduction of the doses by half).

***interaction***
drug1
drug name: COBICISTAT
rxNorm: 1306284
more atc: V03AX03
more atc: J05AR09
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer
severity: CONTRAINDICATION

***interaction***
drug1
drug name: COBICISTAT
rxNorm: 1306284
more atc: V03AX03
more atc: J05AR09
drug2
drug name: TENEFOVIR ALAFENAMIDE
rxNorm: 1721603
With the atazanavir, the darunavir or the lopinavir boosted by cobicistat, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption.
severity: Precaution for use
In case of administration of these together, the dose of tenofovir alafenamide must be limited to 10 mg per day. The combination with the other protease inhibitors of HIV has not been studied.

***interaction***
drug1
drug name: COBICISTAT
rxNorm: 1306284
more atc: V03AX03
more atc: J05AR09
drug2
class name: VINCA ALKALOIDS
class code: L01CA
Increase of the neurotoxicity of the antimitotic due to decrease of its hepatic metabolism by the cobicistat
severity: Precaution for use
Strict clinical monitoring and possible adjustment of the dosage of the antimitotic
139-COCAINE.html


***interaction***
drug1
drug name: COCAINE
rxNorm: 2653
atc: S02DA02
drug2
drug name: DISULFIRAM
rxNorm: 3554
atc: N07BB01
Increase of the concentrations of cocaine due to decrease of its metabolism by the disulfiram, with increased risk of torsades de pointes
severity: Take into account
13-ACITRETIN.html


***interaction***
drug1
drug name: ACITRETIN
rxNorm: 16818
atc: D05BB02
drug2
Drug with no codes: ALCOHOL (DRINK OR INGREDIENT)
With women of child bearing age, risk of transformation of the acitretin into etretinate, a powerful agent of birth defects and malformations with a very prolonged half life (120 days), exposing the woman to a major risk of these birth defects and malformations of the child in case of pregnancy, during the treatment and two months after it ends. 
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ACITRETIN
rxNorm: 16818
atc: D05BB02
drug2
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
Risk of increase of the hepatotoxicity of the methotrexate 
severity: Not recommended
If administering these substances together is judged necessary, strengthen liver function testing. 
140-COLCHICINE.html


***interaction***
drug1
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the colchicine and a week after it is stopped. 

***interaction***
drug1
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
drug2
drug name: CICLOSPORIN
rxNorm: 3008
atc: S01XA18
Risk of addition of the undesirable neuromuscular effects and increase of the toxicity of the colchicine with risk of overdose due to inhibition of its elimination by the ciclosporin, espceially in cases of pre-existing renal insufficiency
severity: Not recommended

***interaction***
drug1
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
drug2
class name: FIBRATES
class code: C01AB-001
Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis
severity: Precaution for use
Clinical and biological monitoring, particularly at the beginning of the administration of these substances together. 

***interaction***
drug1
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
Increase of the undesirable effects of the colchicine, with potentially fatal consequences
severity: Not recommended

***interaction***
drug1
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
drug2
class name: HMG-COA REDUCTASE INHIBITORS (STATINS)
class code: C10AA
Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis
severity: Precaution for use
Clinical and biological monitoring, especially at the beginning of the administration of these substances together.

***interaction***
drug1
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the undesirable effects of the colchicine, with potentially fatal consequences
severity: Contraindication:
--with the macrolides

***interaction***
drug1
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
drug2
class name: MACROLIDES (EXCEPT SPIRAMYCIN)
class code: J01FA
Increase of the undesirable effects of the colchicine, with potentially fatal consequences
severity: CONTRAINDICATION

***interaction***
drug1
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
drug2
class name: OMBITASVIR + PARITAPRVIR
class code: OMPA
Increase od the plasma concentrations of the colchicine due to decrease of its hepatic metabolism by the therapy with ombitasvir + paritaprevir
severity: CONTRAINDICATION
-with patients having renal and/or hepatic insufficiency

***interaction***
drug1
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
drug2
drug name: PRISTINAMYCIN
rxNorm: 66958
atc: J01FG01
Increase of the undesirable effects of the colchicine, with potentially fatal consequences
severity: CONTRAINDICATION

***interaction***
drug1
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Risk of increase of the undesirable effects of the colchicine, due to increase of its plasma concentrations by the verapamil
severity: Not recommended
141-COLISTIN.html


***interaction***
drug1
drug name: COLISTIN
rxNorm: 2709
more atc: A07AA10
more atc: J01XB01
drug2
class name: CURARES
class code: M03A-001
Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent
severity: Precaution for use
Monitor the degree of curarization at the end of anesthesia.
141-CURARES.html


***interaction***
drug1
class name: CURARES
class code: M03A-001
drug2
class name: AMINOGLYCOSIDES
class code: J01GB-001
Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.
severity: Precaution for use
Monitor the degree of curarization at the end of anesthesia

***interaction***
drug1
class name: CURARES
class code: M03A-001
drug2
drug name: COLISTIN
rxNorm: 2709
atc: J01XB01
Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent
severity: Precaution for use
Monitor the degree of the curarization at the end of anesthesia.

***interaction***
drug1
class name: CURARES
class code: M03A-001
drug2
class name: LINCOSANIDES
class code: J01FF0
Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent
severity: Precaution for use
Monitor the degree of curarisation at the end of anesthesia.

***interaction***
drug1
class name: CURARES
class code: M03A-001
drug2
drug name: POLYMYXIN B
rxNorm: 8536
more atc: A07AA05
more atc: J01XB02
more atc: S01AA18
more atc: S02AA11
more atc: S03AA03
Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent
severity: Precaution for use
Monitor the degree of curarisation at the end of anesthesia.
142-CRIZOTINIB.html


***interaction***
drug1
drug name: CRIZOTINIB
rxNorm: 1148495
atc: L01XE16
drug2
class name: SUBSTRATES AT RISK OF CYP3A4
class code: L01N01
Risk of increase of the toxicity of these molecules due to decrease of their metabolism and/or increase of their bioavailability by the crizotinib
severity: Not recommended
144-NON-DEPOLARIZING-CURARES.html


***interaction***
drug1
class name: NON-DEPOLARIZING CURARES
class code: M03A-002
drug2
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
With the glucocorticoids by IV route: risk of severe myopathy, reversible after a possibly long period (several months).
severity: Take into account
145-CYANOCOBALAMIN.html


***interaction***
drug1
drug name: CYANOCOBALAMIN
rxNorm: 11248
more atc: B03BA01
more atc: B03BA02
drug2
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12
severity: Take into account

***interaction***
drug1
drug name: CYANOCOBALAMIN
rxNorm: 11248
more atc: B03BA01
more atc: B03BA02
drug2
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12.
severity: Take into account
146-TETRACYCLINE-ANTIBIOTICS.html


***interaction***
drug1
class name: TETRACYCLINE ANTIBIOTICS
class code: J01AA
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tetracycline antibiotic and after it is stopped. 

***interaction***
drug1
class name: TETRACYCLINE ANTIBIOTICS
class code: J01AA
drug2
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
Decrease of the digestive absorption of the tetracycline antibiotics
severity: Precaution for use
Take the calcium salts at a different time from the tetracycline antibiotic (more than two hours apart, if possible).

***interaction***
drug1
class name: TETRACYCLINE ANTIBIOTICS
class code: J01AA
drug2
drug name: IRON
rxNorm: 1431589
atc: B03A
With the tetracycline antibiotics administered by oral route: decrease of the digestive absorption of the tetracycline antibiotics (formation of complexes)
severity: Precaution for use
Take the iron salts at a different time from the tetracycline antibiotics (more than 2 hours apart, if possible). 

***interaction***
drug1
class name: TETRACYCLINE ANTIBIOTICS
class code: J01AA
drug2
class name: RETINOIDS
class code: D05-D10
Risk of intracranial hypertension
severity: CONTRAINDICATION

***interaction***
drug1
class name: TETRACYCLINE ANTIBIOTICS
class code: J01AA
drug2
drug name: STRONTIUM
rxNorm: 81638
more atc: V10BX01
more atc: M05BX03
Decrease of the digestive absorption of the strontium 
severity: Precaution for use
Take the strontium at a different time from the tetracycline antibiotics (more than two hours apart, if possible).

***interaction***
drug1
class name: TETRACYCLINE ANTIBIOTICS
class code: J01AA
drug2
drug name: VITAMIN A
rxNorm: 11246
more atc: A11CA
more atc: A11CA01
In case of intake of 10,000 IU/day and more: risk of intracranial hypertension 
severity: CONTRAINDICATION

***interaction***
drug1
class name: TETRACYCLINE ANTIBIOTICS
class code: J01AA
drug2
drug name: ZINC
rxNorm: 11416
atc: A12CB
Decrease of the digestive absorption of the tetracycline antibiotics
severity: Precaution for use
Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).
147-CYCLOPHOSPHAMIDE.html


***interaction***
drug1
drug name: CYCLOPHOSPHAMIDE
rxNorm: 3002
atc: L01AA01
drug2
drug name: PENTOSTATIN
rxNorm: 8011
atc: L01XX08
Increase of the risk of pulmonary toxicity which could be fatal
severity: Not recommended
148-CYPROHEPTADINE.html


***interaction***
drug1
drug name: CYPROHEPTADINE
rxNorm: 3013
atc: R06AX02
drug2
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
class code: N06AB
Risk of decrease of the effectiveness of the antidepressant
severity: Take into account 
149-CYPROTERONE.html


***interaction***
drug1
drug name: CYPROTERONE
rxNorm: 3014
atc: G03HB01
drug2
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
Risk of decrease of the concentrations of cyproterone with risk of lower contraceptive effectiveness
severity: Precaution for use
In its use as a hormonal contraceptive: 

***interaction***
drug1
drug name: CYPROTERONE
rxNorm: 3014
atc: G03HB01
drug2
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
Risk of decrease of the effectiveness of the cyproterone
severity: Precaution for use
In its indications as an anti-androgen, clinical monitoring and if possible adjustment of the dosage of the cyproterone during the administration with the bosentan and after it is stopped.

***interaction***
drug1
drug name: CYPROTERONE
rxNorm: 3014
atc: G03HB01
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Risk of decrease of the effectiveness of the cyproterone
severity: Not recommended:
-when used as a hormonal contraceptive: use of another method of contraception in particular a barrier type, is preferred during the length of the administration of these substances together and a cycle following

***interaction***
drug1
drug name: CYPROTERONE
rxNorm: 3014
atc: G03HB01
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Risk of decrease of the effectiveness of the cyproterone
severity: Not recommended
-in its use as a hormonal contraceptive: use instead another method of contraception in particular a barrier type, during the length of the administration of these substances together

***interaction***
drug1
drug name: CYPROTERONE
rxNorm: 3014
atc: G03HB01
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the effectiveness of the cyproterone, due to increase of its hepatic metabolism by the St Johns Wort 
severity: CONTRAINDICATION

***interaction***
drug1
drug name: CYPROTERONE
rxNorm: 3014
atc: G03HB01
drug2
drug name: PERAMPANEL
rxNorm: 1356552
atc: N03AX2
For doses of perampenel >or = to 12 mg/day, risk of decrease of the effectiveness of the cyproterone.
severity: Not recommended
In its use as a hormonal contraceptive: use instead another method of contraception in particular a barrier type, during the length of the administration of these substances together.

***interaction***
drug1
drug name: CYPROTERONE
rxNorm: 3014
atc: G03HB01
drug2
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
Risk of antagonism of the effects of the progestin
severity: Not recommended
Do not take a progestin treatment fewer than 12 hours after the ulipristal is stopped.
14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html


***interaction***
drug1
drug name: ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)
rxNorm: 3992
more atc: A01AD01
drug2
class name: HALOGENATED HYDROCARBON ANESTHETICS
class code: N01AB0-001
Serious ventricular arrhythmias due to increased cardiac sensitization


severity: Precautions for use
Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg per hour for an adult.

***interaction***
drug1
drug name: ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)
rxNorm: 3992
more atc: A01AD01
drug2
class name: TRICYCLIC ANTIDEPRESSANTS
class code: N06AA-001
Serious ventricular arrhythmias due to increased cardiac sensitization
severity: Precaution for use
Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.

***interaction***
drug1
drug name: ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)
rxNorm: 3992
more atc: A01AD01
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Serious ventricular arrhythmias due to increased cardiac sensitization
severity: Precaution for use
Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.

***interaction***
drug1
drug name: ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)
rxNorm: 3992
more atc: A01AD01
drug2
class name: MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS
class code: N06A
Serious ventricular arrhythmias due to increased cardiac sensitization.
severity: Precaution for use
Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.
150-CYTOTOXICS.html


***interaction***
drug1
class name: CYTOTOXICS
class code: L01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the risk of thrombosis and hemorrhage accompanying tumors. In addition, possible interaction between the vitamin K antagonist and the chemotherapy
severity: Precaution for use
More frequent testing of the INR

***interaction***
drug1
class name: CYTOTOXICS
class code: L01
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Excessive immunodepression with risk of lymphoproliferative syndrome
severity: Take into account

***interaction***
drug1
class name: CYTOTOXICS
class code: L01
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Risk of onset of convulsions due to decrease of the digestive absorption of the phenytoin only by the cytotoxic, or risk of increase of the toxicity or loss of effectiveness of the cytotoxic due to the increase of its hepatic metabolism by the phenytoin or the fosphenytoin
severity: Not recommended

***interaction***
drug1
class name: CYTOTOXICS
class code: L01
drug2
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
Risk of general vaccine disease, possibly fatal
severity: Contraindication
--and during the 6 months following the end of the chemotherapy
151-DABIGATRAN.html


***interaction***
drug1
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding


severity: Precaution for use
For post surgical indications:

***interaction***
drug1
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect


severity: Not recommended

***interaction***
drug1
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
drug2
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
Doubling of the plasma concentrations of dabigatran, with increase of the risk of bleeding
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Increase of more than double the plasma concentrations of dabagitan, with increase of the risk of bleeding
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
drug2
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding
severity: Precaution for use
In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose.

***interaction***
drug1
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
more atc: B01AE07
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect
severity: Not recommended

***interaction***
drug1
drug name: DABIGATRAN
rxNorm: 
more atc: 103704
drug2
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
more atc: L04AD02
Risk of increase of the plasma concentrations of dabigatran
severity: Not recommended

***interaction***
drug1
drug name: DABIGATRAN
rxNorm: 
more atc: 103704
more atc: B01AE07
drug2
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding
severity: Take into account

***interaction***
drug1
drug name: DABIGATRAN
rxNorm: 
more atc: 103704
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding
severity: Precaution for use
In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150mg/day in one dose, or even 75mg/day in case of moderate renal insufficiency.
152-DACARBAZINE.html


***interaction***
drug1
drug name: DACARBAZINE
rxNorm: 3098
atc: L01AX04
drug2
drug name: FOTEMUSTINE
rxNorm: 25287
atc: L01AD05
With the dacarbazine in large doses: risk of pulmonary toxicity (adult respiratory distress syndrome).


severity: Precaution for use
Do not use these medications simultaneously, but wait a week between the last administration of fotemustine and the first day of the treatment with dacarbazine. 
153-DACLATASVIR.html


***interaction***
drug1
drug name: DACLATASVIR
rxNorm: 1606218
atc: J05AX14
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Only in the combination daclatasvir/sofosbuvir:

Possibly abrupt onset of bradycardia, that can have fatal consequences
severity: Not recommended
If the administration of these medications together cannot be avoided, strict clinical monitoring and EKG, in particular during the first weeks of treatment with thedaclatasvir/sofosbuvir combination

***interaction***
drug1
drug name: DACLATASVIR
rxNorm: 1606218
atc: J05AX14
drug2
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.
severity: CONTRAINDICATION
With the exception of the dexamethasone administered in a single dose. 

***interaction***
drug1
drug name: DACLATASVIR
rxNorm: 1606218
atc: J05AX14
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.
severity: Contraindication:
-with rifampicin

***interaction***
drug1
drug name: DACLATASVIR
rxNorm: 1606218
atc: J05AX14
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the concentrations of daclatasvir by the inhibitor.
severity: Precaution for use
The dose of daclatasvir must be decreased to 30 mg 1 time per day in case of administration with the inhibitor.

***interaction***
drug1
drug name: DACLATASVIR
rxNorm: 1606218
atc: J05AX14
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the St Johns Wort
severity: CONTRAINDICATION
154-DALFOPRISTIN.html


***interaction***
drug1
drug name: DALFOPRISTIN
rxNorm: 229369
atc: J01FG02
drug2
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DALFOPRISTIN
rxNorm: 229369
atc: J01FG02
drug2
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DALFOPRISTIN
rxNorm: 229369
atc: J01FG02
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.

***interaction***
drug1
drug name: DALFOPRISTIN
rxNorm: 229369
atc: J01FG02
drug2
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
Increased risk of ventricular arrhythmias, especially of torsades de pointes.
severity: Not recommended
155-DANAZOL.html


***interaction***
drug1
drug name: DANAZOL
rxNorm: 3102
atc: G03XA01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the risk of hemorrhage due to the direct effect on coagulation and/or the fibrinolytic systems.
severity: Precaution for use
More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the danazol and after it is stopped. 

***interaction***
drug1
drug name: DANAZOL
rxNorm: 3102
atc: G03XA01
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Increase of the plasma concentrations of carbamazepine with signs of overdose
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the carbamazepine.

***interaction***
drug1
drug name: DANAZOL
rxNorm: 3102
atc: G03XA01
drug2
drug name: CICLOSPORIN
rxNorm: 3008
atc: S01XA18
Increase of the blood concentrations of ciclosporin due to inhibition of its hepatic metabolism
severity: Precaution for use
Blood concentration dosage of ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.

***interaction***
drug1
drug name: DANAZOL
rxNorm: 3102
atc: G03XA01
drug2
drug name: INSULIN
rxNorm: 5856
more atc: A10AC01
more atc: A10AC02
more atc: A10AC03
more atc: A10AC04
more atc: A10AD01
more atc: A10AD02
more atc: A10AD03
more atc: A10AD04
more atc: A10AD05
more atc: A10AE01
more atc: A10AE02
more atc: A10AE03
more atc: A10AE04
more atc: A10AE05
more atc: A10AF01
Diabetes inducing effect of the danazol
severity: Not recommended
If administering these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 

***interaction***
drug1
drug name: DANAZOL
rxNorm: 3102
atc: G03XA01
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DANAZOL
rxNorm: 3102
atc: G03XA01
drug2
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
Diabetes inducing effect of the danazol
severity: Not recommended
If the administration of these substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the antidiabetic during the treatment with the danazol and after it is stopped. 

***interaction***
drug1
drug name: DANAZOL
rxNorm: 3102
atc: G03XA01
drug2
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
more atc: L04AD02
Increase of the blood concentrations of the tacrolimus due to inhibition of its hepatic metabolism
severity: Precaution for use
Blood concentration dosage of the tacrolimus and adjustment of its dosage during the administration of it with the danazol and after it is stopped, with testing of the renal function.
156-DANTROLENE.html


***interaction***
drug1
drug name: DANTROLENE
rxNorm: 3105
more atc: M03CA01
drug2
class name: DIHYDROPYRIDINES
class code: C08CA-002
With the dantrolene administered via IV: cases of fatal ventricular fibrillations are constantly observed in animals when verapamil and dantrolene are administered via IV. The administration of a calcium channel blocker and dantrolene is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident
severity: Not recommended

***interaction***
drug1
drug name: DANTROLENE
rxNorm: 3105
more atc: M03CA01
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DANTROLENE
rxNorm: 3105
more atc: M03CA01
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident
severity: CONTRAINDICATION
157-DAPOXETINE.html


***interaction***
drug1
drug name: DAPOXETINE
rxNorm: 69394
atc: G04BX14
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the undesirable effects, especially of the vertigo or fainting type
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DAPOXETINE
rxNorm: 69394
atc: G04BX14
drug2
class name: MEDICATIONS AT THE ORIGIN OF ORTHOSTATIC HYPOTENSION
class code: N05AA-001
Risk of increase of the undesirable effects, especially of the vertigo and fainting type
severity: Nor recommended
-with the type 5 phosphodiesterase inhibitors 
158-DAPSONE.html


***interaction***
drug1
drug name: DAPSONE
rxNorm: 3108
more atc: D10AX05
more atc: J04BA02
drug2
drug name: ZIDOVUDINE 
rxNorm: 11413
more atc: J05AF01
more atc: J05AR01
more atc: J05AR04
more atc: J05AR05
Increase of the hematological toxicity (addition of effects of bone marrow toxicity)
severity: Precaution for use
More frequent CBC
159-DAPTOMYCIN.html


***interaction***
drug1
drug name: DAPTOMYCIN
rxNorm: 22299
atc: J01XX09
drug2
class name: HMG-COA REDUCTASE INHIBITORS (STATINS)
class code: C10AA
Risk of addition of undesirable effects (dose dependent) of the rhabdomyolysis type.
severity: Not recommended
If administering these substances together cannot be avoided, reinforce biological monitoring (CPK levels more than once a week) and strict clinical monitoring. 
15-AFATINIB.html


***interaction***
drug1
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Increase of the plasma concentrations of afatinib by increase of its absorption by the amiodarone.
severity: Precaution for use
It is recommendedthat the amiodarone be administered as great a distance from the afatanib as possible, preferably at an interval of 6 or of 12 hours from the dose of afatinib.

***interaction***
drug1
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Decrease of the plasma concentrations of afatinib due to increase of its metabolisn by these substances
severity: Precaution for use
Clinical monitoring during the administration of these substances together and 1 to 2 weeks after they are stopped. 

***interaction***
drug1
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Increase of the plasma concentrations of afatinib by increase of its absorption by the ciclosporin
severity: Precaution for use
It is recommendedthat the ciclosporin be administered as great a distance from the afatanib as possible, preferably at an interval of 6 or of 12 hours from the dose of afatinib.

***interaction***
drug1
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin.
severity: Precaution for use
It is recommended that the erythromycin be administered as great a distance from the afatanib as possible, preferably at an interval of 6 or of 12 hours from the dose of afatinib.

***interaction***
drug1
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Increase of the plasma concentrations of afatinib by increase of its absorption by the protease inhibiter.
severity: Precaution for use
It is recommended that the protease inhibitor be administered as great a distance from the afatanib as possible, preferably at an interval of 6 or of 12 hours from the dose of afatinib.

***interaction***
drug1
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increase of the plasma concentrations of afatinib by increase of its absorption by the itraconazole.
severity: Precaution for use
It is recommended that the itraconazole be administered as great a distance from the afatanib as possible, preferably at an interval of 6 or of 12 hours from the dose of afatinib.

***interaction***
drug1
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
atc: J02AB02
Increase of the plasma concentrations of afatinib by increase of its absorption by the ketoconazole.
severity: Precaution for use
It is recommended that the ketoconazole be administered as great a distance from the afatanib as possible, preferably at an interval of 6 or of 12 hours from the dose of afatinib.

***interaction***
drug1
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
drug2
drug name: PRIMIDONE 
rxNorm: 8691
atc: N03AA03
Decrease of the plasma concentrations of the afatinib due to the increase of its metabolism by the primidone
severity: Precaution for use
Clinical monitoring during the administration of these together and 1 to 2 weeks after they are stopped. 

***interaction***
drug1
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of the afatinib due to increase of its metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring during the administration of these together and 1 to 2 weeks after they are stopped. 

***interaction***
drug1
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the plasma concentrations of afatinib by increase of its absorption by the verapamil.
severity: Precaution for use
It is recommended that the verapamil be administered as great a distance from the afatanib as possible, preferably at an interval of 6 or of 12 hours from the dose of afatinib.
160-DARIFENACIN.html


***interaction***
drug1
drug name: DARIFENACIN
rxNorm: 136198
atc: G04BD10
drug2
drug name: FLECAINIDE
rxNorm: 4441
atc: C01BC04
Increase of the plasma concentrations of felcainide, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the flecainide during the treatment with darifenacin.

***interaction***
drug1
drug name: DARIFENACIN
rxNorm: 136198
atc: G04BD10
drug2
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.

***interaction***
drug1
drug name: DARIFENACIN
rxNorm: 136198
atc: G04BD10
drug2
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
Increase of the plasma concentrations of propafenone, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the propafenone during the treatment with darifenacin.
161-DASABUVIR.html


***interaction***
drug1
drug name: DASABUVIR
rxNorm: 1597381
atc: J05AX16
drug2
drug name: ETHINYLESTRADIOL
rxNorm: 4124
more atc: G03AA15
more atc: G03AB07
more atc: G03AA09
more atc: G03AB05
more atc: G03AA12
more atc: G03CA01
more atc: L02AA03
more atc: G03AA01
more atc: G03AA10
more atc: G03AB06
more atc: G03AA07
more atc: G03AB03
more atc: G03AA03
more atc: G03AB02
more atc: G03AA08
more atc: G03AA04
more atc: G03AB01
more atc: G03AA13
more atc: G03AA05
more atc: G03AB04
Increase of the hepatoxicity
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DASABUVIR
rxNorm: 1597381
atc: J05AX16
drug2
drug name: GEMFIBROZIL
rxNorm: 4719
atc: C10AB04
Risk of increase of the plasma concentrations of the dasabuvir by the gemfibrozil
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DASABUVIR
rxNorm: 1597381
atc: J05AX16
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Risk of reduction of the plasma concentrations of the dasabuvir by the inducer.
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DASABUVIR
rxNorm: 1597381
atc: J05AX16
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the plasma concentrations of the dasabuvir by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DASABUVIR
rxNorm: 1597381
atc: J05AX16
drug2
drug name: MITOTANE
rxNorm: 7004
atc: L01XX23
Risk of decrease of the plasma concentrations of the dasabuvir by the mitotane
severity: CONTRAINDICATION
162-DEFERASIROX.html


***interaction***
drug1
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
With acetylsalicyclic acid in anti-inflammatory doses (>=1 gr per dose and/or >= 3 gr per day) or for antalgic or antipyretic doses (>=500 mg per dose and/or <3 gr per day): increase of the risk of digestive ulceration and hemorrhage
severity: Take into account

***interaction***
drug1
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Risk of decrease of the plasma concentrations of deferasirox


severity: Precaution for use
Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjustment of the dosage of deferasirox.

***interaction***
drug1
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Increase of the risk of causing ulcers and digestive hemorrhage
severity: Take into account

***interaction***
drug1
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the risk of causing ulcers and digestive hemorrhage 
severity: Take into account

***interaction***
drug1
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
drug2
drug name: BUSULFAN
rxNorm: 1828
atc: L01AB01
Risk of increase of the toxocity of the bufulfan by decrease of its clearance by the deferasirox.
severity: Take into account

***interaction***
drug1
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
drug2
drug name: DEFERIPRONE
rxNorm: 11645
atc: V03AC02
Risk of hyperchelation
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
drug2
drug name: DEFEROXAMINE
rxNorm: 3131
atc: V03AC01
Risk of hyperchelation
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
drug2
drug name: REPAGLINIDE
rxNorm: 73044
atc: A10BX02
Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the deferasirox
severity: Not recommended
If administering these medications together cannot be avoided, strict clinical and biological monitoring.

***interaction***
drug1
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of decrease of the plasma concentrations of deferasirox
severity: Precaution for use
Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjust the dosage of deferasirox.
163-DEFERIPRONE.html


***interaction***
drug1
drug name: DEFERIPRONE
rxNorm: 11645
atc: V03AC02
drug2
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
Risk of hyperchelation
severity: CONTRAINDICATION
164-DEFEROXAMINE.html


***interaction***
drug1
drug name: DEFEROXAMINE
rxNorm: 3131
atc: V03AC01
drug2
drug name: ASCORBIC ACID
rxNorm: 1151
more atc: A11GA
more atc: A11GA01
more atc: A11GB
more atc: A11GB01
more atc: G01AD03
more atc: S01XA15
With large doses of the ascorbic acid and by intravenous route: 

cardiac function anomalies, even acute heart failure (generally reversible by ending administration of the Vitamin C).
severity: Precaution for use:
In the case of hemochromatosis, only give Vitamin C after having started treatment with the deferoxamine. Monitor cardiac function when these substances are administered together.

***interaction***
drug1
drug name: DEFEROXAMINE
rxNorm: 3131
atc: V03AC01
drug2
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
Risk of hyperchelation
severity: CONTRAINDICATION
165-DEFIBROTIDE.html


***interaction***
drug1
drug name: DEFIBROTIDE
rxNorm: 1311089
atc: B01AX01
drug2
class name: PLATELET AGGREGATION INHIBITORS
class code: B01AC-001
Increased risk of hemorrhage
severity: Not recommended

***interaction***
drug1
drug name: DEFIBROTIDE
rxNorm: 1311089
atc: B01AX01
drug2
class name: ORAL ANTICOAGULANTS
class code: B01A-001
Increased risk of hemorrhage.
severity: Not recommended

***interaction***
drug1
drug name: DEFIBROTIDE
rxNorm: 1311089
atc: B01AX01
drug2
class name: HEPARINS
class code: B01AB
Increased risk of hemorrhage.
severity: Not recommended

***interaction***
drug1
drug name: DEFIBROTIDE
rxNorm: 1311089
atc: B01AX01
drug2
class name: THROMBOLYTICS
class code: B01AD
Increased risk of hemorrhage.
severity: CONTRAINDICATION
166-DELAMANID.html


***interaction***
drug1
drug name: DELAMANID
rxNorm: 1344662
atc: J04AK06
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Decrease of the plasma concentrations de delamanid due to increase of its hepatic metabolism by the inducer
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DELAMANID
rxNorm: 1344662
atc: J04AK06
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of delamanid due to increase of its hepatic metabolism by the inducer
severity: CONTRAINDICATION
167-DERIVATIVES-OF-AMINOSALICYLIC-ACID-(ASA).html


***interaction***
drug1
class name: DERIVATIVES OF AMINOSALICYLIC ACID (ASA)
class code: A07EC-001
drug2
class name: ANTIPURINES
class code: ANTIPUR
Risk of increase of the myelosuppression effect of the immunomodulator by inhibition of its hepatic metabolism by the ASA derivative, especially with patients presenting a partial deficit of thiopurine methyltransferase (TMPT)
severity: Take into account
168-NITRATE-DERIVATIVES-AND-RELATED.html


***interaction***
drug1
class name: NITRATE DERIVATIVES AND RELATED
class code: C01D-001
drug2
class name: TYPE 5 PHOSPHODIESTERASE INHIBITORS
class code: G04BE
Risk of significant hypotension (synergic effect) capable of aggravating the state of myocardial ischemia and especially provoking an acute coronary accident
severity: CONTRAINDICATION

***interaction***
drug1
class name: NITRATE DERIVATIVES AND RELATED
class code: C01D-001
drug2
class name: MEDICATIONS THAT LOWER BLOOD PRESSURE 
class code: MLBP
Increase of the risk of hypotension, especially orthostatic.
severity: Take into account

***interaction***
drug1
class name: NITRATE DERIVATIVES AND RELATED
class code: C01D-001
drug2
drug name: RIOCIGUAT
rxNorm: 1439816
atc: C02KX05
Risk of significant hypotension (synergic effect).
severity: CONTRAINDICATION
169-DESIPRAMINE.html


***interaction***
drug1
drug name: DESIPRAMINE
rxNorm: 3247
atc: N06AA01
drug2
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
Risk of increase of the undesirable effects of the desipramine due to decrease of its hepatic metabolism by the bupropion
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the desipramine during the treatment with the bupropion.
16-AGOMELATINE.html


***interaction***
drug1
drug name: AGOMELATINE
rxNorm: 306718
atc: N06AX22
drug2
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects. 
severity: Not Recommended

***interaction***
drug1
drug name: AGOMELATINE
rxNorm: 306718
atc: N06AX22
drug2
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects.
severity: CONTRAINDICATION
170-DEXAMETHASONE.html


***interaction***
drug1
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
drug2
drug name: AMINOGLUTETHIMIDE
rxNorm: 677
atc: L02BG01
Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism


severity: Precaution for use
Adjustment of the dosage of the dexamethasone. 

***interaction***
drug1
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome
severity: Take into account

***interaction***
drug1
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
drug2
drug name: DACLATASVIR
rxNorm: 1606218
atc: J05AX14
With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer
severity: CONTRAINDICATION
With the exception of dexamethasone administered in a single dose. 

***interaction***
drug1
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: D10AF52
more atc: J01FA01
more atc: S01AA17
Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome
severity: Take into account

***interaction***
drug1
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome
severity: Take into account

***interaction***
drug1
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome
severity: Take into account

***interaction***
drug1
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome
severity: Take into account

***interaction***
drug1
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
drug2
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC0
Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome
severity: Take into account

***interaction***
drug1
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
drug2
drug name: PRAZIQUANTEL
rxNorm: 8628
atc: P02BA01
Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.
severity: Precaution for use
Separate the administration of the two medications by at least a week.

***interaction***
drug1
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
drug2
drug name: RILPIVIRINE
rxNorm: 1102270
atc: J05AG05
With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone
severity: CONTRAINDICATION
With the exception of dexamethasone administered in a single dose.

***interaction***
drug1
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
drug2
drug name: SIMEPREVIR
rxNorm: 1482790
atc: J05AE14
With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir by increase of its hepatic metabolism by the dexamethasone
severity: Not recommended
With the exception of dexamethasone administered in a single dose.

***interaction***
drug1
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
drug2
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome
severity: Take into account

***interaction***
drug1
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome
severity: Take into account
171-DEXTRAN-40.html


***interaction***
drug1
drug name: DEXTRAN 40
rxNorm: 42635
more atc: B05AA05
more atc: B03AC06
drug2
class name: LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)
class code: B01AB-001
Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)
severity: Not recommended

***interaction***
drug1
drug name: DEXTRAN 40
rxNorm: 42635
more atc: B05AA05
more atc: B03AC06
drug2
class name: UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENT)
class code: B01AB-003
Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)
severity: Not recommended
172-DEXTROMETHORPHAN.html


***interaction***
drug1
drug name: DEXTROMETHORPHAN
rxNorm: 3289
more atc: R05DA09
more atc: N07XX59
drug2
drug name: CINACALCET
rxNorm: 407990
atc: H05BX01
Very large increase of the plasma concentrations of dextromethorphan with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DEXTROMETHORPHAN
rxNorm: 3289
more atc: R05DA09
more atc: N07XX59
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DEXTROMETHORPHAN
rxNorm: 3289
more atc: R05DA09
more atc: N07XX59
drug2
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma
severity: Not recommended
173-DIAZEPAM.html


***interaction***
drug1
drug name: DIAZEPAM
rxNorm: 3322
atc: N05BA01
drug2
drug name: BUSPIRONE
rxNorm: 1827
atc: N05BE01
Risk of increase of the undesirable effects of the buspirone
severity: Take into account

***interaction***
drug1
drug name: DIAZEPAM
rxNorm: 3322
atc: N05BA01
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
With the cimetidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness
severity: Precaution for use
Warn the patients of the increase of risk when driving an automobile or using machinery. 

***interaction***
drug1
drug name: DIAZEPAM
rxNorm: 3322
atc: N05BA01
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Unpredictable variations: the plasma concentrations of phenytoin can increase, with signs of overdose, but also decrease or remain stable.
severity: Precaution for use
Clinical monitoring and testing of the plasma concentrations of phenytoin. 

***interaction***
drug1
drug name: DIAZEPAM
rxNorm: 3322
atc: N05BA01
drug2
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
Increase of the plasma concentrations of the diazepam, with risk of overdose, due to inhibition of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol and possible adjustment of the dosage of the anticonvulsant taken with it as well. 
174-DIDANOSINE.html


***interaction***
drug1
drug name: DIDANOSINE
rxNorm: 3364
atc: J05AF02
drug2
drug name: ALLOPURINOL
rxNorm: 519
atc: M04AA01
Increase of the plasma concentrations of didanosine and of its undesirable effects


severity: Not recommended

***interaction***
drug1
drug name: DIDANOSINE
rxNorm: 3364
atc: J05AF02
drug2
drug name: GANCICLOVIR
rxNorm: 4678
more atc: J05AB06
more atc: S01AD09
Risk of increase of the undesirable effects of the didanosine, and especially the mitochondrial toxicity, due to substantial increase of its concentrations. In addition, risk of decrease of the effectiveness of the ganciclovir due to decrease of its concentrations, if the two medications are ingested in an interval of less than 2 hours
severity: Not recommended

***interaction***
drug1
drug name: DIDANOSINE
rxNorm: 3364
atc: J05AF02
drug2
drug name: PENTAMIDINE
rxNorm: 7994
atc: P01CX01
Increased risk of onset of pancreatitis due to addition of undesirable effects
severity: Precaution for use
Monitoring of the blood amylase level. Do not use these two medications together if the blood amylase level is at the high range of normal. 

***interaction***
drug1
drug name: DIDANOSINE
rxNorm: 3364
atc: J05AF02
drug2
drug name: RIBAVIRIN
rxNorm: 9344
atc: J05AB04
Risk of increase of the mitochrondrial toxicity of the didanosine due to increase of its active metabolite
severity: Not recommended

***interaction***
drug1
drug name: DIDANOSINE
rxNorm: 3364
atc: J05AF02
drug2
drug name: TENOFOVIR DISOPROXIL
rxNorm: 300195
more atc: J05AF07
more atc: J05AR06
more atc: J05AR08
more atc: J05AR09
more atc: J05AR03
Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitchondrial toxicity of the didanosine
severity: Not recommended

***interaction***
drug1
drug name: DIDANOSINE
rxNorm: 3364
atc: J05AF02
drug2
drug name: THALIDOMIDE
rxNorm: 10432
atc: L04AX02
Increased risk of onset of peripheral neuropathy due to addition of undesirable effects
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together. 

***interaction***
drug1
drug name: DIDANOSINE
rxNorm: 3364
atc: J05AF02
drug2
drug name: ZALCITABINE
rxNorm: 3363
atc: J05AF03
Increased risk of onset of pancreatitis and of peripheral neuropathy due to addition of undesirable effects
severity: Precaution for use
Regular clinical monitoring and monitoring of the amylasemia. Do not administer these substances together if the amylasemia is at the high range of normal. 
175-DIGOXIN.html


***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Depression of self-regulation (excessive bradycardia) and difficulties with atrioventricular conduction. In addition, increase of the digoninemia due to decrease of the clearance of digoxin
severity: Precaution for use
Clinical monitoring, EKG, and, if there is reason for it, testing of the digoxinemia and adjustment of the dosage.

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: AZITHROMYCIN
rxNorm: 18631
atc: J01FA10
Increase of the digoxinemia due to increase of its absorption
severity: Precaution for use
Clinical monitoring and possibly monitoring of the digoxinemia during treatment with the azithromycin and after it is stopped. 

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
Difficulties with autoregulation (bradycardia, sinus arrest) and difficulties with sinoauricular and atrioventricular conduction
severity: Take into account

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: CALCIUM
rxNorm: 
more atc: A12AA
Risk of serious arrhythmias, even lethal ones with the calcium salts administered via IV
severity: Contraindication
-with the calcium salts by IV route, except for parenteral supplementation.

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Increase of the plasma concentrations of carbamazepine and decrease of the digoxinemia
severity: Precaution for use
Exercise caution in the interpretation of the plasma concentrations.

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Increase of the digoxinemia due to increase of its absorption
severity: Precaution for use
Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the clarithromycin and after it is stopped. 

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
Depression of autoregulation (excessive bradycardia) and disorders of atrioventricular conduction. In addition, increase of the digoxinemia due to decrease of the metabolism of the digoxin. Clinical monitoring and EKG. 
severity: Not recommended
Reduce the doses of digoxin by half. 

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
Increase of the digoxinemia due to increase of its absorption
severity: Precaution for use
Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the erythromycin and after it is stopped. 

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: HYDROQUINIDINE
rxNorm: 27220
Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction).
severity: Precaution for use
Clinical monitoring and EKG. In the case of unexpected results, test the digoxinemia and adjust the dosage. 

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
class name: POTASSIUM LOWERING AGENTS
class code: C03-001
Hypokaliemia producing toxic effects of the digitalics
severity: Precaution for use
Correct beforehand all hypokaliemia and do clinical, electrolytic, and EKG monitoring. 

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Increase of the digoxinemia, more marked for IV route, due to increase of the absorption of the digoxin or decrease of its renal clearance.
severity: Precaution for use
Clinical monitoring and, if there is reason for them, EKG and monitoring of the digoxinemia, with possible adjustment of the dosage of digoxin.

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increase of the digoxinemia with nausea, vomiting, arrhythmias.
severity: Precaution for use
Clinical monitoring, and, if there is reason for them, EKG, and monitoring of the digoxinemia with adjustment of the dosage of the digoxin during the treatment with the itraconazole and after it is stopped.

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: MIDODRINE
rxNorm: 6963
atc: C01CA17
Difficulties with autoregulation (increase of the bradycardia inducing effect of the midodrine) and difficulties with atrioventricular conduction.
severity: Not recommended
If this combination cannot be avoided, reinforce clinical monitoring and EKG. 

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Decrease of the digoxinemia, by reason of the enzyme inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (acute decompensated heart failure). 
severity: CONTRAINDICATION
In the case of the two substances being taken together by accident, do not stop the St Johns wort abruptly, but test the plasma concentrations (or the effectiveness) of the digoxin before and then after the St Johns wort is stopped. 

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: OMEPRAZOLE
rxNorm: 7646
more atc: A02BC01
more atc: A02BD05
more atc: A02BD01
Moderate increase of the digoxinemia due to increase of its absorption by the omeprazole
severity: Precaution for use
Clinical monitoring, EKG, and monitoring of the digoxinemia, particularly with an older patient. 

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
Increase of the digoxinemia with nausea, vomiting, arrhythmias.
severity: Precaution for use
Clinical monitoring, and, if there is reason for them, EKG and monitoring of the digoxinemia, with adjustment of the dosage of the digxoin during the treatment with the posaconazole and after it is stopped.

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
Risk of increase of the digoxinemia, especially with older patients
severity: Precaution for use
Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with propafenone and after it is stopped.

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction)
severity: Precaution for use
Clinical monitoring and EKG. In the case of an unexpected result, test the digoxinemia and adjust the dosage. 

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: QUININE
rxNorm: 9071
more atc: P01BC01
more atc: M09AA72
more atc: M09AA
Moderate increase of the digoxinemia
severity: Precaution for use
Clinical monitoring and EKG, if needed, with possible adjustment of the doses of digoxin.

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: RANOLAZINE
rxNorm: 35829
atc: C01EB18
Increase of the digoxinemia
severity: Precaution for use
Clinical, biological, and possibly EKG monitoring. Adjustment of the dosage of the digoxin if needed.

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: SUCRALFATE
rxNorm: 10156
atc: A02BX02
Decrease of the digestive absorption of the digoxin
severity: Precaution for use
Take the sucralfate at a different time from the digoxin (more than 2 hours apart, if possible).

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: SULFASALAZINE
rxNorm: 9524
atc: A07EC01
Decrease of the digoxinemia that can reach 50%
severity: Precaution for use
Clinical monitoring, EKG, and, possibly, monitoring of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the sulfasalazine and after it is stopped.

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
Increase of the digoxinemia
severity: Precaution for use
Clinical and biological monitoring, and adjustment, if needed, of the dosage of the digoxin during the treatment with the telaprevir and after it is stopped.

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
Increase of the digoxinemia due to increase of its absorption
severity: Precaution for use
Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the telithromycin and after it is stopped

***interaction***
drug1
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Excessive bradycardia and atrioventricular block due to increase of the effects of the digoxin on autoregulation and conduction and due to decrease of the renal and extra-renal elimination of the digoxin
severity: Precaution for use
Clinical monitoring, EKG, and, possibly, testing of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the verapamil and after it is stopped.
176-DIHYDROERGOTAMINE.html


***interaction***
drug1
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
drug2
drug name: DALFOPRISTIN
rxNorm: 229369
atc: J01FG02
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).
severity: CONTRAINDICATION 

***interaction***
drug1
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
drug2
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
drug2
class name: MACROLIDES (EXCEPT SPIRAMYCIN)
class code: J01FA
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
drug2
drug name: QUINUPRISTINE
rxNorm: 135098
atc: J01FG02
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
drug2
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
drug2
drug name: TRICLABENDAZOLE
rxNorm: 38608
atc: P02BX04
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).
severity: CONTRAINDICATION 
Wait 24 hours between stopping the triclabendazole and the dose of the medication derived from ergot of rye, and the reverse.

***interaction***
drug1
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).
severity: CONTRAINDICATION
177-DIHYDROPYRIDINES.html


***interaction***
drug1
class name: DIHYDROPYRIDINES
class code: C08CA-002
drug2
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
Hypotension, heart failure with patients having latent or uncontrolled cardiac insufficiency (addition of the negative inotropic effects). The beta blocking agent can furthermore minimize the sympathetic reflex reaction brought into play in the case of excessive hemodynamic repercussion
severity: Take into account

***interaction***
drug1
class name: DIHYDROPYRIDINES
class code: C08CA-002
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (negative inotropic effect of the dihydropyridines in vitro, more or less marked, and susceptible of adding to the negative inotropic effects of the beta blocking agents). The presence of a beta-blocking treatment can furthermore minimize the sympathetic reflex reaction put into play in cases of excessive hemodynamic repercussion. 
severity: Take into account

***interaction***
drug1
class name: DIHYDROPYRIDINES
class code: C08CA-002
drug2
drug name: DANTROLENE
rxNorm: 3105
atc: M03CA01
With the dantrolene administered via IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered via IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident.
severity: Not recommended
178-DILTIAZEM.html


***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: ALFENTANIL 
rxNorm: 480
atc: N01AH02
Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism
severity: Precaution for use
Adjust the dosage of the alfentanil when there is treatment with the diltiazem. 

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
For diltiazem by injection: risk of bradycardia and of atrioventricular block

For diltiazem by mouth: risk of bradycardia or of atrioventricular block, especially in older persons.
severity: Not recommended
-with diltiazem administered intravenously

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol lowering agent
severity: Precaution for use
Use weaker doses of the cholesterol lowering agent or another statin not affected by this type of interaction.

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure
severity: Not recommended
The administration of these medications together should only be done under strict clinical monitoring and EKG, in particular with older patients or at the beginning of treatment.

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest), and disorders of sinoatrial and atrioventricular conduction
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: BUSPIRONE
rxNorm: 1827
atc: N05BE01
Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the diltiazem, with increase of its undesirable effects
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the buspirone if necessary.

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: CLONIDINE
rxNorm: 2599
more atc: C02AC01
more atc: N02CX02
more atc: S01EA04
Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)
severity: Take into account

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: DANTROLENE
rxNorm: 3105
atc: M03CA01
With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantolene together is thus potentially dangerous. However, some patients have received nifedipine and dantolene together without incident
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker
severity: Precaution for use
Begin the treatment with the calcium channel blocker at the minimum recommended dosages and adjust the doses according to the EKG.

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: ESMOLOL
rxNorm: 49737
atc: C07AB09
Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac arrest.
severity: Not recommended
-in case of alteration of left ventricular function

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: IBRUTINIB
rxNorm: 1442981
atc: L01XE27
Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the diltiazem
severity: Precaution for use
Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg/day during the length of time that these medications are administered together.

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the diltiazem), that add to the bradycardia inducing effects of these molecules. 
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation
severity: Precaution for use
Clinical monitoring and reduction of the dosage during the treatment with the diltiazem

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: NIFEDIPINE
rxNorm: 7417
atc: C08CA05
Large increase of the concentrations of nefidipine due to decrease of its hepatic metabolism by the diltiazem, with risk of severe hypotension
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: OLAPARIB
rxNorm: 
more atc: 1597582
Increase of the plasma concentrations of olaparib by the diltiazem
severity: Not recommended
If administering these together cannot be avoided, limit the dose of olaparib to 200 mg twice a day.

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent
severity: Precaution for use
Do not exceed the dosage of 20 mg/day of simvastatin. If the therapeutic objective is not reached at this dosage, use another statin not affected by this type of interaction

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: TAMSULOSIN
rxNorm: 77492
atc: G04CA02
Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzymatic inhibitor and after it is stopped, if the situation requires.

***interaction***
drug1
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
drug2
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolsim
severity: Take into account
179-DIMETHYL-FUMARATE.html


***interaction***
drug1
drug name: DIMETHYL FUMARATE
rxNorm: 1373478
atc: N07XX09
drug2
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
Possible increase of the risk of infection
severity: Take into account
17-ALBENDAZOLE.html


***interaction***
drug1
drug name: ALBENDAZOLE
rxNorm: 430
atc: P02CA03
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of lower effectiveness.
severity: Precaution for use
Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzyme inducer and after it is stopped. 

***interaction***
drug1
drug name: ALBENDAZOLE
rxNorm: 430
atc: P02CA03
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the ritonavir, with risk of lower effectiveness.
severity: Precaution for use
Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzyme inducer [sic] and after it is stopped. 

***interaction***
drug1
drug name: ALBENDAZOLE
rxNorm: 430
atc: P02CA03
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of lower effectiveness.
severity: Precaution for use
Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzyme inducer and after it is stopped. 
180-DIPROPHYLLINE.html


***interaction***
drug1
drug name: DIPROPHYLLINE
rxNorm: 3714
more atc: R03DA01
more atc: R03DB01
drug2
drug name: PROBENECID
rxNorm: 8698
atc: M04AB01
Risk of overdose due to increase of the plasma concentrations of diprophylline (inhibition of its renal tubular secretion)
severity: Precaution for use
Reduce the dosage of diprophylline during the treatment with the probenicid
181-DIPYRIDAMOLE.html


***interaction***
drug1
drug name: DIPYRIDAMOLE
rxNorm: 3521
atc: B01AC07
drug2
drug name: THEINE
rxNorm: 
With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the theine
severity: Precaution for use
Avoid the consumption of theine based products during the 24 hours before myocardial perfusion imaging with dipyridamole

***interaction***
drug1
drug name: DIPYRIDAMOLE
rxNorm: 3521
atc: B01AC07
drug2
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
With the dipyridamole by injection: increase of the antihypertensive effect
severity: Take into account

***interaction***
drug1
drug name: DIPYRIDAMOLE
rxNorm: 3521
atc: B01AC07
drug2
drug name: CAFFEINE 
rxNorm: 1886
atc: V04CG30
With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the caffeine 
severity: Precaution for use
Interrupt a caffeine based treatment at least 5 days before myocardial perfusion imaging with the dipyridamole and avoid consuming coffee, tea, chocolate, or cola during the 24 hours that precede the test. 

***interaction***
drug1
drug name: DIPYRIDAMOLE
rxNorm: 3521
atc: B01AC07
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the theophylline
severity: Precaution for use
Interrupt a treatment with theophylline at least 5 days before myocardial perfusion imaging with the dipyridamole.
182-DISOPYRAMIDE.html


***interaction***
drug1
drug name: DISOPYRAMIDE
rxNorm: 3541
atc: C01BA03
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Risk of decrease of the concentrations of the disopyramide by the inducer.
severity: Precaution for use
Clinical monitoring and possibly adjustment of the dosage of the disopyramide during the administration of these medications together and 1 to 2 weeks after the inducer is stopped.

***interaction***
drug1
drug name: DISOPYRAMIDE
rxNorm: 3541
atc: C01BA03
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the undesirable effects of the disopyramide due to decrease of its metabolism.
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the disopyramide

***interaction***
drug1
drug name: DISOPYRAMIDE
rxNorm: 3541
atc: C01BA03
drug2
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
Risk of increase of the undesirable effects of the disopyramide: severe hypoglycemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsade de pointes type.
severity: Precaution for use
Regular clinical, biological and EKG monitoring, 
183-DISULFIRAM.html


***interaction***
drug1
drug name: DISULFIRAM
rxNorm: 3554
atc: N07BB01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the disulfiram and a week after it is stopped

***interaction***
drug1
drug name: DISULFIRAM
rxNorm: 3554
atc: N07BB01
drug2
drug name: COCAINE
rxNorm: 2653
more atc: N01BC01
more atc: R02AD03
more atc: S01HA01
more atc: S02DA02
Increase of the concentrations of cocaine due to decrease of its metabolism by the disulfirame, with increased risk of the onset of torsades de pointes
severity: Take into account

***interaction***
drug1
drug name: DISULFIRAM
rxNorm: 3554
atc: N07BB01
drug2
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
Disorders of behavior and of coordination
severity: Not recommended

***interaction***
drug1
drug name: DISULFIRAM
rxNorm: 3554
atc: N07BB01
drug2
drug name: METRONIDAZOLE
rxNorm: 6922
more atc: A02BD08
more atc: A02BD03
more atc: A02BD02
more atc: A01AB17
more atc: D06BX01
more atc: G01AF01
more atc: J01XD01
more atc: P01AB01
more atc: A02BD01
Risk of episodes of acute psychosis or confused state, reversible upon stopping the administration of the two substances together
severity: Not recommended

***interaction***
drug1
drug name: DISULFIRAM
rxNorm: 3554
atc: N07BB01
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Large and rapid increase of the plasma concentrations of phenytoin with signs of toxicity (inhibition of its metabolism)
severity: Not recommended
If the administration of these substances together cannot be avoided, clinical monitoring and monitoring of the plasma concentrations of phenytoin during the treatment with the disulfiram and after it is stopped. 
184-DIURETICS.html


***interaction***
drug1
class name: DIURETICS
class code: C0E-001
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):

Acute renal insufficiency in dehydrated patients due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the anti-hypertensive effect.
severity: Precaution for use
Hydrate the patient and monitor renal function at the start of treatment.

***interaction***
drug1
class name: DIURETICS
class code: C0E-001
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Acute renal insufficiency with the patient at risk (older patient and/or dehydrated one) due to decrease of the glomerular filtration (inhibition of the vasodilator prostaglandins due to the NSAIs). Furthermore, reduction of the antihypertensive effect
severity: Precaution for use
Hydrate the patient and monitor renal function at the start of treatment

***interaction***
drug1
class name: DIURETICS
class code: C0E-001
drug2
class name: IODINATED X-RAY CONTRAST MEDIA
class code: VO8A-001
In case of dehydration caused by the diuretics, increased risk of acute functional renal insufficiency, in particular when large doses of the contrast media are used.
severity: Precaution for use
Rehydrate before administration of the iodinated product
185-LOOP-DIURETICS.html


***interaction***
drug1
class name: LOOP DIURETICS
class code: C03CA-001
drug2
class name: AMINOGLYCOSIDES
class code: J01GB-001
Increase of the nephrotoxic and ototoxic risks of the aminoglycoside (functional renal insufficiency linked to the dehydration caused by the diuretic)


severity: Precaution for use
The two medications may be taken together when there is monitoring of the state of hydration, of the renal and cochleovestibulary functions, and possibly, of the plasma concentrations of the aminoglycoside

***interaction***
drug1
class name: LOOP DIURETICS
class code: C03CA-001
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Increase of the plas ma concentrations of lithium with signs of overdose of lithium as with a low sodium regimen (decrease of the urinary excretion of the lithium)

***interaction***
drug1
class name: LOOP DIURETICS
class code: C03CA-001
drug2
drug name: METFORMIN
rxNorm: 6809
more atc: A10BA02
more atc: A10BD13
more atc: A10BD11
more atc: A10BD05
more atc: A10BD03
more atc: A10BD10
more atc: A10BD07
more atc: A10BD02
more atc: A10BD08
Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics

***interaction***
drug1
class name: LOOP DIURETICS
class code: C03CA-001
drug2
class name: PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS
class code: L01XA
Risk of addition of the ototoxic and/or nephrotoxic effects
186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html


***interaction***
drug1
class name: POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
drug2
class name: OTHER POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)
severity: CONTRAINDICATION
Contraindication unless there is hypokalemia.

***interaction***
drug1
class name: POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
drug2
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
Risk of hyperkalemia (possibly lethal) especially when there is renal insufficiency (addition of the effects of the hyperkalemia inducing substances)
severity: Not recommended
--if administering these medications together is justified, strict testing of the kalemia and of the renal function.

***interaction***
drug1
class name: POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)
severity: Not recommended

***interaction***
drug1
class name: POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
drug2
class name: POTASSIUM LOWERING DIURETICS
class code: C03
The rational choice of these two medications, useful for some patients, does not exclude the onset of hypokalemia or, in particular with patients having renal insufficiency and diabetes, of hyperkalemia
severity: Precaution for use
Monitor the kalemia, possibly EKG and, if there is reason to, reconsider the treatment.

***interaction***
drug1
class name: POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
Risk of hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia producing effects)
severity: Not recommended
-if the administration of the two medications together is justified, strict testing of the kalemia and of the renal function.

***interaction***
drug1
class name: POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
drug2
drug name: LITHIUM 
rxNorm: 6448
atc: D11AX04
Increase of the plasma concentrations of lithium with signs of overdose of lithium, as with a low sodium regimen (decrease of the urinary excretion of the lithium)
severity: Precaution for use
Strict monitoring of the plasma concentrations of lithium and possible adjustment of the dosage of the lithium. 

***interaction***
drug1
class name: POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
drug2
drug name: POTASSIUM
rxNorm: 8588
atc: A12BA
Potentially lethal hyperkalemia, especially with renal insufficiency (addition of the hyperkalemia producing effects)
severity: Contraindication
-aside from hypokalemia or in case of parenteral use of the potassium salts

***interaction***
drug1
class name: POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
drug2
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)
severity: Not recommended
187-POTASSIUM-LOWERING-DIURETICS.html


***interaction***
drug1
class name: POTASSIUM LOWERING DIURETICS
class code: C03
drug2
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
Risk of abrupt arterial hypotension and/or acute renal insufficiency at the beginning of or at an increase in the dosage of a treatment with an angiotensin II antagonist where there is pre-existing fluid depletion. 


severity: Precaution for use
With arterial hypertension, where there has been pre-existing diuretic treatment that has caused fluid depletion, it is necessary:

***interaction***
drug1
class name: POTASSIUM LOWERING DIURETICS
class code: C03
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Risk of symptomatic hyponatremia
severity: Precaution for use
Clinical and biological monitoring. If possible, use another class of diuretics.

***interaction***
drug1
class name: POTASSIUM LOWERING DIURETICS
class code: C03
drug2
drug name: CICLOSPORIN
rxNorm: 3008
atc: S01XA18
Risk of increase of the creatinemia without modification of the blood concentrations of the ciclosporin, even in the absence of fluid depletion. Also risk of hyperuricemia and of complications such as gout
severity: Take into account

***interaction***
drug1
class name: POTASSIUM LOWERING DIURETICS
class code: C03
drug2
class name: POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
The rational choice of these medications, useful for some patients, does not exclude the onset of hypokalemia or, in particular with patients having renal insufficiency and diabetes, of hyperkalemia
severity: Precaution for use
Monitor the kalemia, possibly EKG and, if there is reason to, reconsider the treatment. 

***interaction***
drug1
class name: POTASSIUM LOWERING DIURETICS
class code: C03
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
Risk of abrupt arterial hypotension and/or renal insufficiency at the start of or when there is an increase of the dosage of the treatment with the ACE inhibitor in cases of pre-existing fluid depletion 
severity: Precaution for use
In arterial hypertension, when there is fluid depletion from previous treatment with a diuretic, it is necessary:
188-THIAZIDE-DIURETICS-AND-RELATED.html


***interaction***
drug1
class name: THIAZIDE DIURETICS AND RELATED
class code: C03-003
drug2
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
Risk of hypercalcemia due to decrease of the urinary elimination of the calcium. 
severity: Take into account

***interaction***
drug1
class name: THIAZIDE DIURETICS AND RELATED
class code: C03-003
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Increase of the plasma concentrations of lithium with signs of overdose of lithium, as with a reduced sodium regimen (decrease of the urinary excretion of the lithium)
severity: Not recommended
If administering the substances together cannot be avoided, strict monitoring of the plasma concentrations of lithium and adjustment of the dosage of the lithium.
189-DOCETAXEL.html


***interaction***
drug1
drug name: DOCETAXEL
rxNorm: 72962
atc: L01CD02
drug2
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
Risk of increase of the toxicity of the docetaxel due to decrease of its metabolism 
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzymatic inhibitor.

***interaction***
drug1
drug name: DOCETAXEL
rxNorm: 72962
atc: L01CD02
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness
severity: Take into account

***interaction***
drug1
drug name: DOCETAXEL
rxNorm: 72962
atc: L01CD02
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the undesirable dose-dependent effects of the docetaxel due to inhibition of its metabolism by the enzymatic inhibitor
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzymatic inhibitor.
18-URINARY-ALKALIZERS.html


***interaction***
drug1
class name: URINARY ALKALIZERS
class code: B05-001
drug2
drug name: HYDROQUINIDINE
rxNorm: 27220
Increase of the plasma concentrations of the hydroquinidine and risk of overdose (decrease of the renal excretion of the hydroquinidine by alkalinizing of the urine)
severity: Precaution for use
Clinical monitoring, EKG, and possibly testing of the blood concentrations of the hydroquinidine; if needed, adjustment of the dosage during the alkalinizing treatment and after it is stopped.

***interaction***
drug1
class name: URINARY ALKALIZERS
class code: B05-001
drug2
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
Increase of the plasma concentrations of the quinidine and risk of overdose (decrease of the renal excretion of the quinidine by alkalinizing of the urine).
severity: Precaution for use
Clinical monitoring, EKG, and possibly testing of the blood concentrations of quinidine; if needed, adjustment of the dosage during the alkalinizing treatment and after it is stopped.
190-DOLUTEGRAVIR.html


***interaction***
drug1
drug name: DOLUTEGRAVIR
rxNorm: 1433868
atc: J05AX12
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer
severity: Not recommended
-in case of resistance to the class of integrase inhibitors

***interaction***
drug1
drug name: DOLUTEGRAVIR
rxNorm: 1433868
atc: J05AX12
drug2
drug name: METFORMIN
rxNorm: 6809
more atc: A10BA02
more atc: A10BD13
more atc: A10BD11
more atc: A10BD05
more atc: A10BD03
more atc: A10BD10
more atc: A10BD07
more atc: A10BD02
more atc: A10BD08
Increase of the plasma concentrations of metformin by the dolutegravir and of its undesirable effects of the lactic acidosis type
severity: Precaution for use
--With the patient having moderate renal insufficiency (stage 3a, clearance of the creatinin between 45 and 59 ml/min), clinical and biological monitoring, and possible adjustment of the dosage of metformin.

***interaction***
drug1
drug name: DOLUTEGRAVIR
rxNorm: 1433868
atc: J05AX12
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the St Johns wort.
severity: Not recommended
191-DOMPERIDONE.html


***interaction***
drug1
drug name: DOMPERIDONE
rxNorm: 3626
atc: A03FA03
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
Risk of problems with ventricular rhythm, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DOMPERIDONE
rxNorm: 3626
atc: A03FA03
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of domperidone due to decrease of its hepatic metabolism by the inhibitor
severity: CONTRAINDICATION
192-DOPAMINERGICS.html


***interaction***
drug1
class name: DOPAMINERGICS
class code: N04B-002
drug2
class name: ANTIEMITIC NEUROLEPTICS
class code: A03FA-001
Reciprocal antagonism between the dopaminergic and the neuropleptic
severity: CONTRAINDICATION
Use an antiemetic that does not have extrapyramidal effects. 

***interaction***
drug1
class name: DOPAMINERGICS
class code: N04B-002
drug2
drug name: TETRABENAZINE
rxNorm: 10390
atc: N07XX06
Reciprocal antagonism between the dopaminergic and the tetrabenazine
severity: Not recommended
193-DOPAMINERGICS,-EXCEPT-PARKINSON.html


***interaction***
drug1
class name: DOPAMINERGICS, EXCEPT PARKINSON
class code: G02CB-002
drug2
class name: ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)
class code: N05A-001
Reciprocal antagonism of the dopamine agonist and the neuroleptics
severity: CONTRAINDICATION
194-DOXORUBICIN.html


***interaction***
drug1
drug name: DOXORUBICIN
rxNorm: 3639
atc: L01DB01
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Risk of increase of the toxicity of the doxorubicin due to increase of its plasma concentrations
severity: Take into account
195-DOXYCYCLINE.html


***interaction***
drug1
drug name: DOXYCYCLINE
rxNorm: 3640
atc: J01AA02
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Decrease of the plasma concentations of the doxycycline due to increase of its hepatic metabolism by the inducer
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the doxycycline. 
196-DRONEDARONE.html


***interaction***
drug1
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite
severity: Not recommended

***interaction***
drug1
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the dronedarone and a week after it is stopped. 

***interaction***
drug1
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
drug2
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
Doubling of the plasma concentrations of dabigatran, with increase of the risk of bleeding
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Depression of autoregulation (excessive bradycardia) and disorders of atrioventricular conduction. In addition, increase of the digoxinemia due to decrease of the metabolism of the digoxin. Clinical monitoring and EKG. 
severity: Not recommended
Reduce the doses of digoxin by half. 

***interaction***
drug1
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker
severity: Precaution for use
Start the treatment with the calcium channel blocker with minimum recommended dosages, and adjust the doses according to the EKG.

***interaction***
drug1
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
drug2
drug name: DOCETAXEL
rxNorm: 72962
atc: L01CD02
Risk of increase of the toxicity of the docetaxel due to decrease of its metabolism.
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzyme inhibitor.

***interaction***
drug1
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
drug2
drug name: FIDAXOMICIN
rxNorm: 1111103
atc: A07AA12
Increase of the plasma concentrations of the fidaxomicin.
severity: Not recommended

***interaction***
drug1
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Large increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism
severity: Not recommended

***interaction***
drug1
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Large increase of the concentrations of drodedarone due to decrease of its metabolism
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite
severity: Not recommended

***interaction***
drug1
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
drug2
Drug with no codes: GRAPEFRUIT (JUICE AND FRUIT)
Increase of the concentrations of dronedarone due to inhibition of its metabolism by the grapefruit
severity: Not recommended

***interaction***
drug1
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
drug2
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the quinidine
severity: Precaution for use
Start the treatment with the quinidine at the minimum recommended dosages, and adjust the doses according to the EKG. 

***interaction***
drug1
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.
severity: Not recommended

***interaction***
drug1
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)
severity: Not recommended

***interaction***
drug1
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker
severity: Precaution for use
Start the treatment by the calcium channel blocker with the lowest recommended dosages, and adjust the doses according to the EKG. 
197-DROSPIRENONE.html


***interaction***
drug1
drug name: DROSPIRENONE
rxNorm: 840781
atc: G03AA12
drug2
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
Increase of more than double of the concentrations of drosperinone when taken with the boceprevir
severity: Not recommended
Choose a contraceptive with another progestin, especially in cases of hyperkalemia
198-DULOXETINE.html


***interaction***
drug1
drug name: DULOXETINE
rxNorm: 72625
atc: N06AX21
drug2
drug name: ENOXACIN
rxNorm: 3925
atc: J01MA04
Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the enoxacin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DULOXETINE
rxNorm: 72625
atc: N06AX21
drug2
drug name: FLECAINIDE
rxNorm: 4441
atc: C01BC04
Increase of the plasma concentrations of flecainide with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the flecainide during the treatment with the duloxetine and after it is stopped.

***interaction***
drug1
drug name: DULOXETINE
rxNorm: 72625
atc: N06AX21
drug2
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the fluvoxamine
severity: CONTRAINDICATION

***interaction***
drug1
drug name: DULOXETINE
rxNorm: 72625
atc: N06AX21
drug2
drug name: MEQUITAZINE
rxNorm: 29528
atc: R06AD07
Risk of increase of the undesirable effects of the mequitazine due to inhibition of its metabolism by the enzyme inhibitor 
severity: Not recommended

***interaction***
drug1
drug name: DULOXETINE
rxNorm: 72625
atc: N06AX21
drug2
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. 

***interaction***
drug1
drug name: DULOXETINE
rxNorm: 72625
atc: N06AX21
drug2
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
Increase of the plasma concentrations of propafenone with risk of overdose due to decrease of its hepatic metabolism by the duloxetine
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the propafenone during the treatment with the duloxetine and after it is stopped. 

***interaction***
drug1
drug name: DULOXETINE
rxNorm: 72625
atc: N06AX21
drug2
drug name: TAMOXIFEN
rxNorm: 10324
atc: L02BA01
Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the duloxetine
severity: Not recommended
199-EBASTINE.html


***interaction***
drug1
drug name: EBASTINE
rxNorm: 23796
atc: R06AX22
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)
severity: Not recommended

***interaction***
drug1
drug name: EBASTINE
rxNorm: 23796
atc: R06AX22
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)
severity: Not recommended

***interaction***
drug1
drug name: EBASTINE
rxNorm: 23796
atc: R06AX22
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)
severity: Not recommended

***interaction***
drug1
drug name: EBASTINE
rxNorm: 23796
atc: R06AX22
drug2
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)
severity: Not recommended

***interaction***
drug1
drug name: EBASTINE
rxNorm: 23796
atc: R06AX22
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)
severity: Not recommended
19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html


***interaction***
drug1
class name: DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE 
class code: G02CB-001
drug2
class name: VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE
class code: N02CA0-001
Risk of constriction of blood vessels and/or rapid elevation of blood pressure
severity: Not Recommended

***interaction***
drug1
class name: DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE 
class code: G02CB-001
drug2
class name: ANTIPARKINSONIAN ANTICHOLINERGICS
class code: N04AA-001
Risk of increase of neuropsychological disorders


severity: Precaution for use:
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. 

***interaction***
drug1
class name: DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE 
class code: G02CB-001
drug2
class name: MACROLIDES (EXCEPT SPIRAMYCIN)
class code: J01FA
Increase of the plasma concentrations of the dopaminergic with possible increase of its activity or appearance of signs of overdose. 
severity: Not recommended

***interaction***
drug1
class name: DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE 
class code: G02CB-001
drug2
class name: ALPHA SYMPATHOMIMETICS (ORAL AND/OR NASAL)
class code: R01AA
Risk of constriction of blood vessels and/or rapid elevation of blood pressure


severity: Not recommended

***interaction***
drug1
class name: DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE 
class code: G02CB-001
drug2
class name: INDIRECT SYMPATHOMIMETICS
class code: C01CA-R01BA
Risk of constriction of blood vessels and/or rapid elevation of blood pressure


severity: Not recommended
1-ABATACEPT.html


***interaction***
drug1
drug name: ABATACEPT 
rxNorm: 614391
atc: L04AA24
drug2
drug name: ANTI-TNF ALPHA
rxNorm: 
Increase of immunosupression
severity: Not recommended

***interaction***
drug1
drug name: ABATACEPT 
rxNorm: 614391
atc: L04AA24
drug2
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
Risk of possibly fatal generalized vaccine disease 


severity: Not recommended
as well as for the three months following the end of the treatment.
200-ECONAZOLE.html


***interaction***
drug1
drug name: ECONAZOLE
rxNorm: 3743
atc: G01AF05
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Regardless of the route of administration of the econazole:

increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with econazole and after it is stopped
201-EFAVIRENZ.html


***interaction***
drug1
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist

***interaction***
drug1
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
drug2
drug name: ATAZANAVIR
rxNorm: 343047
atc: J05AE08
Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism
severity: Not recommended
If the administration of the two substances together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together.

***interaction***
drug1
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
drug2
drug name: ATOVAQUONE
rxNorm: 60212
atc: P01AX06
Decrease of the plasma concentrations of atovaquone by the enzymatic inducer
severity: Not recommended

***interaction***
drug1
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
drug2
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
drug2
drug name: ERGOTAMINE
rxNorm: 4025
more atc: N02CA02
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.)
severity: CONTRAINDICATION 

***interaction***
drug1
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
drug2
drug name: FOSAMPRENAVIR
rxNorm: 358262
atc: J05AE07
Risk of reduction of the effectiveness of the amprenavir
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. 

***interaction***
drug1
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
drug2
drug name: INDINAVIR
rxNorm: 114289
atc: J05AE02
Risk of reduction of the effectiveness of the indinavir
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together.

***interaction***
drug1
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
drug2
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
drug2
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
Decrease by about half of the concentrations of rifabutin, due to increase of its hepatic metabolism by the efavirenz
severity: Precaution for use
Adjustment of the dosage of the rifabutin during the treatment with efavirenz.

***interaction***
drug1
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.

***interaction***
drug1
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the efavirenz
severity: Not recommended
If administering these substances together cannot be avoided, strict clinical monitoring and adjustment of the dosage of the voriconazole and of the efavirenz during the administration of the two together. 
202-ELTROMBOPAG.html


***interaction***
drug1
drug name: ELTROMBOPAG
rxNorm: 711942
atc: B02BX05
drug2
class name: HMG-COA REDUCTASE INHIBITORS (STATINS)
class code: C10AA
Risk of increase of the toxicity of the statins, due to inhibition of their hepatic recapture
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the statin.
203-ELVITEGRAVIR.html


***interaction***
drug1
drug name: ELVITEGRAVIR
rxNorm: 1306286
more atc: J05AX11
more atc: J05AR09
drug2
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
Decrease of the concentrations of ethinylestradiol, with risk of lower contraceptive effectiveness. Furthermore, increase of the concentrations of the progestin
severity: Precaution for use
Use an estroprogestin contraceptive with at leaset 30g of ethinylestradiol. 

***interaction***
drug1
drug name: ELVITEGRAVIR
rxNorm: 1306286
more atc: J05AX11
more atc: J05AR09
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increase pf the plasma concentrations of elvitegravir by decrease of its metabolism by the itraconazole
severity: Precaution for use
With the elvitegravir co-administered with cobicistat, clinical monitoring. Limit the maximum dose of itraconazole to 200 mg/day.

***interaction***
drug1
drug name: ELVITEGRAVIR
rxNorm: 1306286
more atc: J05AX11
more atc: J05AR09
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Increase of the plasma concentrations of elvitegravir by decrease of its metabolism by the ketoconazole
severity: Precaution for use
With the elvitegravir co-administered with cobicistat, clinical monitoring. Limit the maximum dose of ketoconazole to 200 mg/day.

***interaction***
drug1
drug name: ELVITEGRAVIR
rxNorm: 1306286
more atc: J05AX11
more atc: J05AR09
drug2
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
Decrease of the minimal concentrations of elvitegravir
severity: Take into account
204-ENOXACIN.html


***interaction***
drug1
drug name: ENOXACIN
rxNorm: 3925
atc: J01MA04
drug2
drug name: CAFFEINE 
rxNorm: 1886
more atc: N06BC01
more atc: V04CG30
Increase of the plasma concentrations of caffeine, which can lead to agitation and hallucinations, due to decrease of its hepatic metabolism
severity: Not recommended

***interaction***
drug1
drug name: ENOXACIN
rxNorm: 3925
atc: J01MA04
drug2
drug name: DULOXETINE
rxNorm: 72625
atc: N06AX21
Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the enoxacin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ENOXACIN
rxNorm: 3925
atc: J01MA04
drug2
drug name: ROPINIROLE
rxNorm: 72302
atc: N04BC04
Increase of the plasma concentrations of ropinirole with signs of overdose due to decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with the enoxacin and after it is stopped. 

***interaction***
drug1
drug name: ENOXACIN
rxNorm: 3925
atc: J01MA04
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Overdose of theophylline due to substantial decrease of its metabolism
severity: CONTRAINDICATION
205-ENTACAPONE.html


***interaction***
drug1
drug name: ENTACAPONE
rxNorm: 60307
atc: N04BX02
drug2
drug name: IRON
rxNorm: 1431589
atc: B03A
Decrease of the digestive absorption of the entacapone and of the iron due to chelation of the latter by the entacapone
severity: Precaution for use
Take the iron salts at a different time from the entacapone (more than 2 hours apart if possible).
206-ENZALUTAMIDE.html


***interaction***
drug1
drug name: ENZALUTAMIDE
rxNorm: 1307298
atc: L02BB04
drug2
drug name: GEMFIBROZIL
rxNorm: 4719
atc: C10AB04
Increase of the active fraction of the enzalutamide
severity: Precaution for use
Reduce the dose of enzalutamide by half when it is administered with the gemfibrozil
207-EPLERENONE.html


***interaction***
drug1
drug name: EPLERENONE
rxNorm: 298869
atc: C03DA04
drug2
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
Increase of the risk of hyperkalemia, especially with older patients
severity: Precaution for use
Strict testing of the kalemia and of the renal function during the administration of these substances together. 

***interaction***
drug1
drug name: EPLERENONE
rxNorm: 298869
atc: C03DA04
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
Increase of the risk of hyperkalemia, especially with older patients.
severity: Precaution for use
Strict testing of the kalemia and of the renal function during the administration of these substances together. 

***interaction***
drug1
drug name: EPLERENONE
rxNorm: 298869
atc: C03DA04
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the plasma concentrations of the eplerenone by the inhibitor and of its undesirable effects, especially hyperkalemia
severity: CONTRAINDICATION
208-ERGOTAMINE.html


***interaction***
drug1
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
drug2
drug name: DALFOPRISTIN
rxNorm: 229369
atc: J01FG02
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye). 
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
drug2
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
drug2
class name: MACROLIDES (EXCEPT SPIRAMYCIN)
class code: J01FA
Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
drug2
drug name: OXPRENOLOL
rxNorm: 7801
atc: C07AA02
Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)
severity: Precaution for use
Reinforced clinical monitoring, in particular during the first weeks of the administration of these medications together. 

***interaction***
drug1
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
drug2
drug name: PROPRANOLOL
rxNorm: 8787
atc: C07AA05
Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)
severity: Precaution for use
Reinforced clinical monitoring, in particular during the first weeks of the administration of these medications together. 

***interaction***
drug1
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
drug2
drug name: QUINUPRISTINE
rxNorm: 135098
atc: J01FG02
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
drug2
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of the ergot of rye).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
drug2
drug name: TRICLABENDAZOLE
rxNorm: 38608
atc: P02BX04
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).
severity: CONTRAINDICATION 
Wait 24 hours between stopping the triclabendazole and the ergotaine, and the reverse
209-ERIBULINE.html


***interaction***
drug1
drug name: ERIBULINE
rxNorm: 1045453
atc: L01XX41
drug2
drug name: CICLOSPORIN
rxNorm: 3008
atc: S01XA18
Increase of the plasma concentrations of eribuline by the ciclosporin.
severity: Not recommended

***interaction***
drug1
drug name: ERIBULINE
rxNorm: 1045453
atc: L01XX41
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Increase of the plasma concentrations of eribuline by the clarithromycin.
severity: Not recommended

***interaction***
drug1
drug name: ERIBULINE
rxNorm: 1045453
atc: L01XX41
drug2
class name: ENZYME INDUCERS
class code: N03-J05-001
Risk of decrease of the plasma concentrations of eribuline by the inducer
severity: Not recommended

***interaction***
drug1
drug name: ERIBULINE
rxNorm: 1045453
atc: L01XX41
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Increase of the plasma concentrations of eribuline by the ritonavir.
severity: Not recommended

***interaction***
drug1
drug name: ERIBULINE
rxNorm: 1045453
atc: L01XX41
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the plasma concentrations of eribuline by the St John's wort.
severity: Not recommended

***interaction***
drug1
drug name: ERIBULINE
rxNorm: 1045453
atc: L01XX41
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the plasma concentrations of eribuline by the verapamil. 
severity: Not recommended
20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html


***interaction***
drug1
class name: VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE
class code: N02CA0-001
drug2
class name: DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE
class code: G02CB-001
Risk of constriction of blood vessels and/or rapid elevation of blood pressure


severity: Not recommended

***interaction***
drug1
class name: VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE
class code: N02CA0-001
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Risk of constriction of coronary blood vessels or of those of the extremities (ergotism), or of rapid elevation of blood pressure.
severity: CONTRAINDICATION

***interaction***
drug1
class name: VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE
class code: N02CA0-001
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of constriction of the coronary arteries or of those of the extremities (ergotism), or of rapid elevation of blood pressure.
severity: CONTRAINDICATION

***interaction***
drug1
class name: VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE
class code: N02CA0-001
drug2
class name: OMBITASVIR + PARITAPVIR
class code: OMPA
Increase of the plasma concentrations of the vasoconstrictor alkaloid of ergot of rye by decrease of its hepatic metabolism by the therapy with the two medications. 
severity: CONTRAINDICATION

***interaction***
drug1
class name: VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE
class code: N02CA0-001
drug2
class name: ALPHA SYMPATHOMIMETICS (ORAL AND/OR NASAL)
class code: R01AA
Risk of constriction of blood vessels and/or of rapid elevation of blood pressure

.
severity: Not recommended

***interaction***
drug1
class name: VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE
class code: N02CA0-001
drug2
class name: INDIRECT SYMPATHOMIMETICS
class code: C01CA-R01BA
Risk of constriction of blood vessels and/or of rapid elevation of blood pressure


severity: Not recommended

***interaction***
drug1
class name: VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE
class code: N02CA0-001
drug2
class name: TRIPTANS
class code: N02CC-001
Risk of arterial hypertension, of constriction of coronary arteries


severity: CONTRAINDICATION 
Wait 6 to 24 hours, depending on the triptan, between its dose and that of the ergot alkaloid.
210-ERYTHROMYCIN.html


***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin
severity: Precaution for use
It is recommendedthat the erythromycin be administered as far as possible from the afatinib, preferably at an interval of 6 to 12 hours from the dose of afatinib.

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: ALFENTANIL
rxNorm: 480
atc: N01AH02
Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism
severity: Precaution for use
Adjust the dosage of the alfentanil when administered with the erythromycin

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol lowering agent
severity: Precaution for use
Use weaker doses of the cholesterol lowering medication. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: BUSPIRONE
rxNorm: 1827
atc: N05BE01
Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation
severity: Not recommended

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism
severity: Not recommended

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome
severity: Take into account 

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Increase of the digoxinemia due to increase of its absorption 
severity: Precaution for use
Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the erithromycin and after it is stopped. 

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: EBASTINE
rxNorm: 23796
atc: R06AX22
Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)
severity: Not recommended

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: FIDAXOMICIN
rxNorm: 1111103
atc: A07AA12
Increase of the plasma concentrations of the fidaxomicin
severity: Not recommended

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: GLIBENCLAMIDE
rxNorm: 4815
atc: A10BB01
Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic
severity: Precaution for use
Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: GLIMEPIRIDE
rxNorm: 25789
atc: A10BD06
Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic
severity: Precaution for use
Inform the patient, reinforce self- monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism
severity: Not recommended
If these medications are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: LUMEFANTRINE
rxNorm: 847728
atc: P01BF01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended
If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring. 

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: MIZOLASTINE
rxNorm: 61455
atc: R06AX25
Risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: NINTEDANIB
rxNorm: 1592737
more atc: L01XE31
Increase of the plasma concentrations of the nintedanib due to increase of its absorption by the erythromycin
severity: Precaution for use
Clinical monitoring during the administration of these substances together.

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: PRAVASTATIN
rxNorm: 42463
atc: C10AA03
With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin
severity: Precaution for use
Clinical and biological monitoring during the treatment with the antibiotic.

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous in children
severity: Not recommended

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
Increase of the concentrations of venlafaxine with risk of overdose
severity: Take into account

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin
severity: Precaution for use
Clinical monitoring and EKG; if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped.

***interaction***
drug1
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
drug2
class name: VINCA ALKALOIDS
class code: L01CA
Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin.
severity: Precaution for use
Strict clinical and biological monitoring. Possibly use another antibiotic.
211-ESMOLOL.html


***interaction***
drug1
drug name: ESMOLOL
rxNorm: 49737
atc: C07AB09
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)
severity: Precaution for use
Clinical monitoring and EKG

***interaction***
drug1
drug name: ESMOLOL
rxNorm: 49737
atc: C07AB09
drug2
class name: CLASS IA ANTIARRHYTHMICS
class code: C01B-002
Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)
severity: Precaution for use
Clinical monitoring and EKG

***interaction***
drug1
drug name: ESMOLOL
rxNorm: 49737
atc: C07AB09
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac arrest
severity: Not recommended
-in case of alteration of left ventricular function

***interaction***
drug1
drug name: ESMOLOL
rxNorm: 49737
atc: C07AB09
drug2
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)
severity: Precaution for use
Clinical monitoring and EKG.

***interaction***
drug1
drug name: ESMOLOL
rxNorm: 49737
atc: C07AB09
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure
severity: Not recommended
-in case of alteration of left ventricular function
212-ESTRAMUSTINE.html


***interaction***
drug1
drug name: ESTRAMUSTINE
rxNorm: 4089
atc: L01XX11
drug2
drug name: CLODRONIC ACID
rxNorm: 3350
atc: M05BA02
Risk of increase of the plasma concentrations of estramustine by the clodronate
severity: Precaution for use
Clinical monitoring during the administration of these substances together. 

***interaction***
drug1
drug name: ESTRAMUSTINE
rxNorm: 4089
atc: L01XX11
drug2
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
Decrease of the digestive absorption of the estramustine
severity: Precaution for use
Take the calcium salts at a different time from the estramustine (more than 2 hours apart if possible).

***interaction***
drug1
drug name: ESTRAMUSTINE
rxNorm: 4089
atc: L01XX11
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
Risk of increase of the undesirable effects of the angioneurotic edema type (angioedema)
severity: Not recommended
213-NON-CONTRACEPTIVE-ESTROGENS.html


***interaction***
drug1
class name: NON-CONTRACEPTIVE ESTROGENS
class code: G03C-001
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Decrease of the effectiveness of the estrogen 

.
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the anticonvulsant inducer and after it is stopped. 

***interaction***
drug1
class name: NON-CONTRACEPTIVE ESTROGENS
class code: G03C-001
drug2
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
Decrease of the effectiveness of the estrogen
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the boceprevir.

***interaction***
drug1
class name: NON-CONTRACEPTIVE ESTROGENS
class code: G03C-001
drug2
class name: THYROID HORMONES
class code: H03AA
Risk of clinical hypothyroidism in cases of estrogen replacement therapy.
severity: Precaution for use
Clinical and biological monitoring; possible adjustment of the doses of the thyroid hormone for menopausal women taking estrogens.

***interaction***
drug1
class name: NON-CONTRACEPTIVE ESTROGENS
class code: G03C-001
drug2
drug name: OXCARBAZEPINE
rxNorm: 32624
atc: N03AF02
Risk of decrease of the effectiveness of the hormonal treatment, due to increase of its hepatic metabolism by the oxcarbazepine.
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the treatment with the oxcarbazepin and after it is stopped.

***interaction***
drug1
class name: NON-CONTRACEPTIVE ESTROGENS
class code: G03C-001
drug2
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
Decrease of the effectiveness of the estrogen.
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the telaprevir and after it is stopped.
214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html


***interaction***
drug1
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
drug2
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
Decrease of the concentrations of the estrogen-progestin or of the progestatif, with risk of lower contraceptive effectiveness.
severity: Precaution for use
Use another method of contraception, in particular a barrier type, during the treatment with the aprepitant and a cycle after. 

***interaction***
drug1
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
drug2
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
Except for the combination with ethinylestradiol (0.035 mg)/norethisterone (1mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir.
severity: Precaution for use
Use an additional or alternative reliable contraceptive method during the length of the administration of these together.

***interaction***
drug1
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
drug2
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive
severity: Precaution for use
Use a reliable contraceptive method, additional or alternative, during the length of time that the two substances are administered together and for a cycle after. 

***interaction***
drug1
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
drug2
drug name: ELVITEGRAVIR
rxNorm: 1306286
more atc: J05AX11
more atc: J05AR09
Decrease of the concentrations of ethinylestradiol, with risk of lower contraceptive effectiveness. In addition, increase of the concentrations of the progestin 
severity: Precaution for use
Use a combined estrogen-progestin contraceptive with at least 30g of ethinylestradiol

***interaction***
drug1
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
drug2
drug name: GRISEOFULVIN
rxNorm: 5021
more atc: D01AA08
more atc: D01BA01
Risk of decrease of the contraceptive effectiveness due to increase of its hepatic metabolism 
severity: Precaution for use
Another method of contraception, in particular a barrier type, should be used during the time the two substances are administered together and a cycle after. 

***interaction***
drug1
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Decrease of the contraceptive effectiveness, due to increase of the hepatic metabolism of the hormonal contraceptive by the inducer
severity: Not recommended
Another method of contraception, in particular a barrier type, should be used during the time the substances are administered together and a cycle after. 

***interaction***
drug1
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of the hormonal contraceptive due to the increase of its hepatic metabolism by the ritonavir.
severity: Not recommended
Another method of contraception, in particular a barrier type (condom or IUD), should be used during the length of the treatment with these medications together and a cycle following. 

***interaction***
drug1
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
drug2
drug name: LAMOTRIGINE
rxNorm: 28439
atc: N03AX09
Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism
severity: Not recommended
-avoid starting an oral contraceptive during the period of adjustment of the dosage of the lamotrigine.

***interaction***
drug1
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
drug2
drug name: ST JOHN'S WORT
rxNorm: 258326
Decrease of the plasma concentrations of the hormonal contraceptive, by reason of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, of the contraceptive, which can possibly have serious consequences (pregnancy).
severity: CONTRAINDICATON

***interaction***
drug1
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
drug2
drug name: MODAFINIL
rxNorm: 30125
atc: N06BA07
Risk of decrease of the contraceptive effectiveness, during the treatment and one cycle after the end of the treatment with the modafinil, due to its enzymatic inducer potential
severity: Not recommended
Use oral contraceptives with 50 micrograms of estrogen or another method of contraception 

***interaction***
drug1
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
drug2
drug name: RUFINAMIDE
rxNorm: 69036
atc: N03AF03
Moderate decrease of the concentrations of ethinylestradiol
severity: Precaution for use
Another contraceptive method, in particular a barrier type, should be used. 

***interaction***
drug1
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
drug2
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the telaprevir
severity: Precaution for use
Use a reliable contraceptive method, additional or alternative, during the time these are administered together and two cycles following. 

***interaction***
drug1
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
drug2
drug name: TOPIRAMATE
rxNorm: 38404
atc: 38404
For doses of topiramate >=200 mg/day: Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of estrogen 
severity: Not recommended
Another method of contraception, in particular a barrier type, should be used.

***interaction***
drug1
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
drug2
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
Risk of antagonism of the effects of the estrogen-progestin contraceptive.
severity: Not recommended
Use an additional contraceptive method of the barrier type for several days after the ulipristal is stopped

***interaction***
drug1
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
drug2
drug name: VEMURAFENIB
rxNorm: 1147220
atc: L01XE15
Risk of decrease of the concentrations of the combined estrogen-progestin contraceptive with the consequence of a risk of ineffectiveness 
severity: Not recommended
215-ETANERCEPT.html


***interaction***
drug1
drug name: ETANERCEPT
rxNorm: 214555
atc: L04AB01
drug2
drug name: ANAKINRA
rxNorm: 72435
atc: L04AC03
Increased risk of serious infections and neutropenia
severity: Not recommended
216-ETHINYLESTRADIOL.html


***interaction***
drug1
drug name: ETHINYLESTRADIOL
rxNorm: 4124
more atc: G03AA15
more atc: G03AB07
more atc: G03AA09
more atc: G03AB05
more atc: G03AA12
more atc: G03CA01
more atc: L02AA03
more atc: G03AA01
more atc: G03AA10
more atc: G03AB06
more atc: G03AA07
more atc: G03AB03
more atc: G03AA03
more atc: G03AB02
more atc: G03AA08
more atc: G03AA04
more atc: G03AB01
more atc: G03AA13
more atc: G03AA05
more atc: G03AB04
drug2
drug name: DASABUVIR
rxNorm: 1597381
atc: J05AX16
Increase of the hepatotoxicity
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ETHINYLESTRADIOL
rxNorm: 4124
more atc: G03AA15
more atc: G03AB07
more atc: G03AA09
more atc: G03AB05
more atc: G03AA12
more atc: G03CA01
more atc: L02AA03
more atc: G03AA01
more atc: G03AA10
more atc: G03AB06
more atc: G03AA07
more atc: G03AB03
more atc: G03AA03
more atc: G03AB02
more atc: G03AA08
more atc: G03AA04
more atc: G03AB01
more atc: G03AA13
more atc: G03AA05
more atc: G03AB04
drug2
drug name: ETORICOXIB
rxNorm: 307296
atc: M01AH05
Increase of the concentrations of ethinylestradiol by the etoricoxib
severity: Take into account

***interaction***
drug1
drug name: ETHINYLESTRADIOL
rxNorm: 4124
more atc: G03AA15
more atc: G03AB07
more atc: G03AA09
more atc: G03AB05
more atc: G03AA12
more atc: G03CA01
more atc: L02AA03
more atc: G03AA01
more atc: G03AA10
more atc: G03AB06
more atc: G03AA07
more atc: G03AB03
more atc: G03AA03
more atc: G03AB02
more atc: G03AA08
more atc: G03AA04
more atc: G03AB01
more atc: G03AA13
more atc: G03AA05
more atc: G03AB04
drug2
class name: OMBITASVIR + PARITAPREVIR
class code: OMPA
Increase of the hepatotoxicity.
severity: CONTRAINDICATION
217-ETHOSUXIMIDE.html


***interaction***
drug1
drug name: ETHOSUXIMIDE
rxNorm: 4135
atc: N03AD51
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Decrease of the plasma concentrations of ethosuximide
severity: Precaution for use
Clinical monitoring, plasma dosage of the ethosuximide and possible increase of its dosage.
218-ETORICOXIB.html


***interaction***
drug1
drug name: ETORICOXIB
rxNorm: 307296
atc: M01AH05
drug2
drug name: ETHINYLESTRADIOL
rxNorm: 4124
more atc: G03AA15
more atc: G03AB07
more atc: G03AA09
more atc: G03AB05
more atc: G03AA12
more atc: G03CA01
more atc: L02AA03
more atc: G03AA01
more atc: G03AA10
more atc: G03AB06
more atc: G03AA07
more atc: G03AB03
more atc: G03AA03
more atc: G03AB02
more atc: G03AA08
more atc: G03AA04
more atc: G03AB01
more atc: G03AA13
more atc: G03AA05
more atc: G03AB04
Increase of the concentrations of ethinylestradiol by the etoricoxib
severity: Take into account
219-ETRAVIRINE.html


***interaction***
drug1
drug name: ETRAVIRINE
rxNorm: 475969
atc: J05AG04
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
In the treatment of infections with Mycobacterium avium complex, risk of decrease of the effectiveness of the clarithromycin due to increase of its hepatic metabolism by the etravirine
severity: Take into account
21-ALDESLEUKIN.html


***interaction***
drug1
drug name: ALDESLEUKIN
rxNorm: 70223
atc: L03AC01
drug2
class name: IODINATED X-RAY CONTRAST MEDIA
class code: VO8A-001
Increase of the risk of reaction to the contrast media in cases of previous treatment with interleukin2: 

skin rash or more rarely low blood pressure, oliguria, or even renal failure
severity: Take into account
220-EVEROLIMUS.html


***interaction***
drug1
drug name: EVEROLIMUS
rxNorm: 141704
more atc: L01XE10
more atc: L04AA18
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together
severity: Precaution for use
Blood concentration dosage of the everolimus, possibly adjustment of the dosage, and testing of the renal function, during the administration of the two together and after it is stopped  

***interaction***
drug1
drug name: EVEROLIMUS
rxNorm: 141704
more atc: L01XE10
more atc: L04AA18
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
Increase of the risk of angioedema
severity: Take into account

***interaction***
drug1
drug name: EVEROLIMUS
rxNorm: 141704
more atc: L01XE10
more atc: L04AA18
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the two medications together and after it is stopped. 
221-EXEMESTANE.html


***interaction***
drug1
drug name: EXEMESTANE
rxNorm: 258494
atc: L02BG06
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer
severity: Take into account
222-EZETIMIBE.html


***interaction***
drug1
drug name: EZETIMIBE
rxNorm: 341248
more atc: C10BA05
more atc: C10AX09
more atc: C10BA02
drug2
drug name: CICLOSPORIN
rxNorm: 3008
atc: S01XA18
For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin
severity: Not recommended

***interaction***
drug1
drug name: EZETIMIBE
rxNorm: 341248
more atc: C10BA05
more atc: C10AX09
more atc: C10BA02
drug2
drug name: FENOFIBRATE
rxNorm: 8703
more atc: C10AB05
more atc: C10BA03
more atc: C10BA04
Risk of gallstones due to increase of the biliary excretion of cholesterol
severity: Not recommended
223-FELBAMATE.html


***interaction***
drug1
drug name: FELBAMATE
rxNorm: 24812
atc: N03AX10
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of felbamate due to increase of its hepatic metabolism by the carbamazepine
severity: Precaution for use
Clinical monitoring, plasma dosages, and possible adjustment of the dosages of the two anticonvulsants.

***interaction***
drug1
drug name: FELBAMATE
rxNorm: 24812
atc: N03AX10
drug2
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
Decrease of the plasma concentrations and of the effectiveness of the felbamate and increase of the plasma concentrations of the phenobarbital, with risk of overdose.
severity: Precaution for use
Clinical monitoring and testing of the plasma concentrations of phenobarbital with adjustment of the dosage if needed. 

***interaction***
drug1
drug name: FELBAMATE 
rxNorm: 24812
atc: N03AX10
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Increase of the plasma concentrations of phenytoin with risk of overdose, due to inhibition of its metabolism by the felbamate
severity: Precaution for use
Clinical monitoring, testing of the plasma concentrations of phenytoin, and if needed, adjustment of its dosage during the treatment with the felbamate.

***interaction***
drug1
drug name: FELBAMATE
rxNorm: 24812
atc: N03AX10
drug2
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
Increase of the plasma concentrations of the valproic acid, with risk of overdose
severity: Precaution for use
Clinical and biological monitoring, and possible adjustment of the dosage of the valproate or of the valpromide during the treatment with the felbamate and after it is stopped. 
224-FENOFIBRATE.html


***interaction***
drug1
drug name: FENOFIBRATE
rxNorm: 8703
more atc: C10AB05
more atc: C10BA03
more atc: C10BA04
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Risk of increase of the nephrotoxicity of the ciclosporin
severity: Precaution for use
Clinical and biological monitoring of the renal function, during and after the administration of the two medications together. 

***interaction***
drug1
drug name: FENOFIBRATE
rxNorm: 8703
more atc: C10AB05
more atc: C10BA03
more atc: C10BA04
drug2
drug name: EZETIMIBE
rxNorm: 341248
more atc: C10BA05
more atc: C10AX09
more atc: C10BA02
Risk of gallstones due to increase of the biliary excretion of cholesterol
severity: Not recommended
225-FENTANYL.html


***interaction***
drug1
drug name: FENTANYL
rxNorm: 4337
more atc: N01AH01
more atc: N02AB03
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the anticonvulsant
severity: Not recommended
Choose another opioid.

***interaction***
drug1
drug name: FENTANYL
rxNorm: 4337
more atc: N01AH01
more atc: N02AB03
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the opioid analgesic's effect of respiratory depression due to slight decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is treatment with a strong inhibitor of CYP3A4.

***interaction***
drug1
drug name: FENTANYL
rxNorm: 4337
more atc: N01AH01
more atc: N02AB03
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin
severity: Not recommended
Choose another opioid.
226-IRON.html


***interaction***
drug1
drug name: IRON
rxNorm: 
more atc: B03A
drug2
drug name: INJECTABLE IRON SALTS
rxNorm: 1431591
more atc: B03AC
more atc: B03AC01
more atc: B03AC02
more atc: B03AC03
more atc: B03AC05
more atc: B03AC06
more atc: B03AC07
Lypothymia, even loss of consciousness attributed to the rapid release of the iron in its complex form and to the saturation of the transferrin
severity: Not recommended

***interaction***
drug1
drug name: IRON
rxNorm: 
more atc: B03A
drug2
drug name: ACETOHYDROXAMIC ACID
rxNorm: 16728
atc: G04BX03
Decrease of the digestive absorption of these two medications due to chelation of the iron
severity: Take into account

***interaction***
drug1
drug name: IRON
rxNorm: 
more atc: B03A
drug2
class name: BISPHOSPHONATES
class code: M05B-001
For the iron salts administered via oral route: decrease of the digestive absorption of the bisphosphonates
severity: Precaution for use
Take the iron salts at a different time from the bisphosphonates (from 30 minutes minimum to more than 2 hours apart, if possible, depending on the bisphosphonate).

***interaction***
drug1
drug name: IRON
rxNorm: 
more atc: B03A
drug2
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
With the iron salts by oral route: decrease of the digestive absorption of the iron salts
severity: Precaution for use
Take the iron salts at a different time from meals and in the absence of calcium. 

***interaction***
drug1
drug name: IRON
rxNorm: 
more atc: B03A
drug2
class name: TETRACYCLINE ANTIBIOTICS
class code: J01AA
With the tetracycline antibiotics administered by oral route: decrease of the digestive absorption of the tetracycline antibiotics (formation of complexes)
severity: Precaution for use
Take the iron salts at a different time from the tetracycline antibiotics (more than 2 hours apart if possible). 

***interaction***
drug1
drug name: IRON
rxNorm: 
more atc: B03A
drug2
drug name: ENTACAPONE
rxNorm: 60307
atc: N04BX02
Decrease of the digestive absorption of the entacapone and of the iron due to chelation of the latter by the entacapone
severity: Precaution for use
Take the iron salts at a different time from the entacapone (more than 2 hours apart if possible).

***interaction***
drug1
drug name: IRON
rxNorm: 
more atc: B03A
drug2
class name: FLUOROQUINOLONES
class code: J01MA-001
Decrease of the digestive absorption of the fluoroquinolones
severity: Precaution for use
Take the iron salts at a different time from the fluoroquinolones (more that 2 hours apart if possible).

***interaction***
drug1
drug name: IRON
rxNorm: 
more atc: B03A
drug2
class name: THYROID HORMONES
class code: H03AA
Decrease of the digestive absorption of the thyroid hormones
severity: Precaution for use
Take the thyroid hormones at a different time from the iron (more than 2 hours apart, if possible).

***interaction***
drug1
drug name: IRON
rxNorm: 
more atc: B03A
drug2
drug name: LEVODOPA
rxNorm: 6375
more atc: N04BA01
more atc: N04BA02
more atc: N04BA03
Decrease of the digestive absorption of the levodopa
severity: Precaution for use
Take the iron salts at a different time from the levodopa (more than 2 hours apart if possible).

***interaction***
drug1
drug name: IRON
rxNorm: 
more atc: B03A
drug2
drug name: METHYLDOPA
rxNorm: 6876
more atc: C02AB
more atc: C02LB
more atc: C02AB01
more atc: C02LB01
more atc: C02AB02
Decrease of the digestive absorption of the methyldopa (formation of complexes)
severity: Precaution for use
Take the iron salts at a different time from the methyldopa (more than two hours apart if possible).

***interaction***
drug1
drug name: IRON
rxNorm: 
more atc: B03A
drug2
drug name: PENICILLAMINE
rxNorm: 7975
atc: M01CC01
Decrease of the digestive absorption of the penicillamine
severity: Precaution for use
Take the iron salts at a different time from the penicillamine (more than 2 hours apart if possible).

***interaction***
drug1
drug name: IRON
rxNorm: 
more atc: B03A
drug2
drug name: STRONTIUM
rxNorm: 81638
more atc: V10BX01
more atc: M05BX03
Decrease of the digestive absorption of the strontium.
severity: Precaution for use
Take the strontium at a different time from the iron salts (more than two hours apart if possible).

***interaction***
drug1
drug name: IRON
rxNorm: 
more atc: B03A
drug2
drug name: ZINC
rxNorm: 1431163
more atc: A12CB
more atc: A12CB01
more atc: A12CB02
more atc: A12CB03
more atc: B05X
more atc: B05XA
more atc: B05XA12
Decrease of the digestive absorption of the zinc by the iron
severity: Precaution for use
Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).
227-FIBRATES.html


***interaction***
drug1
class name: FIBRATES
class code: C01AB-001
drug2
class name: OTHER FIBRATES
class code: C01AB-001
Increased risk of undesirable effects of the rhabdomyolosis type and of pharmacodynamic antagonism between the two molecules
severity: CONTRAINDICATION

***interaction***
drug1
class name: FIBRATES
class code: C01AB-001
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fibrate and a week after it is stopped. 

***interaction***
drug1
class name: FIBRATES
class code: C01AB-001
drug2
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolosis
severity: Precaution for use
Clinical and biological monitoring, particularly at the beginning of the administration of these substances together. 

***interaction***
drug1
class name: FIBRATES
class code: C01AB-001
drug2
class name: HMG-COA REDUCTASE INHIBITORS (STATINS)
class code: C10AA
Risk of addition of undesirable effects (dose-dependent) of the rhabdomyolosis type. Furthermore, with the gemfibrozil, decrease of the metabolism of the simvastatin and of the rosuvastatin, which increases the muscular risk, as well as the nephrotoxicity of the rosuvastatin
severity: Contraindication
--with the gemfibrozil and the simvastatin
228-FIDAXOMICIN.html


***interaction***
drug1
drug name: FIDAXOMICIN
rxNorm: 1111103
atc: A07AA12
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Increase of the plasma concentrations of the fidaxomicin
severity: Not recommended

***interaction***
drug1
drug name: FIDAXOMICIN
rxNorm: 1111103
atc: A07AA12
drug2
drug name: CICLOSPORIN
rxNorm: 3008
atc: S01XA18
Increase of the plasma concentrations of the fidaxomicin
severity: Not recommended

***interaction***
drug1
drug name: FIDAXOMICIN
rxNorm: 1111103
atc: A07AA12
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Increase of the plasma concentrations of the fidaxomicin
severity: Not recommended

***interaction***
drug1
drug name: FIDAXOMICIN
rxNorm: 1111103
atc: A07AA12
drug2
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
Increase of the plasma concentrations of the fidaxomicin
severity: Not recommended

***interaction***
drug1
drug name: FIDAXOMICIN
rxNorm: 1111103
atc: A07AA12
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: D10AF52
more atc: J01FA01
more atc: S01AA17
Increase of the plasma concentrations of the fidaxomicin
severity: Not recommended

***interaction***
drug1
drug name: FIDAXOMICIN
rxNorm: 1111103
atc: A07AA12
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Increase of the plasma concentrations of the fidaxomicin
severity: Not recommended

***interaction***
drug1
drug name: FIDAXOMICIN
rxNorm: 1111103
atc: A07AA12
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the plasma concentrations of the fidaxomicin
severity: Not recommended
229-FINGOLIMOD.html


***interaction***
drug1
drug name: FINGOLIMOD
rxNorm: 1012892
atc: L04AA27
drug2
class name: BRADYCARDIA INDUCING DRUGS
class code: C0N0S0
Increase of the bradycardia inducing effects which can have fatal consequences. The beta-blocking agents are even more at risk since they inhibit the adrenergic compensation mechanisms
severity: Not recommended
Clinical monitoring and continuous EKG during the 24 hours following the first dose.
22-ALFENTANIL.html


***interaction***
drug1
drug name: ALFENTANIL
rxNorm: 480
atc: N01AH02
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
With cimetidine used in doses greater than or equal to 800mg/day: increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism
severity: Precaution for use
Adjust the dosage of the alfentanil when administered with the cimetidine.

***interaction***
drug1
drug name: ALFENTANIL
rxNorm: 480
atc: N01AH02
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism
severity: Precaution for use
Adjust the dosage of the alfentanil when administered with the diltiazem. 

***interaction***
drug1
drug name: ALFENTANIL
rxNorm: 480
atc: N01AH02
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
atc: S01AA17
Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism
severity: Precaution for use
Adjust the dosage of the alfentanil when administered with the erythromycin

***interaction***
drug1
drug name: ALFENTANIL
rxNorm: 480
atc: N01AH02
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
atc: J02AC01
Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism


severity: Precaution for use
Adjust the dosage of the alfentanil when administered with the fluconazole

***interaction***
drug1
drug name: ALFENTANIL
rxNorm: 480
atc: N01AH02
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism

.
severity: Precaution for use 
Clinical monitoring and adjustment of the dosage of the opioid analgesic when administered with a strong inhibitor of CYP3A4.
230-FLECAINIDE.html


***interaction***
drug1
drug name: FLECAINIDE
rxNorm: 4441
atc: C01BC04
drug2
drug name: ABIRATERONE
rxNorm: 
more atc: L02BX03
Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the abiraterone
severity: Precautions for use
Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the abiraterone

***interaction***
drug1
drug name: FLECAINIDE
rxNorm: 4441
atc: C01BC04
drug2
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
Risk of increase of the undesirable effects of the flecainide due to decrease of its hepatic metabolism by the bupropion
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the bupropion.

***interaction***
drug1
drug name: FLECAINIDE
rxNorm: 4441
atc: C01BC04
drug2
drug name: CINACALCET
rxNorm: 407990
atc: H05BX01
Increase of the plasma concentrations of flecanaide with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the flecainide during the treatment with cinacalcet.

***interaction***
drug1
drug name: FLECAINIDE
rxNorm: 4441
atc: C01BC04
drug2
drug name: DARIFENACIN
rxNorm: 136198
atc: G04BD10
Increase of the plasma concentrations of flecainide, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the flecainide during the treatment with darifenacin.

***interaction***
drug1
drug name: FLECAINIDE
rxNorm: 4441
atc: C01BC04
drug2
drug name: DULOXETINE
rxNorm: 72625
atc: N06AX21
Increase of the plasma concentrations of flecainide with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the flecainide during the treatment with the duloxetine and after it is stopped.

***interaction***
drug1
drug name: FLECAINIDE
rxNorm: 4441
atc: C01BC04
drug2
drug name: MIRABEGRON
rxNorm: 1300786
atc: G04BD12
Increase of the plasma concentrations of the flecainide by decrease of its metabolism by the mirabegron
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the flecainide during the administration of it and the mirabegron together.

***interaction***
drug1
drug name: FLECAINIDE
rxNorm: 4441
atc: C01BC04
drug2
drug name: TERBINAFINE
rxNorm: 37801
more atc: D01AE15
more atc: D01BA02
Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the terbinafine
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the terbinafine. 
231-FLUCONAZOLE.html


***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: ALFENTANIL
rxNorm: 480
atc: N01AH02
Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism
severity: Precaution for use
Adjust the dosage of the alfentanil when there is treatment with the fluconazole

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Risk of lengthening of the QT interval
severity: Precaution for use
Clinical monitoring, especially with strong doses of fluconazole (800 mg/day)

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluconazole and a week after it is stopped. 

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: APIXABAN 
rxNorm: 1364430
atc: B01AF02
Increase of the plasma concentrations of the apixaban by the flucoonazole, with increase of the risk of bleeding
severity: Not recommended

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
For doses of fluconazole >=200 mg per day: possible increase of the undesirable effects of the carbamazepine
severity: Precaution for use
Adjust the dosage of carbamazepine, during and after the end of the antifungal treatment

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
Increase of the undesirable effects of the colchicine, with potentially fatal consequences
severity: Not Recommended

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: DOMPERIDONE
rxNorm: 3626
atc: A03FA03
Risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: HALOFANTRINE
rxNorm: 50749
atc: P01BX01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended
If this is possible, interrupt the fluconazole. If administering these medications together cannot be avoided, testing beforhand of the QT and EKG monitoring.

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Risk of increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism and of the creatinemia
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of renal function, and adjustment of the immunosuppressant's dosage during the administration of the substances together and after it is stopped. 

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: IVACAFTOR
rxNorm: 1243041
atc: R07AX02
Increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects
severity: Precaution for use
Reduce the dose by half, that is 150 mg/day.

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: LOSARTAN
rxNorm: 52175
more atc: C09CA01
more atc: C09DB06
more atc: C09DA01
Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole
severity: Take into account

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation.
severity: Not recommended
--with midazolam by mouth

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: NEVIRAPINE
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the nevirapine.

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: OLAPARIB
rxNorm: 1597582
atc: L01XX46
Increase of the plasma concentrations of olaparib by the fluconazole
severity: Not recommended
If administering these medications together cannot be avoided, limit the dose of olaparib to 200mg twice a day.

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: OXYCODONE
rxNorm: 7804
atc: N02AA55
Increase of the undesirable effects, especially respiratory ones, of the oxycodone due to decrease of its metabolism by the fluconazole.
severity: Not recommended
Clinical monitoring and possible adjustment of the dosage of the oxycodone during the treatment with the fluconazole and after it is stopped. 

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Increase of the plasma oncentrations of phenytoin that can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin
severity: Precaution for use
Strict clinical and biological monitoring.

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
Increased risk of ventricular arrhythmias, especially of torsades de pointes.
severity: CONTRAINDICATION

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the treatment with the two medications together. 

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the fluconazole by increase of its metabolism by the rifampacin
severity: Not recommended

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
drug name: RIVAROXABAN
rxNorm: 1114195
atc: B01AF01
Increase of the plasma concentrations of the rivaroxaban by the fluconazole, with increase of the risk of bleeding 
severity: Not recommeded

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
Increase of the half life of the sulfonamide with possible onset of hypoglycemia
severity: Precaution for use
Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the sulfonamide during the treatment with the fluconazole.

***interaction***
drug1
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Increase of the theophyllinemia with risk of overdose (decrease of the clearance of the theophylline)
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the fluconazole and after it is stopped.
232-FLUCYTOSINE.html


***interaction***
drug1
drug name: FLUCYTOSINE
rxNorm: 4451
more atc: D01AE21
more atc: J02AX01
drug2
drug name: ZIDOVUDINE (AZT)
rxNorm: 11413
more atc: J05AF01
more atc: J05AR01
more atc: J05AR04
more atc: J05AR05
Increase of the hematological toxicity (addition of effects of bone marrow toxicity)
severity: Precaution for use
More frequent CBC
233-FLUDARABINE.html


***interaction***
drug1
drug name: FLUDARABINE
rxNorm: 24698
atc: L01BB05
drug2
drug name: PENTOSTATIN
rxNorm: 8011
atc: L01XX08
Increase of the risk of pulmonary toxicity that could be fatal. 
severity: Not recommended
234-FLUOROQUINOLONES.html


***interaction***
drug1
class name: FLUOROQUINOLONES
class code: J01MA-001
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped.

***interaction***
drug1
class name: FLUOROQUINOLONES
class code: J01MA-001
drug2
drug name: IRON
rxNorm: 1431589
atc: B03A
Decrease of the digestive absorption of the fluoroquinolones
severity: Precaution for use
Take the iron salts at a different time from the fluoroquinolones (more that 2 hours apart if possible).

***interaction***
drug1
class name: FLUOROQUINOLONES
class code: J01MA-001
drug2
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
Possible increase of the risk of tendinitis, even of rupture of the tendon (exceptional), particularly in patients receiving prolonged corticotherapy 
severity: Take into account

***interaction***
drug1
class name: FLUOROQUINOLONES
class code: J01MA-001
drug2
Drug with no codes: MYCOPHENOLATE MOFETIL
more atc: MYCOPHEN
more atc: OLIC
more atc: ACID
more atc: MYCOPHEN
more atc: OLATE
more atc: MOFETIL
more atc: MYCOPHEN
more atc: OLIC
more atc: ACID
more atc: MYCOPHEN
more atc: OLIC
more atc: ACID
more atc: 7145
more atc: L04AA06
Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness. 
severity: Take into account

***interaction***
drug1
class name: FLUOROQUINOLONES
class code: J01MA-001
drug2
drug name: STRONTIUM
rxNorm: 81638
more atc: V10BX01
more atc: M05BX03
Decrease of the digestive absorption of the strontium
severity: Precaution for use
Take the strontium at a different time from the fluoroquinolones (more than two hours apart if possible).

***interaction***
drug1
class name: FLUOROQUINOLONES
class code: J01MA-001
drug2
drug name: SUCRALFATE
rxNorm: 10156
atc: A02BX02
Decrease of the digestive absorption of the fluoroquinolones
severity: Precaution for use
Take the sucralfate at a different time from the fluoroquinolone (more than 2 hours apart if possible).

***interaction***
drug1
class name: FLUOROQUINOLONES
class code: J01MA-001
drug2
drug name: ZINC
rxNorm: 1431163
more atc: A12CB
more atc: A12CB01
more atc: A12CB02
more atc: A12CB03
more atc: B05X
more atc: B05XA
more atc: B05XA12
more atc: B05XA12
more atc: B05XA12
more atc: B05XA12
more atc: B05XA12
more atc: B05XA12
more atc: B05XA12
more atc: B05XA12
more atc: B05XA12
more atc: B05XA12
more atc: B05XA12
more atc: B05XA12
more atc: B05XA12
more atc: B05XA12
Decrease of the digestive absorption of the fluoroquinolones
severity: Precaution for use
Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).
235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html


***interaction***
drug1
class name: FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)
class code: L01BC-001
drug2
drug name: FOLINIC ACID
rxNorm: 6313
more atc: B03BB
more atc: B03BB01
more atc: B03BB51
Strengthening of the effects, both cytostatic and undesirable, of the fluorouracil. 
severity: Take into account

***interaction***
drug1
class name: FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)
class code: L01BC-001
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Not recommended
If taking these medications together cannot be avoided, more frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the cytotoxic and a week after it is stopped. 

***interaction***
drug1
class name: FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)
class code: L01BC-001
drug2
drug name: INTERFERON ALFA
rxNorm: 
Increase of the gastrointestinal toxicity of the fluorouracil
severity: Take into account

***interaction***
drug1
class name: FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)
class code: L01BC-001
drug2
drug name: METRONIDAZOLE
rxNorm: 6922
more atc: A02BD08
more atc: A02BD03
more atc: A02BD02
more atc: A01AB17
more atc: D06BX01
more atc: G01AF01
more atc: J01XD01
more atc: P01AB01
more atc: A02BD01
Increase of the toxicity of the fluourouracil due to decrease of its clearance
severity: Take into account

***interaction***
drug1
class name: FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)
class code: L01BC-001
drug2
drug name: ORNIDAZOLE
rxNorm: 7701
more atc: G01AF06
more atc: J01XD03
more atc: P01AB03
Increase of the toxicity of the fluorouracil due to decrease of its clearance
severity: Take into account
236-FLUOXETINE.html


***interaction***
drug1
drug name: FLUOXETINE
rxNorm: 4493
more atc: N06AB03
more atc: N06CA03
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Increase of the plasma concentrations of carbamazepine with signs of overdose
severity: Precaution for use
Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped. 

***interaction***
drug1
drug name: FLUOXETINE
rxNorm: 4493
more atc: N06AB03
more atc: N06CA03
drug2
drug name: MEQUITAZINE
rxNorm: 29528
atc: R06AD07
Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzymatic inhibitor
severity: Not recommended

***interaction***
drug1
drug name: FLUOXETINE
rxNorm: 4493
more atc: N06AB03
more atc: N06CA03
drug2
drug name: METOPROLOL
rxNorm: 6918
atc: C07AB02
Risk of increase of the undesirable effects of the metoprolol, especially with excessive bradycardia, due to inhibition of its metabolism by the fluoxetine. 
severity: Precaution for use
Increased clinical monitoring, if needed, adjustment of the dosage of the metoprolol during the length of the treatment with the fluoxetine and after it is stopped.

***interaction***
drug1
drug name: FLUOXETINE
rxNorm: 4493
more atc: N06AB03
more atc: N06CA03
drug2
drug name: NEBIVOLOL
rxNorm: 31555
more atc: C07AB12
more atc: C07BB12
Risk of increase of the undesirable effects of the nebivolol, especially with excessive bradycardia, due to inhibition of its metabolism by the antidepressant 
severity: Precaution for use
Increased clinical monitoring; if needed, adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.

***interaction***
drug1
drug name:  FLUOXETINE
rxNorm: 4493
more atc: N06AB03
more atc: N06CA03
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the metabolism of the phenytoin
severity: Precaution for use
Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage during the treatment with the fluoxetine and after it is stopped. 

***interaction***
drug1
drug name: FLUOXETINE
rxNorm: 4493
more atc: N06AB03
more atc: N06CA03
drug2
drug name: RISPERIDONE
rxNorm: 35636
atc: N05AX08
Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the fluoxetine, with risk of increase of its undesirable effects
severity: Precaution for use
Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone. 

***interaction***
drug1
drug name: FLUOXETINE
rxNorm: 4493
more atc: N06AB03
more atc: N06CA03
drug2
drug name: TAMOXIFEN
rxNorm: 10324
atc: L02BA01
Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the fluoxetine. 
severity: Not recommended

***interaction***
drug1
drug name: FLUOXETINE
rxNorm: 4493
more atc: N06AB03
more atc: N06CA03
drug2
drug name: VORTIOXETINE
rxNorm: 1455099
atc: N06AX26
Risk of increase of the undesirable effects of the vortioxetine due to decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with fluoxetine and after it is stopped.
237-FLUVOXAMINE.html


***interaction***
drug1
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
drug2
drug name: AGOMELATINE
rxNorm: 306718
atc: N06AX22
Increase of the concentrations of agomelatine, with risk of increase of the undesirable effects.
severity: CONTRAINDICATION

***interaction***
drug1
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Increase of the plasma concentrations of carbamazepine with signs of overdose
severity: Precaution for use
Clinical monitoring, testing of the plasma concentrations of carbamazepine and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped.

***interaction***
drug1
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
drug2
drug name: CLOZAPINE
rxNorm: 2626
atc: N05AH02
Increase of the plasma concentrations of clozapine with signs of overdose
severity: Precaution for use
Increased clinical monitoring; if needed, adjustment of the dosage of the clozapine during the treatment with the fluvoxamine and after it is stopped.

***interaction***
drug1
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
drug2
drug name: DULOXETINE
rxNorm: 72625
atc: N06AX21
Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the fluvoxamine
severity: CONTRAINDICATION

***interaction***
drug1
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
drug2
drug name: LIDOCAINE
rxNorm: 6387
more atc: C01BB01
more atc: C05AD01
more atc: D04AB01
more atc: N01BB02
more atc: R02AD02
more atc: S01HA07
more atc: S02DA01
Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)
severity: Precaution for use
Clinical monitoring, EKG, and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.

***interaction***
drug1
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
drug2
drug name: METHADONE
rxNorm: 6813
atc: N07BC02
Increase of the plasma concentrations of methodone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Strengthen clinical monitoring and EKG; if needed, adjustment of the dosage of the methadone during the treatment with the fluvoxamine and after it is stopped.

***interaction***
drug1
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
drug2
drug name: MEXILETINE
rxNorm: 6926
atc: C01BB02
Risk of increase of the undesirable effects of the mexiletine, due to inhibition of its metabolism by the fluvoxamine
severity: Precaution for use
Clinical monitoring and EKG. Adjustment of the dosage of the mexiletine during the treatment with the fluvoxamine and after it is stopped.

***interaction***
drug1
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
drug2
drug name: OLANZAPINE
rxNorm: 61381
atc: N05AH03
Increase of the concentrations of the olanzapine, with risk of increase of the undesirable effects, due to decrease of its hepatic metabolism by the fluvoxamine
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the olanzapine during the treatment with fluvoxamine.

***interaction***
drug1
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the hepatic metabolism of the phenytoin.
severity: Precaution for use
Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage of the phenytoin during the treatment with the fluvoxamine and after it is stopped. 

***interaction***
drug1
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
drug2
drug name: PIRFENIDONE
rxNorm: 88221
atc: L04AX05
Increase of the plasma concentrations of pirfenidone with signs of overdose
severity: CONTRAINDICATION 

***interaction***
drug1
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
drug2
drug name: PROPRANOLOL
rxNorm: 8787
atc: C07AA05
Increase of the plasma concentrations of propranolol due to inhibition of its hepatic metabolism, with increase of the activity and of the undesirable effects, for example: significant bradycardia
severity: Precaution for use
Increased clinical monitoring, and, if needed, adjustment of the dosage of the propranolol during the treatment with the fluvoxamine and after it is stopped. 

***interaction***
drug1
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
drug2
drug name: ROPINIROLE
rxNorm: 72302
atc: N04BC04
Increase of the concentrations of ropinirole, with risk of overdose, due to decrease of its hepatic metabolism by the fluvoxamine
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with fluvoxamine and after it is stopped. 

***interaction***
drug1
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Increase of the theophyllinemia with signs of overdose (decrease of the hepatic metabolism of the theophylline) 
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia; if needed, adjustment of the dosage of the theophylline during the treatment with fluvoxamine and after it is stopped.
238-FOLATES.html


***interaction***
drug1
class name: FOLATES
class code: V03-
drug2
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
Decrease of the plasma concentrations of the phenobarbital, due to increase of its metabolism of which the folates represent one of the cofactors
severity: Precaution for use
Clinical monitoring, testing of the plasma concentrations, and adjustment, if there is reason for it, of the dosage of the phenobarbital during the folic supplementation and after it is stopped.

***interaction***
drug1
class name: FOLATES
class code: V03-
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Decrease of the plasma concentrations of phenytoin due to increase of its metabolism of which the folates represent one of the cofactors
severity: Precaution for use
Clinical monitoring and testing of the plasma concentrations of phenytoin. Possible adjustment of the dosage of the phenytoin during the folic supplementation and after it is stopped. 
239-FOSAMPRENAVIR.html


***interaction***
drug1
drug name: FOSAMPRENAVIR
rxNorm: 358262
atc: J05AE07
drug2
drug name: BUPRENORPHINE
rxNorm: 1819
more atc: N02AE01
more atc: N07BC01
Risk of increase or of decrease of the effects of the A to take into account buprenorphine [sic], simultaneously by inhibition and acceleration of its metabolism by the protease inhibitor
severity: Take into account

***interaction***
drug1
drug name: FOSAMPRENAVIR
rxNorm: 358262
atc: J05AE07
drug2
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
Risk of lower effectiveness of the amprenavir.
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. 

***interaction***
drug1
drug name: FOSAMPRENAVIR
rxNorm: 358262
atc: J05AE07
drug2
drug name: MARAVIROC
rxNorm: 620216
atc: J05AX09
Significant decrease of the concentrations of amprenavir that can lead to a loss of viralogical response
severity: Not recommended

***interaction***
drug1
drug name: FOSAMPRENAVIR
rxNorm: 358262
atc: J05AE07
drug2
drug name: METHADONE
rxNorm: 6813
more atc: N02AC52
more atc: N07BC02
Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ampernavir
severity: Precaution for use
Regular clinical monitoring and possible adjustment of the dosage of methadone.

***interaction***
drug1
drug name: FOSAMPRENAVIR
rxNorm: 358262
atc: J05AE07
drug2
drug name: NEVIRAPINE
rxNorm: 53654
atc: J05AR05
Risk of lower effectiveness of the amprenavir
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.
23-ALFUZOSIN.html


***interaction***
drug1
drug name: ALFUZOSIN
rxNorm: 17300
atc: G04CA01
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the plasma concentrations of the alfuzosin and of its undesirable effects. 

.
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ALFUZOSIN
rxNorm: 17300
atc: G04CA01
drug2
class name: OMBITASVIR + PARITAPVIR
class code: OMPA
Increase of the plasma concentrations of the alfuzosin by decrease of its hepatic metabolism by the therapy with the two medications.
severity: CONTRAINDICATION
240-FOSCARNET.html


***interaction***
drug1
drug name: FOSCARNET
rxNorm: 33562
atc: J05AD01
drug2
drug name: PENTAMIDINE
rxNorm: 7994
atc: P01CX01
Risk of severe hypocalcemia
severity: Precaution for use
Monitoring of the calcemia and supplementation if necessary.
241-FOTEMUSTINE.html


***interaction***
drug1
drug name: FOTEMUSTINE 
rxNorm: 25287
atc: L01AD05
drug2
drug name: DACARBAZINE
rxNorm: 3098
atc: L01AX04
With the dacarbazine in large doses: risk of pulmonary toxicity (adult acute respiratory distress syndrome ).


severity: Precaution for use
Do not use these medications simultaneously, but wait a week between the last administration of fotemustine and the first day of the treatment with dacarbazine. 
242-FUROSEMIDE.html


***interaction***
drug1
drug name: FUROSEMIDE
rxNorm: 460
more atc: C03CA01
more atc: C03CB01
more atc: C03EB01
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Decrease of the diuretic effect which can reach 50%
severity: Precaution for use
Possibly use higher doses of furosemide. 
243-GANCICLOVIR.html


***interaction***
drug1
drug name: GANCICLOVIR
rxNorm: 4678
more atc: J05AB06
more atc: S01AD09
drug2
drug name: DIDANOSINE
rxNorm: 3364
atc: J05AF02
Risk of increase of the undesirable effects of the didanosine, and especially the mitochondrial toxicity, due to substantial increase of its concentrations. In addition, risk of decrease of the effectiveness of the ganciclovir due to decrease of its concentrations, if the two medications are ingested in an interval of less than 2 hours
severity: Not recommended

***interaction***
drug1
drug name: GANCICLOVIR
rxNorm: 4678
more atc: J05AB06
more atc: S01AD09
drug2
drug name: ZALCITABINE
rxNorm: 3363
atc: J05AF03
Increased risk of onset of peripheral neuropathy due to addition of undesirable effects
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the two medications together. 

***interaction***
drug1
drug name: GANCICLOVIR
rxNorm: 4678
more atc: J05AB06
more atc: S01AD09
drug2
drug name: ZIDOVUDINE 
rxNorm: 11413
more atc: J05AF01
more atc: J05AR01
more atc: J05AR04
more atc: J05AR05
Increase of the hematological toxicity (addition of effects of bone marrow toxicity)
severity: Precaution for use
Stop the zidovudine temporarily; CBC, and, reintroduce, if possible, the zidovudine in small doses. 
244-GEMFIBROZIL.html


***interaction***
drug1
drug name: GEMFIBROZIL
rxNorm: 4719
atc: C10AB04
drug2
drug name: DASABUVIR
rxNorm: 1597381
atc: J05AX16
Risk of increase of the plasma concentrations of the dasabuvir by the gemfibrozil
severity: CONTRAINDICATION

***interaction***
drug1
drug name: GEMFIBROZIL
rxNorm: 4719
atc: C10AB04
drug2
drug name: ENZALUTAMIDE
rxNorm: 130729
atc: L02BB04
Increase of the active fraction of the enzalutamide
severity: Precaution for use
Reduce the dose of enzalutamide by half when administered with the gemfibrozil.

***interaction***
drug1
drug name: GEMFIBROZIL
rxNorm: 4719
atc: C10AB04
drug2
drug name: PIOGLITAZONE
rxNorm: 33738
atc: A10BG03
Risk of increase of the undesirable effects of the glitazone due to decrease of its hepatic metabolism by the gemfibrozil
severity: Not recommended
If administering these medications together cannot be avoided, strict clinical monitoring.

***interaction***
drug1
drug name: GEMFIBROZIL
rxNorm: 4719
atc: C10AB04
drug2
drug name: REPAGLINIDE
rxNorm: 73044
atc: A10BX02
Risk of severe hypoglycemia, even coma, due to substantial increase of the plasma concentrations of repaglinide by the gemfiborzil
severity: CONTRAINDICATION
245-GLIBENCLAMIDE.html


***interaction***
drug1
drug name: GLIBENCLAMIDE
rxNorm: 4815
atc: A10BB01
drug2
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
Risk of reduced effectiveness of the glibenclamide due to decrease of its plasma concentrations, because of the inducer effect of the bosentan. Furthermore, cases of hepatoxicity have been reported with these substances administered together. 
severity: Precaution for use
Monitoring of the glycemia, adjustment of the treatment if needed, and monitoring of the hepatic biological constants 

***interaction***
drug1
drug name: GLIBENCLAMIDE
rxNorm: 4815
atc: A10BB01
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic 
severity: Precaution for use
Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin 

***interaction***
drug1
drug name: GLIBENCLAMIDE
rxNorm: 4815
atc: A10BB01
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic 
severity: Precaution for use
Inform the patient, strengthen self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
246-GLIMEPIRIDE.html


***interaction***
drug1
drug name: GLIMEPIRIDE
rxNorm: 25789
more atc: A10BB12
more atc: A10BD06
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic. 
severity: Precaution for use
Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin

***interaction***
drug1
drug name: GLIMEPIRIDE
rxNorm: 25789
more atc: A10BB12
more atc: A10BD06
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: D10AF52
more atc: J01FA01
more atc: S01AA17
Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic
severity: Precaution for use
Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the erythromycin.
247-GLINIDES.html


***interaction***
drug1
class name: GLINIDES
class code: A10BX-001
drug2
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia
severity: Precaution for use
Inform the patient, and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose

***interaction***
drug1
class name: GLINIDES
class code: A10BX-001
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia
severity: Precaution for use
Inform the patient, and reinforce, especially at the beginning of treatment, self-monitoring of blood glucose.
248-GLIPIZIDE.html


***interaction***
drug1
drug name: GLIPIZIDE
rxNorm: 4821
atc: A10BB07
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
Risk of increase of the plasma concentrations of the glipizide at the origin of potentially severe hypoglycemia. 
severity: Precaution for use
Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during and after the treatment with voriconazole.
249-GLIPTINS.html


***interaction***
drug1
class name: GLIPTINS
class code: A10B-001
drug2
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia
severity: Precaution for use
Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose

***interaction***
drug1
class name: GLIPTINS
class code: A10B-001
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
Increase of the risk of the onset of angioedema, due to the reduction of the activity of the enzyme dipetidyl peptidase-4 (DDP-4) by the gliptin, in patients treated with the angiotensin converting enzyme inhibitor
severity: Take into account
24-ALISKIREN.html


***interaction***
drug1
drug name: ALISKIREN
rxNorm: 325646
atc: C09XA02
drug2
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
Risk of hyperkalemia, of renal insufficiency, of increase of cardiovascular mortality
severity: Contraindication
-for patients with diabetes or renal insufficiency

***interaction***
drug1
drug name: ALISKIREN
rxNorm: 325646
atc: C09XA02
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
The plasma concentrations of aliskiren increase by nearly 5 times and increase of the risk of its undesirable effects. 
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ALISKIREN
rxNorm: 325646
atc: C09XA02
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
Risk of hyperkalemia, of renal insufficiency, of increase of cardiovascular mortality
severity: Contraindication 
-for patients with diabetes or renal insufficiency

***interaction***
drug1
drug name: ALISKIREN
rxNorm: 325646
atc: C09XA02
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
The plasma concentrations of aliskiren increase by nearly 6 times and increase of the risk of its undesirable effects. 
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ALISKIREN
rxNorm: 325646
atc: C09XA02
drug2
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
Risk of decrease of the effectiveness of the aliskiren when grapefruit is consumed
severity: Not recommended

***interaction***
drug1
drug name: ALISKIREN
rxNorm: 325646
atc: C09XA02
drug2
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.


severity: CONTRAINDICATION

***interaction***
drug1
drug name: ALISKIREN
rxNorm: 325646
atc: C09XA02
drug2
drug name: SACUBITRIL
rxNorm: 1656328
With diabetic patients or those with renal insufficiency, increase of the undesirable effects such as hypotension, hyperkaliemia
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ALISKIREN
rxNorm: 325646
atc: C09XA02
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.


severity: Precaution for use
Clinical monitoring
250-ANTI-LYMPHOCYTE-GLOBULINS.html


***interaction***
drug1
class name: ANTI-LYMPHOCYTE GLOBULINS
class code: L04AA0-001
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Excessive immunodepression with risk of lymphoproliferative disorders (LPDs)
severity: Take into account

***interaction***
drug1
class name: ANTI-LYMPHOCYTE GLOBULINS
class code: L04AA0-001
drug2
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
Risk of possibly fatal general illness. This risk is increased in older patients already immunodepressed by the underlying disease.
severity: Take into account
In particular, use an inactivated vaccine when one exists (poliomyelitis)
251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html


***interaction***
drug1
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
Increase of the risk of hemorrhage


severity: Not recommended with:
-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)

***interaction***
drug1
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
drug2
class name: ORAL ANTICOAGULANTS
class code: B01A-001
Glucocorticoids (general and rectal routes): possible impact of the corticotherapy on the metabolism of the Vitamin K antagonist and on that of the factors of coagulation. Risk of hemorrhage specific to the corticotherapy (digestive mucosa, vascular fragility) in large doses or in treatment prolonged beyond 10 days. 
severity: Precaution for use
When administering substances from these groups together is justified, strengthen monitoring: if the situation requires, with the vitamin K antagonists, biological testing on the 8th day, then every two weeks after that during the corticotherapy and after it is stopped.

***interaction***
drug1
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great with patients who have Addisons disease treated with hydrocortisone and in cases of organ transplants
severity: Precaution for use
Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped. 

***interaction***
drug1
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Increase of the risk of ulceration and of gastrointestinal hemorrhage
severity: Take into account

***interaction***
drug1
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
drug2
class name: NON-DEPOLARIZING CURARES
class code: M03A-002
With the glucocorticoids by IV route: risk of severe myopathy, reversible after a possibly long period (several months).
severity: Take into account

***interaction***
drug1
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
drug2
class name: FLUOROQUINOLONES
class code: J01MA-001
Possible increase of the risk of tendinitis, even of rupture of the tendon (exceptional), particularly in patients receiving corticotherapy for a prolonged period
severity: Take into account

***interaction***
drug1
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
drug2
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
Described for prednisolone. 

Decrease of the plasma concentrations of the isoniazid. Mechanism proposed: increase of the hepatic metabolism of the isoniazid and decrease of that of the glucocorticoides
severity: Precaution for use
Clinical and biological monitoring.

***interaction***
drug1
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants
severity: Precaution for use
Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 

***interaction***
drug1
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
drug2
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
With the exception of inhaled and local routes, and for doses greater than 10mg/day of prednisone-equivalent (or > 2mg/kg/day for a child or > 20mg/day for a child weighing more than 10 kg) during more than two weeks and for the "bolus" of corticoids: risk of possibly fatal general vaccine disease.
severity: CONTRAINDICATION
And during the 3 months following the end of the therapy with the corticoid.
252-GLUCOSAMINE.html


***interaction***
drug1
drug name: GLUCOSAMINE
rxNorm: 4845
atc: M01AX05
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K Antagonist
253-GLYCEROL.html


***interaction***
drug1
drug name: GLYCEROL
rxNorm: 4910
more atc: A06AG04
more atc: A06AX01
more atc: A16AX09
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Decrease of the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness
severity: Precaution for use
Strict monitoring of the plasma concentrations of lithium and possible adjustment of the dosage of the lithium. 
254-GRISEOFULVIN.html


***interaction***
drug1
drug name: GRISEOFULVIN
rxNorm: 5021
more atc: D01AA08
more atc: D01BA01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the griseofulvin
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with griseofulvin and a week after it is stopped 

***interaction***
drug1
drug name: GRISEOFULVIN
rxNorm: 5021
more atc: D01AA08
more atc: D01BA01
drug2
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
Risk of decrease of the contraceptive effectiveness due to increase of its hepatic metabolism
severity: Precaution for use
Another method of contraception, in particular a barrier type, should be used during the time the two substances are administered together and a cycle after. 

***interaction***
drug1
drug name: GRISEOFULVIN
rxNorm: 5021
more atc: D01AA08
more atc: D01BA01
drug2
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism
severity: Precaution for use
Use a reliable contraceptive method, additional or alternative, during the length of time these substances are administered together and a cycle following.
255-GUANETHIDINE.html


***interaction***
drug1
drug name: GUANETHIDINE
rxNorm: 5036
more atc: C02CC02
more atc: S01EX01
more atc: C02LF01
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
With the guanethidine used by IV route: risk of unforeseeable vascular reactions, especially hypotension
severity: CONTRAINDICATION
Interrupt the treatment with the MAOI two weeks before the treatment with guanethidine.
256-HALOFANTRINE.html


***interaction***
drug1
drug name: HALOFANTRINE
rxNorm: 50749
atc: P01BX01
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended
If this is possible, interrupt the fluconazole. If the administration of these substances together cannot be avoided, testing beforehand of the QT and EKG monitoring.

***interaction***
drug1
drug name: HALOFANTRINE
rxNorm: 50749
atc: P01BX01
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increased risk of ventricular arryhthmias, especially of torsades de pointes
severity: Not recommended
If this is possible, interrupt the inhibitor. If administering these medications together cannot be avoided, testing beforehand of the QT and EKG monitoring.

***interaction***
drug1
drug name: HALOFANTRINE
rxNorm: 50749
atc: P01BX01
drug2
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended
If this is possible, interrupt the macrolide. If administering the substances together cannot be avoided, testing of the QT interval before the beginning of the treatment and EKG monitoring

***interaction***
drug1
drug name: HALOFANTRINE
rxNorm: 50749
atc: P01BX01
drug2
Drug with no codes: GRAPEFRUIT (JUICE AND FRUIT)
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended

***interaction***
drug1
drug name: HALOFANTRINE
rxNorm: 50749
atc: P01BX01
drug2
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended
257-HALOPERIDOL.html


***interaction***
drug1
drug name: HALOPERIDOL
rxNorm: 5093
atc: N05AD01
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
NB: Carbamazepine is one of the Anticonvulsant Enzymatic Inducers

Clinical monitoring and, if needed, adjustment of the dosage during the treatment with the carbamazepine and after it is stopped
severity: Precaution for use
Clinical monitoring and, if needed, adjustment of the dosage during the treatment with the carbamazepine and after it is stopped. 

***interaction***
drug1
drug name: HALOPERIDOL
rxNorm: 5093
atc: N05AD01
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring, and, if needed, adjustment of the dosage during the treatment with the rifampicin and after it is stopped. 
258-HALOTHANE.html


***interaction***
drug1
drug name: HALOTHANE
rxNorm: 5095
atc: N01AB01
drug2
class name: BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS
class code: R03C-001
In cases of obstetrical surgery, increased uterine inertia with risk of hemorrhage; furthermore serious ventricular arrhythmias, due to increase of the cardiac reactivity
severity: Not recommended
Interrupt treatment with the beta-2 mimetics if the anesthesia must be done with halothane

***interaction***
drug1
drug name: HALOTHANE
rxNorm: 5095
atc: N01AB01
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Serious ventricular arrhythmias due to increase of cardiac sensitization
severity: Not recommended
259-HEPARINS.html


***interaction***
drug1
class name: HEPARINS
class code: B01AB
drug2
class name: PLATELET AGGREGATION INHIBITORS
class code: B01AC-001
Increased risk of hemorrhage 
severity: Take into account

***interaction***
drug1
class name: HEPARINS
class code: B01AB
drug2
drug name: DEFIBROTIDE
rxNorm: 1311089
atc: B01AX01
Accrued risk of hemorrhage
severity: Not recommended
25-ALLOPURINOL.html


***interaction***
drug1
drug name: ALLOPURINOL
rxNorm: 519
atc: M04AA01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)


severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the allopurinol and a week after it is stopped. 

***interaction***
drug1
drug name: ALLOPURINOL
rxNorm: 519
atc: M04AA01
drug2
drug name: DIDANOSINE
rxNorm: 3364
atc: J05AF02
Increase of the plasma concentrations of didanosine and of its undesirable effects


severity: Not recommended

***interaction***
drug1
drug name: ALLOPURINOL
rxNorm: 519
atc: M04AA01
drug2
class name: AMINOPENICILLINS
class code: J01CA
Increased risk of cutaneous reactions


severity: Take into account

***interaction***
drug1
drug name: ALLOPURINOL
rxNorm: 519
atc: M04AA01
drug2
drug name: VIDARABINE
rxNorm: 11194
atc: S01AD06
Increased risk of neurological disorders (trembling, confusion) due to partial inhibition of the metabolism of the antiviral
severity: Not recommended
260-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html


***interaction***
drug1
class name: LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)
class code: B01AB-001
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)
severity: Not recommended with
-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)

***interaction***
drug1
class name: LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)
class code: B01AB-001
drug2
class name: ORAL ANTICOAGULANTS
class code: B01A-001
Increase of the risk of hemorrhage


severity: Precaution for use
If the administration of these together cannot be avoided, strengthen clinical monitoring and, if the situation requires, biological monitoring. 

***interaction***
drug1
class name: LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)
class code: B01AB-001
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)
severity: Not recommended
If administering the substances together cannot be avoided, strict clinical monitoring.

***interaction***
drug1
class name: LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)
class code: B01AB-001
drug2
drug name: DEXTRAN 40
rxNorm: 42635
more atc: B05AA05
more atc: B03AC06
Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)


severity: Not recommended

***interaction***
drug1
class name: LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)
class code: B01AB-001
drug2
class name: THROMBOLYTICS
class code: B01AD
Increase of the risk of hemorrhage
severity: Take into account
261-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html


***interaction***
drug1
class name: LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)
class code: B01AB-002
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
The combination of medications acting at different levels of hemeostasis increases the risk of bleeding. Thus, with patients under 65 years of age, adding heparin or similar substances in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical and possibly biological monitoring.
severity: Take into account

***interaction***
drug1
class name: LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)
class code: B01AB-002
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Increase of the risk of hemorrhage 
severity: Take into account
262-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html


***interaction***
drug1
class name: UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)
class code: B01AB-003
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)
severity: Not recommended with
-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)

***interaction***
drug1
class name: UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)
class code: B01AB-003
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)
severity: Not recommended
If administering the substances together cannot be avoided, strict clinical monitoring.

***interaction***
drug1
class name: UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)
class code: B01AB-003
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the risk of hemorrhage
severity: Precaution for use
When the heparin alternates with the vitamin K antagonist, strengthen clinical monitoring.

***interaction***
drug1
class name: UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)
class code: B01AB-003
drug2
drug name: DEXTRAN 40
rxNorm: 42635
more atc: B05AA05
more atc: B03AC06
Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40) 
severity: Not recommended

***interaction***
drug1
class name: UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)
class code: B01AB-003
drug2
class name: THROMBOLYTICS
class code: B01AD
Increase of the risk of hemorrhage
severity: Take into account
263-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html


***interaction***
drug1
class name: UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)
class code: B01AB-004
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring. 
severity: Take into account

***interaction***
drug1
class name: UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)
class code: B01AB-004
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Increase of the risk of hemorrhage
severity: Take into account
264-THYROID-HORMONES.html


***interaction***
drug1
class name: THYROID HORMONES
class code: H03AA
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Risk of clinically low thyroid in patients with hypothyroidism, due to increase of the metabolism of the T3 and of the T4


severity: Precaution for use
Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with the inducer and after it is stopped. 

***interaction***
drug1
class name: THYROID HORMONES
class code: H03AA
drug2
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
Decrease of absorption of the thyroid hormones
severity: Precaution for use
Take the calcium salts at a different time from the thyroid hormones (more than 2 hours apart, if possible).

***interaction***
drug1
class name: THYROID HORMONES
class code: H03AA
drug2
drug name: CHLOROQUINE
rxNorm: 2393
atc: P01BA01
Risk of clinical hypothyroidism in patients taking thyroid hormones in substitution therapy
severity: Precaution for use
Monitoring of the serum concentrations of T3 and T4 and adjustment of the dosage of the thyroid hormone, if needed, during the treatment with the antimalarial and after it is stopped.

***interaction***
drug1
class name: THYROID HORMONES
class code: H03AA
drug2
class name: NON-CONTRACEPTIVE ESTROGENS
class code: G03C-001
Risk of clinical hypothyroidism in cases of estrogen substitution therapy
severity: Precaution for use
Clinical and biological monitoring; possible adjustment of the doses of the thyroid hormone for menopausal women taking estrogens.

***interaction***
drug1
class name: THYROID HORMONES
class code: H03AA
drug2
drug name: IRON
rxNorm: 1431589
atc: B03A
Decrease of the digestive absorption of the thyroid hormones
severity: Precaution for use
Take the thyroid hormones at a different time from the iron (more than 2 hours apart, if possible).

***interaction***
drug1
class name: THYROID HORMONES
class code: H03AA
drug2
drug name: IMATINIB
rxNorm: 282388
atc: L01XE01
Risk of reduction of the effectiveness of the thyroid hormones
severity: Take into account

***interaction***
drug1
class name: THYROID HORMONES
class code: H03AA
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Risk of reduction of the effectiveness of the thyroid hormones due to the increase of their hepatic metabolism by the ritonavir
severity: Precaution for use
Clinical and biological monitoring and possible adjustment of the dosage of the thyroid hormones.

***interaction***
drug1
class name: THYROID HORMONES
class code: H03AA
drug2
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
Risk of disequilibrium of the thyroid replacement therapy in cases where there is treatment with orlistat
severity: Take into account

***interaction***
drug1
class name: THYROID HORMONES
class code: H03AA
drug2
drug name: PROGUANIL
rxNorm: 2382
atc: P01BB01
more atc: P01BB51
Risk of clinically low thyroid with patients having thyroid replacement therapy
severity: Precaution for use
Monitoring of the serum concentrations of T3 and T4 and adjustment if needed of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped. 

***interaction***
drug1
class name: THYROID HORMONES
class code: H03AA
drug2
class name: CHELATING RESINS
class code: C10-V0
Decrease of the digestive absorption of the thyroid hormones
severity: Precaution for use
Take the thyroid hormones at a different time from the resin (more than 2 hours apart, if possible).

***interaction***
drug1
class name: THYROID HORMONES
class code: H03AA
drug2
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
Described for phenytoin, rifampicin, and carbamazepine. [sic]

Risk of clinical hypothyroidism in patients with low thyroid, due to increase of the metabolism of the T3 and T4
severity: Precaution for use
Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with rifabutin and after it is stopped.

***interaction***
drug1
class name: THYROID HORMONES
class code: H03AA
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of clinically low thyroid in patients with already low thyroid due to increase of the metabolism of the T3 and the T4.
severity: Precaution for use
Monitoring of serum concentrations of T3 and T4 and adjustment if needed of the dosage of the thyroid hormones during treatment with rifampicin and after it is stopped. 

***interaction***
drug1
class name: THYROID HORMONES
class code: H03AA
drug2
drug name: SUCRALFATE
rxNorm: 10156
atc: A02BX02
Decrease of the digestive absorption of the thyroid hormones
severity: Precaution for use
Take the thyroid hormones at a different time from the sulcralfate (more than 2 hours apart if possible).

***interaction***
drug1
class name: THYROID HORMONES
class code: H03AA
drug2
drug name: SUNITINIB
rxNorm: 357977
atc: L01XE04
Risk of reduction of the effectiveness of the thyroid hormones
severity: Take into account
265-MINERAL-OILS.html


***interaction***
drug1
class name: MINERAL OILS
class code: A06AA-
more atc: D02AA
drug2
Drug with no codes: LATEX CONDOMS
Risk of rupture of the condom when used with lubricants containing mineral oils (paraffin oil, silicone oil, etc...)
severity: CONTRAINDICATION
Use hydrosoluble lubricants (glycerin, polyacrylamide...).
266-HYDROCORTISONE.html


***interaction***
drug1
drug name: HYDROCORTISONE
rxNorm: 5492
more atc: A01AC03
more atc: A07EA02
more atc: D07XA01
more atc: H02AB09
more atc: S01BA02
more atc: S01CB03
more atc: S02BA01
more atc: D07AC16
more atc: D07CA01
more atc: S01CA03
more atc: S02CA03
more atc: S03CA04
more atc: D07BA04
more atc: S01BB01
more atc: D07AB11
more atc: D07AB02
more atc: D07BB04
more atc: R01AD60
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants
severity: Precaution for use
Clinical and biological monitoring; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 
267-HYDROQUINIDINE.html


***interaction***
drug1
drug name: HYDROQUINIDINE
rxNorm: 27220
drug2
class name: URINARY ALKALIZERS
class code: B05-001
Increase of the plasma concentrations of the hydroquinidine and risk of overdose (decrease of the renal excretion of the hydroquinidine due to alkalinizing of the urine )
severity: Precaution for use
Clinical monitoring, EKG, and, possibly testing of the concentrations of the hydroquinidine; if needed, adjustment of the dosage during the alkalinizing treatment and after it is stopped. 

***interaction***
drug1
drug name: HYDROQUINIDINE
rxNorm: 27220
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction).
severity: Precaution for use
Clinical monitoring and EKG. In the case of unexpected results, test the digoxinemia and adjust the dosage.

***interaction***
drug1
drug name: HYDROQUINIDINE
rxNorm: 27220
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Risk of tinnitis and/or loss of hearing acuity: cinchonism linked to a decrease of the hepatic metabolism of the antiarrythmic by the itraconazole
severity: Precaution for use
Monitoring of the plasma concentrations of the antiarrythmic and possible decrease of its dosage if necessary.
268-HYDROXYCARBAMIDE.html


***interaction***
drug1
drug name: HYDROXYCARBAMIDE 
rxNorm: 5552
atc: L01XX05
drug2
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
When indicated for a patient with drepanocytosis (sickle cell anemia), theoretical risk of general fatal vaccine disease. 
severity: Not recommended
Administering these together should be considered only if the benefits are estimated to be greater than the this risk.
269-HYDROXYCHLOROQUINE.html


***interaction***
drug1
drug name: HYDROXYCHLOROQUINE
rxNorm: 5521
atc: P01BA02
drug2
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
With the metoprolol used in heart failure: risk of increase of the undesirable effects of metoprolol due to decrease of its hepatic metabolism by the hydroxycloroquine
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the hydroxychloroquine

***interaction***
drug1
drug name: HYDROXYCHLOROQUINE
rxNorm: 5521
atc: P01BA02
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of decrease of the therapeutic effect of the hydroxychloroquine, due to increase of its metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the hydroxychloroquine during the treatment with rifampicin and after it is stopped.

***interaction***
drug1
drug name: HYDROXYCHLOROQUINE
rxNorm: 5521
atc: P01BA02
drug2
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrhythmias, especially of torsades de pointes 
severity: Contraindication
--with the citalopram, the domperidone, the escitalopram, the hydroxyzine and the piperaquine
26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html


***interaction***
drug1
class name: ALPHA BLOCKERS FOR UROLOGICAL USE
class code: G04CA-001
drug2
class name: ANTIHYPERTENSIVE ALPHA BLOCKERS
class code: C02CA0-001
Increase of the hypotensive effect. Risk of severe orthostatic hypotension. 
severity: Not recommended

***interaction***
drug1
class name: ALPHA BLOCKERS FOR UROLOGICAL USE
class code: G04CA-001
drug2
class name: ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS
class code: C0-001
Increase of the hypotensive effect. Increased risk of orthostatic hypotension 
severity: Take into account

***interaction***
drug1
class name: ALPHA BLOCKERS FOR UROLOGICAL USE
class code: G04CA-001
drug2
class name: TYPE 5 PHOSPHODIESTERASE INHIBITORS
class code: G04BE
Risk of orthostatic hypotension, especially in older patients


severity: Not recommended
-with doxazosin
270-HYPERKALEMIA-INDUCING-MEDICATIONS.html


***interaction***
drug1
class name: HYPERKALEMIA INDUCING MEDICATIONS
class code: M01A-001
drug2
class name: OTHER HYPERKALEMIA INDUCING MEDICATIONS
class code: M01A-001
Risk of increase of hyperkalemia, potentially lethal. 
severity: Take into account
271-HYPNOTICS.html


***interaction***
drug1
class name: HYPNOTICS
class code: N05-R06
drug2
class name: OTHER HYPNOTICS
class code: N05-R06
Increase of central nervous system depression
severity: Take into account
272-POTASSIUM-LOWERING-MEDICATIONS.html


***interaction***
drug1
class name: POTASSIUM LOWERING AGENTS
class code: C03-001
drug2
class name: OTHER POTASSIUM LOWERING AGENTS
class code: C03-001
Increased risk of hypokalemia
severity: Precaution for use
Monitoring of kalemia with correction if needed.

***interaction***
drug1
class name: POTASSIUM LOWERING AGENTS
class code: C03-001
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Hypokaliemia that promotes the toxic effects of the digitalics.
severity: Precaution for use
Correct beforehand any hypokaliemia and maintain clinical monitoring, electrolite monitoring, and electrocardiographic monitoring.

***interaction***
drug1
class name: POTASSIUM LOWERING AGENTS
class code: C03-001
drug2
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrhythmias, especially torsades de pointes
severity: Precaution for use
Correct any hypokalemia before administering the product and maintain clinical monitoring, electrolyte monitoring and electrocardiographic monitoring. 
273-HYPONATREMIA-INDUCING-MEDICATIONS.html


***interaction***
drug1
class name: HYPONATREMIA INDUCING MEDICATIONS
class code: C03EA
drug2
class name: OTHER HYPONATREMIA INDUCING MEDICATIONS
class code: C03EA
Increase of the risk of hyponatremia
severity: Take into account
274-IBRUTINIB.html


***interaction***
drug1
drug name: IBRUTINIB
rxNorm: 1442981
atc: L01XE27
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the amiodarone
severity: Precaution for use
Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg per day during the length of time these medications are administered together.

***interaction***
drug1
drug name: IBRUTINIB
rxNorm: 1442981
atc: L01XE27
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the diltiazem
severity: Precaution for use
Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg/day during the length of time these medications are administered together.

***interaction***
drug1
drug name: IBRUTINIB
rxNorm: 1442981
atc: L01XE27
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the plasma concentrations of irutinib due to decrease of its hepatic metabolism by the verapamil
severity: Precaution for use
Strict clinical monitoring and reduction of the dose of ibrutinib to 140mg per day during the length of time these medications are administered together. 
275-IDELALISIB.html


***interaction***
drug1
drug name: IDELALISIB
rxNorm: 1544460
atc: L01XX47
drug2
class name: CALCIUM CHANNEL BLOCKERS 
class code: CO8CA-001
Increase of the undesirable effects of the calcium channel blocker, of the orthostatic hypotension sort, especially with older patients
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the calcium channel blocker during the treatment with idelalisib and after it is stopped. 

***interaction***
drug1
drug name: IDELALISIB
rxNorm: 1544460
atc: L01XX47
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer
severity: Not recommended

***interaction***
drug1
drug name: IDELALISIB
rxNorm: 1544460
atc: L01XX47
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of idelalisib due to decrease of its hepatic metabolism by the inhibitor
severity: Take into account

***interaction***
drug1
drug name: IDELALISIB
rxNorm: 1544460
atc: L01XX47
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of large decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the St Johns wort
severity: Not recommended

***interaction***
drug1
drug name: IDELALISIB
rxNorm: 1544460
atc: L01XX47
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer.
severity: Not recommended

***interaction***
drug1
drug name: IDELALISIB
rxNorm: 1544460
atc: L01XX47
drug2
class name: SUBSTRATES AT RISK OF CYP3A4
class code: L01N01
Increase of the plasma concentrations of the substrate due to decrease of its hepatic metabolism by the idelalisib.
severity: Not recommended
276-IFOSFAMIDE.html


***interaction***
drug1
drug name: IFOSFAMIDE
rxNorm: 5657
atc: L01AA06
drug2
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
Risk of increase of the neurotoxicity of the ifosfamide
severity: Take into account

***interaction***
drug1
drug name: IFOSFAMIDE
rxNorm: 5657
atc: L01AA06
drug2
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
Risk of increase of the neurotoxicity of the ifosfamide due to increase of its hepatic metabolism by the phenobarbital
severity: Not recommended

***interaction***
drug1
drug name: IFOSFAMIDE
rxNorm: 5657
atc: L01AA06
drug2
drug name: VEMURAFENIB
rxNorm: 1147220
atc: L01XE15
Risk of decrease of the concentrations of the ifosfamide, with increase of its active metabolite and increased toxicity
severity: Take into account
277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html


***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
Drug with no codes: ALCOHOL (DRINK OR INGREDIENT)
Increase of the hypertensive and/or hyperthermic effects of the tyramine present in certain alcoholic drinks (chianti, certain beers, etc.)
severity: Not recommended
Avoid taking alcoholic beverages and medications containing alcohol. 

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
class name: ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)
class code: A01AD
Serious ventricular arrhythmias due to increased cardiac sensitization.
severity: Precaution for use
Limit the amount, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
drug name: DEXTROMETHORPHAN
rxNorm: 3289
atc: N07XX59
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma
severity: CONTRAINDICATION

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
drug name: GUANETHIDINE
rxNorm: 5036
more atc: C02CC02
more atc: S01EX01
more atc: C02LF01
With the guanethidine used by IV route: risk of unforeseeable vascular reactions, especially hypotension
severity: CONTRAINDICATION 
Interrupt the treatment with the MAOI two weeks before the treatment with guanethidine.

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
class name: CATECHOL-O-METHYLTRANSFERASE INHIBITORS (COMT) 
class code: COMT
Increase of the pharmacological effects, and especially increase in blood pressure and contraction of the blood vessels by the catecholamines due to the combined inhibition of their metabolism
severity: CONTRAINDICATION

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
class code: N06AB
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma
severity: CONTRAINDICATION
Wait two weeks between the discontinuation of the MAOI and the start of the treatment with the SSRI, and at least a week between the end of treatment with the SSRI (except fluoxetine: five weeks) and the start [sic]. 

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
class name: MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS
class code: N06A
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.
severity: CONTRAINDICATION 
Wait two weeks between stopping the MAOI and the start of the other treatment, and at least a week between the end of that treatment and the start of the MAOI.

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
drug name: MIDODRINE
rxNorm: 6963
atc: C01CA17
Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped.
severity: CONTRAINDICATION

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of appearance of a serotonin syndrome
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. 

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
drug name: PETHIDINE 
rxNorm: 6754
more atc: N02AB02
more atc: N02AG03
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma
severity: CONTRAINDICATION

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
drug name: RESERPINE
rxNorm: 9260
atc: C02AA02
Psychomotor agitation, convulsions, hypertension
severity: CONTRAINDICATION

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
class name: ALPHA SYMPATHOMIMETICS (ORAL AND/OR NASAL ROUTES)
class code: R01AA
Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped
severity: Not recommended

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
class name: ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)
class code: C01CA
Increase of the pressor action of the sympathomimetic, most often moderate.
severity: Precaution for use
Only use under strict medical monitoring. 

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
class name: INDIRECT SYMPATHOMIMETICS
class code: C01CA-R01BA
Paroxysmal hypertension, hyperthermia that can be fatal. Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI has been stopped
severity: CONTRAINDICATION

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
drug name: TETRABENAZINE
rxNorm: 10390
atc: N07XX06
Risk of hypertensive crises. Because of the duration of the action of the MAOI, this interaction is still theoretically possible two weeks after the MAOI is stopped
severity: CONTRAINDICATION

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
drug name: TIANEPTINE
rxNorm: 38252
atc: N06AX14
Risk of drop in blood pressure, paroxysmal hypertension, hyperthermia, convulsions, death
severity: Not recommended

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
drug name: TRAMADOL
rxNorm: 10689
atc: N02AX02
Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma
severity: CONTRAINDICATION

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
class name: TRIPTANS METABOLIZED BY THE MAO
class code: N02CC-002
Risk of arterial hypertension, of constriction of the coronary arteries 
severity: CONTRAINDICATION

***interaction***
drug1
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
drug2
class name: TRIPTANS NOT METABOLIZED BY THE MAO
class code: NO2CC-003
Risk of arterial hypertension, of constriction of the coronary arteries 
severity: Not recommended 
278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html


***interaction***
drug1
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
drug2
drug name: DEXTROMETHORPHAN
rxNorm: 3289
atc: R05DA09
Risk of appearance of serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma
severity: Not Recommended

***interaction***
drug1
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
drug2
class name: MAOI-B 
class code: N04BD0-001
Risk of rapid elevation of blood pressure, due to loss of selectivity on the monoamine oxydase, especially in case of eating food rich in tyramine (cheese, beer, ...)
severity: CONTRAINDICATION

***interaction***
drug1
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
drug2
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
class code: N06AB
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma
severity: Not recommended
If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration at minimum recommended dosages.

***interaction***
drug1
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
drug2
class name: MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS
class code: N06A
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, confusion, even coma
severity: Not recommended
If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration of the substances together with minimum recommended dosages. 

***interaction***
drug1
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
drug2
drug name: ST JOHN'S WORT
rxNorm: 258326
Risk of appearance of a serotonin syndrome
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.

***interaction***
drug1
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
drug2
drug name: PETHIDINE 
rxNorm: 6754
more atc: N02AB02
more atc: N02AG03
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.
severity: CONTRAINDICATION

***interaction***
drug1
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
drug2
class name: ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)
class code: C01CA
By extrapolation from the non selective MAOIs: risk of increase of the pressor action.
severity: Precaution for use
To be used only under strict medical monitoring.

***interaction***
drug1
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
drug2
class name: INDIRECT SYMPATHOMIMETICS
class code: C01CA-R01BA
Risk of constriction of blood vessels and/or rapid elevation of blood pressure
severity: Contraindication:
with the bupropion

***interaction***
drug1
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
drug2
drug name: TRAMADOL
rxNorm: 10689
atc: N02AX02
Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma
severity: Not Recommended

***interaction***
drug1
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
drug2
class name: TRIPTANS METABOLIZED BY THE MAO
class code: N02CC-002
Risk of arterial hypertension, of constriction of coronary arteries
severity: CONTRAINDICATION

***interaction***
drug1
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
drug2
class name: TRIPTANS NOT METABOLIZED BY THE MAO
class code: NO2CC-003
Risk of arterial hypertension, of constriction of coronary arteries
severity: Not Recommended
279-MAOI-B.html


***interaction***
drug1
class name: MAOI-B 
class code: N04BD0-001
drug2
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
Risk of hypertensive crises
severity: CONTRAINDICATION

***interaction***
drug1
class name: MAOI-B 
class code: N04BD0-001
drug2
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
Risk of rapid elevation of blood pressure, due to loss of selectivity on the monamine oydase, especially in case of consuming food rich in tyramine (cheese, beer,)
severity: CONTRAINDICATION

***interaction***
drug1
class name: MAOI-B 
class code: N04BD0-001
drug2
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
class code: N06AB
Risk of appearance of a serotonin syndrome
severity: Take into account

***interaction***
drug1
class name: MAOI-B 
class code: N04BD0-001
drug2
drug name: LEVODOPA
rxNorm: 6375
more atc: N04BA01
more atc: N04BA02
more atc: N04BA03
Increased risk of orthostatic hypotension
severity: Take into account

***interaction***
drug1
class name: MAOI-B 
class code: N04BD0-001
drug2
drug name: PETHIDINE 
rxNorm: 6754
more atc: N02AB02
more atc: N02AG03
Symptoms of central nervous system excitability, evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma
severity: CONTRAINDICATION

***interaction***
drug1
class name: MAOI-B 
class code: N04BD0-001
drug2
drug name: TRAMADOL
rxNorm: 10689
atc: N02AX02
Risk of appearance of a serotonin syndrome
severity: Take into account

***interaction***
drug1
class name: MAOI-B 
class code: N04BD0-001
drug2
class name: TRIPTANS METABOLIZED BY THE MAO
class code: N02CC-002
Risk of arterial hypertension, of constriction of the coronary arteries
severity: CONTRAINDICATION

***interaction***
drug1
class name: MAOI-B 
class code: N04BD0-001
drug2
class name: TRIPTANS NOT METABOLIZED BY THE MAO
class code: NO2CC-003
Risk of arterial hypertension, of constriction of the coronary arteries
severity: Not recommended
27-ALPHA-TOCOPHEROL.html


***interaction***
drug1
drug name: ALPHA-TOCOPHEROL
rxNorm: 11256
more atc: A11HA03
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
With the vitamin E used in doses greater than or equal to 500 mg per day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with vitamin E and after it is stopped. 
280-IMATINIB.html


***interaction***
drug1
drug name: IMATINIB
rxNorm: 282388
atc: L01XE01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the risk of hemorrhage
severity: Not recommended
If administering these together cannot be avoided, strict clinical monitorinig and frequent testing of the INR

***interaction***
drug1
drug name: IMATINIB
rxNorm: 282388
atc: L01XE01
drug2
class name: THYROID HORMONES
class code: H03AA
Risk of reduction of the effectiveness of the thyroid hormones
severity: Take into account
281-IMMUNOSUPPRESSANTS.html


***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
Increase of the blood concentrations of the immunosuppressant (especially for the ciclosporin, extremely large for the tacrolimus)
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage of the immunosuppressant during the administration of the medications together and after it is stopped. 

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism
severity: Not recommended
If these must be administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage. 

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
class name: CYTOTOXICS
class code: L01
Excessive immunodepression with risk of lymphoproliferative syndrome
severity: Take into account

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: DALFOPRISTIN
rxNorm: 229369
atc: J01FG02
Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the treatment with these medications together and after it is stopped.

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
Large increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism
severity: Not recommended

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism
severity: Not recommended
If these are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
Risk of increase of the blood concentrations of the immunosuppressant due to the inhibition of its metabolism and of the creatinemia
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped. 

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
class name: ANTI-LYMPHOCYTE GLOBULINS
class code: L04AA0-001
Excessive immunodepression with risk of lymphoproliferative disorders (LPDs)
severity: Take into account

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Decrease of the blood concentrations and of the effectiveness of the immunosuppressant, due to increase of its hepatic metabolism by the inducer


severity: Precaution for use
Increase the dosage of the immunosuppressant according to tests of the blood concentrations. Reduce the dosage after the inducer is stopped.

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism
severity: Not recommended
If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and adjustment of its dosage.

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism
severity: Not recommended
If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.
severity: Not recommended
If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Decrease of the blood concentrations of the immunosuppressant, due to the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect which can have possibly serious consequences (rejection of a graft).
severity: CONTRAINDICATION

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: NICARDIPINE
rxNorm: 7396
atc: C08CA04
Increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage of the immunosuppressant during the treatment and after it is stopped.

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
Drug with no codes: GRAPEFRUIT (JUICE AND FRUIT)
Increase of the bioavailability of the immunosuppressant and as a result of its undesirable effects. 
severity: Not recommended

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism
severity: Not recommended
If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: PRISTINAMYCIN
rxNorm: 66958
atc: J01FG01
Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of its dosage during the administration of the medications together and after it is stopped.

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: QUINUPRISTINE
rxNorm: 135098
atc: J01FG02
Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism 
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped.

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: RANOLAZINE
rxNorm: 35829
atc: C01EB18
Increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism by the ranolazine
severity: Precaution for use
Clinical and biological monitoring and possible adjustment of the dosage of the immunosuppressant.

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
Increase of the blood concentrations of the immunosuppressant (decrease of its hepatic metabolism)
severity: CONTRAINDICATION

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
Increase of the plasma concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the telaprevir
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of its dosage during the administration of the substances together and after it is stopped. 

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism
severity: Not recommended
If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
Risk of general vaccinal disease, possibly fatal. 
severity: CONTRAINDICATION
And during the 3 months following the treatment. 

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: VEMURAFENIB
rxNorm: 1147220
atc: L01XE15
Risk of decrease of the concentrations of the immunosuppressants, with the consequence of a risk of ineffectiveness
severity: Not recommended

***interaction***
drug1
class name: IMMUNOSUPPRESSANTS
class code: L04A
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the voriconazole


severity: Not recommended
-with the everolimus, the sirolimus, and the temsirolimus
282-INDINAVIR.html


***interaction***
drug1
drug name: INDINAVIR
rxNorm: 114289
atc: J05AE02
drug2
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
Risk of reduction of the effectiveness of the indinavir
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together. 

***interaction***
drug1
drug name: INDINAVIR
rxNorm: 114289
atc: J05AE02
drug2
drug name: NEVIRAPINE
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
Risk of reduction of the effectiveness of the indinavir
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together.
283-ENZYMATIC-INDUCERS.html


***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
class name: ANDROGENS
class code: A14AA0
Risk of decrease of the plasma concentrations of the androgen and as a result of its effectiveness, due to increase of its hepatic metabolism by the inducer
severity: Precaution for use
Clinical and biological monitoring during the administrations of these substances together and 1 to 2 weeks after the inducer is stopped.

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: ARIPIPRAZOLE
rxNorm: 89013
atc: N05AX12
Decrease of the plasma concentrations of the aripiprazole
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the aripiprazole during the administration of these substances together and 1 to 2 weeks after the inducer is stopped

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: BEDAQUILINE
rxNorm: 1364504
atc: J04AK05
Decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer
severity: Not recommended

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: BORTEZOMIB
rxNorm: 358258
atc: L01XX32
Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness
severity: Take into account

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: CABAZITAXEL
rxNorm: 996051
atc: L01CD04
Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness
severity: Take into account

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: CYPROTERONE
rxNorm: 3014
more atc: G03HA01
more atc: G03HB01
Risk of decrease of the effectiveness of the cyproterone
severity: Not recommended
--in its use as a hormonal contraceptive: use instead another method of contraception in particular a barrier type, during the length of the time these substances are administered together and a cycle after

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: DACLATASVIR
rxNorm: 1606218
atc: J05AX14
Decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer
severity: Contraindication
-with the rifampicin

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: DASABUVIR
rxNorm: 1597381
atc: J05AX16
Risk of decrease of the plasma concentrations of the dasabuvir by the inducer.
severity: CONTRAINDICATION

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: DISOPYRAMIDE
rxNorm: 3541
atc: C01BA03
Risk of decrease of the concentrations of the disopyramide by the inducer
severity: Precaution for use
Clinical monitoring and possibly adjustment of the dosage of the disopyramide during the administration of these substances together and 1 to 2 weeks after the inducer is stopped

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: DOCETAXEL
rxNorm: 72962
atc: L01CD02
Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness
severity: Take into account

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: DOLUTEGRAVIR
rxNorm: 1433868
atc: J05AX12
Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer
severity: Not recommended
-in case of resistance to the class of integrase inhibitors

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: ERIBULINE
rxNorm: 1045453
atc: L01XX41
Risk of decrease of the plasma concentrations of eribuline by the inducer.
severity: Not recommended

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
Decrease of the contraceptive effectiveness, due to increase of the hepatic metabolism of the hormonal contraceptive by the inducer
severity: Not recommended
Another method of contraception, in particular a barrier type, should be used during the treatment with these substances together and a cycle following. 

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: HYDROCORTISONE
rxNorm: 5492
more atc: A01AC03
more atc: A07EA02
more atc: C05AA01
more atc: D07AA02
more atc: D07XA01
more atc: H02AB09
more atc: S01BA02
more atc: S01CB03
more atc: S02BA01
Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants
severity: Precaution for use
Clinical and biological monitoring; adjustment of the dosage of the hydrocortisone during the time it is taken with the enzymatic inducer and after the enzymatic inducer is stopped. 

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Decrease of the blood concentrations and of the effectiveness of the immunosuppressant, due to increase of its hepatic metabolism by the inducer
severity: Precaution for use
Increase the dosage of the immunosuppressant according to tests of the blood concentrations. Reduce the dosage after the inducer is stopped.

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: IRINOTECAN
rxNorm: 51499
atc: L01XX19
Probable decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment
severity: Not recommended

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: ISAVUCONAZOLE
rxNorm: 1720882
atc: J02AC05
Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the inducer
severity: CONTRAINDICATION

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the inducer
severity: Not recommended

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: IVACAFTOR
rxNorm: 1243041
atc: R07AX02
Large decrease of the concentrations of the ivacaftor, with risk of loss of effectiveness
severity: Not recommended

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: LURASIDONE
rxNorm: 1040028
atc: N05AE05
Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the inducer.
severity: CONTRAINDICATION

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: MACITENTAN
rxNorm: 1442132
atc: C02KX04
Decrease of the plasma concentrations of macitentan due to increase of its metabolism by the inducer
severity: Not recommended

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: MARAVIROC
rxNorm: 620216
atc: J05AX09
In the absence of co-administration with a strong inhibitor of CYP3A4, decrease of the concentrations of maraviroc by the inducer.
severity: Precaution for use
The dose of maraviroc must be increased to 600mg twice a day in this situation. 

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: METHADONE
rxNorm: 6813
atc: N07BC02
Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism
severity: Precaution for use
Increase the frequency of the doses of methadone (2 to 3 times a day instead of a single dose per day).

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: MIANSERIN
rxNorm: 6929
atc: N06AX03
Risk of ineffectiveness of the mianserin
severity: Not recommended

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: OLAPARIB
rxNorm: 1597582
atc: L01XX46
Decrease, possibly very large depending on the inducer, of the plasma concentrations of the olaparib due to increase of its hepatic metabolism by the inducer
severity: Not recommended

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
class name: OMBITASVIR + PARITAPREVIR
class code: OMPA
Decrease of the plasma concentrations of the bitherapy due to increase of its hepatic metabolism by the inducer
severity: CONTRAINDICATION

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: OXYCODONE
rxNorm: 7804
atc: N02AA05
Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the inducer
severity: Not recommended
Possible adjustment of the dosage of oxycodone

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
Decrease of the contraceptive effectiveness of the hormonal contraceptive, due to increase of its hepatic metabolism by the inducer. 
severity: Not recommended
Another method of contraception, in particular a barrier type, should be used during the length of time that these substances are administered together and one cycle following.

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
class name: NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT
class code: G03-003
Decrease of the effectiveness of the progestogen
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the inducer and after it is stopped. 

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: REGORAFENIB
rxNorm: 1312397
atc: L01XE21
Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the inducer
severity: Not recommended

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: RILPIVIRINE
rxNorm: 1102270
atc: J05AG05
Significant decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the inducer
severity: CONTRAINDICATION

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: SERTRALINE
rxNorm: 36437
atc: N06AB06
Risk of ineffectiveness of the treatment by the antidepressant 
severity: Not recommended

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: SIMEPREVIR
rxNorm: 1482790
atc: J05AE14
Decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the inducer
severity: Not recommended

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: SOFOSBUVIR
rxNorm: 
more atc: J05AX15
Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the inducer.
severity: Contraindication 
--wth the rifampicin 

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: TENEFOVIR ALAFENAMIDE
rxNorm: 1721603
Decrease of the plasma concentrations of the tenofovir alafenamide due to decrease of its absorption by the inducer
severity: Not recommended
If administration of these together cannot be avoided, clinical monitoring during the administration and 1 to 2 weeks after the inducer is stopped

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: VEMURAFENIB
rxNorm: 1147220
atc: L01XE15
Risk of decrease of the concentrations of the vermurafenib, with lower effectiveness
severity: Not recommended

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: VISMODEGIB
rxNorm: 1242987
atc: L01XX43
Risk of decrease of the plasma concentrations of vismodegib due to increase of its hepatic metabolism by the inducer
severity: Not recommended

***interaction***
drug1
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
drug2
drug name: VORTIOXETINE
rxNorm: 1455099
atc: N06AX26
Decrease of the plasma concentrations of the vortioxetine
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the administration with the inducer and 1 to 2 weeks after the inducer is stopped.
284-CATECHOL-O-METHYLTRANSFERASE-INHIBITORS-(COMT).html


***interaction***
drug1
class name: CATECHOL-O-METHYLTRANSFERASE INHIBITORS (COMT) 
class code: COMT
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Increase of the pharmacological effects, and especially increase in blood pressure and contraction of the blood vessels, by the catecholamines due to the combined inhibition of their metabolism
severity: CONTRAINDICATION
285-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html


***interaction***
drug1
class name: TYPE 5 PHOSPHODIESTERASE INHIBITORS
class code: G04BE
drug2
class name: ALPHA BLOCKERS FOR UROLOGICAL USE
class code: G04CA-001
Risk of orthostatic hypotension, especially with older patients


severity: Not recommended
-with the doxazosin

***interaction***
drug1
class name: TYPE 5 PHOSPHODIESTERASE INHIBITORS
class code: G04BE
drug2
class name: ANTIHYPERTENSIVE ALPHA BLOCKERS
class code: C02CA0-001
Risk of orthostatic hypotension, especially with older patients
severity: Not recommended 
-with the doxazosine

***interaction***
drug1
class name: TYPE 5 PHOSPHODIESTERASE INHIBITORS
class code: G04BE
drug2
class name: NITRATE DERIVATIVES AND RELATED
class code: C01D-001
Risk of significant hypotension (synergic effect) capable of aggravating the state of myocardial ischemia and provoking an acute cardiac accident
severity: CONTRAINDICATION

***interaction***
drug1
class name: TYPE 5 PHOSPHODIESTERASE INHIBITORS
class code: G04BE
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase (very large for the avanafil and the vardenafil) of the plasma concentrations of the type 5 phosphodiesterase inhibitor, with risk of hypotension (severe with the vardenafil)
severity: To know the risks and the levels of constraint for each Type 5 phosphodiesterase inhibitor with the strong inhibitors of CYP3A4, consult the AMM ["Authorisation de la mise au march", a French document for all medications authorized to be marketed in France with information about them] specific for each one of them.

***interaction***
drug1
class name: TYPE 5 PHOSPHODIESTERASE INHIBITORS
class code: G04BE
drug2
drug name: RIOCIGUAT
rxNorm: 1439816
atc: C02KX05
Risk of large drop in blood pressure (synergic effect)
severity: CONTRAINDICATION
286-XANTHINE-OXYDASE-INHIBITORS.html


***interaction***
drug1
class name: XANTHINE OXYDASE INHIBITORS
class code: M04AA0
drug2
class name: ANTIPURINES
class code: ANTIPUR
Possibly serious medullary insufficiency
severity: CONTRAINDICATION

***interaction***
drug1
class name: XANTHINE OXYDASE INHIBITORS
class code: M04AA0
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
With large doses of the inhibitor, increase of the plasma concentrations of theophylline due to inhibition of its metabolism. 
severity: Precaution for use
Clinical monitoring and testing of the theohyllinemia up to two to three weeks after the beginning of the treatment with the inhibitor; if there is reason for it, adjustment of the dosage during the treatment with these substances together. 
287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html


***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):

Acute renal insufficiency in dehydrated patients due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.
severity: Precaution for use
Hydrate the patient and monitor renal function at the beginning of treatment.

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
drug name: ALISKIREN
rxNorm: 325646
atc: C09XA02
Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardiovascular disease
severity: Contraindication:
-for patients with diabetes or renal insufficiency

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
In situations where the administration of these medications together is possible, increased risk of degradation of renal function, even acute renal insufficiency, and increase of the hyperkalemia as well as hypotension and fainting or loss of consciousness. 
severity: Take into account

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Acute renal insufficiency with patients at risk (older patients, dehydrated ones, those taking diuretics, those having altered renal function) due to decrease of the glomerular filtration (inhibition of the vasodilating prostaglandins due to the NSAIs). These effects are generally reversible. Furthermore, reduction of the antihypertensive effect.
severity: Precaution for use
Hydrate the patient and monitor renal function at the beginning of treatment and regularly during the administration of these substances together.

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
class name: POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
Risk of hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia producing effects)
severity: Not recommended
--if the administration of these medications together is justified, strict testing of the kalemia and of the renal function.

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
class name: POTASSIUM LOWERING DIURETICS
class code: C03
Risk of abrupt arterial hypotension and/or acute renal insufficiency at the start of or when there is an increase of the dosage of the treatment with the ACE inhibitor in cases of pre-existing fluid depletion 
severity: Precaution for use
In arterial hypertension, when there is fluid depletion from a previous treatment with a diuretic, it is necessary:

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
drug name: EPLERENONE
rxNorm: 298869
atc: C03DA04
Increase of the risk of hyperkalemia, especially with older patients.
severity: Precaution for use
Strict testing of the kalemia and of renal function during the administration of these substances together. 

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
drug name: ESTRAMUSTINE
rxNorm: 4089
atc: L01XX11
Risk of increase of the undesirable effects of the angioneurotic edema type (angioedema) 
severity: Not recommended

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
drug name: EVEROLIMUS
rxNorm: 141704
atc: L04AA18
Increase of the risk of angioedema
severity: Take into account

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
class name: GLIPTINS
class code: A10B-001
Increase of the risk of the onset of angioedema, due to reduction of the activity of the enzyme dipetidyl peptidase-4 (DDP-4) by the gliptin, in patients treated with the ACE inhibitor
severity: Take into account

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
drug name: INSULIN
rxNorm: 5856
more atc: A10AC01
more atc: A10AC02
more atc: A10AC03
more atc: A10AC04
more atc: A10AD01
more atc: A10AD02
more atc: A10AD03
more atc: A10AD04
more atc: A10AD05
more atc: A10AE01
more atc: A10AE02
more atc: A10AE03
more atc: A10AE04
more atc: A10AE05
more atc: A10AF01
The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).
severity: Precaution for use
Reinforce self-monitoring of blood glucose

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Increase of the plasma concentrations of lithium which can reach toxic values (decrease of the renal excretion of the lithium)
severity: Not recommended
If the use of an ACE inhibitor is indispensable, strict monitoring of the plasma concentrations of lithium and adjustment of the dosage of the lithium. 

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
drug name: GOLD
rxNorm: 1311190
atc: V10AX06
more atc: M01CB01
more atc: M01CB02
more atc: M01CB03
more atc: M01CB04
more atc: M01CB05
more atc: V10AX06
With the gold salts administered by IV route: risk of nitritoid reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly a drop in blood pressure)
severity: Take into account

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
drug name: POTASSIUM
rxNorm: 8588
atc: A12BA
Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)
severity: Not recommended
Unless there is hypokalemia.

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
drug name: RACECADOTRIL
rxNorm: 16738
atc: A07XA04
Risk of increase of the undesirable effects of the angioedema type. 
severity: Contraindication
--in case of preceding angioedema with ACE inhibitors

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
drug name: SACUBITRIL
rxNorm: 1656328
more atc: C09DX04
Increase of the risk of angiodema
severity: Contraindication

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
drug name: SPIRONOLACTONE
rxNorm: 9997
atc: C03DA01
With the spironolactone at dosages from 12.5 to 50 mg per day, and with low doses of ACE inhibitors

In the treatment of class III or IV heart failure (NYHA) with an ejection fraction <35% and previous treatment with an ACE inhibitor + a loop diuretic: risk of hyperkalemia, potentially lethal, in case of failure to follow the prescribed doses for this combination of medications.
severity: Precaution for use
Verify the absence of pre-existing hyperkalemia and renal insufficiency. Strict biological monitoring of the kalemia and of the creatinemia (1 time per week during the first month, then one time per month thereafter). 

***interaction***
drug1
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
drug2
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in diabetic patients treated with glucose lowering sulfonamides. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for the glucose lowering sulfonamides)
severity: Precaution for use
Reinforce self-monitoring of blood glucose.
288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html


***interaction***
drug1
class name: HMG-COA REDUCTASE INHIBITORS (STATINS) 
class code: C10AA
drug2
drug name: FUSIDIC ACID
rxNorm: 4608
more atc: D06AX01
more atc: D09AA02
more atc: J01XC01
more atc: S01AA13
Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type. 
severity: CONTRAINDICATION
Stop the treatment with the HMG Co-A reductase inhibitor before starting a treatment with fusidic acid or use another antibiotic

***interaction***
drug1
class name: HMG-COA REDUCTASE INHIBITORS (STATINS) 
class code: C10AA
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist

***interaction***
drug1
class name: HMG-COA REDUCTASE INHIBITORS (STATINS) 
class code: C10AA
drug2
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis
severity: Precaution for use
Clinical and biological monitoring, especially at the beginning of the administration of these substances together.

***interaction***
drug1
class name: HMG-COA REDUCTASE INHIBITORS (STATINS) 
class code: C10AA
drug2
drug name: DAPTOMYCIN
rxNorm: 22299
atc: J01XX09
Risk of addition of the undesirable effects (dose dependent) of the rhabdomyolysis type.
severity: Not recommended
If the administration of these medications together cannot be avoided, reinforce biological monitoring (dosage of the CPK more than once a week) and strict clinical monitoring.

***interaction***
drug1
class name: HMG-COA REDUCTASE INHIBITORS (STATINS) 
class code: C10AA
drug2
drug name: ELTROMBOPAG
rxNorm: 711942
atc: B02BX05
Risk of increase of the toxicity of the statins, due to inhibition of their hepatic recapture
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the statin.

***interaction***
drug1
class name: HMG-COA REDUCTASE INHIBITORS (STATINS) 
class code: C10AA
drug2
class name: FIBRATES
class code: C01AB-001
Risk of addition of undesirable effects (dose-dependent) of the rhabdomyolosis type. Furthermore, with the gemfibrozil, decrease of the metabolism of the simvastatin and of the rosuvastatin, which increases the muscular risk, as well as the nephrotoxicity of the rosuvastatin
severity: Contraindication
--with the gemfibrosil and the simvastatin

***interaction***
drug1
class name: HMG-COA REDUCTASE INHIBITORS (STATINS) 
class code: C10AA
drug2
drug name: LEDIPASVIR
rxNorm: 1591922
Risk of increase of the plasma concentrations of the statin and of its undesirable effects of the rhabdomyolosis type.
severity: Contraindication
--with the rosuvastatin.

***interaction***
drug1
class name: HMG-COA REDUCTASE INHIBITORS (STATINS) 
class code: C10AA
drug2
drug name: LENALIDOMIDE
rxNorm: 342369
atc: L04AX04
Increased risk of the onset of rhabdomyolysis
severity: Precaution for use
Reinforce clinical and biological monitoring, especially during the first weeks of treatment.
289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html


***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
Increase of the plasma concentrations of afatinib due to increase of its absorption by the protease inhibitor
severity: Precaution for use
It is recommended that that the protease inhibitor be administered as far from the afatinib as possible, preferably at an interval of 6 to 12 hours from the dose of afatinib.

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: ALBENDAZOLE
rxNorm: 430
atc: P02CA03
Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the ritonavir, with risk of reduction of its effectiveness.
severity: Precaution for use
Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped. 

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
class name: VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE
class code: N02CA0-001
Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure
severity: CONTRAINDICATION

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Risk of reduction of the effectiveness of the protease inhibitor due to increase of its hepatic metabolism by the inducer


severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Variation of the effect of the vitamin K antagonist, most often by decreasing it
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the length of the treatment

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)
severity: Not recommended
Use weaker doses of atorvastatin. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: ATOVAQUONE
rxNorm: 60212
atc: P01AX06
Decrease, possibly very large, of the plasma concentrations of the atovaquone due to increase of its metabolism
severity: Not recommended

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
class name: OTHER CORTICOIDES, ESPECIALLY INHALED ONES
class code: D07AC-001
In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome, even of adrenal insufficiency 
severity: Take into account

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
Decrease of the concentrations of the boceprevir and of the lopinavir (or darunavir or fosamprenavir), with risk of therapeutic failure 
severity: Not recommended

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: BUPRENORPHINE
rxNorm: 1819
more atc: N02AE01
more atc: N07BC01
Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor
severity: Take into account

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of treatment with these medications together. 

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: CYPROTERONE
rxNorm: 3014
atc: G03HA01
Risk of decrease of the effectiveness of the cyyproterone.
severity: Not recommended
--in its use as a hormonal contraceptive: use instead another method ofcontraception in particular a barrier type, during the administration of these substances together and a cycle following

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome
severity: Take into account

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Increase of the digoxinemia, more marked for intravenous route, due to increase of the absorption of the digoxin or decrease of its renal clearance.
severity: Precaution for use
Clinical monitoring and, if there is reason for them, EKG and monitoring of the digoxinemia, with possible adjustment of the dosage of digoxin.

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: ERIBULINE
rxNorm: 1045453
atc: L01XX41
Increase of the plasma concentrations of eribuline by the ritonavir
severity: Not recommended

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of the hormonal contraceptive, because of the increase of its hepatic metabolism by the ritonavir.
severity: Not recommended
Another method of contraception, in particular a barrier type (condom or IUD), should be used during the length of the treatment with these medications together and a cycle following. 

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
class name: THYROID HORMONES
class code: H03AA
Risk of reduction of the effectiveness of the thyroid hormones due to increase of their hepatic metabolism by the ritonavir
severity: Precaution for use
Clinical and biological monitoring and possible adjustment of the dosage of the thyroid hormones.

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism
severity: Not recommended
If these substances are administered together, strict testing of the renal function, blood concentration dosages of the immunosuppressant, and adjustment of its dosage.

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the plasma concentration of the ritonavir boosted protease inhibitor or of the CYP3A4 inhibitor.
severity: Take into account
To know the risks and levels of severity of each ritonavir boosted protease inhibitor taken with the strong inhibitors of CYP3A4, consult the specificauthorization for sale to the public ("Authorisation de la Mise sur le Marche" a French document) for each one of them. 

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Risk of increase of the concentrations of itraconazole by the protease inhibitor
severity: Precaution for use
Clinical monitoring during the administration of these together. Administering large doses of itraconazole (>200 mg per day) is not recommended.

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: LAMOTRIGINE
rxNorm: 28439
atc: N03AX09
Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism by the ritonavir
severity: Not recommended
 -Avoid beginning the treatment with ritonavir during the period of adjustment of the dosage of lamotrigine

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: LUMEFANTRINE
rxNorm: 847728
atc: P01BF01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: METHADONE
rxNorm: 6813
atc: N07BC02
Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ritonavir
severity: Precaution for use
Regular clinical monitoring and possible adjustment of the dosage of methadone. 

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Decrease of the plasma concentrations of the protease inhibitor, due to the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (reduction of the antiretroviral effectiveness)
severity: CONTRAINDICATION
In the case of the substances being taken together by accident, do not stop the St Johns wort abruptly, but test the plasma concentrations (or the effectiveness) of the protease inhibitor before and then after the St Johns wort is stopped. 

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: MIZOLASTINE
rxNorm: 61455
atc: R06AX25
Risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: NINTEDANIB
rxNorm: 1592737
more atc: L01XE31
Increase of the plasma concentrations of nintedanib due to increase of its absorption by the ritonavir boosted protease inhibitor
severity: Precaution for use
Clinical monitoring during the administration of these substances together.

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
Risk of decrease of the contraceptive effectiveness because of decrease of the concentrations of hormonal contraceptive, due to the increase of its hepatic metabolism by the ritonavir
severity: Not recommended
Another method of contraception, in particular a barrier type (condom or IUD), should be used during the time the substances are administered together and one cycle following. 

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
Risk of reduction of the effectiveness of the protease inhibitor (even more so when the dosage of the rifabutin is large) for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin, for another thing.
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. 

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.

For the combination (saquinavir + ritonavir):

risk of severe hepatocellular toxicity
severity: CONTRAINDICATION
Until additional information about the ritonavir "boosted" protease inhibitors is available.

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: ROSUVASTATIN
rxNorm: 301542
atc: C10AA07
Increase of the plasma concentrations of the rosuvastatin due to increase of its absorption
severity: Precaution for use
Clinical and biological monitoring.

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolisis type (decrease of the hepatic metoblism of the simvastatin).
severity: CONTRAINDICATION

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
Decrease of the concentrations of the telaprevir and of the darunavir or of the fosamprenavir, with risk of therapeutic failure.
severity: Not recommended

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: TENEFOVIR ALAFENAMIDE
rxNorm: 1721603
With the atazanavir, the darunavir or the lopinavir, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption
severity: Precaution for use
In case of administration of these together, the dose of tenofovir alafenamide must be limited to 10 mg per day. The administration with the other protease inhibitors of HIV has not been studied.

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Decrease of the plasma concentrations of the theophylline, due to increase of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the protease inhibitor and after it is stopped.

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03XB02
Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the ritonavir
severity: Not recommended
Choose a therapeutic alternative that is little or not at all metabolized.

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
Increase of the concentrations of venlafaxine with risk of overdose
severity: Take into account

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
class name: VINCA ALKALOIDS
class code: L01CA
Increase of the toxicity of the antimitotic, due to decrease of its hepatic metabolism by the protease inhibitor. 
severity: Precaution for use
Strict clinical monitoring and possible adjustment of the dosage of the antimitotic. 

***interaction***
drug1
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
Very large reduction of the concentrations of the antifungal due to increase of its metabolism by the ritonavir, with risk of failure of the treatment
severity: Not recommended
28-ALPRAZOLAM.html


***interaction***
drug1
drug name: ALPRAZOLAM
rxNorm: 596
atc: N05BA12
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Possible increase of the sedative effect of the alprazolam
severity: Take into account
290-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html


***interaction***
drug1
class name: METABOLIZED TYROSINE-KINASE INHIBITORS
class code: L01XE
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the enzymatic inducer
severity: Not recommended

***interaction***
drug1
class name: METABOLIZED TYROSINE-KINASE INHIBITORS
class code: L01XE
drug2
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
Risk of decrease of the bioavailability of the tyrosine-kinase inhibitor, by reason of its pH dependent absorption
severity: Take into account
-except with the vandetanib.

***interaction***
drug1
class name: METABOLIZED TYROSINE-KINASE INHIBITORS
class code: L01XE
drug2
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
Risk of decrease of the bioavailability of the tyrosine-kinase inhibitor, by reason of its pH dependent absorption
severity: Take into account
-except with the imatinib and the vandetanib

***interaction***
drug1
class name: METABOLIZED TYROSINE-KINASE INHIBITORS
class code: L01XE
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the undesirable effects of the tyrosine kinase inhibitor due to decrease of its metabolism
severity: Not recommeded:
--with the axitinib, the bosutinib, the ceritinib, the cobimetinib, the dabrafenib, the dasatinib, the nilotinib, the sunitinib

***interaction***
drug1
class name: METABOLIZED TYROSINE-KINASE INHIBITORS
class code: L01XE
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Decrease of the plasma concentrations and of the effectiveness of the tyrosine-kinase inhibitor, due to increase of its metabolism by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
class name: METABOLIZED TYROSINE-KINASE INHIBITORS
class code: L01XE
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer
severity: Not recommended
291-DIRECT-THROMBIN-INHIBITORS.html


***interaction***
drug1
class name: DIRECT THROMBIN INHIBITORS
class code: BO1AE
drug2
Drug with no codes: OTHER MEDICATIONS ACTING ON HEMOSTASIS
Increase of the risk of hemorrhage 
severity: Take into account
292-STRONG-INHIBITORS-OF-CYP3A4.html


***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
class name: VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE
class code: N02CA0-001
Risk of constriction of the coronary arteries or of those of the extremities (ergotism), or of rapid elevation of blood pressure.
severity: CONTRAINDICATION

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: ALFENTANIL
rxNorm: 480
atc: N01AH02
Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism

.
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is treatment with a strong inhibitor of CYP3A4

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: ALFUZOSIN
rxNorm: 17300
atc: G04CA01
Risk of increase of the plasma concentrations of the alfuzosin and of its undesirable effects
severity: CONTRAINDICATION

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: ALRRAZOLAM
rxNorm: 596
atc: N05BA12
Possible increase of the sedative effect of the alprazolam
severity: Take into account

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
class name: CALCIUM CHANNEL BLOCKERS
class code: CO8CA-001
Increase of the undesirable effects of the calcium channel blockers, most often of the hypotension type, especially in older patients.
severity: Precaution for use
Clinical monitoring and dosage adjustment during the treatment with the enzyme inhibitor and after it is stopped

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
class name: URINARY ANTISPASMODICS
class code: DFST
Risk of increase of the undesirable effects
severity: Contraindication
--with darifenacine

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: APIXABAN
rxNorm: 1364430
atc: B01AF02
Increase of the plasma concentrations of the apixaban by the inhibitor, with increased risk of bleeding
severity: Not recommended

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: BEDAQUILINE
rxNorm: 1364504
atc: J04AK05
Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor.
severity: Not recommended
If taking these medications together is necessary, more frequent EKG and monitoring of the transaminases are recommended.

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: BORTEZOMIB
rxNorm: 358258
atc: L01XX32
Risk of increase of the undesirable effects, especially neurological, of the bortezomib due to decrease of its metabolism.
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the bortezomib during the length of the treatment with the enzyme inhibitor.

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
Increased risk of the undesirable effects of the bosentan, especially of hepatic attacks, due to decrease of its metabolism by the inhibitor
severity: Precaution for use
Clinical and biological monitoring during the administration of these together

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: BRENTUXIMAB
rxNorm: 1147320
more atc: L01XC12
Increase of the concentrations of the active metabolite of the brentuximab, with risk of neutropenia
severity: Take into account

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: CABAZITAXEL
rxNorm: 996051
atc: L01CD04
Risk of increase of the undesirable dose dependent effects of the cabazitaxel due to inhibition of its metabolism by the enzyme inhibitor
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the cabazitaxel during the treatment with the enzyme inhibitor

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: COBICISTAT
rxNorm: 1306284
atc: V03AX03
Risk of increase of the plasma concentrations of the cobicistat or of the inhibitor of CYP3A4
severity: Take into account
To know the risks and levels of severity of each interaction,consult the specific authorization for sale to the public ("Authorisation de la Mise sur le Marche" a French document) for each one of them.

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
Increase of the undesirable effects of the colchicine, with potentially fatal consequences
severity: Contraindication
--with the macrolides

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: DACLATASVIR
rxNorm: 1606218
atc: J05AX14
Increase of the concentrations of daclatasvir by the inhibitor
severity: Precaution for use
The dose of daclatasvir should be decreased to 30mg once a day when it is administered with the inhibitor. 

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: DAPOXETINE
rxNorm: 69394
atc: G04BX14
Risk of increase of the undesirable effects, especially of the vertigo or fainting type. 
severity: CONTRAINDICATION

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: DISOPYRAMIDE
rxNorm: 3541
atc: C01BA03
Risk of increase of the undesirable effects of the disopyramide due to decrease of its metabolism
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the disopyramide.

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: DOCETAXEL
rxNorm: 72962
atc: L01CD02
Risk of increase of the undesirable dose-dependent effects of the docetaxel due to inhibition of its metabolism by the enzyme inhibitor
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the docetaxel during the treatment with the enzyme inhibitor.

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: DOMPERIDONE
rxNorm: 3626
atc: A03FA03
Increase of the plasma concentrations of domperidone due to decrease of its hepatic metabolism by the inhibitor
severity: CONTRAINDICATION

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
Large increase of the concentrations of dronedarone due to decrease of its metabolism
severity: CONTRAINDICATION

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: EPLERENONE
rxNorm: 298869
atc: C03DA04
Risk of increase of the plasma concentrations of the eplerenone by the inhibitor and of its undesirable effects, especially hyperkalemia
severity: CONTRAINDICATION

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: FENTANYL
rxNorm: 4337
atc: N02AB03
Risk of increase of the opioid analgesic's effect of respiratory depression due to slight decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4.

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: HALOFANTRINE
rxNorm: 50749
atc: P01BX01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended
If this is possible, interrupt the inhibitor. If administering these medications together cannot be avoided, testing beforehand of the QT and EKG monitoring.

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: IDELALISIB
rxNorm: 1544460
atc: L01XX47
Increaese of the plasma concentrations of idelalisib due to decrease of its hepatic metabolism by the inhibitor
severity: Take into account

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
class name: TYPE 5 PHOSPHODIESTERASE INHIBITORS 
class code: G04BE
Increase (very large for avanafil and vardenafil) of the plasma concentrations of the type 5 phospodiesterase inhibitor, with risk of hypotension (severe with vardenafil)
severity: Contraindication - Not recommended - Precaution for use
To know the risks and levels of severity for each type 5 phospodiesterase inhibitor, consult the specific authorization for sale to the public ("Authorisation de la Mise sur le Marche" a French document) for each one of them.

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Risk of increase of the plasma concentrations of the ritonavir boosted protease inhibitor or of the inhibitor of CYP3A4 
severity: Take into account
To know the risks and levels of severity for each protease inhibitor boosted by ritonavir with the strong inhibitors of CYP3A4, consult the specific authorization for sale to the public (Authorisation de la Mise sur le March a French document) for each one of them.

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
class name: METABOLIZED TYROSINE-KINASE INHIBITORS
class code: L01XE
Risk of increase of the undesirable effects of the tyrosine kinase inhibitor due to decrease of its metabolism
severity: Not recommended
-with axitinib, bosutinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: IRINOTECAN
rxNorm: 51499
atc: L01XX19
Risk of increase of the undesirable effects of the irinotecan due to increase of the plasma concentrations of its active metabolite
severity: Not recommended

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: ISAVUCONAZOLE
rxNorm: 1720882
atc: J02AC05
Increase of the plasma concentrations of isavuconazole due to decrease of its hepatic metabolism by the inhibitor
severity: Contraindication
--with the ketoconazole

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the inhibitor).
severity: CONTRAINDICATION

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: IVACAFTOR
rxNorm: 1243041
atc: R07AX02
Large increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects
severity: Precaution for use
Reduce the dose by a fourth, that is 150 mg every other day. 

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: LOMITAPIDE
rxNorm: 1364479
atc: C10AX12
Increase of the plasma concentrations of the lomitapide due to decrease of its hepatic metabolism by the inhibitor
severity: CONTRAINDICATION

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: LURASIDONE
rxNorm: 1040028
atc: N05AE05
Increase of the plasma concentrations of the lurasidone due to decrease of its hepatic metabolism by the inhibitor
severity: CONTRAINDICATION

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: MARAVIROC
rxNorm: 620216
atc: J05AX09
Increase of the concentrations of maraviroc by the inhibitor.
severity: Precaution for use
The dose of maraviroc must be decreased to 150 mg twice a day when administered with this inhibitor. 

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: METHYLPREDNISOLONE
rxNorm: 6902
more atc: D07AA01
more atc: D10AA02
more atc: H02AB04
In case of prolonged use, increase of the plasma concentration of the corticoid due to decrease of its hepatic metabolism by the in inhibitor, with risk of appearance of a cushings syndrome
severity: Take into account

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation
severity: Not recommended
--with the midazolam by mouth

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: OLAPARIB
rxNorm: 1597582
atc: L01XX46
Increase of the plasma concentrations of the olaparib by the inhibitor
severity: Not recommended
If administering these together cannot be avoided, limit the dose of olaparib to 150 mg twice a day.

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
class name: OMBITASVIR + PARITAPREVIR
class code: OMPA
Increase of the plasma concentrations of the ombitsavir + paritaprevir combination due to decrease of its hepatic metabolism by the inhibitor.
severity: CONTRAINDICATION 
--except with ritonavir

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: OXYCODONE
rxNorm: 7804
atc: N02AA05
Increase of the undesirable effects, especially respiratory ones, of the oxycodone due to decrease of its metabolism by the inhibitor
severity: Not recommended
Clinical monitoring and possible adjustment of the dosage of oxycodone during the treatment with the inhibitor and after it is stopped.

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: PANOBINOSTAT
rxNorm: 1603350
atc: L01XX42
Risk of increase of the undesirable effects, especially cardiac ones, of the panobinostat due to decrease of its metabolism by the inhibitor
severity: Precaution for use
Clinical monitoring and EKG. Possible adjustment of the dosage of the panobinostat

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
Risk increase of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: QUETIAPINE
rxNorm: 51272
atc: N05AH04
Large increase of the concentrations of quetiapine, with risk of overdose
severity: CONTRAINDICATION

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: QUININE
rxNorm: 9071
atc: P01BC01
Risk of increase of the undesirable effects of the quinine, especially ventricular arrhythmias and neurosensory disorders (cinchonism).
severity: Not recommended
-with the protease inhibitors

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A
class code: J02-J05
drug2
drug name: RANOLAZINE
rxNorm: 35829
atc: C01EB18
Increase of the concentrations of ranolazine due to decrease of its metabolism by the inhibitor
severity: CONTRAINDICATION

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A
class code: J02-J05
drug2
drug name: REGORAFENIB
rxNorm: 1312397
atc: L01XE21
Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the inhibitor
severity: Not recommended

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: RIOCIGUAT
rxNorm: 1439816
atc: C02KX05
Increase of the plasma concentrations of riociquat due to decrease of its hepatic metabolism by the inhibitor
severity: Not recommended

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: RIVAROXABAN
rxNorm: 1114195
atc: B01AF01
Increase of the plasma concentrations of rivaroxaban, with increase of the risk of bleeding
severity: Not recommended

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: SIMEPREVIR
rxNorm: 1482790
atc: J05AE14
Risk of increase of the plasma concentrations of simeprevir due to decrease of its hepatic metabolism by the inhibitor
severity: Not recommended

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
class name: SUBSTRATES AT RISK OF CYP3A4
class code: L01N01
Increase of the undesirable effects specific to each substrate, with frequently severe consequences
severity: Take into account

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: SUFENTANIL
rxNorm: 56795
atc: N01AH03
Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4.

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: TAMSULOSIN
rxNorm: 77492
atc: G04CA02
Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism 
severity: Not recommended

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
Risk of increase of the undesirable effects, especially of the cardiac arrhythmia type. 
severity: CONTRAINDICATION
with the patient who has severe renal or hepatic insufficiency

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
Increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism by the inhibitor
severity: CONTRAINDICATION

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: TRASTUZUMAB EMTANSINE
rxNorm: 
more atc: 1371041
Increase of the plasma concentrations of the DM1, a componant element of the trastuzumab emtansine, due to inhibition of its metabolism by the inhibitor
severity: Not recommended

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: VERAPAMIL 
rxNorm: 11170
atc: C08DA01
Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the inhibitor
severity: Precaution for use
Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the verapamil during the treatment with the inhibitor, and after it is stopped, if the situation requires. 

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: ZOLPIDEM
rxNorm: 39993
more atc: N05CF02
Slight increase of the sedative effect of the zolpidem
severity: Take into account

***interaction***
drug1
class name: STRONG INHIBITORS OF CYP3A4 
class code: J02-J05
drug2
drug name: ZOPICLONE
rxNorm: 40001
atc: N05CF01
Slight increase of the sedative effect of the zopiclone
severity: Take into account
293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html


***interaction***
drug1
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) 
class code: N06AB
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
Increase of the risk of hemorrhage
severity: Take into account

***interaction***
drug1
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) 
class code: N06AB
drug2
class name: ORAL ANTICOAGULANTS 
class code: B01A-001
Increase of the risk of hemorrhage
severity: Precaution for use
Clinical monitoring and, if the situation requires, more frequent testing of the INR. Possible adjustment of the dosage of the oral anticoagulant during the administration with the SSRI and after it is stopped. 

***interaction***
drug1
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) 
class code: N06AB
drug2
class name: TRICYCLIC ANTIDEPRESSANTS
class code: N06AA-001
Increase of the plasma concentrations of the tricyclic antidepressant with risk of convulsions and increase of the undesirable effects


severity: Precaution for use
Increased clinical monitoring and, if necessary, adjustment of the dosage 

***interaction***
drug1
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) 
class code: N06AB
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Increase of the risk of hemorrhage
severity: Take into account

***interaction***
drug1
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) 
class code: N06AB
drug2
drug name: CYPROHEPTADINE
rxNorm: 3013
atc: R06AX02
Risk of decrease of the effectiveness of the antidepressant
severity: Take into account 

***interaction***
drug1
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) 
class code: N06AB
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma
severity: CONTRAINDICATION
Wait at least two weeks between the discontinuation of the irreversible MAOI and the start of treatment with the SSRI, and at least a week between the end of treatment with the SSRI (except fluoxetine: five weeks) and the beginning. 

***interaction***
drug1
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) 
class code: N06AB
drug2
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma
severity: Not recommended
If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration with minimum recommended dosages.

***interaction***
drug1
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) 
class code: N06AB
drug2
class name: MAOI-B 
class code: N04BD0-001
Risk of appearance of a serotonin syndrome
severity: Take into account

***interaction***
drug1
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) 
class code: N06AB
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Risk of appearance of a serotonin syndrome
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. 

***interaction***
drug1
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) 
class code: N06AB
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of appearance of a serotonin syndrome
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. 

***interaction***
drug1
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) 
class code: N06AB
drug2
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
Risk of therapeutic failure when there is concomitant treatment with orlistat
severity: Take into account

***interaction***
drug1
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) 
class code: N06AB
drug2
drug name: TRAMADOL 
rxNorm: 10689
atc: N02AX02
Risk of appearance of convulsions and/or a serotonin syndrome
severity: Take into account

***interaction***
drug1
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) 
class code: N06AB
drug2
class name: TRIPTANS
class code: N02CC-001
Risk of appearance of a serotonin syndrome 
severity: Take into account
294-INSULIN.html


***interaction***
drug1
drug name: INSULIN
rxNorm: 5856
more atc: A10AC01
more atc: A10AC02
more atc: A10AC03
more atc: A10AC04
more atc: A10AD01
more atc: A10AD02
more atc: A10AD03
more atc: A10AD04
more atc: A10AD05
more atc: A10AE01
more atc: A10AE02
more atc: A10AE03
more atc: A10AE04
more atc: A10AE05
more atc: A10AF01
drug2
Drug with no codes: ALCOHOL (DRINK OR INGREDIENT)
Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)
severity: Not recommended
Avoid taking alcoholic beverages and medications containing alcohol.

***interaction***
drug1
drug name: INSULIN
rxNorm: 5856
more atc: A10AC01
more atc: A10AC02
more atc: A10AC03
more atc: A10AC04
more atc: A10AD01
more atc: A10AD02
more atc: A10AD03
more atc: A10AD04
more atc: A10AD05
more atc: A10AE01
more atc: A10AE02
more atc: A10AE03
more atc: A10AE04
more atc: A10AE05
more atc: A10AF01
drug2
class name: SOMATOSTATIN ANALOGS
class code: H01CB0-001
Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon
severity: Precaution for use
Inform the patient of the risk of hypoglycemia or hyperglycemia, strengthen self-monitoring of blood glucose, and adjust the dosage of the insulin if needed during the treatment with the somatostatin analog.

***interaction***
drug1
drug name: INSULIN
rxNorm: 5856
more atc: A10AC01
more atc: A10AC02
more atc: A10AC03
more atc: A10AC04
more atc: A10AD01
more atc: A10AD02
more atc: A10AD03
more atc: A10AD04
more atc: A10AD05
more atc: A10AE01
more atc: A10AE02
more atc: A10AE03
more atc: A10AE04
more atc: A10AE05
more atc: A10AF01
drug2
class name: BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS
class code: R03C-001
Elevation of the glycemia by the beta-2 mimetic
severity: Precaution for use
Strengthen blood and urine monitoring

***interaction***
drug1
drug name: INSULIN
rxNorm: 5856
more atc: A10AC01
more atc: A10AC02
more atc: A10AC03
more atc: A10AC04
more atc: A10AD01
more atc: A10AD02
more atc: A10AD03
more atc: A10AD04
more atc: A10AD05
more atc: A10AE01
more atc: A10AE02
more atc: A10AE03
more atc: A10AE04
more atc: A10AE05
more atc: A10AF01
drug2
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia
severity: Precaution for use
Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose. 

***interaction***
drug1
drug name: INSULIN
rxNorm: 5856
more atc: A10AC01
more atc: A10AC02
more atc: A10AC03
more atc: A10AC04
more atc: A10AD01
more atc: A10AD02
more atc: A10AD03
more atc: A10AD04
more atc: A10AD05
more atc: A10AE01
more atc: A10AE02
more atc: A10AE03
more atc: A10AE04
more atc: A10AE05
more atc: A10AF01
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia
severity: Precaution for use
Inform the patient and, especially at the start of treatment, strengthen self-monitoring of blood glucose

***interaction***
drug1
drug name: INSULIN
rxNorm: 5856
more atc: A10AC01
more atc: A10AC02
more atc: A10AC03
more atc: A10AC04
more atc: A10AD01
more atc: A10AD02
more atc: A10AD03
more atc: A10AD04
more atc: A10AD05
more atc: A10AE01
more atc: A10AE02
more atc: A10AE03
more atc: A10AE04
more atc: A10AE05
more atc: A10AF01
drug2
drug name: CHLORPROMAZINE
rxNorm: 2403
atc: N05AA01
With large dosages (100 mg per day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)
severity: Precaution for use
Inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the neuroleptic and after it is stopped. 

***interaction***
drug1
drug name: INSULIN
rxNorm: 5856
more atc: A10AC01
more atc: A10AC02
more atc: A10AC03
more atc: A10AC04
more atc: A10AD01
more atc: A10AD02
more atc: A10AD03
more atc: A10AD04
more atc: A10AD05
more atc: A10AE01
more atc: A10AE02
more atc: A10AE03
more atc: A10AE04
more atc: A10AE05
more atc: A10AF01
drug2
drug name: DANAZOL
rxNorm: 3102
atc: G03XA01
Diabetes inducing effect of the danazol 
severity: Not recommended
If administering these substances together cannot be avoided, inform the patient and strengthen self-monitoring of blood glucose. Possibly adjust the dosage of the insulin during the treatment with the danazol and after it is stopped. 

***interaction***
drug1
drug name: INSULIN 
rxNorm: 5856
more atc: A10AC01
more atc: A10AC02
more atc: A10AC03
more atc: A10AC04
more atc: A10AD01
more atc: A10AD02
more atc: A10AD03
more atc: A10AD04
more atc: A10AD05
more atc: A10AE01
more atc: A10AE02
more atc: A10AE03
more atc: A10AE04
more atc: A10AE05
more atc: A10AF01
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).
severity: Precaution for use
Strengthen self-monitoring of blood glucose
295-INTERFERON-ALFA.html


***interaction***
drug1
Drug with no codes: INTERFERON ALFA
more atc: 1431112
more atc: L03AB01
more atc: 5879
more atc: L03AB04
more atc: 5880
more atc: L03AB05
more atc: 202912
more atc: L03AB06
drug2
class name: FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)
class code: L01BC-001
Increase of the gastrointestinal toxicity of the fluorouracil
severity: Take into account
296-IPILIMUMAB.html


***interaction***
drug1
drug name: IPILIMUMAB
rxNorm: 1094833
atc: L01XC11
drug2
class name: ORAL ANTICOAGULANTS 
class code: B01A-001
Increase of the risk of digestive system hemorrhage
severity: Precaution for use
Strict clinical monitoring
297-IRINOTECAN.html


***interaction***
drug1
drug name: IRINOTECAN
rxNorm: 51499
atc: L01XX19
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Probable decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment
severity: Not recommended

***interaction***
drug1
drug name: IRINOTECAN
rxNorm: 51499
atc: L01XX19
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the undesirable effects of the irinotecan due to increase of the plasma concentrations of its active metabolite
severity: Not recommended

***interaction***
drug1
drug name: IRINOTECAN
rxNorm: 51499
atc: L01XX19
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment
severity: CONTRAINDICATION
298-ISAVUCONAZOLE.html


***interaction***
drug1
drug name: ISAVUCONAZOLE
rxNorm: 1720882
atc: J02AC05
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the inducer
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ISAVUCONAZOLE
rxNorm: 1720882
atc: J02AC05
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of isavuconazole due to decrease of its hepatic metabolism by the inhibitor
severity: Contraindication
--with the ketoconazole

***interaction***
drug1
drug name: ISAVUCONAZOLE
rxNorm: 1720882
atc: J02AC05
drug2
drug name: ST JOHN'S WORT
rxNorm: 258326
Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the St Johns wort
severity: CONTRAINDICATION
299-ISONIAZID.html


***interaction***
drug1
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
drug2
class name: HALOGENATED HYDROCARBON ANESTHETICS
class code: N01AB0-001
Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites.

.


severity: Precaution for use
In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 

***interaction***
drug1
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism
severity: Not recommended

***interaction***
drug1
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
drug2
drug name: DISULFIRAM
rxNorm: 3554
atc: N07BB01
Disorders of behavior and of coordination
severity: Not recommended

***interaction***
drug1
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
drug2
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
Described for the prednisolone. 

Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides
severity: Precaution for use
Clinical and biological monitoring.

***interaction***
drug1
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Decrease of the plasma concentrations of ketoconazole
severity: Precaution for use
Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. 

***interaction***
drug1
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Overdose of phenytoin (decrease of its metabolism)
severity: Precaution for use
Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 

***interaction***
drug1
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
drug2
drug name: PYRAZINAMIDE
rxNorm: 8987
more atc: J04AK01
more atc: J04AM05
more atc: J04AM06
Addition of the hepatotoxic effects.
severity: Precaution for use
Clinical and biological monitoring.

***interaction***
drug1
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)
severity: Precaution for use
Clinical and biological monitoring of this classic combination. In case of hepatitis, stop the isoniazid.

***interaction***
drug1
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
drug2
drug name: STAVUDINE
rxNorm: 59763
atc: J05AF04
Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
29-ALUMINUM-(SALTS).html


***interaction***
drug1
class name: ALUMINUM (SALTS)
class code: A02AD0-001
drug2
class name: CITRATES
class code: V09HX
Risk of facilitating systemic uptake of the aluminum salts especially when there is altered renal function


severity: Precaution for use
Take aluminum based gastrointestinal medications at a different time (more than 2 hours apart if possible) from the citrates, including the natural ones such as citrus fruits and juices. 
2-ABIRATERONE.html


***interaction***
drug1
drug name: ABIRATERONE
rxNorm: 1100072
atc: L02BX03
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS 
class code: N03A-001
Notable decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness
severity: Not recommended

***interaction***
drug1
drug name: ABIRATERONE
rxNorm: 1100072
atc: L02BX03
drug2
drug name: FLECAINIDE
rxNorm: 4441
atc: C01BC04
Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the abiraterone.
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the flecainide during the treatment with the abiraterone

***interaction***
drug1
drug name: ABIRATERONE
rxNorm: 1100072
atc: L02BX03
drug2
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the abiraterone.
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the metopolol during the treatment with the abiraterone

***interaction***
drug1
drug name: ABIRATERONE
rxNorm: 1100072
atc: L02BX03
drug2
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the abiraterone
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the abiraterone

***interaction***
drug1
drug name: ABIRATERONE
rxNorm: 1100072
atc: L02BX03
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Substantial decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness
severity: Not recommended
300-ISOPRENALINE.html


***interaction***
drug1
drug name: ISOPRENALINE
rxNorm: 6054
more atc: C01CA02
more atc: R03AB02
more atc: R03CB01
more atc: R03AK02
more atc: R03CB51
drug2
class name: HALOGENATED HYDROCARBON ANESTHETICS
class code: N01AB0-001
Serious ventricular arrhythmias due to increase of cardiac sensitization


severity: Not recommended
301-ITRACONAZOLE.html


***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
Increase of the plasma concentrations of afatinib due to increase of its absorption by the itraconazole. 
severity: Precaution for use
It is recommended that the itraconazole be administered as far distant from the afatinib as possible, preferably at an interval of 6 to 12 hours away from the dose of afatinib. 

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: ALISKIREN
rxNorm: 325646
atc: C09XA02
Increase by nearly six times of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory
severity: Take into account

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the proton pump inhibitor
severity: Take into account

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the itraconazole and a week after it is stopped

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
Increase of the concentrations of aprepitant due to decrease of its hepatic metabolism by the intraconazole.
severity: Take into account

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
class name: OTHER CORTICOIDES, ESPECIALLY INHALED ONES
class code: D07AC-001
In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the itraconazole, with risk of appearance of Cushings syndrome, even adrenal insufficiency 
severity: Take into account

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: BUPRENORPHINE
rxNorm: 1819
more atc: N02AE01
more atc: N07BC01
Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: BUSPIRONE
rxNorm: 1827
atc: N05BE01
Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation
severity: Not recommended

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: BUSULFAN
rxNorm: 1828
atc: L01AB01
With the busulfan in large doses: doubling of the concentrations of busulfan by the itraconazole
severity: Not recommended

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: COBICISTAT
rxNorm: 1306284
atc: VO3AX03
Risk of increase of the concentrations of itraconazole by the cobicistat
severity: Precaution for use
Clinical monitoring during the administration of these together. The administration of large doses of itraconazole (>200mg per day) is not recommended

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome
severity: Take into account

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Increase of the digoxinemia with nausea, vomiting, arrhythmias
severity: Precaution for use
Clinical monitoring, and, if there is reason for them, EKG and monitoring of the digoxinemia with adjustment of the dosage of the digoxin during the treatment with the itraconazole and after it is stopped.

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: EBASTINE
rxNorm: 23796
atc: R06AX22
Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)
severity: Not recommended

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: ELVITEGRAVIR
rxNorm: 1306286
atc: J05AR09
Increase of the plasma concentrations of elvitegravir due to decrease of its metabolism by the itraconazole
severity: Precaution for use
With the elvitegravir in combination with cobicistat, clinical monitoring. Limit the maximum dose of itraconazole to 200 mg/day.

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: HYDROQUINIDINE
rxNorm: 27220
Risk of tinnitis and/or loss of hearing acuity: cinchonism linked to a decrease of the hepatic metabolism of the antiarrhythmic by the itraconazole 
severity: Precaution for use
Monitoring of the plasma concentrations of the antiarrhythmic and possible decrease of its dosage if necessary.

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Very large increase of the blood concentrations of the immusuppressant due to inhibition of its hepatic metabolism
severity: Not recommended
If these substances are administered together, strict testing of the renal function, blood concentration dosage of the immunosuppressant and possible adjustment of the dosage.

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
class name: ENZYME INDUCERS
class code: N03-J05-001
Decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the inducer.
severity: Not recommended

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Risk of increase of the concentrations of itraconazole by the protease inhibitor
severity: Precaution for use
Clinical monitoring during the administration of these medications together. Administering large doses of itraconazole (>200 mg per day) is not recommended.

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: LERCANIDIPINE
rxNorm: 135056
atc: C08CA13
Increased risk of undesirable effects, especially of edema, due to decrease of the hepatic metabolism of the dihydorpyridine
severity: Not recommended

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: LUMEFANTRINE
rxNorm: 847728
atc: P01BF01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended
If this is possible, interrupt the torsadegenic medication. If administering these two together cannot be avoided, testing of the QT beforehand and EKG monitoring.

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of large decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: MIZOLASTINE
rxNorm: 61455
atc: R06AX25
Risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: NINTEDANIB
rxNorm: 1592737
more atc: L01XE31
Increase of the plasma concentrations of the nintedanib due to increase of its absorption by the itraconazole
severity: Precaution for use
Clinical monitoring during the administration of these medications together.

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
Increased risk of ventricular arrhythmias, especially of torsades de pointes, as well as tinnitis and/or decrease of auditory acuity (cinchonism), due to decrease of the hepatic metabolism of the quinidine
severity: CONTRAINDICATION 

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: SALMETEROL
rxNorm: 36117
atc: R03AC12
Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the itraconazole
severity: Take into account

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolosis type (decrease of the hepatic metabolism of the simvastatin)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
Risk of increase of the plasma concentrations of telaprevir and of the itraconazole. 
severity: Precaution for use
Clinical monitoring. Avoid large doses of itraconazole (>200 mg per day). 

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: TENEFOVIR ALAFENAMIDE
rxNorm: 1721603
Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption. 
severity: Precaution for use
In case of co-administration with the itraconazole, the dose of tenofovir alafenamide should be limited to 10 mg per day.

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: TRABECTEDIN
rxNorm: 1716278
atc: L01CX01
Risk of increase of the plasma concentrations of the trabectedin by the itraconazole
severity: Not recommended
If administering these medications together is necessary, clinical monitoring and possible adjustment of the dosage of the trabectedin during the length of the treatment with the itraconazole.

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
Increase of the concentrations of venlafaxine with risk of overdose
severity: Take into account

***interaction***
drug1
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
drug2
class name: VINCA ALKALOIDS
class code: L01CA
Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the itraconazole
severity: Not recommended
302-IVABRADINE.html


***interaction***
drug1
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the inducer

.
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of these substances together and after the inducer is stopped. 

***interaction***
drug1
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
drug2
drug name: AZITHROMYCIN 
rxNorm: 18631
atc: J01FA10
Increased risk of ventricular arrhythmias, especially of torsades de pointes. In addition, increase of the plasma concentrations of the ivabradine due to decrease of its metabolism by the azithromycin
severity: Precaution for use
Clinical monitoring and EKG during the administration of these substances together. 

***interaction***
drug1
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the diltiazem), that add to the bradycardia inducing effects of these molecules
severity: CONTRAINDICATION

***interaction***
drug1
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the inhibitor).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
drug2
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the josamycin).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the St Johns wort
severity: Not recommended

***interaction***
drug1
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
drug2
Drug with no codes: GRAPEFRUIT (JUICE AND FRUIT)
Increase of the plasma concentrations of the ivabradine and of its undesirable effects (inhibition of its intestinal metabolism by the grapefruit).
severity: Not recommended

***interaction***
drug1
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin 
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after the rifampicin is stopped.

***interaction***
drug1
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules
severity: CONTRAINDICATION
303-IVACAFTOR.html


***interaction***
drug1
drug name: IVACAFTOR
rxNorm: 1243041
atc: R07AX02
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
atc: J02AC01
Increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects
severity: Precaution for use
Reduce the dose by half, that is 150 mg/day.

***interaction***
drug1
drug name: IVACAFTOR
rxNorm: 1243041
atc: R07AX02
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Large decrease of the concentrations of the ivacaftor, with risk of loss of effectiveness
severity: Not recommended

***interaction***
drug1
drug name: IVACAFTOR
rxNorm: 1243041
atc: R07AX02
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Large increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects
severity: Precaution for use
Reduce the dose by a fourth, that is 150 mg every other day. 
304-JOSAMYCIN.html


***interaction***
drug1
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Increase of the plasma concentrations of carbamazepine with signs of overdose, due to decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and. if needed, plasma dosage and possible reduction of the dosage of the carbamazepine.

***interaction***
drug1
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Risk of increase of the blood concentrations of ciclosporin and of the creatinemia
severity: Precaution for use
Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped.

***interaction***
drug1
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
drug2
drug name: DISOPYRAMIDE
rxNorm: 3541
atc: C01BA03
Risk of increase of the undesirable effects of the disopyramide: severe hypoglyclemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type
severity: Not recommended
Regular clinical, biological and electrocardiographic monitoring.

***interaction***
drug1
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
drug2
drug name: EBASTINE
rxNorm: 23796
atc: R06AX22
Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)
severity: Not recommended

***interaction***
drug1
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
drug2
drug name: HALOFANTRINE
rxNorm: 50749
atc: P01BX01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended
If this is possible, interrupt the macrolide. If administering these substances together cannot be avoided, testing before hand of the QT and EKG monitoring.

***interaction***
drug1
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
drug2
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the josamycin).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
drug2
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
drug2
drug name: SILDENAFIL
rxNorm: 136411
atc: G04BE03
Increase of the plasma concentrations of sildenafil, with risk of hypotension
severity: Precaution for use
Start the treatment with sildenafil at the minimun dose when it is administered with josamycin.

***interaction***
drug1
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
drug2
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
more atc: L04AD02
Increase of the blood concentrations of tacrolimus and of the creatinemia, due to inhibition of the hepatic metabolism of the tacrolimus by the josamycin
severity: Not recommended

***interaction***
drug1
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Risk of increase of the theophyllinemia, particularly with children
severity: Take into account
305-KETOCONAZOLE.html


***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
Increase of the plasma concentrations of afatinib due to increase of its absorption by the ketoconazole.
severity: Precaution for use
It is recommended that the ketoconazole be administered as far from the afatinib as possible, preferably at an interval of 6 or 12 hours away from doses of the afatinib

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory
severity: Take into account

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the anitsecretory
severity: Take into account

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
class name: OTHER CORTICOIDES, ESPECIALLY INHALED ONES 
class code: D07AC-001
In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the ketoconazole, with risk of appearance of Cushings syndrome, even adrenal insufficiency 
severity: Take into account

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: BUPRENORPHINE
rxNorm: 1819
more atc: N02AE01
more atc: N07BC01
Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the buprenorphine during the treatment with the inhibitor and, if the situation requires, after it is stopped.

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
Increase of more than double of the plasma concentrations of dabigatran, with increase of the risk of bleeding
severity: CONTRAINDICATION

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome
severity: Take into account

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: EBASTINE
rxNorm: 23796
atc: R06AX22
Increased risk of ventricular arrhythmias with predisposed patients (congenital long QT syndrome)
severity: Not recommended

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: ELVITEGRAVIR
rxNorm: 1306286
atc: J05AR09
Increase of the plasma concentrations of elvitegravir due to decrease of its metabolism by the ketoconazole
severity: Precaution for use
With the elvitegravir combined with cobicistat, clinical monitoring. Limit the maximum dose of ketoconazole to 200 mg/day.

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: FIDAXOMICIN
rxNorm: 1111103
atc: A07AA12
Increase of the plasma concentrations of the fidaxomicine
severity: Not recommended

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.
severity: Not recommended
If these substances are administered together, strict monitoring of the renal function, blood concentration dosage of the immunosuppressant, and possible adjustment of the dosage.

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
Decrease of the plasma concentrations of ketoconazole
severity: Precaution for use
Space the doses of the two anti-infectives at lease 12 hours apart. Monitor plasma concentrations of the ketoconazole and possibly adjust its dosage. 

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: LERCANIDIPINE
rxNorm: 135056
atc: C08CA13
Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine
severity: Not recommended

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: LUMEFANTRINE
rxNorm: 847728
atc: P01BF01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended
If this is possible, interrupt the medication tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand, and EKG monitoring. 

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: MIZOLASTINE
rxNorm: 61455
atc: R06AX25
Risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: NEVIRAPINE
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing
severity: CONTRAINDICATION

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: NINTEDANIB
rxNorm: 1592737
more atc: L01XE31
Increase of the plasma concentrations of nintedanib due to increase of its absorption by the ketoconazole
severity: Precaution for use
Clinical monitoring during the administration of these substances together. 

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)
severity: Not recommended

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: SALMETEROL
rxNorm: 36117
atc: R03AC12
Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole
severity: Take into account

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolisis type (decrease of the hepatic metabolism of the cholesterol lowering substance)
severity: CONTRAINDICATION
Use a statin not affected by this type of interaction.

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: TENEFOVIR ALAFENAMIDE
rxNorm: 1721603
Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption
severity: Precaution for use
In case of co-administration with the ketoconazole, the dose of tenofovir alafenamide must be limited to 10 mg per day.

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
Increase of the concentrations of vanlafaxine with risk of overdose 
severity: Take into account

***interaction***
drug1
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
drug2
class name: VINCA ALKALOIDS
class code: L01CA
Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the ketoconazole
severity: Not recommended
306-LAMIVUDINE.html


***interaction***
drug1
drug name: LAMIVUDINE
rxNorm: 68244
atc: J05AF05
drug2
drug name: CLADRIBINE
rxNorm: 44157
atc: L01BB04
Risk of decrease of the effectiveness of the cladribine by the lamivudine
severity: Not recommended

***interaction***
drug1
drug name: LAMIVUDINE
rxNorm: 68244
atc: J05AF05
drug2
drug name: ZALCITABINE
rxNorm: 3363
atc: J05AF03
Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites
severity: Not recommended
307-LAMOTRIGINE.html


***interaction***
drug1
drug name: LAMOTRIGINE
rxNorm: 28439
atc: N03AX09
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Risk of increase of the neurological effects (vertigo, ataxia, diplopia) of the carbamazepine when the lamotrigine is introduced
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the carbamazepine. 

***interaction***
drug1
drug name: LAMOTRIGINE
rxNorm: 28439
atc: N03AX09
drug2
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism
severity: Not recommended
-avoid starting an oral contraceptive during the period of adjustment of the dosage of the lamotrigine.

***interaction***
drug1
drug name: LAMOTRIGINE
rxNorm: 28439
atc: N03AX09
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism by the ritonavir
severity: Not recommended
-Avoid beginning the treatment with ritonavir during the period of adjustment of the dosage of the lamotrigine

***interaction***
drug1
drug name: LAMOTRIGINE
rxNorm: 28439
atc: N03AX09
drug2
drug name: OXCARBAZEPINE
rxNorm: 32624
atc: N03AF02
Decrease of the concentrations of the lamotrigine with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine
severity: Precaution for use
Clinical monitoring and testing of the plasma concentrations, with adjustment of the dosage of the lamotrigine if needed.

***interaction***
drug1
drug name: LAMOTRIGINE
rxNorm: 28439
atc: N03AX09
drug2
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
Increased risk of serious cutaneous reactions (Lyell's syndrome). In addition, increase of the plasma concentrations of lamotrigine (decrease of its hepatic metabolism by the sodium valproate)
severity: Not recommended
If this combination of medications is judged necessary, strict clinical monitoring.
308-LANSOPRAZOLE.html


***interaction***
drug1
drug name: LANSOPRAZOLE
rxNorm: 17128
more atc: A02BC03
more atc: A02BD07
more atc: A02BD03
more atc: A02BD02
drug2
drug name: TACROLIMUS
rxNorm: 42316
atc: L04AD02
Increase of the blood concentrations of the tacrolimus
severity: Precaution for use
Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of these medications together and after it is stopped. 
309-LEDIPASVIR.html


***interaction***
drug1
drug name: LEDIPASVIR
rxNorm: 1591922
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Only with the bitherapy ledipasvir/sofosbuvir, onset of bradycardia, possibly abruptly, which can have fatal consequences.
severity: Not recommended
If administering these together cannot be avoided, strict monitoring of patients is recommended, in particular during the first weeks of treatment with the bitherapy (clinical monitoring and EKG).

***interaction***
drug1
drug name: LEDIPASVIR
rxNorm: 1591922
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer.
severity: CONTRAINDICATION

***interaction***
drug1
drug name: LEDIPASVIR
rxNorm: 1591922
drug2
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
Decrease of the concentrations of the ledipasvir when the proton pump inhibitor is administered before the ledipasvir
severity: Precaution for use
It is recommended that the proton pump inhibitor and the ledipasvir be administered simultaneously 

***interaction***
drug1
drug name: LEDIPASVIR
rxNorm: 1591922
drug2
class name: HMG-COA REDUCTASE INHIBITORS (STATINS)
class code: C10AA
Risk of increase of the plasma concentrations of the statin and of its undesirable effects of the rhabdomyolysis type
severity: Contraindication
--with the rosuvastatin

***interaction***
drug1
drug name: LEDIPASVIR
rxNorm: 1591922
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: LEDIPASVIR
rxNorm: 1591922
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the ripampicin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: LEDIPASVIR
rxNorm: 1591922
drug2
drug name: TENOFOVIR DISOPROXIL
rxNorm: 300195
atc: J05AF07
When co-administered with a protease inhibitor, increase of the plasma concentrations of the tenofovir by the ledipasvir
severity: Precaution for use
Clinical and biological monitoring, especially of the renal function
30-AMBRISENTAN.html


***interaction***
drug1
drug name: AMBRISENTAN
rxNorm: 358274
atc: C02KX02
drug2
drug name: CICLOSPORIN
rxNorm: 3008
atc: S01XA18
Doubling of the concentrations of ambrisentan, with increase of the vasodilator effect (severe headaches )
severity: Take into account
310-LENALIDOMIDE.html


***interaction***
drug1
drug name: LENALIDOMIDE
rxNorm: 342369
atc: L04AX04
drug2
class name: HMG-COA REDUCTASE INHIBITORS (STATINS)
class code: C10AA
Increased risk of onset of rhabdomyolysis
severity: Precaution for use
Strengthen clinical and biological monitoring, especially during the first weeks of treatment.
311-LERCANIDIPINE.html


***interaction***
drug1
drug name: LERCANIDIPINE
rxNorm: 135056
more atc: C09BB02
more atc: C08CA13
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Moderate increase of the blood concentrations of the immunosuppressant and more notable increase of the concentrations of the lercanidipine
severity: Precaution for use
Separate the time when the two medications are taken. Blood concentration dosage of the immunosuppressant, and adjustment if necessary of its dosage during the administration of the medications together and after it is stopped

***interaction***
drug1
drug name: LERCANIDIPINE
rxNorm: 135056
more atc: C09BB02
more atc: C08CA13
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydorpyridine
severity: Not recommended

***interaction***
drug1
drug name: LERCANIDIPINE
rxNorm: 135056
more atc: C09BB02
more atc: C08CA13
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine
severity: Not recommended

***interaction***
drug1
drug name: LERCANIDIPINE
rxNorm: 135056
more atc: C09BB02
more atc: C08CA13
drug2
Drug with no codes: GRAPEFRUIT (JUICE AND FRUIT)
Increased risk of undesirable effects, especially of edema, due to decrease of the intestinal metabolism of the dihydropyridine
severity: Take into account
312-LEVOCARNITINE.html


***interaction***
drug1
drug name: LEVOCARNITINE
rxNorm: 42955
atc: A16AA01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the levocarnitine and a week after it is stopped. 
313-LEVODOPA.html


***interaction***
drug1
drug name: LEVODOPA
rxNorm: 6375
atc: N04BA01
drug2
drug name: BACLOFEN
rxNorm: 1292
atc: M03BX01
Risk of aggravation of the Parkinsonian syndrome or of undesirable central effects (visual hallucinations, confusion, headaches)
severity: Take into account

***interaction***
drug1
drug name: LEVODOPA
rxNorm: 6375
atc: N04BA01
drug2
drug name: IRON
rxNorm: 1431589
atc: B03A
Decrease of the digestive absorption of the levodopa
severity: Precaution for use
Take the iron salts at a different time from the levodopa (more than 2 hours apart if possible).

***interaction***
drug1
drug name: LEVODOPA
rxNorm: 6375
atc: N04BA01
drug2
class name: MAOI-B 
class code: N04BD0-001
Increase of the risk of orthostatic hypotension
severity: Take into account

***interaction***
drug1
drug name: LEVODOPA
rxNorm: 6375
atc: N04BA01
drug2
drug name: METHYLDOPA
rxNorm: 6876
more atc: C02AB
more atc: C02AB01
more atc: C02AB02
Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa
severity: Precaution for use
Clinical monitoring and possibly decrease of the doses of levodopa.

***interaction***
drug1
drug name: LEVODOPA
rxNorm: 6375
atc: N04BA01
drug2
class name: ANTIEMITIC NEUROLEPTICS
class code: A03FA-001
Reciprocal antagonism between the levodopa and the neuroleptic 


severity: CONTRAINDICATION
Use an antiemitic without extrapyramidal effects.

***interaction***
drug1
drug name: LEVODOPA
rxNorm: 6375
atc: N04BA01
drug2
class name: ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)
class code: N05A-001
Reciprocal antagonism between the levodopa and the neuroleptics
severity: Not recommended
With a parkinsons patient, use the minimum effective doses of each of the two medications. 

***interaction***
drug1
drug name: LEVODOPA
rxNorm: 6375
atc: N04BA01
drug2
drug name: RESERPINE
rxNorm: 9260
atc: C02AA02
Inhibition of the effects of the levodopa
severity: CONTRAINDICATION

***interaction***
drug1
drug name: LEVODOPA
rxNorm: 6375
atc: N04BA01
drug2
drug name: SPIRAMYCIN
rxNorm: 9991
atc: J01FA02
When administered with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the levodopa. 

***interaction***
drug1
drug name: LEVODOPA
rxNorm: 6375
atc: N04BA01
drug2
drug name: TETRABENAZINE
rxNorm: 10390
atc: N07XX06
Reciprocal antagonism between the levodopa and the tetrabenazine
severity: Not recommended
314-LEVOFLOXACIN.html


***interaction***
drug1
drug name: LEVOFLOXACINE
rxNorm: 82122
more atc: J01MA12
more atc: S01AE05
drug2
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG during the administrations of these substances together. 
315-LIDOCAINE.html


***interaction***
drug1
drug name: LIDOCAINE
rxNorm: 6387
more atc: C01BB01
more atc: C05AD01
more atc: D04AB01
more atc: N01BB02
more atc: R02AD02
more atc: S01HA07
more atc: S02DA01
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone
severity: Precautions for use
Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.

***interaction***
drug1
drug name: LIDOCAINE
rxNorm: 6387
more atc: C01BB01
more atc: C05AD01
more atc: D04AB01
more atc: N01BB02
more atc: R02AD02
more atc: S01HA07
more atc: S02DA01
drug2
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)
severity: Precaution for use
Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment if needed of the dosage of the lidocaine

***interaction***
drug1
drug name: LIDOCAINE
rxNorm: 6387
more atc: C01BB01
more atc: C05AD01
more atc: D04AB01
more atc: N01BB02
more atc: R02AD02
more atc: S01HA07
more atc: S02DA01
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
Negative inotropic effect with risk of acute decompensated heart failure
severity: Take into account

***interaction***
drug1
drug name: LIDOCAINE
rxNorm: 6387
more atc: C01BB01
more atc: C05AD01
more atc: D04AB01
more atc: N01BB02
more atc: R02AD02
more atc: S01HA07
more atc: S02DA01
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)
severity: Precaution for use
Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the lidocaine; if there is reason for it, adjustment of the dosage of the lidocaine during the treatment with the cimetidine and after it is stopped. 

***interaction***
drug1
drug name: LIDOCAINE
rxNorm: 6387
more atc: C01BB01
more atc: C05AD01
more atc: D04AB01
more atc: N01BB02
more atc: R02AD02
more atc: S01HA07
more atc: S02DA01
drug2
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)
severity: Precaution for use
Clinical monitoring, EKG and possibly testing of the plasma concentrations of the lidocaine during and after the administration of the two substances together. Adjustment, if needed, of the dosage of the lidocaine.
316-LINCOSANIDES.html


***interaction***
drug1
class name: LINCOSANIDES
class code: J01FF0
drug2
class name: CURARES
class code: M03A-001
Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent
severity: Precaution for use
Monitor the degree of curarisation at the end of anesthesia.
317-LINEZOLIDE.html


***interaction***
drug1
drug name: LINEZOLIDE
rxNorm: 190376
atc: J01XX08
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Risk of increase of the undesirable effects of the linezolide by the clarithromycin, due to increase of its absorption
severity: Take into account

***interaction***
drug1
drug name: LINEZOLIDE
rxNorm: 190376
atc: J01XX08
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.
severity: Precaution for use
Clinical monitoring and possible increase of the dosage of the linezolide during the treatment with the rifampicin.
318-LITHIUM.html


***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
drug name: ACETAZOLAMIDE
rxNorm: 167
atc: S01EC01
Decrease of the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness
severity: Precautions for use
Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of lithium.

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
Increase of the the plasma concentrations of lithium that can attain toxic values (decrease of the renal excretion of the lithium)

.
severity: Not recommended
If the use of the angiotensin II antagonist is indispensable, strict monitoring of the the plasma concentrations of lithium and adjustment of the dosage

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Increase of the the plasma concentrations of lithium that can reach toxic values (decrease of the renal excretion of the lithium)


severity: Not recommended
If administering the substances together cannot be avoided, monitor the the plasma concentrations of lithium closely and adjust the dosage of the lithium during the administration of the substances together and after the NSAI is stopped.

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
drug name: CAFFEINE 
rxNorm: 1886
more atc: N06BC01
more atc: V04CG30
In case of sudden discontinuation of consumption of coffee or of medications containing caffeine, risk of increase of the the plasma concentrations of lithium
severity: Take into account

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
drug name: CALCITONIN
rxNorm: 36118
more atc: H05BA
more atc: H05BA03
more atc: H05BA02
more atc: H05BA01
more atc: H05BA01
Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Risk of neurotoxicity manifesting as disorders of the cerebellum, confusion, drowsiness, ataxia. These disorders are reversible when the treatment with lithium is stopped
severity: Not recommended

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
class name: LOOP DIURETICS
class code: C03CA-001
Increase of the the plasma concentrations of lithium with signs of overdose of lithium as with a low sodium regimen (decrease of the urinary excretion of the lithium) 
severity: Not recommended
If administering these substances together cannot be avoided, strict monitoring of the the plasma concentrations of lithium and adjustment of the dosage of lithium. 

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
class name: POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
Increase of the the plasma concentrations of lithium with signs of overdose of lithium, as with a low sodium regimen (decrease of the urinary excretion of the lithium)
severity: Precaution for use
Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of the lithium. 

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
class name: THIAZIDE DIURETICS AND RELATED
class code: C03-003
Increase of the the plasma concentrations of lithium with signs of overdose of lithium, as with a low sodium regimen (decrease of the urinary excretion of the lithium) 
severity: Not recommended
If administering the substances together cannot be avoided, strict monitoring of the the plasma concentrations of lithium and adjustment of the dosage of the lithium. 

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
drug name: GLYCEROL
rxNorm: 4910
more atc: A06AG04
more atc: A06AX01
more atc: A16AX09
Decrease of the the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness
severity: Precaution for use
Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of lithium.

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
Increase of the the plasma concentrations of lithium which can reach toxic values (decrease of the renal excretion of the lithium)
severity: Not recommended
If the use of an ACE inhibitor is indispensable, strict monitoring of the the plasma concentrations of lithium and adjustment of the dosage of the lithium. 

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
class code: N06AB
Risk of appearance of a serotonin syndrome
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. 

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
drug name: MANNITOL
rxNorm: 6628
more atc: A06AD16
more atc: B05BC01
more atc: B05CX04
more atc: R05CB16
Decrease of the the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness
severity: Precaution for use
Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of lithium. 

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
drug name: METHYLDOPA 
rxNorm: 6876
more atc: C02AB
more atc: C02LB
more atc: C02AB01
more atc: C02LB01
more atc: C02AB02
Increase of the the plasma concentrations of lithium which can attain toxic values, with signs of overdose of lithium 
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of lithium. 

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
drug name: METRONIDAZOLE
rxNorm: 6922
more atc: A02BD08
more atc: A02BD03
more atc: A02BD02
more atc: A01AB17
more atc: D06BX01
more atc: G01AF01
more atc: J01XD01
more atc: P01AB01
more atc: A02BD01
Increase of the the plasma concentrations of lithium which can attain toxic values with signs of overdose of lithium.
severity: Precaution for use
Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of the lithium. 

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
class name: NEUROLEPTICS
class code: N05AA-003
Risk of appearance of neuropsychic signs evocative of a neuroleptic malignant syndrome or of lithium poisoning
severity: Precaution for use
Regular clinical amd biological monitoring, especially at the beginning of the administration of the substances together.

***interaction***
drug1
drug name:  LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
Risk of therapeutic failure when there is concomitant treatment with orlistat
severity: Take into account

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
drug name: SODIUM BICARBONATE
rxNorm: 
Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts
severity: Precaution for use
Avoid excessive sodium and take account of the presence of sodium in certain medications such as antacids.

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
drug name: SODIUM CHLORIDE
rxNorm: 9863
more atc: A12CA01
more atc: B05CB01
more atc: B05XA03
Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts.
severity: Precaution for use
Avoid excessive sodium and take account of the presence of sodium in certain medications such as antacids.

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
drug name: THEOPHYLLINE 
rxNorm: 10438
atc: R03DA04
Decrease of the the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness
severity: Precaution for use
Strict monitoring of the lithemia and possible adjustment of the dosage of the the plasma concentrations of lithium.

***interaction***
drug1
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
drug2
drug name: TOPIRAMATE
rxNorm: 38404
atc: 38404
For doses of topiramate >= 200 mg/day: increase of the the plasma concentrations of lithium that can reach toxic values, with signs of overdose of lithium.
severity: Precaution for use
Clinical and biological monitoring. Adjustment of the dosage of the lithium. 
319-LOMITAPIDE.html


***interaction***
drug1
drug name: LOMITAPIDE
rxNorm: 1364479
atc: C10AX12
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of the lomitapide due to decrease of its hepatic metabolism by the inhibitor
severity: CONTRAINDICATION

***interaction***
drug1
drug name: LOMITAPIDE
rxNorm: 1364479
atc: C10AX12
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the plasma concentrations of the lomitapide
severity: Not recommended
31-AMINOGLUTETHIMIDE.html


***interaction***
drug1
drug name: AMINOGLUTETHIMIDE
rxNorm: 677
atc: L02BG01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Described for warfarin and acenocoumarol. 

Decrease of the effect of the vitamin K antagonist, due to increase of its hepatic metabolism by the aminoglutethimide

.
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist during the treatment with aminoglutethimide and two weeks after it is stopped. 

***interaction***
drug1
drug name: AMINOGLUTETHIMIDE
rxNorm: 677
atc: L02BG01
drug2
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism


severity: Precaution for use
Adjustment of the dosage of the dexamethasone. 
320-LOMUSTINE.html


***interaction***
drug1
drug name: LOMUSTINE
rxNorm: 6466
atc: L01AD02
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the lomustine)
severity: Not recommended
321-LOSARTAN.html


***interaction***
drug1
drug name: LOSARTAN
rxNorm: 52175
more atc: C09CA01
more atc: C09DB06
more atc: C09DA01
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole
severity: Take into account
322-LUMEFANTRINE.html


***interaction***
drug1
drug name: LUMEFANTRINE
rxNorm: 847728
atc: P01BF01
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended
If this is possible, interrupt the substance tending to cause torsades de pointes. If administering the two together cannot be avoided, testing of the QT before hand and EKG monitoring. 

***interaction***
drug1
drug name: LUMEFANTRINE
rxNorm: 847728
atc: P01BF01
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended
If this is possible, interrupt the substance tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring. 

***interaction***
drug1
drug name: LUMEFANTRINE
rxNorm: 847728
atc: P01BF01
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended

***interaction***
drug1
drug name: LUMEFANTRINE
rxNorm: 847728
atc: P01BF01
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended
If this is possible, interrupt the substance tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.

***interaction***
drug1
drug name: LUMEFANTRINE
rxNorm: 847728
atc: P01BF01
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended
If this is possible, interrupt the substance tending to cause torsades de pointes. If administering the substances together cannot be avoided, testing of the QT beforehand and EKG monitoring.
323-LURASIDONE.html


***interaction***
drug1
drug name: LURASIDONE
rxNorm: 1040028
atc: N05AE05
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the inducer
severity: CONTRAINDICATION

***interaction***
drug1
drug name: LURASIDONE
rxNorm: 1040028
atc: N05AE05
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of the lurasidone due to decrease of its hepatic metabolism by the inhibitor
severity: CONTRANDICATION

***interaction***
drug1
drug name: LURASIDONE
rxNorm: 1040028
atc: N05AE05
drug2
drug name: ST JOHN'S WORT
rxNorm: 258326
Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: LURASIDONE
rxNorm: 1040028
atc: N05AE05
drug2
Drug with no codes: GRAGEFRUIT (JUICE AND FRUIT)
Increase of the plasma concentrations of the lurasidone due to decrease of its metabolism by the grapefruit
severity: Not recommended
324-MACITENTAN.html


***interaction***
drug1
drug name: MACITENTAN
rxNorm: 1442132
atc: C02KX04
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Decrease of the plasma concentrations of macitentan due to increase of its metabolism by the inducer
severity: Not recommended

***interaction***
drug1
drug name: MACITENTAN
rxNorm: 1442132
atc: C02KX04
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the plasma concentrations of macitentan due to increase of its metabolism by the St Johns wort
severity: Not recommended
325-MACROLIDES-(EXCEPT-SPIRAMYCIN).html


***interaction***
drug1
class name: MACROLIDES (EXCEPT SPIRAMYCIN)
class code: J01FA
drug2
class name: DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE
class code: G02CB-001
Increase of the plasma concentrations of the dopaminergic with possible increase of its activity or appearance of signs of overdose. 
severity: Not recommended

***interaction***
drug1
class name: MACROLIDES (EXCEPT SPIRAMYCIN)
class code: J01FA
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the macrolide and after it is stopped

***interaction***
drug1
class name: MACROLIDES (EXCEPT SPIRAMYCIN)
class code: J01FA
drug2
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
Increase of the undesirable effects of the colchicine, with potentially fatal consequences
severity: CONTRAINDICATION

***interaction***
drug1
class name: MACROLIDES (EXCEPT SPIRAMYCIN)
class code: J01FA
drug2
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye).
severity: CONTRAINDICATION

***interaction***
drug1
class name: MACROLIDES (EXCEPT SPIRAMYCIN)
class code: J01FA
drug2
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).
severity: CONTRAINDICATION
326-MANNITOL.html


***interaction***
drug1
drug name: MANNITOL
rxNorm: 6628
more atc: A06AD16
more atc: B05BC01
more atc: B05CX04
more atc: R05CB16
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Decrease of the the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness
severity: Precaution for use
Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of the lithium. 
327-MARAVIROC.html


***interaction***
drug1
drug name: MARAVIROC
rxNorm: 620216
atc: J05AX09
drug2
drug name: FOSAMPRENAVIR
rxNorm: 358262
atc: J05AE07
Significant decrease of the concentrations of amprenavir that could lead to a loss of the virological response
severity: Not recommended

***interaction***
drug1
drug name: MARAVIROC
rxNorm: 620216
atc: J05AX09
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
In the absence of the administration at the same time with a strong inhibitor of CYP3A4, decrease of the concentrations of maraviroc by the inducer
severity: Precaution for use
The dose of maraviroc must be increased to 600 mg twice a day in this situation. 

***interaction***
drug1
drug name: MARAVIROC
rxNorm: 620216
atc: J05AX09
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the concentrations of maraviroc by the inhibitor
severity: Precaution for use
The dose of maraviroc must be reduced to 150 mg twice a day if it is taken with this inhibitor.

***interaction***
drug1
drug name: MARAVIROC
rxNorm: 620216
atc: J05AX09
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the plasma concentrations of maraviroc that could lead to a loss of the virological response
severity: Not recommended
328-MEDICATIONS-AT-THE-ORIGIN-OF-A-SEROTONIN-SYNDROME.html


***interaction***
drug1
class name: MEDICATIONS AT THE ORIGIN OF A SEROTONIN SYNDROME
class code: N06A-002
drug2
class name: OTHER MEDICATIONS AT THE ORIGIN OF A SEROTONIN SYNDROME
class code: N06A-002
Risk of appearance or of increased severity of a serotonin syndrome in case of administering any of these medications with any of the others.
severity: Take into account
329-MEDICATIONS-AT-THE-ORIGIN-OF-ORTHOSTATIC-HYPOTENSION.html


***interaction***
drug1
class name: MEDICATIONS AT THE ORIGIN OF ORTHOSTATIC HYPOTENSION
class code: N05AA-001
drug2
drug name: DAPOXETINE
rxNorm: 69394
atc: G04BX14
Risk of increase of the undesirable effects, especially of the vertigo and fainting type
severity: Not recommended
-with the type 5 phospohdisterase inhibitors

***interaction***
drug1
class name: MEDICATIONS AT HE ORIGIN OF ORTHOSTATIC HYPOTENSION
class code: N05AA-001
drug2
class name: MEDICATIONS THAT LOWER BLOOD PRESSURE 
class code: MLBP
Risk of increase of hypotension, especially orthostatic
severity: Take into account
32-AMINOGLYCOSIDES.html


***interaction***
drug1
class name: AMINOGLYCOSIDES 
class code: J01GB-001
drug2
class name: OTHER AMINOGLYCOSIDES 
class code: J01GB-001
Increased risk of nephrotoxicity and ototoxicity (the ototoxicity is cumulative in cases of successive administrations of the aminoglycosides)
severity: Contraindication
-in case of simultaneous administration

***interaction***
drug1
class name: AMINOGLYCOSIDES 
class code: J01GB-001
drug2
drug name: AMPHOTERICIN B 
rxNorm: 732
more atc: A01AB04
more atc: A07AA07
more atc: G01AA03
more atc: J02AA01
With the amphotericin B administered intravenously:

increased risk of nephrotoxicity 
severity: Take into account

***interaction***
drug1
class name: AMINOGLYCOSIDES 
class code: J01GB-001
drug2
drug name: ATALUREN
rxNorm: 
more atc: M09AX03
Risk of increase of the renal toxicity of the aminoglycoside.
severity: CONTRAINDICATION

***interaction***
drug1
class name: AMINOGLYCOSIDES 
class code: J01GB-001
drug2
drug name: BOTULINUM TOXIN
rxNorm: 1716
atc: M03AX01
Risk of increase of the effects of the botulinum toxin with the aminoglycosides (due to extrapolation from the effects observed during the course of the botulism)
severity: Not recommended
Use another antibiotic

***interaction***
drug1
class name: AMINOGLYCOSIDES 
class code: J01GB-001
drug2
drug name: CEFALOTIN
rxNorm: 2236
atc: J01DB03
Increase of the nephrotoxicity of the aminoglycosides by the cefalotin is under discussion
severity: Precaution for use
Monitoring of renal function

***interaction***
drug1
class name: AMINOGLYCOSIDES 
class code: J01GB-001
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Larger increase of the creatinemia than with ciclosporin alone, with increase of the nephrotoxic risk 
severity: Take into account

***interaction***
drug1
class name: AMINOGLYCOSIDES 
class code: J01GB-001
drug2
class name: CURARES
class code: M03A-001
Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.
severity: Precaution for use
Monitor the degree of curarization at the end of anesthesia

***interaction***
drug1
class name: AMINOGLYCOSIDES 
class code: J01GB-001
drug2
class name: LOOP DIURETICS
class code: C03CA-001
Increase of the nephrotoxic and ototoxic risks of the aminoglycoside (functional renal insufficiency linked to the dehydration caused by the diuretic)


severity: Precaution for use
The two medications may be taken together when there is monitoring of the state of hydration, of the renal and cochleovestibulary functions, and, possibly, of the plasma concentrations of the aminoglycoside.

***interaction***
drug1
class name: AMINOGLYCOSIDES 
class code: J01GB-001
drug2
class name: PLATINUM-BASED ANTINEOPLASTIC DRUGS
class code: ORGAPLA
Addition of the nephrotoxic and/or ototoxic effects, especially in the case of pre-existing renal insufficiency
severity: Take into account

***interaction***
drug1
class name: AMINOGLYCOSIDES 
class code: J01GB-001
drug2
drug name: POLYMYXIN B
rxNorm: 8536
more atc: A07AA05
more atc: J01XB02
more atc: S01AA18
more atc: S02AA11
more atc: S03AA03
Addition of the nephrotoxic effects


severity: Not recommended
If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification

***interaction***
drug1
class name: AMINOGLYCOSIDES 
class code: J01GB-001
drug2
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
more atc: L04AD02
Greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)
severity: Take into account
330-MEDICATIONS-AT-RISK-WHEN-WITHDRAWING-FROM-TOBACCO.html


***interaction***
drug1
class name: MEDICATIONS AT RISK WHEN WITHDRAWING FROM TOBACCO
class code: N0-R0-002
drug2
class name: NICOTINE SUBSTITUTION TREATMENT
class code: N07BA
Risk of overdose when replacing tobacco by the replacement therapy
severity: Take into account
331-MEDICATIONS-THAT-LOWER-BLOOD-PRESSURE.html


***interaction***
drug1
class name: MEDICATIONS THAT LOWER BLOOD PRESSURE 
class code: MLBP
drug2
class name: NITRATE DERIVATIVES AND RELATED
class code: C01D-001
Increase of the risk of hypotension, especially orthostatic
severity: Take into account

***interaction***
drug1
class name: MEDICATIONS THAT LOWER BLOOD PRESSURE 
class code: MLBP
drug2
class name: MEDICATIONS AT THE ORIGIN OF ORTHOSTATIC HYPOTENSION
class code: N05AA-001
Risk of increase of hypotension, especially orthostatic
severity: Take into account
332-MEDICATIONS-THAT-LOWER-THE-EPILEPTIC-THRESHOLD.html


***interaction***
drug1
class name: MEDICATIONS THAT LOWER THE EPILEPTIC THRESHOLD
class code: N05AA-002
drug2
class name: OTHER MEDICATIONS THAT LOWER THE EPILEPTIC THRESHOLD
class code: N05AA-002
Accrued risk of convulsions
severity: Take into account
333-ATROPINIC-MEDICATIONS.html


***interaction***
drug1
class name: ATROPINIC MEDICATIONS
class code: R06AA
drug2
class name: OTHER ATROPINIC MEDICATIONS
class code: R06AA
Addition of the undesirable atropinic effects such as urinary retention, constipation, dry mouth 
severity: Take into account
334-METHEMOGLOBINIZIN-MEDICATIONS.html


***interaction***
drug1
class name: METHEMOGLOBINIZING MEDICATIONS 
class code: METGL
drug2
class name: OTHER METHEMOGLOBINIZING MEDICATIONS 
class code: METGL
Risk of addition of the effects of the methomoglobinizing agents.
severity: Take into account
335-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html


***interaction***
drug1
class name: MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS
class code: N06A
drug2
drug name: ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)
rxNorm: 
more atc: 3992
Serious ventricular arrhythmias due to increased cardiac sensitization.
severity: Precautions for use
Limit the amount of adrenaline, for example: less than 0.1 mg of adrenaline in 10 minutes or 0.3 mg in an hour for an adult.

***interaction***
drug1
class name: MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS
class code: N06A
drug2
class name: ORAL ANTICOAGULANTS 
class code: B01A-001
Increase of the risk of hemorrhage
severity: Precaution for use
Clinical monitoring and, if the situation requires, more frequent testing of the INR. Possible adjustment of the dosage of the oral anticoagulant during the administration of these medications together and after it is stopped. 

***interaction***
drug1
class name: MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS
class code: N06A
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.
severity: CONTRAINDICATION
Wait two weeks between stopping the MAOI and the start of the other treatment, and at least a week between the end of that treatment and the start of the MAOI. 

***interaction***
drug1
class name: MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS
class code: N06A
drug2
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, confusion, even coma
severity: Not recommended
If administering these substances together cannot be avoided, very strict clinical monitoring. Begin the administration of the substances together with minimum recommended dosages.

***interaction***
drug1
class name: MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS
class code: N06A
drug2
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
Risk of therapeutic failure when there is concomitant treatment with orlistat
severity: Take into account

***interaction***
drug1
class name: MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS
class code: N06A
drug2
class name: ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)
class code: C01CA
Paroxysmal hypertension with possibility of ventricular arrhythmias (inhibition of the entry of the sympathomimetic into the sympathic fiber)
severity: Not recommended
336-NEPHROTOXIC-MEDICATIONS.html


***interaction***
drug1
class name: NEPHROTOXIC MEDICATIONS 
class code: J01-J05
drug2
class name: OTHER NEPHROTOXIC MEDICATIONS 
class code: J01-J05
Risk of increase of the nephrotoxicity
severity: Take into account
337-OTOTOXIC-MEDICATIONS.html


***interaction***
drug1
class name: OTOTOXIC MEDICATIONS
class code: J01GB-J01XA
drug2
class name: OTHER OTOTOXIC MEDICATIONS
class code: J01GB-J01XA
Increase of the ototoxicity
severity: Take into account
338-SEDATIVE-MEDICATIONS.html


***interaction***
drug1
class name: SEDATIVE MEDICATIONS
class code: N04-N05-N06
drug2
Drug with no codes: ALCOHOL (DRINK OR INGREDIENT)
Increase by the alcohol of the sedative effect of these substances. The alteration of alertness can make driving vehicles or using machines dangerous
severity: Not recommended
Avoid taking alcoholic beverages or medications containing alcohol.

***interaction***
drug1
class name: SEDATIVE MEDICATIONS
class code: N04-N05-N06
drug2
class name: OTHER SEDATIVE MEDICATIONS
class code: N04-N05-N06
Increase of central nervous center depression. The alteration of alertness can make driving vehicles or using machines dangerous
severity: Not recommended
--with sodium oxybate
339-MEFLOQUINE.html


***interaction***
drug1
drug name: MEFLOQUINE
rxNorm: 6694
more atc: P01BF02
more atc: P01BC02
drug2
drug name: QUININE
rxNorm: 9071
more atc: P01BC01
For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects
severity: Not recommended
Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. 
33-AMIODARONE.html


***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
Increase of the plasma concentrations of afatinib by increase of its absorption by the amiodarone. 
severity: Precaution for use
It is recommended that the amiodarone be administered as far as possible from the afatinib, preferably at an interval of 6 to 12 hours from the dose of afatinib.

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage 


severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the amiodarone and a week after it is stopped.

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)
class code: C07AB-001
Disorders of autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)
severity: Precaution for use
Clinical monitoring and EKG

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia
severity: Precaution for use
Regular clinical monitoring and EKG

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Increase of the blood concentrations of ciclosporin, due to decrease of its hepatic metabolism, with risk of nephrotoxic effects


severity: Not recommended
Blood concentration dosages of ciclosporin, testing of the renal function, and adjustment of the dosage of the ciclosporin during the treatment with the amiodarone.

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: COBICISTAT
rxNorm: 1306284
atc: VO3AX03
Risk of increase of the undesirable effects of the amiodarone due to decrease of its metabolism by the cobicistat
severity: CONTRAINDICATION

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
Increase of the plasma concentrations of dabigatran, with greater risk of bleeding


severity: Precaution for use
For post surgical indications:

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: DACLATASVIR
rxNorm: 1606218
atc: J05AX14
Only with the bitherapy daclatasvir/sofosbuvir:

Appearance of bradycardia, possibly abrupt, that can have fatal consequences.
severity: Not recommended
If administering these drugs together cannot be avoided, clinical monitoring and strict EKG, in particular during the first weeks of treatment with the bitherapy

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Depression of autoregulation (excessive bradycardia) and difficulties with atrioventricular conduction. Furthermore, increase of the blood concentrations of digoxin due to decrease of the clearance of the digoxin.
severity: Precaution for use
Clinical monitoring and EKG and, if there is need for it, testing of the digoxinemia and adjustment of the dosage of the digoxin. 

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
For diltiazem by injection: risk of bradycardia and of atrioventricular block

For diltiazem by mouth: risk of bradycardia or of atrioventricular block, especially in older persons.
severity: Not recommended 
-with diltiazem administered by IV

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: ESMOLOL
rxNorm: 49737
atc: C07AB09
Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)
severity: Precaution for use
Clinical monitoring and EKG

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: FIDAXOMICIN 
rxNorm: 1111103
atc: A07AA12
Increase of the plasma concentrations of the fidaxomicin
severity: Not recommended

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
Risk of lengthening of the QT interval
severity: Precaution for use
Clinical monitoring, particularly with large doses of fluconazole (800mg/d)

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: IBRUTINIB
rxNorm: 1442981
atc: L01XE27
Increase of the plasma concentrations of ibrutinib by decease of its hepatic metabolism by the amiodarone
severity: Precaution for use
Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg per day during the time these two medications are administered together. 

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: LEDIPASVIR
rxNorm: 1591922
more atc: LEDIPASV
more atc: SOFOSBUV
more atc: 1591942
more atc: J05AX65
Only with the ledipasvir/sofosbuvir bitherapy, appearance of bradycardia, possibly abrupt, that can have fatal consequences
severity: Not recommended
If the use of these medications together cannot be avoided, close monitoring of patients is recommended, in particular during the first weeks of treatment with the bitherapy (clinical monitoring and EKG).

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: LIDOCAINE
rxNorm: 6387
more atc: C01BB01
more atc: C05AD01
more atc: D04AB01
more atc: N01BB02
more atc: R02AD02
more atc: S01HA07
more atc: S02DA01
Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone
severity: Precaution for use
Clinical monitoring, EKG, and possibly testing of the plasma concentrations of lidocaine. If needed, adjustment of the dosage of the lidocaine during the treatment with amiodarone and after it is stopped.

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: NINTEDANIB
rxNorm: 1592737
atc: L01XE31
Increase of the plasma concentrations of nintedanib due to increase of its absorption by the amiodarone.
severity: Precaution for use
Clinical monitoring during the administration of these medications together. 

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: OLAPARIB
rxNorm: 1597582
atc: L01XX46
Increase of the plasma concentrations of olaparib by the amiodarone
severity: Not recommended
If administering these together cannot be avoided, limit the dose of olaparib to 200 mg twice a day with the amiodarone. 

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
class name: OMBITASVIR + PARITAPVIR
class code: OMPA
Increase of the plasma concentrations of the amiodarone due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir
severity: CONTRAINDICATION

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
Risk of decrease of the plasma concentrations of the amiodarone and of its active metabolite


severity: Precaution for use
Clinical monitoring and, if needed, EKG

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Increase of the plasma concentrations of the phenytoin with signs of overdose, in particular neurological ones (decrease of the hepatic metabolism of the phenytoin)
severity: Precaution for use
Clinical monitoring, testing of the plasma concentrations of phenytoin and possible adjustment of its dosage

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin).
severity: Precaution for use
Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: SOFOSBUVIR
rxNorm: 1484911
atc: J05AX15
more atc: LEDIPASV
more atc: SOFOSBUV
more atc: 1591939
more atc: 1591940
more atc: J05AX65
more atc: J05AX65
more atc: J05AX65
more atc: J05AX65
more atc: J05AX65
more atc: J05AX65
more atc: J05AX65
more atc: J05AX65
more atc: J05AX65
more atc: J05AX65
more atc: J05AX65
more atc: J05AX65
more atc: J05AX65
more atc: J05AX65
more atc: J05AX65
more atc: J05AX65
Only when administered with the combinations daclatasvir/sofosbuvir or ledispasvir/sofosbuvir:

Possibly abrupt appearance of bradycardia, which can have fatal consequences.
severity: Not recommended
If administering these medications together cannot be avoided, strict clinical monitoring and EKG, in particular during the first weeks of treatment with the combinations with sofosbuvir.

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
more atc: L04AD02
Increase of the blood concentrations of tacrolimus due to inhibition of its metabolism by the amiodarone.


severity: Precaution for use
Blood concentration dosage of tacrolimus, testing of the renal function, and adjustment of the dosage of tacrolimus during the administration of it and the amiodarone together and when the amiodarone is stopped. 

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: TAMSULOSIN
rxNorm: 77492
atc: G04CA02
Risk of increase of the undesirable effects of the tamsulosin due to inhibition of its hepatic metabolism


severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzymatic inhibitor and after it is stopped, if the situation requires. 

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia
severity: CONTRAINDICATION

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 
more atc: C01BD01
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
For verapamil by injection: 

-risk of bradycardia or of atrioventricular block. 

For verapamil by mouth:

-risk of bradycardia or of atrioventricular block, especially with older patients
severity: Not recommended with:
-verapamil administered via IV

***interaction***
drug1
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
Increased risk of ventricular arrhythmias, especially of torsades de pointes, due to possible decrease of the metabolism of the amiodarone
severity: Precaution for use
Clinical monitoring and EKG, and possible adjustment of the dosage of the amiodarone.
340-MEQUITAZINE.html


***interaction***
drug1
drug name: MEQUITAZINE
rxNorm: 29528
atc: R06AD07
drug2
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor
severity: Not recommended

***interaction***
drug1
drug name: MEQUITAZINE
rxNorm: 29528
atc: R06AD07
drug2
drug name: CINACALCET
rxNorm: 407990
atc: H05BX01
Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor
severity: Not recommended

***interaction***
drug1
drug name: MEQUITAZINE
rxNorm: 29528
atc: R06AD07
drug2
drug name: DULOXETINE
rxNorm: 72625
atc: N06AX21
Risk of increase of the undesirable effects of the mequitazine due to inhibition of its metabolism by the enzyme inhibitor
severity: Not recommended

***interaction***
drug1
drug name: MEQUITAZINE
rxNorm: 29528
atc: R06AD07
drug2
drug name: FLUOXETINE
rxNorm: 4493
atc: N06CA03
Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor
severity: Not recommended

***interaction***
drug1
drug name: MEQUITAZINE
rxNorm: 29528
atc: R06AD07
drug2
drug name: PAROXETINE
rxNorm: 32937
atc: N06AB05
Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor
severity: Not recommended

***interaction***
drug1
drug name: MEQUITAZINE
rxNorm: 29528
atc: R06AD07
drug2
drug name: TERBINAFINE
rxNorm: 37801
more atc: D01AE15
more atc: D01BA02
Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor
severity: Not recommended
341-METFORMIN.html


***interaction***
drug1
drug name: METFORMIN
rxNorm: 6809
more atc: A10BA02
more atc: A10BD13
more atc: A10BD11
more atc: A10BD05
more atc: A10BD03
more atc: A10BD10
more atc: A10BD07
more atc: A10BD02
more atc: A10BD08
drug2
Drug with no codes: ALCOHOL (DRINK OR INGREDIENT)
Increased risk of lactic acidosis when there is acute alcohol intoxication, particularly in cases of fasting or undernourishment, or in cases of liver failure
severity: Not recommended
Avoid taking alcoholic beverages and medications containing alcohol. 

***interaction***
drug1
drug name: METFORMIN
rxNorm: 6809
more atc: A10BA02
more atc: A10BD13
more atc: A10BD11
more atc: A10BD05
more atc: A10BD03
more atc: A10BD10
more atc: A10BD07
more atc: A10BD02
more atc: A10BD08
drug2
class name: LOOP DIURETICS
class code: C03CA-001
Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics
severity: Precaution for use
Do not use metformin when the creatinemia is greater than 15mg/l (135 mol/l) for men, and 12 mg/l (110mol/l) for women.

***interaction***
drug1
drug name: METFORMIN
rxNorm: 6809
more atc: A10BA02
more atc: A10BD13
more atc: A10BD11
more atc: A10BD05
more atc: A10BD03
more atc: A10BD10
more atc: A10BD07
more atc: A10BD02
more atc: A10BD08
drug2
drug name: DOLUTEGRAVIR
rxNorm: 1433868
atc: J05AX12
Increase of the plasma concentrations of metformin by the dolutegravir and of its undesirable effects of the lactic acidosis type
severity: Precaution for use
--with the patient having moderate renal insufficiency (stage 3a, clearance of the creatinine between 45 and 59 ml/min), clinical and biological monitoring , and possible adjustment of the dosage of metformin 

***interaction***
drug1
drug name: METFORMIN
rxNorm: 6809
more atc: A10BA02
more atc: A10BD13
more atc: A10BD11
more atc: A10BD05
more atc: A10BD03
more atc: A10BD10
more atc: A10BD07
more atc: A10BD02
more atc: A10BD08
drug2
class name: IODINATED X-RAY CONTRAST MEDIA
class code: VO8A-001
Lactic acidosis linked to elevated concentrations of metformin in relation to the functional renal insufficiency induced by the radiological exam.
severity: CONTRAINDICATION
The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
342-METHADONE.html


***interaction***
drug1
drug name: METHADONE
rxNorm: 6813
more atc: N02AC52
more atc: N07BC02
drug2
class name: MORPHINE LIKE ANTITUSSIVES
class code: R05DA0-001
Increased risk of respiratory depression, which can be fatal in case of overdose
severity: Take into account

***interaction***
drug1
drug name: METHADONE
rxNorm: 6813
more atc: N02AC52
more atc: N07BC02
drug2
class name: TRUE MORPHINE ANTITUSSIVES
class code: R0GDA0-002
Increased risk of respiratory depression which can be fatal in case of overdose
severity: Take into account

***interaction***
drug1
drug name: METHADONE
rxNorm: 6813
more atc: N02AC52
more atc: N07BC02
drug2
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
Decrease of the plasma concentrations of methadone, with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism by the boceprevir
severity: Precaution for use
Regular clinical monitoring and possible adjustment of the dosage of methadone.

***interaction***
drug1
drug name: METHADONE
rxNorm: 6813
more atc: N02AC52
more atc: N07BC02
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.
severity: Precaution for use
Strengthen clinical and electrocardiographic monitoring; if needed, adjustment of the dosage of the methadone during treatment with the cimetidine and after it is stopped. 

***interaction***
drug1
drug name: METHADONE
rxNorm: 6813
more atc: N02AC52
more atc: N07BC02
drug2
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Strengthen clinical and electrocardiographic monotoring; if needed, adjustment of the dosage of the methadone during the treatment with the fluvoxamine and after it is stopped.

***interaction***
drug1
drug name: METHADONE
rxNorm: 6813
more atc: N02AC52
more atc: N07BC02
drug2
drug name: FOSAMPRENAVIR
rxNorm: 358262
atc: J05AE07
Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the amprenavir
severity: Precaution for use
Regular clinical monitoring and possible adjustment of the dosage of methadone. 

***interaction***
drug1
drug name: METHADONE
rxNorm: 6813
more atc: N02AC52
more atc: N07BC02
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism
severity: Precaution for use
Increase the frequency of the doses of methadone (2 to 3 times a day instead of once a day). 

***interaction***
drug1
drug name: METHADONE
rxNorm: 6813
more atc: N02AC52
more atc: N07BC02
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ritonavir
severity: Precaution for use
Regular clinical monitoring and possible adjustment of the dosage of methadone. 

***interaction***
drug1
drug name: METHADONE
rxNorm: 6813
more atc: N02AC52
more atc: N07BC02
drug2
class name: AGONIST-ANTAGONIST OPIOIDS 
class code: NO2A-001
Decrease of the effect of the methadone due to competitive blockage of the receptors.
severity: CONTRAINDICATION

***interaction***
drug1
drug name: METHADONE
rxNorm: 6813
more atc: N02AC52
more atc: N07BC02
drug2
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Contraindication
--with the citalopram, the domperidone, the escitalopram, the hydroxyzine and the piperaquine
343-METHENAMINE.html


***interaction***
drug1
drug name: METHENAMINE
rxNorm: 6832
atc: J01XX05
drug2
drug name: SULFAMETHIZOLE
rxNorm: 10179
more atc: B05CA04
more atc: J01EB02
Precipitation of crystals in the urinary tract (due to the acidification of the urine)
severity: Not recommended
344-METHOTREXATE.html


***interaction***
drug1
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
Increase of the toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)
severity: With doses of methotrexate > 20 mg/week
Contraindication  with acetylsalicylic acid used in anatalgic, antipyretic, or anti-inflammatory doses

***interaction***
drug1
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
drug2
drug name: ACITRETIN
rxNorm: 16818
atc: D05BB02
Risk of increase of the hepatoxicity of the methotrexate
severity: Not recommended
If administering these substances together is judged necessary, strengthen liver function testing 

***interaction***
drug1
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Increase of the hematological toxicity of the methotrexate (decrease of the renal clearance of the methotrexate by the NSAIs).
severity: Not recommended
--for doses of methotrexate greater than 20mg per week

***interaction***
drug1
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
drug2
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
Risk of increase of the toxicity of the methotrexate due to decrease of its elimination
severity: Not recommended
--with the methotrexate in doses > 20mg /week

***interaction***
drug1
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications
severity: Precaution for use
Blood concentration dosages of ciclosporin and of methotrexate. Adjustment of the dosage if necessary during the administration of the two together and after it is stopped.

***interaction***
drug1
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
drug2
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin
severity: Not recommended

***interaction***
drug1
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
drug2
class name: PENICILLINS
class code: J01C
Increase of the effects and of the hematological toxicity of the methothrexate: inhibition of the renal tubular secretion of the methotrexate by the penicillins
severity: Not recommended

***interaction***
drug1
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
drug2
drug name: PROBENECID
rxNorm: 8698
atc: M04AB01
Increase of the toxicity of the methotrexate: inhibition of the renal tubular secretion of the methotrexate by the probenecid
severity: CONTRAINDICATION

***interaction***
drug1
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
drug2
class name: ANTIBACTERIAL SULFONAMIDES
class code: JO1E
Increase of the hematological toxicity of the methotrexate
severity: Precaution for use
Concentration dosage of methotrexate. Adjustment of the dosage if necessary during the administration of the substances together and after it is stopped. 

***interaction***
drug1
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
drug2
drug name: TRIMETHOPRIM
rxNorm: 10829
atc: J01EA01
Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)
severity: CONTRAINDICATION
345-METHYLDOPA.html


***interaction***
drug1
drug name: METHYLDOPA
rxNorm: 6876
more atc: C02AB
more atc: C02AB01
more atc: C02AB02
drug2
drug name: IRON
rxNorm: 1431589
atc: B03A
Decrease of the digestive absorption of the methyldopa (formation of complexes)
severity: Precaution for use
Take the iron salts at a different time from the methyldopa (more than two hours apart, if possible).

***interaction***
drug1
drug name: METHYLDOPA
rxNorm: 6876
more atc: C02AB
more atc: C02AB01
more atc: C02AB02
drug2
drug name: LEVODOPA
rxNorm: 6375
atc: N04BA01
Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa
severity: Precaution for use
Clinical monitoring and possible decrease of the doses of levodopa.

***interaction***
drug1
drug name: METHYLDOPA
rxNorm: 6876
more atc: C02AB
more atc: C02AB01
more atc: C02AB02
drug2
drug name: LITHIUM
rxNorm: 6448
atc: N05AN01
Increase of the plasma concentrations of lithium which can attain toxic values, with signs of overdose of lithium
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of lithium. 
346-METHYLPREDNISOLONE.html


***interaction***
drug1
drug name: METHYLPREDNISOLONE
rxNorm: 6902
more atc: D07AA01
more atc: D10AA02
more atc: H02AB04
more atc: D07CA02
more atc: S01CA08
more atc: H02BX01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
Testing of the INR 2 to 4 days after the bolus of mythylprednisolone or in the presence of signs of hemorrhage

***interaction***
drug1
drug name: METHYLPREDNISOLONE
rxNorm: 6902
more atc: D07AA01
more atc: D10AA02
more atc: H02AB04
more atc: D07CA02
more atc: S01CA08
more atc: H02BX01
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin
severity: Take into account

***interaction***
drug1
drug name: METHYLPREDNISOLONE
rxNorm: 6902
more atc: D07AA01
more atc: D10AA02
more atc: H02AB04
more atc: D07CA02
more atc: S01CA08
more atc: H02BX01
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
In case of prolonged use, increase of the plasma concentrations of the corticoid, because of decrease of its hepatic metabolism by the inhibitor, with risk of appearance of cushing syndrome
severity: Take into account
347-METOPROLOL.html


***interaction***
drug1
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
more atc: C07BB52
more atc: C07AB52
drug2
drug name: ABIRATERONE
rxNorm: 1100072
atc: L02BX03
With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the abiraterone.
severity: Precaution for use:
Clinical monitoring. If needed, adjustment of the dosage of the metropolol during the treatment with the abiraterone

***interaction***
drug1
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
more atc: C07BB52
more atc: C07AB52
drug2
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the bupropion

***interaction***
drug1
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
more atc: C07BB52
more atc: C07AB52
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with cimetidine

***interaction***
drug1
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
more atc: C07BB52
more atc: C07AB52
drug2
drug name: CINACALCET
rxNorm: 407990
atc: H05BX01
Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the metopolol during the treatment with cinacalcet.

***interaction***
drug1
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
more atc: C07BB52
more atc: C07AB52
drug2
drug name: DARIFENACIN
rxNorm: 136198
atc: G04BD10
Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with darifenacin.

***interaction***
drug1
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
more atc: C07BB52
more atc: C07AB52
drug2
drug name: DULOXETINE
rxNorm: 72625
atc: N06AX21
Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the metoprolol during the treatment with the duloxetine and after it is stopped. 

***interaction***
drug1
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
more atc: C07BB52
more atc: C07AB52
drug2
drug name: FLUOXETINE
rxNorm: 4493
atc: N06CA03
Risk of increase of the undesirable effects of the metoprolol, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine 
severity: Precaution for use
Increased clinical monitoring; if needed, adjustment of the dosage of the metoprolol during the length of the treatment with the fluoxetine and after it is stopped.

***interaction***
drug1
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
more atc: C07BB52
more atc: C07AB52
drug2
drug name: HYDROXYCHLOROQUINE
rxNorm: 5521
atc: P01BA02
With the metoprolol used in heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the hydroxychloroquine
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the hydroxychloroquine

***interaction***
drug1
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
more atc: C07BB52
more atc: C07AB52
drug2
drug name: MIRABEGRON
rxNorm: 1300786
atc: G04BD12
With the metoprolol used in heart failure, increase of the plasma concentrations of the metoprolol due to decrease of its metabolism by the mirabegron
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the metoprolol during the administration of it with the mirabegron

***interaction***
drug1
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
more atc: C07BB52
more atc: C07AB52
drug2
drug name: PAROXETINE
rxNorm: 32937
atc: N06AB05
Risk of increase of the undesirable effects of the metoprolol, especially with excessive bradycardia, due to inhibition of its metabolism by the paroxetine 
severity: Precaution for use
Increased clinical monitoring; if needed, adjustment of the dosage of the metoprolol during the treatment with the paroxetine and after it is stopped.

***interaction***
drug1
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
more atc: C07BB52
more atc: C07AB52
drug2
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)
severity: Take into account

***interaction***
drug1
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
more atc: C07BB52
more atc: C07AB52
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)
severity: Take into account

***interaction***
drug1
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
more atc: C07BB52
more atc: C07AB52
drug2
drug name: TERBINAFINE
rxNorm: 37801
atc: D01BA02
With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 
348-METRONIDAZOLE.html


***interaction***
drug1
drug name: METRONIDAZOLE
rxNorm: 6922
more atc: A02BD08
more atc: A02BD03
more atc: A02BD02
more atc: A01AB17
more atc: D06BX01
more atc: G01AF01
more atc: J01XD01
more atc: P01AB01
more atc: A02BD01
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer


severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the inducer and after it is stopped. 

***interaction***
drug1
drug name: METRONIDAZOLE
rxNorm: 6922
more atc: A02BD08
more atc: A02BD03
more atc: A02BD02
more atc: A01AB17
more atc: D06BX01
more atc: G01AF01
more atc: J01XD01
more atc: P01AB01
more atc: A02BD01
drug2
drug name: BUSULFAN
rxNorm: 1828
atc: L01AB01
With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole
severity: Not recommended

***interaction***
drug1
drug name: METRONIDAZOLE
rxNorm: 6922
more atc: A02BD08
more atc: A02BD03
more atc: A02BD02
more atc: A01AB17
more atc: D06BX01
more atc: G01AF01
more atc: J01XD01
more atc: P01AB01
more atc: A02BD01
drug2
drug name: DISULFIRAM
rxNorm: 3554
atc: N07BB01
Risk of episodes of acute psychosis or of confused state, reversible upon stopping the administration of the two substances together
severity: Not recommended

***interaction***
drug1
drug name: METRONIDAZOLE
rxNorm: 6922
more atc: A02BD08
more atc: A02BD03
more atc: A02BD02
more atc: A01AB17
more atc: D06BX01
more atc: G01AF01
more atc: J01XD01
more atc: P01AB01
more atc: A02BD01
drug2
class name: FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)
class code: L01BC-001
Increase of the toxicity of the fluorouracil due to decrease of its clearance
severity: Take into account

***interaction***
drug1
drug name: METRONIDAZOLE
rxNorm: 6922
more atc: A02BD08
more atc: A02BD03
more atc: A02BD02
more atc: A01AB17
more atc: D06BX01
more atc: G01AF01
more atc: J01XD01
more atc: P01AB01
more atc: A02BD01
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Increase of the the plasma concentrations of lithium which can attain toxic values with signs of overdose of lithium.
severity: Precaution for use
Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of the lithium. 

***interaction***
drug1
drug name: METRONIDAZOLE
rxNorm: 6922
more atc: A02BD08
more atc: A02BD03
more atc: A02BD02
more atc: A01AB17
more atc: D06BX01
more atc: G01AF01
more atc: J01XD01
more atc: P01AB01
more atc: A02BD01
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 
349-METYRAPONE.html


***interaction***
drug1
drug name: METYRAPONE
rxNorm: 6923
atc: V04CD01
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Risk of false negative results of the test with metyrapone, due to a decrease of its plasma concentrations, because of increase of its hepatic metabolism by the phenytoin.
severity: Precaution for use
Double the dosage of the metyrapone.
34-AMLODIPINE.html


***interaction***
drug1
drug name: AMLODIPINE
rxNorm: 17767
atc: C08CA01
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication).
severity: Precaution for use
Do not exceed the dosage of 40 mg/day of simvastatin or use another statin not affected by this type of interaction
350-MEXILETINE.html


***interaction***
drug1
drug name: MEXILETINE
rxNorm: 6926
atc: C01BB02
drug2
drug name: CAFFEINE 
rxNorm: 1886
more atc: N06BC01
more atc: V04CG30
Increase of the plasma concentrations of caffeine, due to inhibition of its hepatic metabolism by the mexiletine
severity: Take into account

***interaction***
drug1
drug name: MEXILETINE
rxNorm: 6926
atc: C01BB02
drug2
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
Risk of increase of the undesirable effects of the mexiletine, due to inhibition of its metabolism by the fluvoxamine
severity: Precaution for use
Clinical monitoring and EKG. Adjustment of the dosage of the mexiletine during the treatment with the fluvoxamine and after it is stopped.

***interaction***
drug1
drug name: MEXILETINE
rxNorm: 6926
atc: C01BB02
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Decrease of the antiarrhythmic activity, of the plasma concentrations, and of the half life of the mexiletine (increase of its hepatic metabolism)
severity: Precaution for use
Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the mexiletine; if there is reason for it, adjustment of the dosage of the mexiletine during the treatment with the phenytoin and after it is stopped.

***interaction***
drug1
drug name: MEXILETINE
rxNorm: 6926
atc: C01BB02
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Increase of the theophyllinemia with risk of overdose (decrease of the hepatic metabolism of the theophylline)
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the mexiletine and after it is stopped.
351-MIANSERIN.html


***interaction***
drug1
drug name: MIANSERIN
rxNorm: 6929
atc: N06AX03
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Risk of ineffectiveness of the mianserin 
severity: Not recommended
352-MICONAZOLE.html


***interaction***
drug1
drug name: MICONAZOLE
rxNorm: 6932
more atc: A01AB09
more atc: A07AC01
more atc: D01AC02
more atc: G01AF04
more atc: J02AB01
more atc: S02AA13
more atc: D01AC52
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Unpredictable hemorrhages, possibly serious
severity: CONTRAINDICATION

***interaction***
drug1
drug name: MICONAZOLE
rxNorm: 6932
more atc: A01AB09
more atc: A07AC01
more atc: D01AC02
more atc: G01AF04
more atc: J02AB01
more atc: S02AA13
more atc: D01AC52
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.
severity: Precaution for use
Strict clinical monitoring. 

***interaction***
drug1
drug name: MICONAZOLE
rxNorm: 6932
more atc: A01AB09
more atc: A07AC01
more atc: D01AC02
more atc: G01AF04
more atc: J02AB01
more atc: S02AA13
more atc: D01AC52
drug2
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma
severity: CONTRAINDICATION
353-MIDAZOLAM.html


***interaction***
drug1
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Risk of decrease of the plasma concentrations of the midazolam by the anticonvulsant


severity: Take into account

***interaction***
drug1
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation
severity: Precaution for use
Clinical monitoring and reduction of the dosage during the treatment with the diltiazem

***interaction***
drug1
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
Increase of the plasma concentrations of midazolam due to reduction of its hepatic metabolism, with increase of sedation
severity: Not recommended
--with the midazolam by mouth

***interaction***
drug1
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation
severity: Not recommended:
--with the midazolam by mouth

***interaction***
drug1
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the plasma concentrations of midazolam by the St Johns wort
severity: Take into account

***interaction***
drug1
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
drug2
class name: OMBITASVIR + PARITAPREVIR
class code: OMPA
Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism by the ombitasvir+ paritaprevir
severity: CONTRAINDICATION

***interaction***
drug1
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism
severity: Not recommended

***interaction***
drug1
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
drug2
drug name: ROXITHROMYCIN
rxNorm: 9478
atc: J01FA06
Slight increase of sedation
severity: Take into account

***interaction***
drug1
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
drug2
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism with increase of sedation
severity: Precaution for use
Clinical monitoring and reduction of the dosage during the treatment with the stiripentol.

***interaction***
drug1
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the plasma concentrations of midazolam (decrease of its hepatic metabolism with increase of sedation)
severity: Precaution for use
Clinical monitoring and reduction of the dosage of midazolam during the treatment with the verapamil.
354-MIDECAMYCIN.html


***interaction***
drug1
drug name: MIDECAMYCIN
rxNorm: 30005
atc: J01FA05
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Risk of increase of the blood concentrations of ciclosporin and of the creatinemia
severity: Precaution for use
Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration of the substances together and after the macrolide is stopped. 
355-MIDODRINE.html


***interaction***
drug1
drug name: MIDODRINE
rxNorm: 6963
atc: C01CA17
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Disorders of autoregulation (increase of the bradycardia inducing effect of the midodrine) and disorders of atrioventricular conduction
severity: Not recommended
If administering these substances together cannot be avoided, strengthen clinical monitoring and EKG.

***interaction***
drug1
drug name: MIDODRINE
rxNorm: 6963
atc: C01CA17
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped.
severity: CONTRAINDICATION
356-ST-JOHNS-WORT.html


***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
class name: METABOLIZED ANTICONVULSANTS
class code: N03A-002
Risk of decrease of the plasma concentrations and of the effectiveness of the anticonvulsant

.
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
Risk of ineffectiveness of the treatment by the proton pump inhibitor due to decrease of its metabolism by the St Johns wort
severity: Take into account

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Decrease of the plasma concentrations of the vitamin K antagonist, by reason of its enzymatic inducer effect, with risk of reduction of effectiveness, even complete loss of the effect, which could have possibly serious consequences (thrombolitic event)
severity: CONTRAINDICATION
In case of an accidental use of the two substances together, do not stop the St Johns Wort suddenly, but test the INR before and then after the St Johns Wort is stopped.

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: BEDAQUILINE
rxNorm: 1364504
atc: J04AK05
Risk of decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Risk of decrease of the plasma concentrations and of the effectiveness of the carbamazepine
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: COBICISTAT
rxNorm: 1306284
more atc: V03AX03
more atc: J05AR09
Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: CYPROTERONE
rxNorm: 3014
atc: G03HA01
more atc: G03HB01
Risk of decrease of the effectiveness of the cyproterone, due to increase of its hepatic metabolism by the St Johns Wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: DACLATASVIR
rxNorm: 1606218
atc: J05AX14
Risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: DASABUVIR
rxNorm: 1597381
atc: J05AX16
Risk of decrease of the plasma concentrations of the dasabuvir by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: DIGOXIN
rxNorm: 3407
atc: C01AA05
Decrease of the digoxinemia, because of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (acute decompensated heart failure).
severity: CONTRAINDICATION
In the case of the two substances being taken by accident, do not stop the St Johns Wort abruptly but test the plasma concentrations (or the effectiveness) of the digoxin before and then after the St Johns Wort is stopped. 

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: DOLUTEGRAVIR
rxNorm: 1433868
atc: J05AX12
Risk of decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the St Johns wort
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: ERIBULINE
rxNorm: 1045453
atc: L01XX41
Risk of decrease of the plasma concentrations of eribuline by the St Johns wort
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
Decrease of the plasma concentrations of the hormonal contraceptive, because of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect which can have possibly serious consequences (pregnancy).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: IDELALISIB
rxNorm: 1544460
atc: L01XX47
Risk of large decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the St Johns wort
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Risk of appearance of a serotonin syndrome
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. 

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
Risk of appearance of a serotonin syndrome
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Decrease of the blood concentrations of the immunosuppressant, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which could have possibly serious consequences (rejection of a graft)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Decrease of the plasma concentrations of the protease inhibitor, due to the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (reduction of the antiretroviral effectiveness)
severity: CONTRAINDICATION
In the case of the substances being taken together by accident, do not stop the St Johns Wort abruptly, but test the plasma concentrations (or the effectiveness) of the protease inhibitor before and then after the St Johns Wort is stopped. 

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
class name: METABOLIZED TYROSINE-KINASE INHIBITORS 
class code: L01XE
Decrease of the plasma concentrations and of the effectiveness of the tyrosine-kinase inhibitor, due to increase of its metabolism by the St Johns Wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
class code: N06AB
Risk of appearance of a serotonin syndrome
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. 

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: IRINOTECAN
rxNorm: 51499
atc: L01XX19
Decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: ISAVUCONAZOLE
rxNorm: 1720882
atc: J02AC05
Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Risk of large decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
Risk of decrease of the effectiveness of the ivabradine due to increase of its metabolism by the St Johns wort
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: LEDIPASVIR
rxNorm: 1591922
Risk of large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolidm by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: LOMITAPIDE
rxNorm: 1364479
atc: C10AX12
Risk of decrease of the plasma concentrations of the lomitapide
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: LURASIDONE
rxNorm: 1040028
atc: N05AE05
Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: MACITENTAN
rxNorm: 1442132
atc: C02KX0
Risk of decrease of the plasma concentrations of macitentan due to increase of its metabolism by the St Johns wort
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: MARAVIROC
rxNorm: 620216
atc: J05AX09
Risk of decrease of the plasma concentrations of maraviroc that could lead to a loss of virological response
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
Risk of decrease of the plasma concentrations of midazolam by the St Johns wort
severity: Take into account

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: NEVIRAPINE
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
Risk of significant decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: NINTEDANIB
rxNorm: 1592737
more atc: L01XE31
Decrease of the plasma concentrations of the nintedanib due to decrease of its absorption by the St Johns Wort
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: OXYCODONE
rxNorm: 7804
atc: N02AA55
Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the St Johns wort
severity: Not recommended
Possible adjustment of the dosage of the oxycodone.

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
Decrease of the plasma concentrations of the hormonal contraceptive, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (pregnancy)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the St Johns wort
severity: Precaution for use
Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the time the substances are administered together and after the St Johns wort is stopped. 

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: QUETIAPINE
rxNorm: 51272
atc: N05AH04
Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: REGORAFENIB
rxNorm: 1312397
atc: L01XE21
Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the St Johns wort
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: RILPIVIRINE
rxNorm: 1102270
atc: J05AG05
Risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: SIMEPREVIR
rxNorm: 1482790
atc: J05AE14
Risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the St Johns wort
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Decrease of the effectiveness of the cholesterol lowering agent due to increase of its hepatic metabolism by the St Johns wort
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: SOFOSBUVIR
rxNorm: 
more atc: J05AX15
Risk of decrease of the plasma concentrations of sofobusvir due to decrease of its intestinal absorption by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
Risk of very large decrease of the concentrations of telaprevir
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the St Johns wort
severity: Not recommended

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Decrease of the plasma concentrations of the theophylline, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (onset of an obstructive pulmonary syndrome) 
severity: CONTRAINDICATION
In case of accidental use of the substances together, do not stop the St Johns wort abruptly but test the plasma concentrations (or the effectiveness) of the medication taken with it before and then after stopping the St Johns wort. 

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
Risk of large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the St Johns wort, with decrease of its therapeutic effect
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer
severity: Not recommended
Choose a therapeutic alternative that is little or not metabolized.

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Large reduction of the concentrations of verapamil, with risk of loss of its therapeutic effect
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: VISMODEGIB
rxNorm: 1242987
atc: L01XX43
Risk of decrease of the plasma concentrations of vismodegib
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ST JOHNS WORT
rxNorm: 258326
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
Large reduction of the concentrations of voriconazole, with risk of loss of its therapeutic effect
severity: CONTRAINDICATION
357-MINERALOCORTICOIDS.html


***interaction***
drug1
class name: MINERALOCORTICOIDS
class code: H02AA0
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great in patients with Addisons disease treated with the hydrocortisone and in the case of transplants.
severity: Precaution for use
Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped. 

***interaction***
drug1
class name: MINERALOCORTICOIDS
class code: H02AA0
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison's disease treated with the hydrocortisone and in the case of transplants
severity: Precaution for use
Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 
358-MIRABEGRON.html


***interaction***
drug1
drug name: MIRABEGRON
rxNorm: 1300786
atc: G04BD12
drug2
drug name: FLECAINIDE
rxNorm: 4441
atc: C01BC04
Increase of the plasma concentrations of the flecainide by decrease of its metabolism by the mirabegron
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the flecainide during the administration of these medications together.

***interaction***
drug1
drug name: MIRABEGRON
rxNorm: 1300786
atc: G04BD12
drug2
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
With the metoprolol used in heart failure, increase of the plasma concentrations of the metoprolol due to decrease of its metabolism by the mirabegron
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the metoprolol during the administration of these medications together. 

***interaction***
drug1
drug name: MIRABEGRON
rxNorm: 1300786
atc: G04BD12
drug2
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
Increase of the plasma concentrations of the propafenone by decrease of its metabolism by the mirabegron
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the propafenone during the administration with the mirabegron
359-MITOMYCIN-C.html


***interaction***
drug1
drug name: MITOMYCIN C
rxNorm: 632
atc: L01DC03
drug2
class name: VINCA ALKALOIDS
class code: L01CA
Risk of increase of the pulmonary toxicity of the mitomycin and of the vinca-alkaloids
severity: Take into account
35-AMPHOTERICIN-B.html


***interaction***
drug1
drug name: AMPHOTERICIN B 
rxNorm: 732
atc: J02AA01
drug2
class name: AMINOGLYCOSIDES 
class code: J01GB-001
With the amphotericin B administered intravenously: increased risk of nephrotoxicity
severity: Take into account

***interaction***
drug1
drug name: AMPHOTERICIN B 
rxNorm: 732
atc: J02AA01
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
With the amphotericin B administered intravenously:

greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances).
severity: Take into account

***interaction***
drug1
drug name: AMPHOTERICIN B 
rxNorm: 732
atc: J02AA01
drug2
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
more atc: L04AD02
With the amphotericin B administered intravenously: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances).
severity: Take into account

***interaction***
drug1
drug name: AMPHOTERICIN B 
rxNorm: 732
atc: J02AA01
drug2
drug name: ZIDOVUDINE
rxNorm: 11413
more atc: J05AF01
more atc: J05AR01
more atc: J05AR04
more atc: J05AR05
With the amphotericin B administered intravenously:

increase of the hematological toxicity (addition of effects of bone marrow toxicity)
severity: Precaution for use
More frequent CBC.
360-MITOTANE.html


***interaction***
drug1
drug name: MITOTANE
rxNorm: 7004
atc: L01XX23
drug2
drug name: DASABUVIR
rxNorm: 1597381
atc: J05AX16
Risk of decrease of the plasma concentrations of the dasabuvir by the mitotane
severity: CONTRAINDICATION

***interaction***
drug1
drug name: MITOTANE
rxNorm: 7004
atc: L01XX23
drug2
drug name: SPIRONOLACTONE
rxNorm: 9997
atc: C03DA01
Risk of blockage of the action of the mitotane by the spironolactone
severity: CONTRAINDICATION
361-MIZOLASTINE.html


***interaction***
drug1
drug name: MIZOLASTINE
rxNorm: 61455
atc: R06AX25
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: MIZOLASTINE
rxNorm: 61455
atc: R06AX25
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
Risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: MIZOLASTINE
rxNorm: 61455
atc: R06AX25
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: MIZOLASTINE
rxNorm: 61455
atc: R06AX25
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: MIZOLASTINE
rxNorm: 61455
atc: R06AX25
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: MIZOLASTINE
rxNorm: 61455
atc: R06AX25
drug2
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION
362-MOCLOBEMIDE.html


***interaction***
drug1
drug name: MOCLOBEMIDE
rxNorm: 30121
atc: N06AG02
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the moclobemide, due to decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring with possible adjustment of the dosage of moclobemide
363-MODAFINIL.html


***interaction***
drug1
drug name: MODAFINIL
rxNorm: 30125
atc: N06BA07
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Risk of decrease of the blood concentrations and of the effectiveness of the immunosuppressant
severity: Not recommended

***interaction***
drug1
drug name: MODAFINIL
rxNorm: 30125
atc: N06BA07
drug2
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
Risk of decrease of the contraceptive effectiveness, during the treatment and one cycle after the end of the treatment with the modafinil, due to its enzymatic inducer potential
severity: Not recommended
Use oral contraceptives containing estrogens and progestins that have 50 micrograms of estrogen or another method of contraception. 

***interaction***
drug1
drug name: MODAFINIL
rxNorm: 30125
atc: N06BA07
drug2
drug name: SOFOSBUVIR
rxNorm: 
more atc: J05AX15
Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the modafinil
severity: Not recommended
364-MONTELUKAST.html


***interaction***
drug1
drug name: MONTELUKAST
rxNorm: 88249
atc: R03DC03
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Risk of lower effectiveness of the montelukast due to increase of its hepatic metabolism by the inducer
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the inducer and after it is stopped. 

***interaction***
drug1
drug name: MONTELUKAST
rxNorm: 88249
atc: R03DC03
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of lower effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the rifampicin and after it is stopped.
365-MORPHINE.html


***interaction***
drug1
drug name: MORPHINE
rxNorm: 7052
more atc: N02AA01
more atc: N02AG01
more atc: R05DA05
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 
366-OPIOIDS.html


***interaction***
drug1
class name: OPIOIDS
class code: N0-R0
drug2
class name: BARBITURATES
class code: N05CA-001
Increased risk of respiratory depression, which could be fatal in case of overdose
severity: Take into account

***interaction***
drug1
class name: OPIOIDS
class code: N0-R0
drug2
class name: BENZODIAZEPINES AND RELATED
class code: N05-001
Increased risk of respiratory depression, which could be fatal in case of overdose
severity: Take into account
367-AGONIST-ANTAGONIST-OPIOIDS.html


***interaction***
drug1
class name: AGONIST-ANTAGONIST OPIOIDS 
class code: NO2A-001
drug2
class name: STEP II OPIOID ANALGESICS
class code: N02A-003
Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome. 
severity: Not recommended

***interaction***
drug1
class name: AGONIST-ANTAGONIST OPIOIDS 
class code: NO2A-001
drug2
class name: STEP III OPIOID ANALGESICS
class code: N02A-002
Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome
severity: CONTRAINDICATION

***interaction***
drug1
class name: AGONIST-ANTAGONIST OPIOIDS 
class code: NO2A-001
drug2
class name: TRUE MORPHINE ANTITUSSIVES
class code: R0GDA0-002
Decrease of the antalgic or antitussive effect of the opioid, due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome
severity: Not recommended 

***interaction***
drug1
class name: AGONIST-ANTAGONIST OPIOIDS 
class code: NO2A-001
drug2
drug name: METHADONE
rxNorm: 6813
atc: N07BC02
Decrease of the effect of the methadone due to competitive blocking of the receptors
severity: CONTRAINDICATION

***interaction***
drug1
class name: AGONIST-ANTAGONIST OPIOIDS 
class code: NO2A-001
drug2
class name: PARTIAL AGONIST OPIOIDS
class code: PARAG
Risk of decrease of the antalgic effect and/or of appearance of a withdrawal syndrome
severity: CONTRAINDICATION
368-PARTIAL-AGONIST-OPIOIDS.html


***interaction***
drug1
class name: PARTIAL AGONIST OPIOIDS
class code: PARAG
drug2
class name: STEP II OPIOID ANALGESICS
class code: N02A-003
Risk of decrease of the antalgic effect
severity: Not Recommended

***interaction***
drug1
class name: PARTIAL AGONIST OPIOIDS
class code: PARAG
drug2
class name: STEP III OPIOID ANALGESICS
class code: N02A-002
Risk of decrease of the antalgic effect
severity: CONTRAINDICATION

***interaction***
drug1
class name: PARTIAL AGONIST OPIOIDS
class code: PARAG
drug2
class name: AGONIST-ANTAGONIST OPIOIDS 
class code: NO2A-001
Risk of decrease of the antalgic effect and/or appearance of a withdrawal syndrome
severity: CONTRAINDICATION

***interaction***
drug1
class name: PARTIAL AGONIST OPIOIDS
class code: PARAG
drug2
class name: OPIOIDS FOR REPLACEMENT THERAPY
class code: N07BC
Risk of appearance of a withdrawal syndrome
severity: CONTRAINDICATION
369-OPIOIDS-FOR-REPLACEMENT-THERAPY.html


***interaction***
drug1
class name: OPIOIDS FOR REPLACEMENT THERAPY
class code: N07BC
drug2
class name: PARTIAL AGONIST OPIOIDS
class code: PARAG
Risk of appearance of a withdrawal syndrome 
severity: CONTRAINDICATION
36-ANAGRELIDE.html


***interaction***
drug1
drug name: ANAGRELIDE
rxNorm: 596724
atc: L01XX35
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
Increase of hemorrhagic events 
severity: Not recommended

***interaction***
drug1
drug name: ANAGRELIDE
rxNorm: 596724
atc: L01XX35
drug2
class name: PLATELET AGGREGATION INHIBITORS
class code: B01AC-001
Increase of hemorraghic events 
severity: Not recommended

***interaction***
drug1
drug name: ANAGRELIDE
rxNorm: 596724
atc: L01XX35
drug2
class name: MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG during the administration of these medications together. 
370-MYCOPHENOLATE-MOFETIL.html


***interaction***
drug1
drug name: MYCOPHENOLATE MOFETIL
rxNorm: 7145
drug2
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness
severity: Take into account

***interaction***
drug1
drug name: MYCOPHENOLATE MOFETIL
rxNorm: 7145
more atc: L04AA06
drug2
class name: FLUOROQUINOLONES
class code: J01MA-001
Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness
severity: Take into account

***interaction***
drug1
drug name: MYCOPHENOLATE MOFETIL
rxNorm: 7145
more atc: L04AA06
drug2
class name: AMINOPENICILLINS
class code: J01CA
Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness
severity: Take into account

***interaction***
drug1
drug name: MYCOPHENOLATE MOFETIL
rxNorm: 7145
more atc: L04AA06
drug2
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
Risk of general vaccine disease, possibly fatal.


severity: CONTRAINDICATION
And during the 3 months following the end of the treatment
371-MYCOPHENOLATE-SODIUM.html


***interaction***
drug1
drug name: MYCOPHENOLATE SODIUM 
rxNorm: 408142
drug2
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
Risk of general vaccine disease, possibly fatal 
severity: CONTRAINDICATION
And during the 3 months following the end of the treatment with these substances together.
372-NEBIVOLOL.html


***interaction***
drug1
drug name: NEBIVOLOL
rxNorm: 31555
more atc: C07AB12
more atc: C07BB12
drug2
drug name: FLUOXETINE
rxNorm: 4493
more atc: N06AB03
more atc: N06CA03
Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant
severity: Precaution for use
Increased clinical monitoring; if needed, adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped.

***interaction***
drug1
drug name: NEBIVOLOL
rxNorm: 31555
more atc: C07AB12
more atc: C07BB12
drug2
drug name: PAROXETINE
rxNorm: 32937
atc: N06AB05
Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant
severity: Precaution for use
Increased clinical monitoring; if needed adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped. 
373-NEUROLEPTICS.html


***interaction***
drug1
class name: NEUROLEPTICS
class code: N05AA-003
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
Vasidilator effect and risk of hypotension, especially orthostatic (additive effect)
severity: Take into account

***interaction***
drug1
class name: NEUROLEPTICS
class code: N05AA-003
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Risk of appearance of neuropsychic signs evocative of a neuroleptic malignant syndrome or of lithium poisoning
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.

***interaction***
drug1
class name: NEUROLEPTICS
class code: N05AA-003
drug2
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
Risk of therapeutic failure when there is concomitant treatment with orlistat
severity: Take into account
374-ANTIEMETIC-NEUROLEPTICS.html


***interaction***
drug1
class name: ANTIEMITIC NEUROLEPTICS
class code: A03FA-001
drug2
class name: DOPAMINERGICS
class code: N04B-002
Reciprocal antagonism between the dopaminergic and the neuropleptic
severity: CONTRAINDICATION
Use an antiemetic without extrapyramidal effects. 

***interaction***
drug1
class name: ANTIEMITIC NEUROLEPTICS
class code: A03FA-001
drug2
drug name: LEVODOPA
rxNorm: 6375
more atc: N04BA01
more atc: N04BA02
more atc: N04BA03
Reciprocal antagonism between the levodopa and the neuroleptic
severity: CONTRAINDICATION
Use an antiemitic without extrapyramidal effects.
375-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html


***interaction***
drug1
class name: ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)
class code: N05A-001
drug2
class name: ANTIPARKINSONIAN DOPAMINERGICS
class code: N04B-001
Reciprocal antagonism of the dopaminergic and the neuroleptics. The dopaminergic can cause or increase the psychotic disorders. When a treatment with neuroleptics is necessary for a parkinsons patient treated with dopaminergics, these latter must be decreased progressively until they are stopped (their abrupt discontinuation exposes the patient to a risk of "neuroleptic malignant syndrome" (NMS)).
severity: Not recommended

***interaction***
drug1
class name: ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)
class code: N05A-001
drug2
class name: DOPAMINERGICS, EXCEPT PARKINSON
class code: G02CB-002
Reciprocal antagonism of the dopamine agonist and the neuroleptics
severity: CONTRAINDICATION

***interaction***
drug1
class name: ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)
class code: N05A-001
drug2
drug name: LEVODOPA
rxNorm: 6375
more atc: N04BA01
more atc: N04BA02
more atc: N04BA03
Reciprocal antagonism of the levodopa and the neuroleptics
severity: Not recommended
With a parkinsons patient, use the minimum effective doses of each of the two medications. 
376-NEUROLEPTICS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html


***interaction***
drug1
class name: NEUROLEPTICS THAT TEND TO INDUCE TORSADES DE POINTES
class code: N05A-002
drug2
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Contraindication
-with citalopram, domperidone, escitalopram, hydroxyzine and piperaquine
377-NEVIRAPINE.html


***interaction***
drug1
drug name: NEVIRAPINE
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism
severity: Precaution for use
More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist

***interaction***
drug1
drug name: NEVIRAPINE
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
drug2
drug name: ATAZANAVIR
rxNorm: 343047
atc: J05AE08
Risk of reduction of the effectiveness of the atanazavir due to increase of its hepatic metabolism
severity: Not recommended
If the administration of these medications together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together

***interaction***
drug1
drug name: NEVIRAPINE
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the nevirapine.

***interaction***
drug1
drug name: NEVIRAPINE
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
drug2
drug name: FOSAMPRENAVIR
rxNorm: 358262
atc: J05AE07
Risk of reduction of the effectiveness of the amprenavir
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. 

***interaction***
drug1
drug name: NEVIRAPINE
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
drug2
drug name: INDINAVIR
rxNorm: 114289
atc: J05AE02
Risk of reduction of the effectiveness of the indinavir
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together.

***interaction***
drug1
drug name: NEVIRAPINE
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole, for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing. 
severity: CONTRAINDICATION

***interaction***
drug1
drug name: NEVIRAPINE
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of significant decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: NEVIRAPINE
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin
severity: Not recommended

***interaction***
drug1
drug name: NEVIRAPINE
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the nevirapine.
severity: Not recommended
If the administration of the substances together cannot be avoided, strict clinical monitoring and possible adjustment of the dosage of the voriconazole during the administration of the substances together.
378-NICARDIPINE.html


***interaction***
drug1
drug name: NICARDIPINE
rxNorm: 7396
atc: C08CA04
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Increase of the blood concentrations of the immunosuppressant, due to inhibition of its hepatic metabolism
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage of the immunosuppressant during the treatment with nicardipine and after it is stopped.
379-NIFEDIPINE.html


***interaction***
drug1
drug name: NIFEDIPINE
rxNorm: 7417
atc: C08CA05
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Risk of addition of undesirable effects of the gum disorders type
severity: Not recommended
Use another dihydropyridine

***interaction***
drug1
drug name: NIFEDIPINE
rxNorm: 7417
atc: C08CA05
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine
severity: Precaution for use
Increased clinical monitoring: adjust the dosage of the nifedipine during the treatment with the cimetidine and after it is stopped. 

***interaction***
drug1
drug name: NIFEDIPINE
rxNorm: 7417
atc: C08CA05
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Large increase of the concentrations of nefedipine due to decrease of its hepatic metabolism by the diltiazem, with risk of severe hypotension
severity: CONTRAINDICATION
37-ANAKINRA.html


***interaction***
drug1
drug name: ANAKINRA
rxNorm: 72435
atc: L04AC03
drug2
class name: ANTI-TNF ALPHA
class code: 4ABO
Increased risk of serious infections and of neutropenia.
severity:  Not recommended

***interaction***
drug1
drug name: ANAKINRA
rxNorm: 72435
atc: L04AC03
drug2
drug name: ETANERCEPT
rxNorm: 214555
atc: L04AB01
Increased risk of serious infections and of neutropenia
severity: Not recommended
380-NIMODIPINE.html


***interaction***
drug1
drug name: NIMODIPINE
rxNorm: 7426
atc: C08CA06
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism by the inducer


severity: Not recommended
Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the inducer and after it is stopped

***interaction***
drug1
drug name: NIMODIPINE
rxNorm: 7426
atc: C08CA06
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism
severity: Not recommended
Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the rifampicin and after it is stopped.

***interaction***
drug1
drug name: NIMODIPINE
rxNorm: 7426
atc: C08CA06
drug2
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
With the nimodipine by oral route, and by extrapolation, by injection: risk of increase of the hypotensive effect of the nimodipine due to increase of its plasma concentrations (decrease of its metabolism by the valproic acid).
severity: Take into account
381-NINTEDANIB.html


***interaction***
drug1
drug name: NINTEDANIB
rxNorm: 1592737
atc: LO1XE31
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Increase of the plasma concentrations of the nintedanib by increase of its absorption by the amiodarone
severity: Precaution for use
Clinical monitoring during the administration of these medications together. 

***interaction***
drug1
drug name: NINTEDANIB
rxNorm: 1592737
atc: LO1XE31
drug2
drug name: CARBAMAZAPINE
rxNorm: 2002
atc: N03AF01
Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the carbamazepine
severity: Precaution for use
Clinical monitoring during the administration of these medications together

***interaction***
drug1
drug name: NINTEDANIB
rxNorm: 1592737
atc: LO1XE31
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Increase of the plasma concentrations of the nintedanib by increase of its absorption by the ciclosporin
severity: Precaution for use
Clinical monitoring during the administration of these medications together

***interaction***
drug1
drug name: NINTEDANIB
rxNorm: 1592737
atc: LO1XE31
drug2
drug name: ERYTHROMYCIN
rxNorm: 
Increase of the plasma concentrations of the nintedanib by increase of its absorption by the erythromycin
severity: Precaution for use
Clinical monitoring during the administration of these medications together

***interaction***
drug1
drug name: NINTEDANIB
rxNorm: 1592737
atc: LO1XE31
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Increase of the plasma concentrations of the nintedanib by increase of its absorption by the ritonavir boosted protease inhibitor
severity: Precaution for use
Clinical monitoring during the administration of these medications together

***interaction***
drug1
drug name: NINTEDANIB
rxNorm: 1592737
atc: LO1XE31
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increase of the plasma concentrations of the nintedanib by increase of its absorption by the itraconazole
severity: Precaution for use
Clinical monitoring during the administration of these medications together

***interaction***
drug1
drug name: NINTEDANIB
rxNorm: 1592737
atc: LO1XE31
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Increase of the plasma concentrations of the nintedanib by increase of its absorption by the ketoconazole
severity: Precaution for use
Clinical monitoring during the administration of these medications together

***interaction***
drug1
drug name: NINTEDANIB
rxNorm: 1592737
atc: LO1XE31
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the St Johns Wort
severity: Not recommended

***interaction***
drug1
drug name: NINTEDANIB
rxNorm: 1592737
atc: LO1XE31
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the phenytoin or the fosphenytoin
severity: Precaution for use
Clinical monitoring during the administration of these medications together

***interaction***
drug1
drug name: NINTEDANIB
rxNorm: 1592737
atc: LO1XE31
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the rifampicin
severity: Precaution for use
Clinical monitoring during the administration of these medications together

***interaction***
drug1
drug name: NINTEDANIB
rxNorm: 1592737
atc: LO1XE31
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the plasma concentrations of the nintedanib by increase of its absorption by the verapamil
severity: Precaution for use
Clinical monitoring during the administration of these medications together
382-NORFLOXACIN.html


***interaction***
drug1
drug name: NORFLOXACIN
rxNorm: 7517
more atc: J01MA06
more atc: S01AE02
drug2
drug name: CAFFEINE 
rxNorm: 1886
atc: V04CG30
Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine
severity: Take into account

***interaction***
drug1
drug name: NORFLOXACIN
rxNorm: 7517
more atc: J01MA06
more atc: S01AE02
drug2
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrhythmias, especially of torsades de points. 
severity: Precaution for use
Clinical monitoring and EKG during the administration of these substances together. 

***interaction***
drug1
drug name: NORFLOXACIN
rxNorm: 7517
more atc: J01MA06
more atc: S01AE02
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia. 
383-NORTRIPTYLINE.html


***interaction***
drug1
drug name: NORTRIPTYLINE
rxNorm: 7531
atc: N06AA10
drug2
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
Risk of increase of the undesirable effects of the nortriptyline due to decrease of its hepatic metabolism by the bupropion
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the nortriptyline during the treatment with the bupropion.
384-NOSCAPINE.html


***interaction***
drug1
drug name: NOSCAPINE
rxNorm: 7533
atc: R05DA07
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Not recommended
385-OLANZAPINE.html


***interaction***
drug1
drug name: OLANZAPINE
rxNorm: 61381
atc: N05AH03
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Risk of decrease of the plasma concentrations of the olanzapine and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the carbamazepine
severity: Precaution for use
Clinical monitoring, and if needed, adjustment of the dosage of the olanzapine. 

***interaction***
drug1
drug name: OLANZAPINE
rxNorm: 61381
atc: N05AH03
drug2
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
Increase of the concentrations of the olanzapine, with risk of increase of its undesirable effects, due to decrease of its hepatic metabolism by the fluvoxamine
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the olanzapine during the treatment with fluvoxamine.
386-OLAPARIB.html


***interaction***
drug1
drug name: OLAPARIB
rxNorm: 1597582
atc: L01XX46
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Increase of the plasma concentrations of olaparib by the amiodarone
severity: Not recommended
If administering these medications together cannot be avoided, limit the dose of olaparib to 200 mg twice a day with the amiodarone

***interaction***
drug1
drug name: OLAPARIB
rxNorm: 1597582
atc: L01XX46
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Increase of the plasma concentrations of olaparib by the diltiazam
severity: Not recommended
If administering these medications together cannot be avoided, limit the dose of olaparib to 200 mg twice a day. 

***interaction***
drug1
drug name: OLAPARIB
rxNorm: 1597582
atc: L01XX46
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
Increase of the plasma concentrations of olaparib by the fluconazole
severity: Not recommended
If administering these medications together cannot be avoided, limit the dose of olaparib to 200 mg twice a day.

***interaction***
drug1
drug name: OLAPARIB
rxNorm: 1597582
atc: L01XX46
drug2
class name: ENZYME INDUCERS
class code: N03-J05-001
Decrease, possibly very large depending on the inducer, of the plasma concentrations of the olaparib due to increase of its hepatique metabolism by the inducer
severity: Not recommended

***interaction***
drug1
drug name: OLAPARIB
rxNorm: 1597582
atc: L01XX46
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of olaparib by the inhibitor
severity: Not recommended
If administering these medications together cannot be avoided, limit the dose of olaparib to 150 mg twice a day.

***interaction***
drug1
drug name: OLAPARIB
rxNorm: 1597582
atc: L01XX46
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the plasma concentrations of olaparib by the verapamil.
severity: Not recommended
If administering these medications together cannot be avoided, limit the dose of olaparid to 200 mg twice a day.
387-OMBITASVIR-PARITAPREVIR.html


***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
drug name: FUSIDIC ACID
rxNorm: 4608
more atc: D06AX01
more atc: D09AA02
more atc: J01XC01
more atc: S01AA13
Increase of the plasma concentrations of the fusidic acid due to decrease of its hepatic metabolism by the bitherapy.
severity: CONTRAINDICATION

***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
class name: VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE
class code: N02CA0-001
Increase of the plasma concentrations of the vasoconstrictor alkaloid of ergot of rye due to decrease of its hepatic metabolism by the bitherapy.
severity: CONTRAINDICATION

***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
drug name: ALFUZOSIN
rxNorm: 17300
atc: G04CA01
Increase of the plasma concentrations of the alfuzosin due to decrease of its hepatic metabolism by the bitherapy.
severity: CONTRAINDICATION

***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Increase of the plasma concentrations of the amiodarone due to decrease of its hepatic metabolism by the bitherapy.
severity: CONTRAINDICATION

***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increase of the plasma concentrations of the atorvastatin due to decrease of its hepatic metabolism by the bitherapy.
severity: CONTRAINDICATION

***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
Increase of the plasma concentrations of the colchicine due to decrease of its hepatic metabolism by the bitherapy.
severity: CONTRAINDICATION 
--with patients having renal and/or hepatic insufficiency

***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
drug name: ETHINYLESTRADIOL
rxNorm: 4124
more atc: G03AA15
more atc: G03AB07
more atc: G03AA09
more atc: G03AB05
more atc: G03AA12
more atc: G03CA01
more atc: L02AA03
more atc: G03AA01
more atc: G03AA10
more atc: G03AB06
more atc: G03AA07
more atc: G03AB03
more atc: G03AA03
more atc: G03AB02
Increase of the hepatotoxicity
severity: CONTRAINDICATION

***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Decrease of the plasma concentrations of the bitherapy due to increase of its hepatic metabolism by the inducer
severity: CONTRAINDICATION

***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of the bitherapy due to decrease of its hepatic metabolism by the inhibitor
severity: CONTRAINDICATION 
--except with the ritonavir

***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism by the bitherapy
severity: CONTRAINDICATION

***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
Increase of the plasma concentrations of the pimozide due to decrease of its hepatic metabolism by the bitherapy
severity: CONTRAINDICATION

***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
drug name: QUETIAPINE
rxNorm: 51272
atc: N05AH04
Increase of the plasma concentrations of the quetiapine due to decrease of its hepatic metabolism by the bitherapy
severity: CONTRAINDICATION

***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
Increase of the plasma concentrations of the quinidine due to decrease of its hepatic metabolism by the bitherapy
severity: CONTRAINDICATION

***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
drug name: SILDENAFIL
rxNorm: 136411
atc: G04BE03
Increase of the plasma concentrations of the sildenafil due to decrease of its hepatic metabolism by the bitherapy
severity: CONTRAINDICATION

***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increase of the plasma concentrations of the simvastatin due to decrease of its hepatic metabolism by the bitherapy
severity: CONTRAINDICATION

***interaction***
drug1
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
drug2
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
Increase of the plasma concentrations of the ticagrelor due to decrease of its hepatic metabolism by the bitherapy
severity: CONTRAINDICATION
388-OMEPRAZOLE.html


***interaction***
drug1
drug name: OMEPRAZOLE
rxNorm: 7646
more atc: A02BC01
more atc: A02BD05
more atc: A02BD01
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Moderate increase of the digoxinemia due to increase of its absorption by the omeprazole
severity: Precaution for use
Clinical monitoring, EKG, and monitoring of the digoxinemia, particularly with an older patient. 

***interaction***
drug1
drug name: OMEPRAZOLE
rxNorm: 7646
more atc: A02BC01
more atc: A02BD05
more atc: A02BD01
drug2
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
Increase of the blood concentrations of the tacrolimus
severity: Precaution for use
Blood concentration dosage of the tacrolimus, testing of the renal function and adjustment of the dosage during the administration of the substances together and after it is stopped. 
389-ONDANSETRON.html


***interaction***
drug1
drug name: ONDANSETRON
rxNorm: 26225
atc: A04AA01
drug2
drug name: APOMORPHINE
rxNorm: 1043
more atc: G04BE07
more atc: N04BC07
Severe hypotension and loss of consciousness have been reported when ondansetron is administered with apomorphine
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ONDANSTRON
rxNorm: 26225
atc: A04AA01
drug2
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrhythmias, especially of torsades de pointes 
severity: Precaution for use
Clinical monitoring and EKG during the administration of these medications together. 

***interaction***
drug1
drug name: ONDANSETRON
rxNorm: 26225
atc: A04AA01
drug2
drug name: TRAMADOL
rxNorm: 10689
atc: N02AX02
Decrease of the intensity and of the duration of the analgesic effect of the tramadol and risk of decrease of the antiemetic effect of the ondansetron
severity: Take into account
38-AGONIST-OPIOID-ANALGESICS.html


***interaction***
drug1
class name: AGONIST OPIOID ANALGESICS
class code: N01A-N02A
drug2
class name: OTHER AGONIST OPIOID ANALGESICS
class code: N01A-N02A
Increased risk of respiratory depression which can be fatal in case of overdose
severity: Take into account

***interaction***
drug1
class name: AGONIST OPIOID ANALGESICS
class code: N01A-N02A
drug2
class name: MORPHINE LIKE ANTITUSSIVES
class code: R05DA0-001
Increased risk of respiratory depression, which can be fatal in cases of overdose
severity: Take into account

***interaction***
drug1
class name: AGONIST OPIOID ANALGESICS
class code: N01A-N02A
drug2
class name: TRUE MORPHINE ANTITUSSIVES
class code: R0GDA0-002
Increased risk of respiratory depression which can be fatal in cases of overdose
severity: Take into account
390-GOLD.html


***interaction***
drug1
drug name: GOLD
rxNorm: 1311190
more atc: M01CB
more atc: M01CB01
more atc: M01CB02
more atc: M01CB03
more atc: M01CB04
more atc: M01CB05
more atc: V10AX06
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly sudden drop in blood pressure)
severity: Take into account
391-PLATINUM-BASED-ANTINEOPLASTIC-CANCER-DRUGS.html


***interaction***
drug1
class name: PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS
class code: L01XA
drug2
class name: AMINOGLYCOSIDES
class code: J01GB-001
Addition of the nephrotoxic and/or ototoxic effects, especially in the case of pre-existing renal insufficiency
severity: Take into account

***interaction***
drug1
class name: PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS
class code: L01XA
drug2
class name: LOOP DIURETICS
class code: C03CA-001
Risk of addition of the ototoxic and/or nephrotoxic effects
severity: Take into account
392-ORLISTAT.html


***interaction***
drug1
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Risk of decrease of the plasma concentrations of the amiodarone and of its active metabolite


severity: Precaution for use
Clinical monitoring and, if needed, EKG

***interaction***
drug1
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
drug2
class name: TRICYCLIC ANTIDEPRESSANTS
class code: N06AA-001
Risk of therapeutic failure when there is concomitant treatment with orlistat
severity: Take into account

***interaction***
drug1
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the orlistat and after it is stopped. 

***interaction***
drug1
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Decrease of the blood concentrations of ciclosporin due to decrease of its intestinal absorption, with risk of loss of the immunosuppressive activity
severity: Not recommended
Take the orlistat at a different time from the ciclosporin (at least three hours apart). Reinforce testing of the blood dosages of ciclosporin, especially at the beginning of the administration of the two medications together, and at the time of a possible increase of the dosage of the orlistat.

***interaction***
drug1
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
drug2
class name: THYROID HORMONES
class code: H03AA
Risk of disequilibrium of the thyroid replacement therapy when there is treatment with orlistat
severity: Take into account 

***interaction***
drug1
drug name: ORLISTAT 
rxNorm: 37925
atc: A08AB01
drug2
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
class code: N06AB
Risk of therapeutic failure when there is concomitant treatment with orlistat
severity: Take into account

***interaction***
drug1
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Risk of therapeutic failure when there is concomitant treatment with orlistat
severity: Take into account

***interaction***
drug1
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
drug2
class name: MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS
class code: N06A
Risk of therapeutic failure when there is concomitant treatment with orlistat
severity: Take into account

***interaction***
drug1
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
drug2
class name: NEUROLEPTICS
class code: N05AA-003
Risk of therapeutic failure when there is concomitant treatment with orlistat
severity: Take into account

***interaction***
drug1
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
drug2
class name: VITAMIN D
class code: A11CC
Decrease of the absorption of the vitamin D
severity: Take into account
393-ORNIDAZOLE.html


***interaction***
drug1
drug name: ORNIDAZOLE
rxNorm: 7701
more atc: G01AF06
more atc: J01XD03
more atc: P01AB03
drug2
class name: FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)
class code: L01BC-001
Increase of the toxicity of the fluorouracil due to decrease of its clearance
severity: Take into account
394-OXCARBAZEPINE.html


***interaction***
drug1
drug name: OXCARBAZEPINE
rxNorm: 32624
atc: N03AF02
drug2
class name: NON-CONTRACEPTIVE ESTROGENS
class code: G03C-001
Risk of decrease of the effectiveness of the hormonal treatment, due to increase of its hepatic metabolism by the oxcarbazepine.
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the treatment with the oxcarbazepine and after it is stopped.

***interaction***
drug1
drug name: OXCARBAZEPINE
rxNorm: 32624
atc: N03AF02
drug2
drug name: LAMOTRIGINE
rxNorm: 28439
atc: N03AX09
Decrease of the concentrations of the lamotrigine with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine
severity: Precaution for use
Clinical monitoring and testing of the plasma concentrations, with adjustment of the dosage of the lamotrigine if needed.

***interaction***
drug1
drug name: OXCARBAZEPINE
rxNorm: 32624
atc: N03AF02
drug2
drug name: PERAMPANEL
rxNorm: 1356552
atc: N03AX22
Decrease by half of the concentrations of perampanel and slight increase of those of the oxcarbazepine.
severity: Take into account

***interaction***
drug1
drug name: OXCARBAZEPINE
rxNorm: 32624
atc: N03AF02
drug2
drug name: TOPIRAMATE
rxNorm: 38404
atc: 38404
Risk of decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine
severity: Precaution for use
Clinical monitoring and, if needed, adjustment of the dosage of the topiramate during the treatment with the oxcarbazepine and after it is stopped. 
395-OXPRENOLOL.html


***interaction***
drug1
drug name: OXPRENOLOL
rxNorm: 7801
atc: C07AA02
drug2
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)
severity: Precaution for use
Reinforce clinical monitoring, in particular during the first weeks of the administration of these substances together. 
396-OXYCODONE.html


***interaction***
drug1
drug name: OXYCODONE
rxNorm: 7804
atc: N02AA05
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
atc: J02AC01
Increase of the undesirable effects, especially respiratory ones, of the oxycodone due to decrease of its metabolism by the fluconazole
severity: Not recommended
Clinical monitoring and possible adjustment of the dosage of the oxycodone during the treatment with the fluconazole and after it is stopped. 

***interaction***
drug1
drug name: OXYCODONE
rxNorm: 7804
atc: N02AA05
drug2
class name: ENZYME INDUCERS
class code: N03-J05-001
Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the inducer
severity: Not recommended
Possible adjustment of the dosage of the oxycodone

***interaction***
drug1
drug name: OXYCODONE
rxNorm: 7804
atc: N02AA05
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the undesirable effects, especially respiratory ones, of the oxycodone due to decrease of its metabolism by the inhibitor
severity: Not recommended
Clinical monitoring and possible adjustment of the dosage of the oxycodone during the treatment with the inhibitorand after it is stopped

***interaction***
drug1
drug name: OXYCODONE
rxNorm: 7804
atc: N02AA05
drug2
drug name: ST JOHN'S WORT
rxNorm: 258326
Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the St Johns wort
severity: Not recommended
Possible adjustment of the dosage of the oxycodone
397-PACLITAXEL.html


***interaction***
drug1
drug name: PACLITAXEL
rxNorm: 56946
atc: L01CD01
drug2
drug name: CLOPIDOGREL
rxNorm: 32968
atc: B01AC04
Increase of the concentrations of the paclitaxel by the clopidogrel, with risk of increase of the undesirable effects. 
severity: Take into account
398-GRAPEFRUIT-(JUICE-OR-FRUIT).html


***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: ALISKIREN
rxNorm: 325646
atc: C09XA02
Risk of decrease of the effectiveness of the aliskiren when grapefruit is consumed
severity: Not recommended

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increase of the plasma concentrations of the cholesterol lowering medication, with risk of appearance of undesirable effects, especially muscular ones
severity: Take into account

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: AVANAFIL
rxNorm: 1291301
atc: G04BE10
Increase of the plasma concentrations of the avanafil, with risk of hypotension


severity: Not recommended

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: BUSPIRONE
rxNorm: 1827
atc: N05BE01
Risk of increase of the undesirable effects of the buspirone due to decrease of its metabolism by the grapefruit
severity: Take into account

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Increase of the plasma concentrations of carbamazepine, with risk of overdose, due to inhibition of its metabolism by the grapefruit
severity: Not recommended

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
Increase of the concentrations of dronedarone due to inhibition of its metabolism by the grapefruit
severity: Not recommended

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: HALOFANTRINE
rxNorm: 50749
atc: P01BX01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Increase of the bioavailability of the immunosuppressant and as a result of its undesirable effects
severity: Not recommended

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
Increase of the plasma concentrations of the ivabradine and of its undesirable effects (inhibition of its intestinal metabolism by the grapefruit)
severity: Not recommended

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: LERCANIDIPINE
rxNorm: 135056
atc: C08CA13
Increased risk of undesirable effects, especially edema, due to decrease of the intestinal metabolism of the dihydropyridine
severity: Take into account

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: LURASIDONE
rxNorm: 1040028
atc: N05AE05
Increase of the plasma concentrations of the lurasidone due to decrease of its metabolism by the grapefruit
severity: Not recommended

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: REGORAFENIB
rxNorm: 1312397
atc: L01XE21
Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the grapefruit
severity: Not recommended

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: SERTRALINE
rxNorm: 36437
atc: N06AB06
Sometimes large increase of the plasma concentrations of the antidepressant with certain patients due to decrease of intestinal metabolism
severity: Not recommended

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Large increase of the plasma concentrations of the cholesterol lowering medication, with risk of onset of undesirable effects, especially muscular ones.
severity: Not recommended

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
Doubling of the plasma concentrations of the platelet aggregation inhibitor, with risk of increase of the undesirable effects, especially hemorrhagic
severity: Not recommended

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: VARDENAFIL
rxNorm: 306674
atc: G04BE09
Increase of the plasma concentrations of the vardenafil, with risk of hypotension
severity: Not recommended

***interaction***
drug1
Drug with no codes: GRAPEFRUIT
more atc: JUICE
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
more atc: FRUIT
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the plasma concentrations of verapamil, with risk of onset of undesirable effects
severity: Take into account
399-PANOBINOSTAT.html


***interaction***
drug1
drug name: PANOBINOSTAT
rxNorm: 1603350
atc: L01XX42
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the undesirable effects, especially cardiac ones, of the panobinostat due to decrease of its metabolism by the inhibitor
severity: Precaution for use
Clinical monitoring and EKG. Possible adjustment of the dosage of the panobinostat
39-STEP-II-OPIOID-ANALGESICS.html


***interaction***
drug1
class name: STEP II OPIOID ANALGESICS
class code: N02A-003
drug2
class name: AGONIST-ANTAGONIST OPIOIDS 
class code: NO2A-001
Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome
severity: Not recommended

***interaction***
drug1
class name: STEP II OPIOID ANALGESICS
class code: N02A-003
drug2
class name: PARTIAL AGONIST OPIOIDS
class code: PARAG
Risk of decrease of the antalgic effect
severity: Not recommended
3-ACETAZOLAMIDE.html


***interaction***
drug1
drug name: ACETAZOLAMIDE
rxNorm: 167
atc: S01EC01
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
Increase of the undesirable effects, and especially of metabolic acidosis, of the acetylsalicylic acid in large doses and of the acetazolamide, due to decrease of the elimination of the acetylsalicylic acid by the acetazolamide
severity: Not recommended

***interaction***
drug1
drug name: ACETAZOLAMIDE
rxNorm: 167
atc: S01EC01
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Increase of the plasma concentrations of carbamazepine with signs of overdose
severity: Precaution for use
Clinical monitoring, and, if needed, testing of the plasma concentrations of carbamazepine and possible reduction of its dosage. 

***interaction***
drug1
drug name: ACETAZOLAMIDE
rxNorm: 167
atc: S01EC01
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Decrease of the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness
severity: Precaution for use
Strict monitoring of the plasma concentrations of lithium and possible adjustment of the dosage of the lithium.

***interaction***
drug1
drug name: ACETAZOLAMIDE
rxNorm: 167
atc: S01EC01
drug2
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
Increase of the hyperammonemia, with incresed risk of encephalopathy
severity: Precaution for use
Regular clinical and biological monitoring.
400-PARACETAMOL.html


***interaction***
drug1
drug name: PARACETAMOL
rxNorm: 161
more atc: N02BE01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage when taking paracetamol in maximal doses (4g/day) for at least 4 days
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the paracetamol and after it is stopped. 
401-PAROXETINE.html


***interaction***
drug1
drug name: PAROXETINE
rxNorm: 32937
atc: N06AB05
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Increase of the plasma concentrations of carbamazepine with signs of overdose
severity: Precaution for use
Clinical monitoring, testing of the plasma concentrations of carbamazepine, and possible reduction of the dosage of the carbamazepine during the treatment with the serotoninergic antidepressant and after it is stopped. 

***interaction***
drug1
drug name: PAROXETINE
rxNorm: 32937
atc: N06AB05
drug2
drug name: MEQUITAZINE
rxNorm: 29528
atc: R06AD07
Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor
severity: Not recommended

***interaction***
drug1
drug name: PAROXETINE
rxNorm: 32937
atc: N06AB05
drug2
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
Risk of increase of the undesirable effects of the metoprolol, with especially excessive bradycardia, due to inhibition of its metaboilsm by the paroxetine
severity: Precaution for use
Increased clinical monitoring; if needed, adjustment of the dosage of the metoprolol during the length of the treatment with the paroxetine and after it is stopped

***interaction***
drug1
drug name: PAROXETINE
rxNorm: 32937
atc: N06AB05
drug2
drug name: NEBIVOLOL
rxNorm: 31555
more atc: C07AB12
more atc: C07BB12
Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant
severity: Precaution for use
Increased clinical monitoring; if needed adjustment of the dosage of the nebivolol during the length of the treatment with the antidepressant and after it is stopped. 

***interaction***
drug1
drug name: PAROXETINE
rxNorm: 32937
atc: N06AB05
drug2
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: C0NTRAINDICATION

***interaction***
drug1
drug name: PAROXETINE
rxNorm: 32937
atc: N06AB05
drug2
drug name: RISPERIDONE
rxNorm: 35636
atc: N05AX08
Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the paroxetine, with risk of increase of the undesirable effects. 
severity: Precaution for use
Clinical monitoring and, if needed, adjustment of the dosage of the risperidone. 

***interaction***
drug1
drug name: PAROXETINE
rxNorm: 32937
atc: N06AB05
drug2
drug name: TAMOXIFEN
rxNorm: 10324
atc: L02BA01
Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the paroxetine
severity: Not recommended

***interaction***
drug1
drug name: PAROXETINE
rxNorm: 32937
atc: N06AB05
drug2
drug name: VORTIOXETINE
rxNorm: 1455099
atc: N06AX26
Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the paroxetine and after it is stopped.
402-PEFLOXACIN.html


***interaction***
drug1
drug name: PEFLOXACIN
rxNorm: 7960
atc: J01MA03
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia.
403-PEG-INTERFERON-ALFA-2A.html


***interaction***
drug1
drug name: PEG-INTERFERON ALFA-2A
rxNorm: 120608
more atc: L03AB11
drug2
drug name: TELBIVUDINE
rxNorm: 474128
atc: J05AF11
Increased risk of peripheral neuropathy
severity: CONTRAINDICATION
404-PEMETREXED.html


***interaction***
drug1
drug name: PEMETREXED
rxNorm: 68446
atc: L01BA04
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).
severity: Not recommended
-in case of weak to moderate renal function 

***interaction***
drug1
drug name: PEMETREXED
rxNorm: 68446
atc: L01BA04
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the NSAIs)
severity: Not recommended
--in case of weak to moderate renal function 
405-PENEMS.html


***interaction***
drug1
class name: PENEMS
class code: J01DH
drug2
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
Risk of onset of convulsive crises, due to rapid decrease of the plasma concentrations of the valproic acid, that can become undetectable.
severity: Not recommended
406-PENICILLAMINE.html


***interaction***
drug1
drug name: PENICILLAMINE
rxNorm: 7975
atc: M01CC01
drug2
drug name: IRON
rxNorm: 1431589
atc: B03A
Decrease of the digestive absorption of the penicillamine
severity: Precaution for use
Take the iron salts at a different time from the penicillamine (more than 2 hours apart if possible).
407-PENICILLINS.html


***interaction***
drug1
class name: PENICILLINS
class code: J01C
drug2
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
Increase of the effects and of the hematological toxicity of the methothrexate: inhibition of the renal tubular secretion of the methotrexate by the penicillins
severity: Not recommended
408-AMINOPENICILLINS.html


***interaction***
drug1
class name: AMINOPENICILLINS
class code: J01CA
drug2
drug name: ALLOPURINOL
rxNorm: 519
atc: M04AA01
Increased risk of cutaneous reactions


severity: Take into account

***interaction***
drug1
class name: AMINOPENICILLINS
class code: J01CA
drug2
drug name: MYCOPHENOLATE MOFETIL
rxNorm: 7145
more atc: L04AA06
Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness
severity: Take into account
409-PENTAMIDINE.html


***interaction***
drug1
drug name: PENTAMIDINE
rxNorm: 7994
atc: P01CX01
drug2
drug name: DIDANOSINE
rxNorm: 3364
atc: J05AF02
Increased risk of onset of pancreatitis due to addition of undesirable effects
severity: Precaution for use
Monitoring of the blood amylase level. Do not use these two medications together if the blood amylase level is at the high range of normal. 

***interaction***
drug1
drug name: PENTAMIDINE
rxNorm: 7994
atc: P01CX01
drug2
drug name: FOSCARNET
rxNorm: 33562
atc: J05AD01
Risk of severe hypocalcemia
severity: Precaution for use
Monitoring of the calcemia and supplementation if necessary.

***interaction***
drug1
drug name: PENTAMIDINE
rxNorm: 7994
atc: P01CX01
drug2
drug name: STAVUDINE
rxNorm: 59763
atc: J05AR07
Increased risk of onset of peripheral neuropathy due to addition of undesirable effects
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together

***interaction***
drug1
drug name: PENTAMIDINE
rxNorm: 7994
atc: P01CX01
drug2
drug name: ZALCITABINE
rxNorm: 3363
atc: J05AF03
Increased risk of peripheral neuropathy due to addition of undesirable effects
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together
40-STEP-III-OPIOID-ANALGESICS.html


***interaction***
drug1
class name: STEP III OPIOID ANALGESICS
class code: N02A-002
drug2
class name: AGONIST-ANTAGONIST OPIOIDS 
class code: NO2A-001
Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome
severity: CONTRAINDICATION

***interaction***
drug1
class name: STEP III OPIOID ANALGESICS
class code: N02A-002
drug2
class name: PARTIAL AGONIST OPIOIDS
class code: PARAG
Risk of decrease of the antalgic effect
severity: CONTRAINDICATION
410-PENTOSTATIN.html


***interaction***
drug1
drug name: PENTOSTATIN
rxNorm: 8011
atc: L01XX08
drug2
drug name: CYCLOPHOSPHAMIDE
rxNorm: 3002
atc: L01AA01
Increase of the risk of pulmonary toxicity which could be fatal
severity: Not recommended

***interaction***
drug1
drug name: PENTOSTATIN
rxNorm: 8011
atc: L01XX08
drug2
drug name: FLUDARABINE
rxNorm: 24698
atc: L01BB05
Increase of the risk of pulmonary toxicity which could be fatal
severity: Not recommended
411-PENTOXIFYLLINE.html


***interaction***
drug1
drug name: PENTOXIFYLLINE
rxNorm: 8013
atc: C04AD03
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Increase of the risk of hemorrhage


severity: Take into account

***interaction***
drug1
drug name: PENTOXIFYLLINE
rxNorm: 8013
atc: C04AD03
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pentoxifylline and a week after it is stopped.

***interaction***
drug1
drug name: PENTOXIFYLLINE
rxNorm: 8013
atc: C04AD03
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Increase of the theophyllinemia with risk of overdose (competition at the level of the hepatic metabolism of the theophylline)
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the pentoxifylline and after it is stopped.
412-PERAMPANEL.html


***interaction***
drug1
drug name: PERAMPANEL
rxNorm: 1356552
atc: N03AX22
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Large decrease (up to two thirds) of the concentrations of perampanel


severity: Take into account

***interaction***
drug1
drug name: PERAMPANEL
rxNorm: 1356552
atc: N03AX22
drug2
drug name: CYPROTERONE
rxNorm: 3014
more atc: G03HA01
more atc: G03HB01
For doses of perampanel > or = to 12 mg/day, risk of decrease of the effectiveness of the cyproterone
severity: Not recommended
For its indication as a hormonal contraceptive: the use of another method of contraception in particular a barrier type is preferred for the length of time these substances are taken together and a cycle following

***interaction***
drug1
drug name: PERAMPANEL
rxNorm: 1356552
atc: N03AX22
drug2
drug name: OXCARBAZEPINE
rxNorm: 32624
atc: N03AF02
Decrease by half of the concentrations of perampanel and slight increase of those of the oxcarbazepine.
severity: Take into account

***interaction***
drug1
drug name: PERAMPANEL
rxNorm: 1356552
atc: N03AX22
drug2
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
For doses of perampanel >=12 mg/day: Risk of decrease of the contraceptive effectiveness
severity: Not recommended
Another method of contraception, in particular a barrier type, should be used.

***interaction***
drug1
drug name: PERAMPANEL
rxNorm: 1356552
atc: N03AX22
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Large decrease (up to two thirds) of the concentrations of perampanel
severity: Take into account
413-PETHIDINE.html


***interaction***
drug1
drug name: PETHIDINE 
rxNorm: 6754
more atc: N02AB02
more atc: N02AG03
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma
severity: CONTRAINDICATION

***interaction***
drug1
drug name: PETHIDINE 
rxNorm: 6754
more atc: N02AB02
more atc: N02AG03
drug2
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.
severity: CONTRAINDICATION

***interaction***
drug1
drug name: PETHIDINE 
rxNorm: 6754
more atc: N02AB02
more atc: N02AG03
drug2
class name: MAOI-B 
class code: N04BD0-001
Symptoms of central nervous system excitability evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma
severity: CONTRAINDICATION 
414-PHENOBARBITAL-(AND,-BY-EXTRAPOLATION,-PRIMIDONE).html


***interaction***
drug1
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
drug2
drug name: CHOLIC ACID 
rxNorm: 1440856
atc: A05AA03
Antagonist effect of the barbiturate
severity: CONTRAINDICATION

***interaction***
drug1
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Progressive decrease of the plasma concentrations of carbamazepine and of its active metabolite without apparent modification of its anticonvulsive effectiveness
severity: Take into account
Use prudence with respect to the interpretation of the plasma concentrations.

***interaction***
drug1
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
drug2
drug name: FELBAMATE
rxNorm: 24812
atc: N03AX10
Decrease of the plasma concentrations and of the effectiveness of the felbamate and increase of the plasma concentrations of the phenobarbital, with risk of overdose.
severity: Precaution for use
Clinical monitoring and testing of the plasma concentrations of phenobarbital with adjustment of the dosage if needed. 

***interaction***
drug1
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
drug2
class name: FOLATES
class code: V03-
Decrease of the plasma concentrations of the phenobarbital, due to increase of its metabolism of which the folates represent one of the cofactors
severity: Precaution for use
Clinical monitoring, testing of the plasma concentrations, and adjustment, if there is reason for it, of the dosage of the phenobarbital during the folic supplementation and after it is stopped.

***interaction***
drug1
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
drug2
drug name: IFOSFAMIDE
rxNorm: 5657
atc: L01AA06
Risk of increase of the neurotoxicity of the ifosfamide due to increase of its hepatic metabolism by the phenobarbital
severity: Not recommended

***interaction***
drug1
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
drug2
drug name: METOPROLOL
rxNorm: 6918
more atc: C07AB02
more atc: C07FB02
more atc: C07CB02
more atc: C07BB02
Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)
severity: Take into account

***interaction***
drug1
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
In cases of previous treatment with the phenobarbital or the primidone, and the addition of phenytoin, increase of the plasma concentrations of phenobarbital that can lead to toxic signs (inhibition of the metabolism by competition)

In cases of previous treatment with the pheyntoin and the addition of phenobarbital or of primidone, unpredictable changes:

--the plasma concentrations of phenytoin are most often decreased (increase of the metabolism) without this decrease affecting the anticonvulsant activity unfavorably. When the phenobarbital or the primidone is stopped, possibility of toxic effects of the phenytoin.

--it can happen that the concentrations of phenytoin are increased (inhibition of the metabolism due to competition)
severity: Take into account

***interaction***
drug1
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
drug2
drug name: PROPRANOLOL
rxNorm: 8787
atc: C07AA05
Decrease of the plasma concentrations of the propranolol with reduction of its clinical effects (increase of its hepatic metabolism)
severity: Take into account

***interaction***
drug1
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
drug2
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
Increase of the hyperammonemia with increased risk of encephalopathy
severity: Precaution for use
Regular clinical and biological monitoring. 
415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html


***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Increase of the plasma concentrations of the phenytoin with signs of overdose, in particular neurological ones (decrease of the hepatic metabolism of the phenytoin)
severity: Precaution for use
Clinical monitoring, testing of the plasma concentrations of phenytoin, and possible adjustment of its dosage 

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Reciprocal reduction of the plasma concentrations (increase of the metabolism without apparent modification of the anticonvulsive effectiveness)
severity: Take into account
Use prudence in the interpretation of the plasma concentrations. 

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of phenytoin with the possibility of appearance of the usual signs of overdose
severity: Not recommended
If administering the substances together cannot be avoided, strict clinical monitoring, plasma concentration dosages of phenytoin, and possible adjustment of its dosage during the treatment with the cimetidine and after it is stopped.

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
Variation, possibly large, of the concentrations of phenytoin in the case of treatment with the ciprofloxacin
severity: Precaution for use
Clinical monitoring and testing of the plasma concentrations of the anticonvulsant during the treatment with ciprofloacin and after it is stopped.

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: CLOPIDOGREL
rxNorm: 32968
atc: B01AC04
Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)
severity: Precaution for use
Clinical monitoring and testing of the plasma concentrations of phenytoin.

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: CLOZAPINE
rxNorm: 2626
atc: N05AH02
Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)
severity: Precaution for use
Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the phenytoin.

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
class name: CYTOTOXICS
class code: L01
Risk of onset of convulsions due to decrease of the digestive absorption of the phenytoin only [not the fosphenytoin] by the cytotoxic, or risk of increase of the toxicity or loss of the effectiveness of the cytotoxic due to the increase of its hepatic metabolism by the phenytoin or the fosphenytoin
severity: Not recommended

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: DIAZEPAM
rxNorm: 3322
atc: N05BA01
Unpredictable variations: the plasma concentrations of phenytoin can increase, with signs of overdose, but also decrease or remain stable.
severity: Precaution for use
Clinical monitoring and testing of the plasma concentrations of phenytoin. 

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: DISULFIRAM
rxNorm: 3554
atc: N07BB01
Large and rapid increase of the plasma concentrations of phenytoin with signs of toxicity (inhibition of its metabolism)
severity: Not recommended
If the administration of these substances together cannot be avoided, clinical monitoring and monitoring of the plasma concentrations of phenytoin during the treatment with the disulfiram and after it is stopped. 

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: FELBAMATE
rxNorm: 24812
atc: N03AX10
Increase of the plasma concentrations of phenytoin with risk of overdose, due to inhibition of its metabolism by the felbamate
severity: Precaution for use
Clinical monitoring, testing of the plasma concentrations of phenytoin, and if needed, adjustment of its dosage during the treatment with the felbamate.

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
Increase of the plasma concentrations of phenytoin that can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin
severity: Precaution for use
Strict clinical and biological monitoring.

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: FLUOXETINE
rxNorm: 4493
more atc: N06AB03
more atc: N06CA03
Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the metabolism of the phenytoin
severity: Precaution for use
Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage during the treatment with the fluoxetine and after it is stopped. 

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the hepatic metabolism of the phenytoin.
severity: Precaution for use
Clinical monitoring and possibly testing of the plasma concentrations of phenytoin. If needed, adjustment of the dosage of the phenytoin during the treatment with the fluvoxamine and after it is stopped. 

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
class name: FOLATES
class code: V03-
Decrease of the plasma concentrations of phenytoin due to increase of its metabolism of which the folates represent one of the cofactors
severity: Precaution for use
Clinical monitoring and testing of the plasma concentrations of phenytoin. Possible adjustment of the dosage of the phenytoin during the folic supplementation and after it is stopped. 

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: FUROSEMIDE
rxNorm: 460
more atc: C03CA01
more atc: C03CB01
more atc: C03EB01
Decrease of the diuretic effect which can reach 50%
severity: Precaution for use
Possibly use higher doses of furosemide.

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
Overdose of phenytoin (decrease of its metabolism)
severity: Precaution for use
Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. 

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: METYRAPONE
rxNorm: 6923
atc: V04CD01
Risk of false negative results of the test with metyrapone, due to a decrease of its plasma concentrations, because of the increase of its hepatic metabolism by the phenytoin.
severity: Precaution for use
Double the dosage of the metyrapone.

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: MEXILETINE
rxNorm: 6926
atc: C01BB02
Decrease of the antiarrythmic activity, of the plasma concentrations, and of the half life of the mexiletine (increase of its hepatic metabolism)
severity: Precaution for use
Clinical monitoring, EKG, and, possibly monitoring of the plasma concentrations of the mexiletine; if there is reason for it, adjustment of the dosage of the mexiletine during the treatment with the phenytoin and after it is stopped.

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: MICONAZOLE
rxNorm: 6932
more atc: A01AB09
more atc: A07AC01
more atc: D01AC02
more atc: G01AF04
more atc: J02AB01
more atc: S02AA13
Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.
severity: Precaution for use
Strict clinical monitoring. 

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: NINTEDANIB
rxNorm: 1592737
more atc: L01XE31
Decrease of the plasma concentrations of the nintedanib due to decrease of its absorption by the phenytoin or the fosphenytoin.
severity: Precaution for use
Clinical monitoring during the administration of these substances together

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
In cases of previous treatment with the phenobarbital or the primidone, and the addition of phenytoin, increase of the plasma concentrations of phenobarbital that can lead to toxic signs (inhibition of the metabolism by competition)

In cases of previous treatment with the phenytoin and the addition of phenobarbital or of primidone, unpredictable changes:

--the plasma concentrations of phenytoin are most often decreased (increase of the metabolism) without this decrease affecting the anticonvulsant activity unfavorably. When the phenobarbital or the primidone is stopped, possibility of toxic effects of the phenytoin.

--it can happen that the concentrations of phenytoin are increased (inhibition of the metabolism due to competition)
severity: Take into account

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: SUCRALFATE
rxNorm: 10156
atc: A02BX02
Decrease of the digestive absorption of the phenytoin.
severity: Precaution for use
Take the sucralfate at a different time from the phenytoin (more than 2 hours apart if possible).

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: SULFAFURAZOLE
rxNorm: 10207
more atc: J01EB05
more atc: S01AB02
Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)
severity: Not recommended
Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped. 

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: SULFAMETHIZOLE
rxNorm: 10179
more atc: B05CA04
more atc: D06BA04
more atc: J01EB02
more atc: S01AB01
Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)
severity: Not recommended
Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped. 

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: SULFAMETHOXAZOLE
rxNorm: 10180
more atc: J01EC01
more atc: J01EE01
Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism). 
severity: Not recommended
Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped. 

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
drug name: TICLOPIDINE
rxNorm: 10594
atc: B01AC05
Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin).
severity: Precaution for use
Clinical monitoring and testing of the plasma concentrations of phenytoin.

***interaction***
drug1
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
drug2
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
Increase of the hyperammoniemia, with increased risk of encephalopathy


severity: Precaution for use
Regular clinical and biological monitoring 
416-PILOCARPINE.html


***interaction***
drug1
drug name: PILOCARPINE
rxNorm: 8328
more atc: N07AX01
more atc: S01EB01
drug2
class name: ACETYL-CHOLINESTERASE INHIBITORS 
class code: NO6DA-001
Risk of addition of the undesirable cholinergic effects, especially digestive 


severity: Take into account
417-PIMOZIDE.html


***interaction***
drug1
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
drug2
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
drug2
drug name: DALFOPRISTIN
rxNorm: 229369
atc: J01FG02
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended

***interaction***
drug1
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
drug2
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
drug2
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
drug2
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
Increase of the plasma concentrations of the pimozide due to decrease of its hepatic metabolism by the combination ombitasvir + paritaprevir
severity: CONTRAINDICATION

***interaction***
drug1
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
drug2
drug name: PAROXETINE
rxNorm: 32937
atc: N06AB05
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
drug2
drug name: QUINUPRISTINE
rxNorm: 135098
atc: J01FG02
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended

***interaction***
drug1
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
drug2
drug name: SERTRALINE
rxNorm: 36437
atc: N06AB06
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
drug2
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
drug2
drug name: TRICLABENDAZOLE
rxNorm: 38608
atc: P02BX04
Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the medication that tends to induce torsades de pointes).
severity: CONTRAINDICATION 
Wait 24 hours between stopping the triclabendazole and the dose of the medication that tends to induce torsades de pointes and vice versa.
418-PIOGLITAZONE.html


***interaction***
drug1
drug name: PIOGLITAZONE
rxNorm: 33738
atc: A10BG03
drug2
class name: SOMATOSTATIN ANALOGS
class code: H01CB0-001
Risk of hyypoglycemia or hyperglycemia: decrease or increase of the need for glitazone, due to decrease of increase of the secretion of endogenous glucagon
severity: Precaution for use
Increase self monitoring of blood glucose and adjust if needed the dosage of the glitazone during the treatment with the somatostatin analog

***interaction***
drug1
drug name: PIOGLITAZONE
rxNorm: 33738
atc: A10BG03
drug2
drug name: GEMFIBROZIL
rxNorm: 4719
atc: C10AB04
Risk of increase of the undesirable effects of the glitazone due to decrease of its hepatic metabolism by the gemfibrozil
severity: Not recommended
If administering these medications together cannot be avoided, strict clinical monitoring.

***interaction***
drug1
drug name: PIOGLITAZONE
rxNorm: 33738
atc: A10BG03
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampcin
severity: Precaution for use
Clinical and biological monitoring; adjustment of the dosage of the glitazone during the treatment with the rifampicin and after it is stopped. 
419-PIRFENIDONE.html


***interaction***
drug1
drug name: PIRFENIDONE
rxNorm: 88221
atc: L04AX05
drug2
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
Increase of the plasma concentrations of pirfenidone with signs of overdose
severity: CONTRAINDICATION 
41-SOMATOSTATIN-ANALOGS.html


***interaction***
drug1
class name: SOMATOSTATIN ANALOGS
class code: H01CB0-001
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
With the ciclosporin administered orally:

reduction of the blood concentrations of ciclosporin (decrease of its intestinal absorption).


severity: Precaution for use
Increase the doses of ciclosporin according to testing of the plasma concentrations and reduction of the dosage after the treatment with the somatostatin analogue is stopped.

***interaction***
drug1
class name: SOMATOSTATIN ANALOGS
class code: H01CB0-001
drug2
drug name: INSULIN
rxNorm: 5856
more atc: A10AC01
more atc: A10AC02
more atc: A10AC03
more atc: A10AC04
more atc: A10AD01
more atc: A10AD02
more atc: A10AD03
more atc: A10AD04
more atc: A10AD05
more atc: A10AE01
more atc: A10AE02
more atc: A10AE03
more atc: A10AE04
more atc: A10AE05
more atc: A10AF01
Risk of hypoglycemia or hyperglycemia:

decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon


severity: Precaution for use
Inform the patient of the risk of hypoglycemia or hyperclycemia, strengthen self- monitoring of blood glucose, and adjust the dosage of insulin if needed during the treatment with the somatostatin analog.

***interaction***
drug1
class name: SOMATOSTATIN ANALOGS
class code: H01CB0-001
drug2
drug name: PIOGLITAZONE
rxNorm: 33738
more atc: A10BG03
more atc: A10BD05
more atc: A10BD06
more atc: A10BD09
more atc: A10BD12
Risk of hypoglycemia or hyperglycemia: decrease of increase of the need for glitazone, due to decrease or increase of the secretion of endogenous glucogon
severity: Precaution for use
Reinforce self-monitoring of blood glucose and adjust the dosage of glitazone if needed during the treatment with the somatastin analog. 

***interaction***
drug1
class name: SOMATOSTATIN ANALOGS
class code: H01CB0-001
drug2
drug name: REPAGLINIDE
rxNorm: 73044
atc: A10BX02
Risk of hypoglycemia or hyperglycemia:

decrease or increase of the needs for repaglinde due to decrease or increase of the secretion of endogenous glucagon .
severity: Precaution for use
Strengthen self-monitoring of blood glucose, and adjust the dosage of the repaglinide if needed during the treatment with the somatostatin analog.

***interaction***
drug1
class name: SOMATOSTATIN ANALOGS
class code: H01CB0-001
drug2
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
Risk of hypoglycemia or hyperglycemia:

decrease or increase of the needs for the blood glucose lowering sufonamide, due to decrease or increase of the secretion of endogenous glucagon
severity: Precaution for use
Strengthen self-monitoring of blood glucose, and adjust the dosage of the sulfonamide if needed during the treatment with the somatostatin analog. 
420-PITAVASTATIN.html


***interaction***
drug1
drug name: PITAVASTATIN
rxNorm: 861634
atc: C10AA08
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the pitavastatin
severity: CONTRAINDICATION
421-POLYMYXIN-B.html


***interaction***
drug1
drug name: POLYMYXIN B
rxNorm: 8536
more atc: A07AA05
more atc: J01XB02
more atc: S01AA18
more atc: S02AA11
more atc: S03AA03
drug2
class name: AMINOGLYCOSIDES
class code: J01GB-001
Addition of the nephrotoxic effects

.
severity: Not recommended
If administering these substances together cannot be avoided, strict monitoring with an indisputable bacteriological justification

***interaction***
drug1
drug name: POLYMYXIN B
rxNorm: 8536
more atc: A07AA05
more atc: J01XB02
more atc: S01AA18
more atc: S02AA11
more atc: S03AA03
drug2
class name: CURARES
class code: M03A-001
Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.
severity: Precaution for use
Monitor the degree of curarization at the end of anesthesia
422-POSACONAZOLE.html


***interaction***
drug1
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Decrease of the plasma concentrations and of the effectiveness of the posaconazole


severity: Precaution for use
Clinical monitoring. If possible, plasma dosages of the posaconazole and possible adjustment of its dosage.

***interaction***
drug1
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
drug2
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the H2 receptor antagonist
severity: Not recommended
--only with the oral suspension form of posaconazole

***interaction***
drug1
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
drug2
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
Decrease of the absorption of the azole antifungal, due to increase of the gastric pH by the inhibitor
severity: Not recommended
--only for the oral suspension form of posaconazole

***interaction***
drug1
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
drug2
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome
severity: Take into account

***interaction***
drug1
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Increase of the digoxinemia with nausea, vomiting, arrhythmias.
severity: Precaution for use
Clinical monitoring, and, if there is reason for them, EKG and monitoring of the digoxinemia, with adjustment of the dosage of the digoxin during the treatment with the posaconazole and after it is stopped.

***interaction***
drug1
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism
severity: Not recommended
If these medications are administered together, strict testing of renal function, blood concentration dosages of the immunosuppressant, and possible adjustment of the dosage.

***interaction***
drug1
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
drug2
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite
severity: Not recommended
Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together. 

***interaction***
drug1
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)
severity: Not recommended

***interaction***
drug1
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)
severity: CONTRAINDICATION 

***interaction***
drug1
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
drug2
class name: VINCA ALKALOIDS
class code: L01CA
Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the posaconazole
severity: Not recommended
423-POTASSIUM.html


***interaction***
drug1
drug name: POTASSIUM
rxNorm: 8588
atc: A12BA
drug2
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects).
severity: Not recommended
Avoid administering these substances together unless there is pre-existing hypokalemia. 

***interaction***
drug1
drug name: POTASSIUM
rxNorm: 8588
atc: A12BA
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)
severity: Not recommended
Avoid administration of these substances together unless there is pre-existing hypokalemia.

***interaction***
drug1
drug name: POTASSIUM
rxNorm: 8588
atc: A12BA
drug2
class name: POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
Potentially lethal hyperkalemia, especially with patients having renal insufficiency (addition of the hyperkaliemia producing effects)
severity: Contraindication:
-aside from hypokalemia or in case of parenteral use of the potassium salts

***interaction***
drug1
drug name: POTASSIUM
rxNorm: 8588
atc: A12BA
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)
severity: Not recommended
Unless there is hypokalemia.

***interaction***
drug1
drug name: POTASSIUM
rxNorm: 8588
atc: A12BA
drug2
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
Essentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia producing effects) 
severity: Not recommended
Avoid administering these substances together unless there is preexisting hypokalemia. 
424-POVIDONE-IODINE.html


***interaction***
drug1
drug name: POVIDONE-IODINE
rxNorm: 8611
more atc: D08AG02
more atc: D09AA09
more atc: D11AC06
more atc: G01AX11
more atc: R02AA15
more atc: S01AX18
drug2
class name: MERCURIAL ANTISEPTICS
class code: D08AK0
Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurial and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.
severity: Not recommended
425-PRAVASTATIN.html


***interaction***
drug1
drug name: PRAVASTATIN
rxNorm: 42463
atc: C10AA03
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Increase of the plasma concentration of the pravastatin by the clarithromycin
severity: Precaution for use
Clinical and biological monitoring during the treatment with the antibiotic

***interaction***
drug1
drug name: PRAVASTATIN
rxNorm: 42463
atc: C10AA03
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin
severity: Precaution for use
Clinical and biological monitoring during the treatment with the antibiotic.
426-PRAZIQUANTEL.html


***interaction***
drug1
drug name: PRAZIQUANTEL
rxNorm: 8628
atc: P02BA01
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Very large decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment due to increase of its hepatic metabolism by the inducer
severity: Not recommended

***interaction***
drug1
drug name: PRAZIQUANTEL
rxNorm: 8628
atc: P02BA01
drug2
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.
severity: Precaution for use
Separate the administration of the two medications by at least a week.

***interaction***
drug1
drug name: PRAZIQUANTEL
rxNorm: 8628
atc: P02BA01
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin
severity: CONTRAINDICATION
427-PREDNISOLONE.html


***interaction***
drug1
drug name: PREDNISOLONE
rxNorm: 8638
more atc: A07EA01
more atc: C05AA04
more atc: D07AA03
more atc: D07XA02
more atc: H02AB06
more atc: R01AD02
more atc: S01BA04
more atc: S01CB02
more atc: S02BA03
more atc: S03BA02
more atc: D07CA03
more atc: S01CA02
more atc: S02CA01
more atc: S03CA02
more atc: D07BA01
more atc: S01BB02
more atc: V03AB05
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)
severity: Take into account
428-LATEX-CONDOMS.html


***interaction***
drug1
Drug with no codes: LATEX CONDOMS
drug2
class name: MINERAL OILS
class code: A06AA-
more atc: D02AA
Risk of rupture of the condom when used with lubricants containing mineral oils (paraffin oil, silicone oil, etc...)
severity: CONTRAINDICATION
Use a hydrosoluble lubricant (glycerin, polyacrylamide...).
429-PRIMIDONE.html


***interaction***
drug1
drug name: PRIMIDONE 
rxNorm: 8691
atc: N03AA03
drug2
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
Decrease of the plasma concentrations of the afatinib due to increase of its metabolism by the primidone
severity: Precaution for use
Clinical monitoring during the administration of these together and 1 to 2 weeks after they are stopped. 
42-ANDROGENS.html


***interaction***
drug1
class name: ANDROGENS
class code: A14AA0
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the risk of hemorrhage due to the direct effect on coagulation and/or the fibrinolytic systems.


severity: Precaution for use
More frequent testing of the INR. Adjustment of the dosage of the Vitamin K antagonist during the treatment with the androgen and after it is stopped. 

***interaction***
drug1
class name: ANDROGENS
class code: A14AA0
drug2
class name: ENZYME INDUCERS
class code: N03-J05-001
Risk of decrease of the plasma concentrations of the androgen and consequently of its effectiveness, due to increase of its hepatic metabolism by the inducer
severity: Precaution for use
Clinical and biological monitoring during the administration of these substances together and 1 to 2 weeks after the inducer is stopped. 
430-PRISTINAMYCIN.html


***interaction***
drug1
drug name: PRISTINAMYCIN
rxNorm: 66958
atc: J01FG01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pristinamycin and after it is stopped

***interaction***
drug1
drug name: PRISTINAMYCIN
rxNorm: 66958
atc: J01FG01
drug2
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
Increase of the undesirable effects of the colchicine with potentially fatal consequences
severity: CONTRAINDICATION

***interaction***
drug1
drug name: PRISTINAMYCIN
rxNorm: 66958
atc: J01FG01
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function and adjustment of its dosage during the administration of the medications together and after it is stopped.
431-PROBENECID.html


***interaction***
drug1
drug name: PROBENECID
rxNorm: 8698
atc: M04AB01
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
Decrease of the uricosuric effect due to competition of the elimination of the uric acid at the level of the renal tubules
severity: Not recommended

***interaction***
drug1
drug name: PROBENECID
rxNorm: 8698
atc: M04AB01
drug2
drug name: DIPROPHYLLINE
rxNorm: 3714
more atc: R03DA01
more atc: R03DB01
more atc: R03DA51
Risk of overdose due to increase of the plasma concentrations of diprophylline (inhibition of its renal tubular secretion)
severity: Precaution for use
Reduce the dosage of diprophylline during the treatment with the probenicid

***interaction***
drug1
drug name: PROBENECID
rxNorm: 8698
atc: M04AB01
drug2
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
Increase of the toxicity of the methotrexate: inhibition of the renal tubular secretion of the methotrexate by the probenecid
severity: CONTRAINDICATION
432-PROCARBAZINE.html


***interaction***
drug1
drug name: PROCARBAZINE
rxNorm: 8702
atc: L01XB01
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Increase of the hypersensitivity reactions (hypereosinophilia, rash), due to increase of the metabolism of the procarbazine by the inducer
severity: Take into account
433-IODINATED-X-RAY-CONTRAST-MEDIA.html


***interaction***
drug1
class name: IODINATED X-RAY CONTRAST MEDIA
class code: VO8A-001
drug2
drug name: ALDESLEUKIN
rxNorm: 70223
atc: L03AC01
Increase of the risk of reaction to the contrast media in cases of previous treatment with interleukin2: 

skin rash or more rarely low blood pressure, oliguria or even renal failure
severity: Take into account

***interaction***
drug1
class name: IODINATED X-RAY CONTRAST MEDIA
class code: VO8A-001
drug2
class name: DIURETICS
class code: C0E-001
In case of dehydration caused by the diuretics, increased risk of acute functional renal insufficiency, in particular when large doses of the contrast media are used
severity: Precaution for use
Rehydrate before administration of the iodinated product

***interaction***
drug1
class name: IODINATED X-RAY CONTRAST MEDIA
class code: VO8A-001
drug2
drug name: METFORMIN
rxNorm: 6809
more atc: A10BA02
more atc: A10BD13
more atc: A10BD11
more atc: A10BD05
more atc: A10BD03
more atc: A10BD10
more atc: A10BD07
more atc: A10BD02
more atc: A10BD08
Lactic acidosis linked to elevated concentrations of metformin in relation to functional renal insufficiency induced by the radiological exam. 
severity: CONTRAINDICATION
The treatment with metformin should be suspended at the time of the radiological exam and only started again 2 days later. 
434-PROGESTIN-CONTRACEPTIVES.html


***interaction***
drug1
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
drug2
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
(Except IUD), decrease of the concentrations of progestin, with risk of lower contraceptive effectiveness 
severity: Precaution for use
Use another method of contraception, in particular a barrier type, during the length of time that these are administered together and one cycle after.

***interaction***
drug1
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
drug2
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
Aside from the combination ethinylestradiol (0.035mg)/norethisterone (1 mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir
severity: Precaution for use
Use an additional or alternative, reliable contraceptive method during the administration of these medications together. 

***interaction***
drug1
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
drug2
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism 
severity: Precaution for use
Use an additional or alternative, reliable contraceptive method during the administration of these medications together and a cycle after. 

***interaction***
drug1
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
drug2
drug name: GRISEOFULVIN
rxNorm: 5021
more atc: D01AA08
more atc: D01BA01
Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism
severity: Precaution for use
Use an additional or alternative, reliable contraceptive method during the administration of these medications together and a cycle after. 

***interaction***
drug1
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
drug2
class name: ENZYME INDUCERS
class code: N03-J05-001
Decrease of the contraceptive effectiveness of the hormonal contraceptive, due to increase of its hepatic metabolism by the inducer
severity: Not recommended
Another reliable contraceptive method, in particular a barrier type, should be used during the administration of these medications together and a cycle after. 

***interaction***
drug1
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Risk of decrease of the contraceptive effectiveness because of decrease of the concentrations of hormonal contraceptive, due to the increase of its hepatic metabolism by the ritonavir 
severity: Not recommended
Another method of contraception, in particular a barrier type (condom or IUD), should be used during the time the substances are administered together and one cycle following. 

***interaction***
drug1
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Decrease of the plasma concentrations of the hormonal contraceptive, by reason of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (pregnancy) 
severity: CONTRAINDICATION

***interaction***
drug1
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
drug2
drug name: PERAMPANEL
rxNorm: 1356552
atc: N03AX22
For doses of perampanel >=12 mg/day: Risk of decrease of the contraceptive effectiveness
severity: Not recommended
Another method of contraception, in particular a barrier type, should be used.

***interaction***
drug1
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
drug2
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
Risk of antagonism of the effects of the progestin contraceptive
severity: Not recommended
Do not restart the progestin contraceptive treatment fewer than 12 days after stopping the ulipristal.
435-NON-CONTRACEPTIVE-PROGESTOGENS,-COMBINED-WITH-AN-ESTROGEN-OR-NOT.html


***interaction***
drug1
class name: NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT
class code: G03-003
drug2
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
Risk of decrease of the effectiveness of the progestogen
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the bosentan and after it is stopped

***interaction***
drug1
class name: NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT
class code: G03-003
drug2
class name: ENZYME INDUCERS
class code: N03-J05-001
Decrease of the effectiveness of the progestogen
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the inducer and after it is stopped. 

***interaction***
drug1
class name: NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT
class code: G03-003
drug2
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
Risk of antagonism of the effects of the progestogen
severity: Not recommended
Use an additional contraceptive method of the barrier type for several days after the ulipristal is stopped
436-PROGUANIL.html


***interaction***
drug1
drug name: PROGUANIL
rxNorm: 2382
more atc: P01BB01
more atc: P01BB51
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the proguanil and after it is stopped. 

***interaction***
drug1
drug name: PROGUANIL
rxNorm: 2382
more atc: P01BB01
more atc: P01BB51
drug2
class name: THYROID HORMONES
class code: H03AA
Risk of clinically low thyroid with patients having thyroid replacement therapy
severity: Precaution for use
Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormone during the treatment with the antimalarial and after it is stopped. 
437-PROPAFENONE.html


***interaction***
drug1
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
drug2
drug name: ABIRATERONE
rxNorm: 1100072
atc: L02BX03
Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the abiraterone
severity: Precautions for use
Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the abiraterone

***interaction***
drug1
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the inducer


severity: Precaution of use
Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of it and the inducer together and after the inducer is stopped.

***interaction***
drug1
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the anticoagulant effect and of the risk of hemorrhage. Mechanism proposed: inhibition of the metabolism of the vitamin K antagonist
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the propafenone and after it is stopped. 

***interaction***
drug1
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
drug2
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)
severity: Precaution for use
Clinical monitoring and EKG.

***interaction***
drug1
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
drug2
drug name: BUPROPION
rxNorm: 42347
atc: N06AX12
Risk of increase of the undesirable effects of the propafenone due to decrease of its hepatic metabolism by the bupropion
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the bupropion.

***interaction***
drug1
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
drug2
drug name: CINACALCET
rxNorm: 407990
atc: H05BX01
Increase of the plasma concentrations of propafenone with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the propafenone during the treatment with cinacalcet.

***interaction***
drug1
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
drug2
drug name: DARIFENACIN
rxNorm: 136198
atc: G04BD10
Increase of the plasma concentrations of propafenone, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin
severity: Precaution for use.
Clinical monitoring and reduction of the dosage of the propafenone during the treatment with darifenacin.

***interaction***
drug1
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Risk of increase of the digoxinemia, especially with older patients
severity: Precaution for use
Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with propafenone and after it is stopped.

***interaction***
drug1
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
drug2
drug name: DULOXETINE
rxNorm: 72625
atc: N06AX21
Increase of the plasma concentrations of propafenone with risk of overdosage due to decrease of its hepatic metabolism by the duloxetine
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the propafenone during the treatment with the duloxetine and after it is stopped. 

***interaction***
drug1
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
drug2
drug name: ESMOLOL
rxNorm: 49737
atc: C07AB09
Disorders of contractility, autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)
severity: Precaution for use
Clinical monitoring and EKG.

***interaction***
drug1
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the St Johns wort
severity: Precaution for use
Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the time the substances are administered together and after the St Johns wort is stopped.

***interaction***
drug1
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
drug2
drug name: MIRABEGRON
rxNorm: 1300786
atc: G04BD12
Increase of the plasma concentrations of the propafenone by decrease of its metabolism by the mirabegron
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the propafenone during the administration of these substances together.

***interaction***
drug1
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of the substances together and after the rifampicin is stopped.

***interaction***
drug1
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
drug2
drug name: TERBINAFINE
rxNorm: 37801
more atc: D01AE15
more atc: D01BA02
Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the terbinafine
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the terbinafine. 

***interaction***
drug1
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
drug2
drug name: THEOPHYLLINE 
rxNorm: 10438
atc: R03DA04
Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone. 
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia.
438-PROPRANOLOL.html


***interaction***
drug1
drug name: PROPRANOLOL
rxNorm: 8787
atc: C07AA05
drug2
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)
severity: Precaution for use
Reinforce clinical monitoring, in particular during the first weeks of the administration of these medications together. 

***interaction***
drug1
drug name: PROPRANOLOL
rxNorm: 8787
atc: C07AA05
drug2
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
Increase of the plasma concentrations of propranolol due to inhibition of its hepatic metabolism, with increase of the activity and of the undesirable effects, for example: significant bradycardia
severity: Precaution for use
Increased clinical monitoring, and, if needed, adjustment of the dosage of the propranolol during the treatment with the fluvoxamine and after it is stopped. 

***interaction***
drug1
drug name: PROPRANOLOL
rxNorm: 8787
atc: C07AA05
drug2
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
Decrease of the plasma concentrations of the propranolol with reduction of its clinical effects (increase of its hepatic metabolism)
severity: Take into account

***interaction***
drug1
drug name: PROPRANOLOL
rxNorm: 8787
atc: C07AA05
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)
severity: Take into account
439-PYRAZINAMIDE.html


***interaction***
drug1
drug name: PYRAZINAMIDE
rxNorm: 8987
more atc: J04AK01
more atc: J04AM05
more atc: J04AM06
drug2
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
Addition of the hepatotoxic effects.
severity: Precaution for use
Clinical and biological monitoring.
43-HALOGENATED-HYDROCARBON-ANESTHETICS.html


***interaction***
drug1
class name: HALOGENATED HYDROCARBON ANESTHETICS
class code: N01AB0-001
drug2
class name: ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)
class code: A01AD
Serious ventricular arrhythmias due to increased cardiac sensitization


severity: Precaution for use
Limit the amount of adrenaline, for example: less then 0.1 mg of adrenaline in 10 minutes or 0.3 mg per hour for an adult

***interaction***
drug1
class name: HALOGENATED HYDROCARBON ANESTHETICS
class code: N01AB0-001
drug2
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
Reduction of the compensatory cardiovascular reactions by the beta blocking agents. The beta-andrenergic inhibition can be elevated by the beta-mimetics during surgery. 
severity: Precaution for use
As a general rule, do not stop the treatment with the beta-blocking agent and, in any event, avoid stopping it abruptly. Inform the anesthesiologist of this treatment. 

***interaction***
drug1
class name: HALOGENATED HYDROCARBON ANESTHETICS
class code: N01AB0-001
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
Reduction of the compensatory cardiovascular reactions by the beta blocking agents. The beta-adrenergic inhibition can be elevated during the surgery by the beta-stimulants.
severity: Precaution for use
As a general rule, do not stop the treatment with the beta blocking agent and, in any case, avoid stopping it abruptly. Inform the anesthesiologist of this treatment.

***interaction***
drug1
class name: HALOGENATED HYDROCARBON ANESTHETICS
class code: N01AB0-001
drug2
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites.

.


severity: Precaution for use
In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. 

***interaction***
drug1
class name: HALOGENATED HYDROCARBON ANESTHETICS
class code: N01AB0-001
drug2
drug name: ISOPRENALINE
rxNorm: 6054
more atc: C01CA02
more atc: R03AB02
more atc: R03CB01
more atc: R03AK02
Serious ventricular arrhythmias due to increase of cardiac sensitization 
severity: Not recommended

***interaction***
drug1
class name: HALOGENATED HYDROCARBON ANESTHETICS
class code: N01AB0-001
drug2
class name: ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)
class code: C01CA
Serious ventricular arrhythmias due to increase of cardiac sensitization
severity: Not recommended

***interaction***
drug1
class name: HALOGENATED HYDROCARBON ANESTHETICS
class code: N01AB0-001
drug2
class name: INDIRECT SYMPATHOMIMETICS
class code: C01CA-R01BA
Perioperative hypertension 


severity: Precaution for use
In the case of scheduled surgery, it is preferable to stop the treatment several days before surgery. 
440-PYRIMETHAMINE.html


***interaction***
drug1
drug name: PYRIMETHAMINE
rxNorm: 9010
more atc: P01BD01
more atc: P01BF04
drug2
drug name: TRIMETHOPRIM
rxNorm: 10829
atc: J01EA01
Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)
severity: Precaution for use
Regular CBC and addition of a treatment with folic acid (regular IM injections). 
441-QUETIAPINE.html


***interaction***
drug1
drug name: QUETIAPINE
rxNorm: 51272
atc: N05AH04
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.
severity: Not recommended

***interaction***
drug1
drug name: QUETIAPINE 
rxNorm: 51272
atc: N05AH04
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Large increase of the concentrations of quetiapine, with risk of overdose
severity: CONTRAINDICATION

***interaction***
drug1
drug name: QUETIAPINE
rxNorm: 51272
atc: N05AH04
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness
severity: Not recommended

***interaction***
drug1
drug name: QUETIAPINE
rxNorm: 51272
atc: N05AH04
drug2
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
Increase of the plasma concentrations of the quetiapine due to decrease of its hepatic metabolism by the ombitasvir+paritaprevir combination
severity: CONTRAINDICATION 

***interaction***
drug1
drug name: QUETIAPINE
rxNorm: 51272
atc: N05AH04
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.
severity: Not recommended
442-QUINIDINE.html


***interaction***
drug1
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
drug2
class name: URINARY ALKALIZERS
class code: B05-001
Increase of the plasma concentrations of the quinidine and risk of overdose (decrease of the renal excretion of the quinidine by alkalinizing of the urine).
severity: Precaution for use
Clinical monitoring, EKG, and possibly testing of the quinidinemia; if there is reason for it, adjustment of the dosage during the alkalinizing treatment and after it is stopped.

***interaction***
drug1
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
drug2
drug name: ALISKIREN
rxNorm: 325646
more atc: C09XA02
more atc: C09DX02
Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.
severity: CONTRAINDICATION

***interaction***
drug1
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
drug2
drug name: COBICISTAT
rxNorm: 1306284
more atc: V03AX03
more atc: J05AR09
Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat
severity: CONTRAINDICATION

***interaction***
drug1
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
drug2
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding
severity: Precaution for use
In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose.

***interaction***
drug1
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction)
severity: Precaution for use
Clinical monitoring and EKG. In the case of an unexpected result, test the digoxinemia and adjust the dosage. 

***interaction***
drug1
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
drug2
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the quinidine
severity: Precaution for use
Start the treatment with quinidine at minimum recommended dosages, and adjust the doses according to the EKG. 

***interaction***
drug1
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increased risk of ventricular arrhythmias, especially of torsades de pointes, as well as tinnitis and/or decrease of auditory acuity (cinchonism), due to decrease of the hepatic metabolism of the quinidine
severity:  CONTRAINDICATION

***interaction***
drug1
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
drug2
class name: OMBITASVIR + PARITAPREVIR 
class code: OMPA
Increase of the plasma concentrations of the quidinine due to decrease of its hepatic metabolism by the ombitasvir+paritaprevir combination
severity: CONTRAINDICATION

***interaction***
drug1
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
drug2
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
drug2
drug name: TAMOXIFEN
rxNorm: 10324
atc: L02BA01
Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the quinidine
severity: Not recommended

***interaction***
drug1
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
drug2
drug name: TRICLABENDAZOLE
rxNorm: 38608
atc: P02BX04
Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)
severity: CONTRAINDICATION 
Wait 24 hours between stopping the triclabendazole and the dose of the torsade inducing medication, and the reverse.

***interaction***
drug1
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia
severity: Not recommended

***interaction***
drug1
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
drug2
drug name: VORTIOXETINE
rxNorm: 1455099
atc: N06AX26
Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the quinidine and after it is stopped. 
443-QUININE.html


***interaction***
drug1
drug name: QUININE
rxNorm: 9071
more atc: P01BC01
more atc: M09AA72
more atc: M09AA
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer. 


severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the quinine during the treatment with the inducer and after it is stopped. 

***interaction***
drug1
drug name: QUININE
rxNorm: 9071
more atc: P01BC01
more atc: M09AA72
more atc: M09AA
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Moderate increase of the digoxinemia
severity: Precaution for use
Clinical monitoring and EKG, if needed, with possible adjustment of the doses of digoxin.

***interaction***
drug1
drug name: QUININE
rxNorm: 9071
more atc: P01BC01
more atc: M09AA72
more atc: M09AA
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the undesirable effects of the quinine, especially ventricular arrhythmias and neurosensory difficulties (cinchonism) 
severity: Not recommended
-with the protease inhibitors 

***interaction***
drug1
drug name: QUININE
rxNorm: 9071
more atc: P01BC01
more atc: M09AA7
more atc: M09AA
drug2
drug name: MEFLOQUINE
rxNorm: 6694
more atc: P01BF02
more atc: P01BC02
For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects
severity: Not recommended
Wait at least 12 hours between the end of the administration via IV of the quinine and the beginning of the administration of the mefloquine. 

***interaction***
drug1
drug name: QUININE
rxNorm: 9071
more atc: P01BC01
more atc: M09AA72
more atc: M09AA
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer
severity: Not recommended
444-QUINUPRISTINE.html


***interaction***
drug1
drug name: QUINUPRISTINE
rxNorm: 135098
atc: J01FG02
drug2
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: QUINUPRISTINE
rxNorm: 135098
atc: J01FG02
drug2
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).
severity: CONTRAINDICATION 

***interaction***
drug1
drug name: QUINUPRISTINE
rxNorm: 135098
atc: J01FG02
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism 
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped. 

***interaction***
drug1
drug name: QUINUPRISTINE
rxNorm: 135098
atc: J01FG02
drug2
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Not recommended
445-RACECADOTRIL.html


***interaction***
drug1
drug name: RACECADOTRIL
rxNorm: 16738
atc: A07XA04
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
Risk of increase of the undesirable effects of the angioedema type. 
severity: Contraindication
-in case of previous angioedema while taking ACE inhibitors
446-RALTEGRAVIR.html


***interaction***
drug1
drug name: RALTEGRAVIR
rxNorm: 719872
atc: J05AX08
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the concentrations of the raltegravir by the rifampicin
severity: Not recommended
If administering these medications together cannot be avoided, doubling the dose of raltegravir can be considered 
447-RANOLAZINE.html


***interaction***
drug1
drug name: RANOLAZINE
rxNorm: 35829
atc: C01EB18
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Risk of large decrease of the concentrations of ranolazine


severity: Not recommended

***interaction***
drug1
drug name: RANOLAZINE
rxNorm: 35829
atc: C01EB18
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to inhibition of the metabolism of the atorvastatin by the ranolazine
severity: Precaution for use
Use weaker doses of the cholesterol lowering agent or another statin not affected by this type of interaction.

***interaction***
drug1
drug name: RANOLAZINE
rxNorm: 35829
atc: C01EB18
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Increase of the digoxinemia
severity: Precaution for use
Clinical and biological monitoring, and possibly EKG. Adjustment of the dosage of the digoxin if needed.

***interaction***
drug1
drug name: RANOLAZINE
rxNorm: 35829
atc: C01EB18
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism by the ranolazine
severity: Precaution for use
Clinical and biological monitoring, and possible adjustment of the dosage of the immunosuppressant.

***interaction***
drug1
drug name: RANOLAZINE
rxNorm: 35829
atc: C01EB18
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the concentrations of ranolazine due to decrease of its metabolism by the inhibitor
severity: CONTRAINDICATION

***interaction***
drug1
drug name: RANOLAZINE
rxNorm: 35829
atc: C01EB18
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Very large decrease of the concentrations of ranolazine. 
severity: Not recommended

***interaction***
drug1
drug name: RANOLAZINE
rxNorm: 35829
atc: C01EB18
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type due to inhibition of the metabolism of the simvastatin by the ranolazine
severity: Precaution for use
Do not exceed the dosage of 20 mg/day of simvastatin or use another statin not affected by this type of interaction.
448-REGORAFENIB.html


***interaction***
drug1
drug name: REGORAFENIB
rxNorm: 1312397
atc: L01XE21
drug2
class name: ENZYME INDUCERS
class code: N03-J05-001
Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the inducer
severity:  Not recommended

***interaction***
drug1
drug name: REGORAFENIB
rxNorm: 1312397
atc: L01XE21
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the inhibitor
severity: Not recommended

***interaction***
drug1
drug name: REGORAFENIB
rxNorm: 1312397
atc: L01XE21
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the St Johns wort
severity: Not recommended

***interaction***
drug1
drug name: REGORAFENIB
rxNorm: 1312397
atc: L01XE21
drug2
Drug with no codes: GRAPEFRUIT (JUICE and FRUIT)
Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the grapefruit
severity: Not recommended
449-REPAGLINIDE.html


***interaction***
drug1
drug name: REPAGLINIDE
rxNorm: 73044
atc: A10BX02
drug2
class name: SOMATOSTATIN ANALOGS
class code: H01CB0-001
Risk of hypoglycemia or hyperglycemia:

decrease or increase of the need for repaglinde due to decrease or increase of the secretion of endogenous glucagon.
severity: Precaution for use
Strengthen self-monitoring of blood glucose, and adjust the dosage of the repaglinide if needed during the treatment with the somatostatin analog

***interaction***
drug1
drug name: REPAGLINIDE
rxNorm: 73044
atc: A10BX02
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Increase of more than double of the concentrations of the repaglinide due to increase of its absorption
severity: Not recommended

***interaction***
drug1
drug name: REPAGLINIDE
rxNorm: 73044
atc: A10BX02
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide
severity: Precaution for use
Inform the patient, reinforce self-monitoring of blood glucose, and possibly adjust the dosage of the blood glucose lowering agent during the treatment with the clarithromycin.

***interaction***
drug1
drug name: REPAGLINIDE
rxNorm: 73044
atc: A10BX02
drug2
drug name: CLOPIDOGREL
rxNorm: 32968
atc: B01AC04
Increase of the concentrations of repaglinide by the clopidogrel, with risk of increase of undesirable effects
severity: Take into account

***interaction***
drug1
drug name: REPAGLINIDE
rxNorm: 73044
atc: A10BX02
drug2
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
Risk of increase of the plasma concentrations of repaglinide, due to inhibition of its hepatic metabolism by the deferasirox
severity: Not recommended
If administering these medications together cannot be avoided, strict clinical and biological monitoring.

***interaction***
drug1
drug name: REPAGLINIDE
rxNorm: 73044
atc: A10BX02
drug2
drug name: GEMFIBROZIL
rxNorm: 4719
atc: C10AB04
Risk of severe hypoglycemia, even coma, due to large increase of the plasma concentrations of repaglinide by the gemfibrozil
severity: CONTRAINDICATION

***interaction***
drug1
drug name: REPAGLINIDE
rxNorm: 73044
atc: A10BX02
drug2
drug name: TRIMETHOPRIM
rxNorm: 10829
atc: J01EA01
Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim
severity: Not recommended
If the administration of these medications together cannot be avoided, strict clinical and biological monitoring.
44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html


***interaction***
drug1
class name: ANTABUSE (REACTION)
class code: 123-ANT
drug2
Drug with no codes: ALCOHOL 
more atc: DRINK
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
more atc: INGREDIE
Antabuse effect (heat, redness, vomiting, tachycardia)


severity: Not recommended
Avoid taking alcoholic beverages and medications containing alcohol. Take into account the complete elimination of the medications by referring to their half-life before re-starting alcoholic beverages or medications containing alcohol. 
450-RESERPINE.html


***interaction***
drug1
drug name: RESERPINE
rxNorm: 9260
atc: C02AA02
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Psychomotor agitation, convulsions, hypertension
severity: CONTRAINDICATION

***interaction***
drug1
drug name: RESERPINE
rxNorm: 9260
atc: C02AA02
drug2
drug name: LEVODOPA
rxNorm: 6375
more atc: N04BA01
more atc: N04BA02
more atc: N04BA03
Inhibition of the effects of the levodopa
severity: CONTRAINDICATION
451-CHELATING-RESINS.html


***interaction***
drug1
class name: CHELATING RESINS
class code: C10-V0
drug2
Drug with no codes: MEDICATIONS ADMINISTERED BY ORAL ROUTE
Taking chelating resins can decrease the intestinal absorption and, potentially, the effectiveness of other medications taken simultaneously
severity: Precaution for use
As a general rule, the doses of the resin should be taken at a different time from that of other medications, at an interval of more than 2 hours apart, if possible

***interaction***
drug1
class name: CHELATING RESINS
class code: C10-V0
drug2
class name: THYROID HORMONES
class code: H03AA
Decrease of the digestive absorption of the thyroid hormones 
severity: Precaution for use
Take the thyroid hormones at a different time from the resin (more than 2 hours apart, if possible).
452-RETINOIDS.html


***interaction***
drug1
class name: RETINOIDS
class code: D05-D10
drug2
class name: OTHER RETINOIDS
class code: D05-D10
Risk of symptoms evocative of hypervitaminosis A
severity: CONTRAINDICATION

***interaction***
drug1
class name: RETINOIDS
class code: D05-D10
drug2
class name: TETRACYCLINE ANTIBIOTICS
class code: J01AA
Risk of intracranial hypertension
severity: CONTRAINDICATION

***interaction***
drug1
class name: RETINOIDS
class code: D05-D10
drug2
drug name: VITAMIN A
rxNorm: 11246
more atc: A11C
more atc: A11CA
more atc: A11CA01
more atc: A11CA02
Risk of symptoms evocative of hypervitaminosis A
severity: CONTRAINDICATION
453-RIBAVIRIN.html


***interaction***
drug1
drug name: RIBAVIRIN
rxNorm: 9344
atc: J05AB04
drug2
class name: ANTIPURINES
class code: ANTIPUR
Increased risk of serious undesirable effects, due to inhibition of the metabolism of the immunomodulator by the ribavirin
severity: Not recommended

***interaction***
drug1
drug name: RIBAVIRIN
rxNorm: 9344
atc: J05AB04
drug2
drug name: DIDANOSINE
rxNorm: 3364
atc: J05AF02
Risk of increase of the mitochrondrial toxicity of the didanosine due to increase of its active metabolite
severity: Not recommended

***interaction***
drug1
drug name: RIBAVIRIN
rxNorm: 9344
atc: J05AB04
drug2
drug name: STAVUDINE
rxNorm: 59763
atc: J05AF04
Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. 

***interaction***
drug1
drug name: RIBAVIRIN
rxNorm: 9344
atc: J05AB04
drug2
drug name: ZIDOVUDINE 
rxNorm: 11413
more atc: J05AF01
more atc: J05AR01
more atc: J05AR04
more atc: J05AR05
Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. 
454-RIFABUTIN.html


***interaction***
drug1
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
drug2
drug name: ATOVAQUONE
rxNorm: 60212
atc: P01AX06
Moderate decrease of the plasma concentrations of atovaquone by the enzymatic inducer
severity: Take into account

***interaction***
drug1
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and of those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the two medications together.

***interaction***
drug1
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
drug2
drug name: COBICISTAT
rxNorm: 1306284
atc: J05AR09
Very large increase of the metabolite of the rifabutin, with risk of increase of its toxicity (uveitis, neutropenia). Furthermore, possible decrease of the concentrations of cobicistat
severity: Precaution for use
Adjustment of the dosage of the rifabutin (in principle, reduction of the doses by half). 

***interaction***
drug1
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
drug2
drug name: EFAVIRENZ
rxNorm: 195085
atc: J05AR06
Decrease of the concentrations of rifabutin by about half, due to increase of its hepatic metabolism by the efavirenz 
severity: Precaution for use
Adjustment of the dosage of the rifabutin during the treatment with efavirenz.

***interaction***
drug1
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
drug2
drug name: ELVITEGRAVIR
rxNorm: 1306286
atc: J05AR09
Decrease of the minimal concentrations of elvitegravir
severity: Take into account

***interaction***
drug1
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
atc: J02AC01
Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the treatment with the two medications together. 

***interaction***
drug1
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
drug2
class name: THYROID HORMONES
class code: H03AA
Described for phenytoin, rifampicin, and carbamazepine. Risk of clinical hypothyroidism in patients with low thyroid, due to increase of the metabolism of the T3 and T4
severity: Precaution for use
Monitoring of serum concentrations of T3 and of T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with rifabutin and after it is stopped.

***interaction***
drug1
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Risk of reduction of the effectiveness of the protease inhibitor (even more so when the dosage of the rifabutin is large) for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin for another. 
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. 

***interaction***
drug1
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
drug2
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite
severity: Not recommended
Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together. 

***interaction***
drug1
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
Decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifabutin for one thing; and risk of increase of the undesirable effects (uveitis) of the rifabutin for another
severity: Not recommended
If the administration of these substances together is judged necessary, clinical monitoring and adjustment of the dosage of the voriconazole (generally doubled) during the treatment with the rifabutin. 
455-RIFAMPICIN.html


***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: ABIRATERONE
rxNorm: 1100072
atc: L02BX03
Large decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
Decrease of the plasma concentrations of the afatinib due to increase of its metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring during the administration of these medications together and 1 to 2 weeks after they are stopped.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: ALBENDAZOLE
rxNorm: 430
atc: P02CA03
Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of reduction of its effectiveness
severity: Precaution for use
Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzymatic inducer and after it is stopped.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
class name: CALCIUM CHANNEL BLOCKERS
class code: CO8CA-001
Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism


severity: Not recommended 
--with the nimodipine

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
class name: CLASS IA ANTIARRHYTHMICS
class code: C01B-002
Decrease of the plasma concentrations and of the effectiveness of the antiarrythmic (increase of its hepatic metabolism). 


severity: Precaution for use
Clinical monitoring, EKG, and possibly monitoring of the plasma concentration of the antiarrythmic. If needed, adjustment of the dosage of the antiarrythmic during the treatment with the rifampicin and after it is stopped (risk of overdose of the antiarrythmic) 

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin. 
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the rifampicin and a week after it is stopped. 

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: APIXABAN
rxNorm: 1364430
atc: B01AF02
Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect.
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
Very large decrease of the concentrations of aprepitant
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: ATOVAQUONE
rxNorm: 60212
atc: P01AX06
Decrease of the plasma concentrations of atorvaquone by the enzymatic inducer
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
Risk of decrease of the plasma concentrations of boceprevir
severity: Not recommended
If administering these together cannot be avoided, regular clinical and biological monitoring, especially at the beginning of treatment with the two medications together. 

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: BUSPIRONE
rxNorm: 1827
atc: N05BE01
Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the buspirone during the treatment with rifampicin and after it is stopped.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring, testing of the plasma concentrations and adjustment of the dosage of the carbamazepine during the treatment with the rifampicin and after it is stopped.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: CARVEDILOL
rxNorm: 
more atc: C07AG02
Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Regular clinical monitoring and adjustment of the dosage of the carvedilol during the treatment with the rifampicin. When the rifampicin is stopped, risk of large increase of the plasma concentrations of carvedilol imposing a reduction of the dosage and strict clinical monitoring.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Decrease of the plasma concentrations and risk of lower effectiveness of the clarithromycin, especially with HIV patients, due to increase of its metabolism by the rifampicin
severity: Precaution for use
Regular clinical and biological monitoring.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: CLOZAPINE
rxNorm: 2626
atc: N05AH02
Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)
severity: Precaution for use
Clinical monitoring and possible increase of the dosage of the clozapine during the treatment with the rifampicin.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: COBICISTAT
rxNorm: 1306284
atc: V03AX03
Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer
severity: CONTRAINDICATION

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
Risk of decrease of the plasma concentrations of deferasirox
severity: Precaution for use
Monitor the ferritinemia during and after the treatment with the enzymatic inducer. If needed, adjustment of the dosage of deferasirox.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: DELAMANID
rxNorm: 1344662
atc: J04AK06
Decrease of the plasma concentrations of delamanid due to increase of its hepatic metabolism by the inducer
severity: CONTRAINDICATION

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: EFAVIRENZ
rxNorm: 195085
atc: J05AG03
Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: EXEMESTANE
rxNorm: 258494
atc: L02BG06
Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer
severity: Take into account

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: FENTANYL
rxNorm: 4337
atc: N02AB03
Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.
severity: Not recommended
Choose another opioid.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
atc: J02AC01
Decrease of the plasma concentrations and of the effectiveness of the fluconazole due to increase of its metabolism by the rifampicin
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants
severity: Precaution for use
Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: HALOPERIDOL
rxNorm: 5093
atc: N05AD01
Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring, and, if needed, adjustment of the dosage during the treatment with the rifampicin and after it is stopped. 

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
class name: THYROID HORMONES
class code: H03AA
Risk of clinically low thyroid in patients with already low thyroid, due to increase of the metabolism of the T3 and of the T4.
severity: Precaution for use
Monitoring of serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with the rifampicin and after it is stopped. 

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: HYDROXYCHLOROQUINE
rxNorm: 5521
atc: P01BA02
Risk of lower therapeutic effect of the hydroxychloroquine, due to increase of its metabolism by the rifampicin
severity: Precaution for use
Clinical monitoringand possible adjustment of the dosage of the hydroxychloroquine during the treatment with rifampicin and after it is stopped.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: IDELALISIB
rxNorm: 1544460
atc: L01XX47
Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.

For the combination (saquinavir + ritonavir):

risk of severe hepatocellular toxicity
severity: CONTRAINDICATION
Until additional data with the ritonavir boosted inhibitors is available.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
class name: METABOLIZED TYROSINE-KINASE INHIBITORS
class code: L01XE
Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)
severity: Precaution for use
Clinical and biological monitoring of this classic combination. In case of hepatitis, stop the isoniazid.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of the two substances together and after the rifampicin is stopped.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Decrease of the plasma concentrations and of the effectiveness of the two anti-antibiotics (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: LEDIPASVIR
rxNorm: 1591922
Large decrease of the plasma concentrations of ledipasvir due to increase of its hepatic metabolism by the rifampicin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: LINEZOLIDE
rxNorm: 190376
atc: J01XX08
Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.
severity: Precaution for use
Clinical monitoring and possible increase of the dosage of the linezolide during the treatment with the rifampicin.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: METOPROLOL
rxNorm: 6918
atc: C07AB02
Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)
severity: Take into account

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: METRONIDAZOLE
rxNorm: 6922
more atc: A01AB17
more atc: D06BX01
more atc: G01AF01
more atc: J01XD01
more atc: P01AB01
Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the rifampicin and after it is stopped. 

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
class name: MINERALOCORTICOIDS
class code: H02AA0
Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison's disease treated with the hydrocortisone and in cases of organ transplants
severity: Precaution for use
Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. 

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: MONTELUKAST
rxNorm: 88249
atc: R03DC03
Risk of reduction of the effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the rifampicin and after it is stopped. 

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: MORPHINE
rxNorm: 7052
atc: N02AA01
Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the morphine during the treatment with the rifampicin and after it is stopped. 

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: NEVIRAPINE
rxNorm: 53654
atc: J05AG01
Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: NIMODIPINE
rxNorm: 7426
atc: C08CA06
Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism
severity: Not recommended
Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the rifampicin and after it is stopped.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: NINTEDANIB
rxNorm: 1592737
more atc: L01XE31
Decrease of the plasma concentrations of the nintedanib due to decrease of its absorption by the rifampicin
severity: Precaution for use
Clinical monitoring during the administration of these medications together.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: PERAMPANEL
rxNorm: 1356552
atc: N03AX22
Large decrease (up to two thirds) of the concentrations of perampanel
severity: Take into account

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: PIOGLITAZONE
rxNorm: 33738
atc: A10BG03
Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampicin
severity: Precaution for use
Clinical and biological monitoring; adjustment of the dosage of the glitazone during the treatment with the rifampicin and after it is stopped. 

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
Decrease of the plasma concentrations and of the effectiveness of the two antibiotics (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: PRAZIQUANTEL
rxNorm: 8628
atc: P02BA01
Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin
severity: Precautions for use
Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the administration of the two substances together and after the rifampicin is stopped.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: PROPRANOLOL
rxNorm: 8787
atc: C07AA05
Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)
severity: Take into account

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: QUETIAPINE
rxNorm: 51272
atc: N05AH04
Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: QUININE
rxNorm: 9071
atc: P01BC01
Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: RALTEGRAVIR
rxNorm: 719872
atc: J05AX08
Decrease of the concentrations of the raltegravir by the rifampicin
severity: Not recommended
If administering these together cannot be avoided, doubling the dose of raltegravir can be considered

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: RANOLAZINE
rxNorm: 35829
atc: C01EB18
Very large decrease of the concentrations of ranolazine. 
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: RIVAROXABAN
rxNorm: 1114195
atc: B01AF01
Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Very large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism by the rifampicin.
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
Very large decrease of the concentrations of telaprevir
severity: CONTRAINDICATION

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the rifampicin. 
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: TENOFOVIR ALAFENAMIDE
rxNorm: 1721603
Decrease of the plasma concentrations of the tenofovir alafenamide due to decrease of its absorption by the rifampicin
severity: Not recommended
Clinical monitoring during the administration of these medications together and 1 to 2 weeks after the rifampicin is stopped.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: TERBINAFINE
rxNorm: 37801
atc: D01BA02
Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction)
severity: Precaution for use
Clinical monitoring and, if needed, monitoring of the theophyllinemia. Adjust, if there is reason to, the dosage of the theophylline during the treatment with the rifampicin and after it is stopped. 

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: TIAGABINE
rxNorm: 31914
atc: N03AG06
Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism
severity: Precaution for use
An increase of the dosage of the tiagabine can prove necessary in cases where it is administered with the rifampicin.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect. 
severity: Not recommended

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer.
severity: Not recommended
Choose a therapeutic alternative that is little or not at all metabolized.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin
severity: Precaution for use
Clinical and biological monitoring, and possible adjustment of the dosage of the anticonvulsant during the treatment with the rifampicin and after it is stopped. 

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
class name: VITAMIN D
class code: A11CC
Decrease of the concentrations of vitamin D more marked than in the absence of the treatment with the rifampicin
severity: Precaution for use
Concentration dosage of vitamin D and supplementation if necessary.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: ZOLPIDEM
rxNorm: 39993
more atc: N05CF02
Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring. Possibly use another hypnotic.

***interaction***
drug1
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
drug2
drug name: ZOPICLONE
rxNorm: 40001
atc: N05CF01
Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring. Possibly use another hypnotic.
456-RILPIVIRINE.html


***interaction***
drug1
drug name: RILPIVIRINE
rxNorm: 1102270
atc: J05AG05
drug2
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
Risk of decrease of the plasma concentrations of the rilpivirine
severity: Take into account
If necessary, use an H2 receptor antagonist in one dose per day, to be taken at least 12 hours before or at least 4 hours after.

***interaction***
drug1
drug name: RILPIVIRINE
rxNorm: 1102270
atc: J05AG05
drug2
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
Decrease of the plasma concentrations of rilpivirine by the proton pump inhibitor (decreased absorption because of increase of the gastric pH)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: RILPIVIRINE
rxNorm: 1102270
atc: J05AG05
drug2
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone
severity: CONTRAINDICATION 
With the exception of dexamethasone administered in a single dose

***interaction***
drug1
drug name: RILPIVIRINE
rxNorm: 1102270
atc: J05AG05
drug2
class name: ENZYME INDUCERS
class code: N03-J05-001
Large decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the inducer
severity: CONTRAINDICATION

***interaction***
drug1
drug name: RILPIVIRINE
rxNorm: 1102270
atc: J05AG05
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the plasma concentratons of rilpivirine due to increase of its hepatic metabolism by the St Johns wort
severity: CONTRAINDICATION
457-RIOCIGUAT.html


***interaction***
drug1
drug name: RIOCIGUAT
rxNorm: 1439816
atc: C02KX05
drug2
class name: NITRATE DERIVATIVES AND RELATED
class code: C01D-001
Risk of serious hypotension (synergic effect)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: RIOCIGUAT
rxNorm: 1439816
atc: C02KX05
drug2
class name: TYPE 5 PHOSPHODIESTERASE INHIBITORS
class code: G04BE
Risk of serious hypotension (synergic effect)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: RIOCIGUAT
rxNorm: 1439816
atc: C02KX05
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of riociguat due to decrease of its hepatic metabolism by the inhibitor
severity: Not recommended
458-RISPERIDONE.html


***interaction***
drug1
drug name: RISPERIDONE
rxNorm: 35636
atc: N05AX08
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Risk of decrease of the active fraction of the risperidone and of its therapeutic effectiveness due to increase of its hepatic metabolism by the carbamazepine
severity: Precaution for use
Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone.

***interaction***
drug1
drug name: RISPERIDONE
rxNorm: 35636
atc: N05AX08
drug2
drug name: FLUOXETINE
rxNorm: 4493
atc: N06AB03
Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the fluoxetine, with risk of increase of the undesirable effects
severity: Precaution for use
Clinical monitoring, and, if needed, adjustment of the dosage of the risperidone. 

***interaction***
drug1
drug name: RISPERIDONE
rxNorm: 35636
atc: N05AX08
drug2
drug name: PAROXETINE
rxNorm: 32937
atc: N06AB05
Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the paroxetine, with risk of increase of the undesirable effects. 
severity: Precaution for use
Clinical monitoring and, if needed, adjustment of the dosage of the risperidone. 
459-RIVAROXABAN.html


***interaction***
drug1
drug name: RIVAROXABAN
rxNorm: 1114195
atc: B01AF01
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect
severity: Not recommended

***interaction***
drug1
drug name: RIVAROXABAN
rxNorm: 1114195
atc: B01AF01
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
atc: J02AC01
Increase of the plasma concentrations of the rivaroxaban by the fluconazole, with increase of the risk of bleeding
severity: Not recommended

***interaction***
drug1
drug name: RIVAROXABAN
rxNorm: 1114195
atc: B01AF01
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of rivaroxaban, with increase of the risk of bleeding
severity: Not recommended

***interaction***
drug1
drug name: RIVAROXABAN
rxNorm: 1114195
atc: B01AF01
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect
severity: Not recommended
45-CALCIUM-CHANNEL-BLOCKERS.html


***interaction***
drug1
class name: CALCIUM CHANNEL BLOCKERS
class code: CO8CA-001
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism


severity: Not recommended:
with the nimodipine

***interaction***
drug1
class name: CALCIUM CHANNEL BLOCKERS
class code: CO8CA-001
drug2
drug name: IDELALISIB 
rxNorm: 1544460
atc: L01XX47
Increase of the undesirable effects of the calcium channel blockers, of the orthostatic hypotension sort, especially with older patients
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the calcium channel blocker during the treatment with idelalisib and after it is stopped.

***interaction***
drug1
class name: CALCIUM CHANNEL BLOCKERS
class code: CO8CA-001
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the undesirable effects of the calcium channel blockers, most often of the hypotension type, especially in older patients.
severity: Precaution for use
Clinical monitoring and dosage adjustment during the treatment with the enzymatic inhibitor and after it is stopped. 

***interaction***
drug1
class name: CALCIUM CHANNEL BLOCKERS
class code: CO8CA-001
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism


severity: Not recommended
with the nimodipine
460-ROPINIROLE.html


***interaction***
drug1
drug name: ROPINIROLE
rxNorm: 72302
atc: N04BC04
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with ropinirole and after it is stopped. 

***interaction***
drug1
drug name: ROPINIROLE
rxNorm: 72302
atc: N04BC04
drug2
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin
severity: Precaution for use
Clinical monitoring and possible reduction of the dosage of the ropinirole during the treatment with the ciprofloxacin and after it is stopped. 

***interaction***
drug1
drug name: ROPINIROLE
rxNorm: 72302
atc: N04BC04
drug2
drug name: ENOXACIN
rxNorm: 
more atc: J01MA04
Increase of the plasma concentrations of ropinirole with signs of overdose due to decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with the enoxacin and after it is stopped. 

***interaction***
drug1
drug name: ROPINIROLE
rxNorm: 72302
atc: N04BC04
drug2
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
Increase of the concentrations of ropinirole, with risk of overdose, due to decrease of its hepatic metabolism by the fluvoxamine
severity: Precaution for use
Clinical monitoring and reduction of the dosage of the ropinirole during the treatment with fluvoxamine and after it is stopped. 
461-ROSUVASTATIN.html


***interaction***
drug1
drug name: ROSUVASTATIN
rxNorm: 301542
atc: C10AA07
drug2
drug name: CICLOSPORIN
rxNorm: 3008
atc: S01XA18
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the rosuvastatin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ROSUVASTATIN
rxNorm: 301542
atc: C10AA07
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Increase of the plasma concentrations of the rosuvastatin due to increase of its absorption
severity: Precaution for use
Clinical and biological monitoring.
462-ROXITHROMYCIN.html


***interaction***
drug1
drug name: ROXITHROMYCIN
rxNorm: 9478
atc: J01FA06
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type
severity: Precaution for use
Use weaker doses of the cholesterol lowering medication

***interaction***
drug1
drug name: ROXITHROMYCIN
rxNorm: 9478
atc: J01FA06
drug2
drug name: CICLOSPORIN
rxNorm: 3008
atc: S01XA18
Risk of increase of the blood concentrations of ciclosporin and of the creatinemia
severity: Precaution for use
Blood concentration dosage of the ciclosporin, testing of renal function, and adjustment of the dosage during the administration with the macrolide and after it is stopped. 

***interaction***
drug1
drug name: ROXITHROMYCIN
rxNorm: 9478
atc: J01FA06
drug2
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
Slight increase of sedation
severity: Take into account

***interaction***
drug1
drug name: ROXITHROMYCIN
rxNorm: 9478
atc: J01FA06
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type
severity: Precaution for use
Use weaker doses of the cholesterol lowering medication

***interaction***
drug1
drug name: ROXITHROMYCIN
rxNorm: 9478
atc: J01FA06
drug2
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG during the administration of these substances together.

***interaction***
drug1
drug name: ROXITHROMYCIN
rxNorm: 9478
atc: J01FA06
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Risk of increase of the theophyllinemia, particularly with children
severity: Take into account
463-RUFINAMIDE.html


***interaction***
drug1
drug name: RUFINAMIDE
rxNorm: 69036
atc: N03AF03
drug2
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
Moderate decrease of the concentrations of ethinylestradiol
severity: Precaution for use
Another contraceptive method, in particular a barrier type, should be used. 

***interaction***
drug1
drug name: RUFINAMIDE
rxNorm: 69036
atc: N03AF03
drug2
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
Possible increase of the concentrations of rufinamide, especially with children who weigh less than 30 kg.
severity: Precaution for use
With children who weigh less than 30 kg: do not exceed the total dose of 600mg/day after the period of titration. 
464-SACUBITRIL.html


***interaction***
drug1
drug name: SACUBITRIL
rxNorm: 1656328
drug2
drug name: ALISKIREN
rxNorm: 325646
atc: C09XA02
With diabetic patients or those with renal insufficiency, increase of the undesirable effects such as hypotension, hyperkaliemia
severity: CONTRAINDICATION

***interaction***
drug1
drug name: SACUBITRIL
rxNorm: 1656328
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
Increase of the risk of angioedema
severity: CONTRAINDICATION
465-SALMETEROL.html


***interaction***
drug1
drug name: SALMETEROL
rxNorm: 36117
atc: R03AC12
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the itraconazole
severity: Take into account

***interaction***
drug1
drug name: SALMETEROL
rxNorm: 36117
atc: R03AC12
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole
severity: Take into account
466-SERTRALINE.html


***interaction***
drug1
drug name: SERTRALINE
rxNorm: 36437
atc: N06AB06
drug2
class name: ENZYME INDUCERS
class code: N03-J05-001
Risk of ineffectiveness of the antidepressant treatment 


severity: Not recommended

***interaction***
drug1
drug name: SERTRALINE
rxNorm: 36437
atc: N06AB06
drug2
Drug with no codes: GRAPEFRUIT (JUICE AND FRUIT)
Increase, sometimes large, of the concentrations of the antidepressant with some patients due to decrease of its intestinal metabolism
severity: Not recommended

***interaction***
drug1
drug name: SERTRALINE
rxNorm: 36437
atc: N06AB06
drug2
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION
467-SILDENAFIL.html


***interaction***
drug1
drug name: SILDENAFIL
rxNorm: 136411
atc: G04BE03
drug2
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
Increase of the plasma concentrations of sildenafil, with risk of hypotension
severity: Precaution for use
Start the treatment with sildenafil at the minimum dose when it is administered with the josamycin

***interaction***
drug1
drug name: SILDENAFIL
rxNorm: 136411
atc: G04BE03
drug2
class name: OMBITASVIR + PARITAPREVIR
class code: OMPA
Increase of the plasma concentrations of the sildenafil due to decrease of its hepatic metabolism by the therapy with the ombitasvir+paritaprevir
severity: CONTRAINDICATION
468-SIMEPREVIR.html


***interaction***
drug1
drug name: SIMEPREVIR
rxNorm: 1482790
atc: J05AE14
drug2
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone
severity: Not recommended
With the exception of dexamethasone administered in a single dose

***interaction***
drug1
drug name: SIMEPREVIR
rxNorm: 1482790
atc: J05AE14
drug2
class name: ENZYME INDUCERS
class code: N03-J05-001
Decrease of he plasma concentrations of simeprevir due to increase of its hepatic metabolism by the inducer
severity: Not recommended

***interaction***
drug1
drug name: SIMEPREVIR
rxNorm: 1482790
atc: J05AE14
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the plasma concentrations of simeprevir due to decrease of its heptatic metabolism by the inhibitor
severity: Not recommended

***interaction***
drug1
drug name: SIMEPREVIR
rxNorm: 1482790
atc: J05AE14
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the St Johns wort
severity: Not recommended
469-SIMVASTATIN.html


***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)
severity: Precaution for use
Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: AMLODIPINE
rxNorm: 17767
atc: C08CA01
Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). 
severity: Precaution for use
Do not exceed the dosage of 20 mg/day of simvastatin or use another statin not affected by this type of interaction

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: AZITHROMYCIN 
rxNorm: 18631
atc: J01FA10
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. 
severity: Precaution for use
Use weaker doses of the cholesterol lowering agent or another statin not affected by this type of interaction

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type, due to decrease of the metabolism of the simvastatin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism
severity: Not recommended

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. 
severity: CONTRAINDICATION

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: DANAZOL
rxNorm: 3102
atc: G03XA01
Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. 
severity: Precaution for use
Do not exceed the dosage of 20mg/day of simvastatin. If the therapeutic objective is not reached at this dosage, use another statin not affected by this type of interaction. 

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)
severity: Not recommended

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)
severity: CONTRAINDICATION 
Use a statin not affected by this type of interaction

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Decrease of the effectiveness of the cholesterol lowering agent due to increase of its hepatic metabolism by the St Johns wort
severity: Not recommended

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
class name: OMBITASVIR + PARITAPRVIR
class code: OMPA
Increase of the plasma concentrations of the simvastatin due to decrease of its hepatic metabolism by the therapy with ombitavir+paritaprevir
severity: CONTRAINDICATION

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
Drug with no codes: GRAPEFRUIT (JUICE AND FRUIT)
Significant increase of the plasma concentrations of the cholesterol lowering agent, with risk of onset of undesirable effects, especially muscular
severity: Not recommended

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: RANOLAZINE
rxNorm: 35829
atc: C01EB18
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to inhibition of the metabolism of the simvastatin by the ranolazine
severity: Precaution for use
Do not exceed the dosage of 20 mg/day of simvastatin or use another statin not affected by this type of interaction

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Very large decrease of the plasma concentrations of simvastatin due to increase of its hepatic metabolism by the rifampicin.
severity: Not recommended

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: ROXITHROMYCIN
rxNorm: 9478
atc: J01FA06
Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type
severity: Precaution for use
Use weaker doses of cholesterol lowering agent.

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)
severity: Precaution for use
Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction

***interaction***
drug1
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the hepatic metabolism of the simvastatin
severity: CONTRAINDICATION
46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html


***interaction***
drug1
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
For anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3 g per day) or for analgesic or antipyretic doses (>= 500 mg per dose and/or <=3 gr per day):

Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins.

Furthermore, reduction of the antihypertensive effect. 
severity: Precaution for use
Hydrate the patient and monitor renal function at the beginning of treatment. 

***interaction***
drug1
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
drug2
drug name: ALISKIREN
rxNorm: 325646
atc: C09XA02
Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardiovascular disease
severity: Contraindication
- for patients with diabetes or renal insufficiency

***interaction***
drug1
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Acute renal insufficiency with patients at risk (older patient, dehydration, treatment with diuretics, changes in renal function), due to decrease of the glomerular filtration (inhibition of the vasodilater prostaglandins due to the non steroidal anti-inflammatories.) These effects are generally reversible. In addition, reduction of the antihypertensive effect.
severity: Precaution for use
Hydrate the patient and monitor renal function at the beginning of treatment and regularly while these substances are administered together. 

***interaction***
drug1
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
drug2
class name: POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
Risk of hyperkalemia (potentially lethal) especially in case of renal insufficiancy (addition of the hyperkaliemia inducing effects)/
severity: Not recommended
--if the combination of these durgs is justified, strict testing of the kaliemia and of renal function

***interaction***
drug1
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
drug2
class name: POTASSIUM LOWERING DIURETICS
class code: C03
Risk of abrupt arterial hypotension and/or acute renal insufficiency at the beginning of or at an increase of the dosage of a treatment with an angiotensin II antagonist in cases where there is pre-existing fluid depletion. 


severity: Precaution for use
With arterial hypertension, where there has been pre-existing diuretic treatment that has caused fluid depletion, it is necessary:

***interaction***
drug1
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
drug2
drug name: EPLERENONE
rxNorm: 298869
atc: C03DA04
Increase of the risk of hyperkalemia, especially with older patients


severity: Precaution for use
Strict testing of the kalemia and of the renal function during the administration of these substances together. 

***interaction***
drug1
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
In indications where the administration of these substances together is possible, increased risk of degradation of renal function, even acute renal insufficiency, and increase of the hyperkalemia as well as hypotension and fainting or loss of consciousness. 
severity: Take into account

***interaction***
drug1
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Increase of the plasma concentrations of lithium that can reach toxic values (decrease of the renal excretion of the lithium)


severity: Not recommended
If the use of an angiotensin II antagonist is indispensable, strict monitoring of the plasma concentrations of lithium and adjustment of the dosage

***interaction***
drug1
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
drug2
drug name: POTASSIUM
rxNorm: 8588
atc: A12BA
Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects).
severity: Not recommended
Avoid administering these substances together unless there is pre-existing hypokelimia. 
470-SIROLIMUS.html


***interaction***
drug1
drug name: SIROLIMUS
rxNorm: 35302
atc: L04AA10
drug2
drug name: CICLOSPORIN
rxNorm: 3008
atc: S01XA18
Increase of the blood concentrations of sirolimus by the ciclosporin. The nephrotoxicity of the ciclosporin is also increased when the two medications are administered together 
severity: Precaution for use
It is recommended that the sirolimus be administered 4 hours after the cyclosporine. Testing of the renal function, during the administration of the two medications together and after it is stopped

***interaction***
drug1
drug name: SIROLIMUS
rxNorm: 35302
atc: L04AA10
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the blood concentrations of the sirolimus (decrease of its hepatic metabolism by the verapamil)
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.
471-SODIUM-BICARBONATE.html


***interaction***
drug1
drug name: SODIUM BICARBONATE
rxNorm: 
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts. 
severity: Precaution for use
Avoid excess amounts of sodium and take into account the presence of sodium in certain medications such as antacids.
472-SODIUM-CHLORIDE.html


***interaction***
drug1
drug name: SODIUM CHLORIDE
rxNorm: 9863
more atc: A12CA01
more atc: B05CB01
more atc: B05XA03
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts
severity: Precaution for use
Avoid excessive sodium and take into account the presence of sodium in some medications such as antacids.
473-SOFOSBUVIR.html


***interaction***
drug1
drug name: SOFOSBUVIR
rxNorm: 
more atc: J05AX15
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Only for interactions with the combinatons daclatasvir/sofosbuvir or ledispavir/sofosbuvir:

Possibly abrupt onset of bradycardia, that can have fatal consequences 
severity: Not recommended
If administering these together cannot be avoided, clinical monitoring and strict EKG, in particular during the first weeks of treatment with the bitherapy.

***interaction***
drug1
drug name: SOFOSBUVIR
rxNorm: 
more atc: J05AX15
drug2
class name: ENZYME INDUCERS
class code: N03-J05-001
Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the enzymatic inducer
severity: Contraindication
--with the rifampicin

***interaction***
drug1
drug name: SOFOSBUVIR
rxNorm: 
more atc: J05AX15
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the St Johns wort
severity: CONTRAINDICATION

***interaction***
drug1
drug name: SOFOSBUVIR
rxNorm: 
more atc: J05AX15
drug2
drug name: MODAFINIL
rxNorm: 30125
atc: N06BA07
Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the modafinil
severity: Not recommended
474-SORBITOL.html


***interaction***
drug1
drug name: SORBITOL
rxNorm: 9945
more atc: A06AD18
more atc: A06AG07
more atc: B05CX02
more atc: V04CC01
drug2
Drug with no codes: The French document lists Catioresine Sulfo Calcique
With the resin administered by oral and rectal route: risk of colonic necrosis, possibly fatal
severity: CONTRAINDICATION

***interaction***
drug1
drug name: SORBITOL
rxNorm: 9945
more atc: A06AD18
more atc: A06AG07
more atc: B05CX02
more atc: V04CC01
drug2
Drug with no codes: The French document lists Catioresine Sulfo Sodique
With the resin administered by oral and rectal route: risk of colonic necrosis, possibly fatal. 
severity: Not recommended
475-SPERMICIDES.html


***interaction***
drug1
class name: SPERMICIDES
class code: R02AA
drug2
Drug with no codes: MEDICATIONS USED BY VAGINAL ROUTE
All topical vaginal treatment is susceptible to disrupting the action of a topical spermicidal contraceptive
severity: Not recommended
476-SPIRAMYCIN.html


***interaction***
drug1
drug name: SPIRAMYCIN
rxNorm: 9991
atc: J01FA02
drug2
drug name: LEVODOPA
rxNorm: 6375
atc: N04BA01
In case of administration with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa 
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the levodopa. 
477-SPIRONOLACTONE.html


***interaction***
drug1
drug name: SPIRONOLACTONE
rxNorm: 9997
atc: C03DA01
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
With the spironolactone in dosages from 12.5 to 50 mg per day, and with weak doses of the ACE inhibitor.

In the treatment of class III or IV heart failure (NYHA) with an ejection fraction <35% and previous treatment with an ACE inhibitor + a loop diuretic: risk of hyperkalemia, potentially lethal, in case of failure to follow the prescription conditions for this combination of medications. 
severity: Precaution for use
Verify the absence of pre-existing hyperkalemia and renal insufficiency. Strict biological monitoring of the kalemia and of the creatinemia (1 time per week during the first month, then one time per month thereafter).

***interaction***
drug1
drug name: SPIRONOLACTONE
rxNorm: 9997
atc: C03DA01
drug2
drug name: MITOTANE
rxNorm: 7004
atc: L01XX23
Risk of blocking of the action of the mitotane by the spironolactone
severity: CONTRAINDICATION
478-STAVUDINE.html


***interaction***
drug1
drug name: STAVUDINE
rxNorm: 59763
atc: 05AR07
drug2
drug name: ISONIAZID
rxNorm: 6038
atc: J04AC01
Increased risk of onset of peripheral neuropathy due to addition of undesirable effects
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together.

***interaction***
drug1
drug name: STAVUDINE
rxNorm: 59763
atc: 05AR07
drug2
drug name: PENTAMIDINE
rxNorm: 7994
atc: P01CX01
Increased risk of onset of peripheral neuropathy due to addition of undesirable effects. 
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. 

***interaction***
drug1
drug name: STAVUDINE
rxNorm: 59763
atc: 05AR07
drug2
drug name: RIBAVIRIN
rxNorm: 9344
atc: J05AB04
Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites 
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. 

***interaction***
drug1
drug name: STAVUDINE
rxNorm: 59763
atc: 05AR07
drug2
drug name: THALIDOMIDE
rxNorm: 10432
atc: L04AX02
Increased risk of onset of peripheral neuropathy due to addition of undesirable effects
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. 

***interaction***
drug1
drug name: STAVUDINE
rxNorm: 59763
atc: 05AR07
drug2
drug name: ZALCITABINE
rxNorm: 3363
atc: J05AF03
Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. 
severity: Not recommended

***interaction***
drug1
drug name: STAVUDINE
rxNorm: 59763
atc: 05AR07
drug2
drug name: ZIDOVUDINE 
rxNorm: 11413
atc: J05AF01
Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites. 
severity: Not recommended
479-STIRIPENTOL.html


***interaction***
drug1
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Increase of the plasma concentrations of the anticonvulsant, with risk of overdose, due to inhibition of its hepatic metabolism by the stiripentol
severity: Precaution for use
Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol, and possible adjustment of its dosage. 

***interaction***
drug1
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the chlosterol lowering medication)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
drug2
drug name: CAFFEINE 
rxNorm: 1886
atc: V04CG30
Possible increase of the plasma concentrations of the caffeine, with risk of overdose, due to inhibition of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of caffeine. 

***interaction***
drug1
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
drug2
drug name: CLOBAZAM
rxNorm: 21241
atc: N05BA09
Increase of the plasma concentrations of these anticonvulsants, with risk of overdose, due to inhibition of their hepatic metabolism
severity: Precaution for use
Clinical monitoring, plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol, and possible adjustment of the dosage of that anticonvulsant as well.

***interaction***
drug1
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
drug2
drug name: DIAZEPAM
rxNorm: 3322
atc: N05BA01
Increase of the plasma concentrations of the diazepam, with risk of overdose, due to inhibition of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol, and possible adjustment of the dosage of the anticonvulsant as well.

***interaction***
drug1
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
drug2
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
drug2
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
drug2
drug name: HALOFANTRINE
rxNorm: 50749
atc: P01BX01
Increased risk of ventricular arrhythmias, especially of torsades de pointes. 
severity: Not recommended

***interaction***
drug1
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Increase of the blood concentrations of the immunosuppressant (decrease of its hepatic metabolism)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
drug2
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism with increase of sedation
severity: Precaution for use
Clinical monitoring and reduction of the dosage during the treatment with the stiripentol.

***interaction***
drug1
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
drug2
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
drug2
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Possible increase of the theophyllinemia, with risk of overdose, due to inhibition of its hepatic metabolism 
severity: Precaution for use
Clinical monitoring, plasma dosage, and possible adjustment of the dosage of theophylline.
47-PLATELET-AGGREGATION-INHIBITORS.html


***interaction***
drug1
class name: PLATELET AGGREGATION INHIBITORS
class code: B01AC-001
drug2
drug name: ANAGRELIDE
rxNorm: 596724
atc: L01XX3
Increase of hemorrhagic events 


severity: Not recommended

***interaction***
drug1
class name: PLATELET AGGREGATION INHIBITORS
class code: B01AC-001
drug2
class name: ORAL ANTICOAGULANTS
class code: B01A-001
Increase of the risk of hemorrhage 
severity: Take into account

***interaction***
drug1
class name: PLATELET AGGREGATION INHIBITORS
class code: B01AC-001
drug2
drug name: DEFIBROTIDE
rxNorm: 1311089
atc: B01AX01
Increased risk of hemorrhage
severity: Not recommended

***interaction***
drug1
class name: PLATELET AGGREGATION INHIBITORS
class code: B01AC-001
drug2
class name: HEPARINS
class code: B01AB
Increase of the risk of hemorrhage 
severity: Take into account

***interaction***
drug1
class name: PLATELET AGGREGATION INHIBITORS
class code: B01AC-001
drug2
class name: THROMBOLYTICS
class code: B01AD
Increase of the risk of hemorrhage
severity: Take into account
480-STRONTIUM.html


***interaction***
drug1
drug name: STRONTIUM
rxNorm: 81638
more atc: V10BX01
more atc: M05BX03
drug2
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
With the calcium salts administered by oral route: decrease of the digestive absorption of the strontium
severity: Precaution for use
Take the strontium at a different time from the calcium salts (more than two hours apart, if possible).

***interaction***
drug1
drug name: STRONTIUM
rxNorm: 81638
more atc: V10BX01
more atc: M05BX03
drug2
class name: TETRACYCLINE ANTIBIOTICS
class code: J01AA
Decrease of the digestive absorption of the strontium
severity: Precaution for use
Take the strontium at a different time from the tetracycline antibiotics (more than two hours apart, if possible).

***interaction***
drug1
drug name: STRONTIUM
rxNorm: 81638
more atc: V10BX01
more atc: M05BX03
drug2
drug name: IRON
rxNorm: 1431589
atc: B03A
Decrease of the digestive absorption of the strontium
severity: Precaution for use
Take the strontium at a different time from the iron salts (more than two hours apart, if possible).

***interaction***
drug1
drug name: STRONTIUM
rxNorm: 81638
more atc: V10BX01
more atc: M05BX03
drug2
class name: FLUOROQUINOLONES
class code: J01MA-001
Decrease of the digestive absorption of the strontium
severity: Precaution for use
Take the strontium at a different time from the fluoroquinolones (more than two hours apart, if possible).

***interaction***
drug1
drug name: STRONTIUM
rxNorm: 81638
more atc: V10BX01
more atc: M05BX03
drug2
drug name: ZINC
rxNorm: 1431163
atc: A12CB
Decrease of the digestive absorption of the strontium.
severity: Precaution for use
Take the strontium at a different time from the zinc salts (more than two hours apart, if possible). 
481-SUBSTANCES-WITH-ABSORPTION-REDUCED-BY-GASTRO-INTESTINAL-TARGETED-MEDICATIONS,-ANTACIDS,-AND-ABSORBANTS.html


***interaction***
drug1
class name: SUBSTANCES WITH ABSORPTION REDUCED BY GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS 
class code: RBGI
drug2
class name: GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS
class code: A07BC-A02AD
Decrease of the absorption of these substances
severity: Precaution for use
Take the gastro-intestinal targeted medications, antacids, absorbants at a different time from these substances (more than 2 hours apart, if possible). 
482-SUBSTANCES-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html


***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
drug name: ANAGRELIDE
rxNorm: 596724
atc: L01XX35
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG during the administration of these together.

***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
class name: ANTIPARASITICS THAT TEND TO INDUCE TORSADES DE POINTES
class code: P01B-001
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Contraindication
--with citalopram, domperidone, escitalopram, hydroxyzine, and piperaquin

***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
drug name: AZITHROMYCIN 
rxNorm: 18631
atc: J01FA10
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG during the administration of these substances together. 

***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG

***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
class name: BRADYCARDIA INDUCING DRUGS
class code: C0N0S0
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG during the administration of these together

***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG during the administration of these substances together

***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG during the administration of these substances together.

***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
drug name: HYDROXYCHLOROQUINE
rxNorm: 5521
atc: P01BA02
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Contraindication
--with citalopram, domperidone, escitalopram, hydroxyzine and piperaquine

***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
class name: POTASSIUM LOWERING AGENTS
class code: C03-001
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Correct all hypokaliemia before administering the product and do clinical and electrolyte monitoring and EKG.

***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
drug name: LEVOFLOXACIN
rxNorm: 82122
atc: S01AE05
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG during the administration of these medications together. 

***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
drug name: METHADONE
rxNorm: 6813
atc: N07BC02
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Contraindication
--with citalopram, dromperidone, escitalopram, hydroxyzine, piperaquine

***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
class name: NEUROLEPTICS THAT TEND TO INDUCE TORSADES DE POINTES
class code: N05A-002
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Contraindication
--with citalopram, dromperidone, escitalopram, hydroxyzine, piperaquine

***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
drug name: NORFLOXACIN
rxNorm: 7517
atc: S01AE02
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG during the administration of these substances together

***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
drug name: ONDANSETRON
rxNorm: 26225
atc: A04AA01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG during the administration of these substances together

***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
drug name: ROXITHROMYCIN
rxNorm: 9478
atc: J01FA06
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG during the administration of these substances together

***interaction***
drug1
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
drug2
class name: TORSADES DE POINTES INDUCING MEDICATIONS (EXCEPT ANTIPARASITICS, NEUROLEPTICS, METHADONE)
class code: C01B
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Contraindication
--For erythromycin, and vicamine, only the forms administerd by IV route are concerned by this interaction
483-SUBSTRATES-AT-RISK-OF-CYP3A4.html


***interaction***
drug1
class name: SUBSTRATES AT RISK OF CYP3A4
class code: L01N01
drug2
drug name: CRIZOTINIB
rxNorm: 1148495
atc: L01XE16
Risk of increase of the toxicity of these molecules due to decrease of their metabolism and/or increase of their bioavailability by the crizotinib
severity: Not recommended

***interaction***
drug1
class name: SUBSTRATES AT RISK OF CYP3A4
class code: L01N01
drug2
drug name: IDELALISIB
rxNorm: 1544460
atc: L01XX47
Increase of the plasma concentrations of the substrate due to decrease of its hepatic metabolism by the idealisib
severity: Not recommended

***interaction***
drug1
class name: SUBSTRATES AT RISK OF CYP3A4
class code: L01N01
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the undesirable effects particular to each substrate, with frequently severe consequences
severity: Take into account
484-SUCRALFATE.html


***interaction***
drug1
drug name: SUCRALFATE
rxNorm: 10156
atc: A02BX02
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Decrease of the digestive absorption of the vitamin K antagonist
severity: Precaution for use
Take the sucralfate at a different time from the vitamin K antagonist (more than 2 hours apart, if possible).

***interaction***
drug1
drug name: SUCRALFATE
rxNorm: 10156
atc: A02BX02
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Decrease of the digestive absorption of the digoxin
severity: Precaution for use
Take the sucralfate at a different time from the digoxin (more that 2 hours apart, if possible).

***interaction***
drug1
drug name: SUCRALFATE
rxNorm: 10156
atc: A02BX02
drug2
class name: FLUOROQUINOLONES
class code: J01MA-001
Decrease of the digestive absorption of the fluorquinolones
severity: Precaution for use
Take the sucralfate at a different time from the fluoroquinolones (more than 2 hours apart, if possible). 

***interaction***
drug1
drug name: SUCRALFATE
rxNorm: 10156
atc: A02BX02
drug2
class name: THYROID HORMONES
class code: H03AA
Decrease of the digestive absorption of the thyroid hormones. 
severity: Precaution for use
Take the thyroid hormones at a different time from the sucralfate (more than 2 hours apart, if possible).

***interaction***
drug1
drug name: SUCRALFATE
rxNorm: 10156
atc: A02BX02
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Decrease of the digestive absorption of the phenytoin
severity: Precaution for use
Take the sucalfate at a different time from the phenytoin (more than 2 hours apart, if possible).

***interaction***
drug1
drug name: SUCRALFATE
rxNorm: 10156
atc: A02BX02
drug2
drug name: SULPIRIDE
rxNorm: 10239
atc: N05AL01
Decrease of the digestive absorption of the sulpiride
severity: Precaution for use
Take the sucralfate at a different time from the sulpiride (more than 2 hours apart, if possible).
485-SUFENTANIL.html


***interaction***
drug1
drug name: SUFENTANIL
rxNorm: 56795
atc: N01AH03
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the opioid analgesics effect of respiratory depression due to decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the opioid analgesic when there is also treatment with a strong inhibitor of CYP3A4. 
486-SULFAFURAZOLE.html


***interaction***
drug1
drug name: SULFAFURAZOLE
rxNorm: 10207
more atc: J01EB05
more atc: S01AB02
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution of use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the antibiotic and a week after it is stopped.

***interaction***
drug1
drug name: SULFAFURAZOLE
rxNorm: 10207
more atc: J01EB05
more atc: S01AB02
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)
severity: Not recommended
The use of another class of antibiotic is preferred; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped.
487-SULFAMETHIZOLE.html


***interaction***
drug1
drug name: SULFAMETHIZOLE
rxNorm: 10179
more atc: B05CA04
more atc: D06BA04
more atc: J01EB02
more atc: S01AB01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the antibiotic treatment and a week after it is stopped. 

***interaction***
drug1
drug name: SULFAMETHIZOLE
rxNorm: 10179
more atc: B05CA04
more atc: D06BA04
more atc: J01EB02
more atc: S01AB01
drug2
drug name: METHENAMINE
rxNorm: 6832
atc: J01XX05
Precipitation of crystals in the urinary tract (due to the acidification of the urine)
severity: Not recommended

***interaction***
drug1
drug name: SULFAMETHIZOLE
rxNorm: 10179
more atc: B05CA04
more atc: D06BA04
more atc: J01EB02
more atc: S01AB01
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)
severity: Not recommended
Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the antibacterial sulfonamide and after it is stopped. 
488-SULFAMETHOXAZOLE.html


***interaction***
drug1
drug name: SULFAMETHOXAZOLE
rxNorm: 10180
more atc: J01EC01
more atc: J01EE01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Not recommended
If the administration of the substances together cannot be avoided, more frequent testing of the INR and adjustment of the dosage of the vitamin K antagonist during the treatment with cotrimoxazole and after it is stopped. 

***interaction***
drug1
drug name: SULFAMETHOXAZOLE
rxNorm: 10180
more atc: J01EC01
more atc: J01EE01
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)
severity: Not recommended
Another class of antibiotic should be used; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the antibacterial sulfonamide and after it is stopped.
489-ANTIBACTERIAL-SULFONAMIDES.html


***interaction***
drug1
class name: ANTIBACTERIAL SULFONAMIDES
class code: JO1E
drug2
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
Increase of the hematological toxicity of the methotrexate
severity: Precaution for use
Concentration dosage of methotrexate. Adjustment of the dosage if necessary during the administration of the substances together and after it is stopped. 
48-ANTIARRHYTHMIC-AGENTS.html


***interaction***
drug1
class name: ANTIARRHYTHMIC AGENTS
class code: C01B-001
drug2
class name: OTHER ANTIARRHYTHMIC AGENTS
class code: C01B-001
The combination of two antiarrhythmic agents is very delicate. In the majority of cases, it is contraindicated or not recommended.
severity: Contraindication
Not recommended 
490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html


***interaction***
drug1
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
drug2
Drug with no codes: ALCOHOL (DRINK OF INGREDIENT)
Antabuse effect, especially for glibenclamide, glipizide, tolbutamide. Increase of the hypoglycemic reaction (inhibition of the compensation reactions) that can make possible the onset of hypoglycemic coma
severity: Not recommended
Avoid taking alcoholic beverages and medications containing alcohol. 

***interaction***
drug1
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
drug2
class name: SOMATOSTATIN ANALOGS
class code: H01CB0-001
Risk of hypoglycemia or hyperglycemia: decrease or increase of the need for the blood glucose lowering sufonamide, due to decrease or increase of the secretion of endogenous glucagon
severity: Precaution for use
Reinforce self-monitoring of blood glucose and adjust the dosage of the blood glucose lowering sulfonamide if needed during the treatment with the somatostatin analog. 

***interaction***
drug1
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
drug2
class name: BETA-2 MIMETICS or BETA 2 ADRENERGIC AGONISTS
class code: R03C-001
Elevation of the glycemia by the beta-2 mimetic
severity: Precaution for use
Reinforce blood and urine monitoring. Possibly change to insulin if the situation requires. 

***interaction***
drug1
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
drug2
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
All the beta blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia
severity: Precaution for use
Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of treatment. 

***interaction***
drug1
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
All the beta blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia
severity: Precaution for use
Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of the treatment.

***interaction***
drug1
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
drug2
drug name: CHLORPROMAZINE
rxNorm: 
more atc: N05AA01
With large doses (100mg per day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin) 
severity: Precaution for use
Inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the neuroleptic during the treatment and after it is stopped. 

***interaction***
drug1
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetique
severity: Precaution for use
Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during the treatment with the clarithromycin.

***interaction***
drug1
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
drug2
drug name: DANAZOL
rxNorm: 3102
atc: G03XA01
Diabetes inducing effect of the danazol
severity: Not recommended
If the administration of the substances together cannot be avoided, inform the patient and reinforce self-monitoring of blood glucose. Possibly adjust the dosage of the antidiabetic during the treatment with the danazol and after it is stopped. 

***interaction***
drug1
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
Increase of the half life of the sulfonamide with possible onset of manifestations of hypoglymemia
severity: Precaution for use
Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the sulfonamide during the treatment with the fluconazole. 

***interaction***
drug1
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in diabetic patients treated with glucose lowering sulfonamides. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for the glucose lowering sulfonamides)
severity: Precaution for use
Reinforce self -monitoring of blood glucose.

***interaction***
drug1
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
drug2
drug name: MICONAZOLE
rxNorm: 6932
more atc: A01AB09
more atc: A07AC01
more atc: D01AC02
more atc: G01AF04
more atc: J02AB01
more atc: S02AA13
With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma
severity: CONTRAINDICATION
491-SULFASALAZINE.html


***interaction***
drug1
drug name: SULFASALAZINE
rxNorm: 9524
atc: A07EC01
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Decrease of the digoxinemia that can reach 50%
severity: Precaution for use
Clinical monitoring, EKG, and, possibly, monitoring of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the sulfasalazine and after it is stopped.
492-SULFINPYRAZONE.html


***interaction***
drug1
drug name: SULFINPYRAZONE
rxNorm: 10205
atc: M04AB02
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Decrease of the blood concentrations of ciclosporin due to increase of its metabolism by the sulfinpyrazone
severity: Precaution for use
Testing of blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with sulfinpyrazone and after it is stopped. 
493-SULPIRIDE.html


***interaction***
drug1
drug name: SULPIRIDE
rxNorm: 10239
atc: N05AL01
drug2
drug name: SUCRALFATE
rxNorm: 10156
atc: A02BX02
Decrease of the digestive absorption of the sulpiride
severity: Precaution for use
Take the sucralfate at a different time from the sulpiride (more than 2 hours apart, if possible). 
494-SUNITINIB.html


***interaction***
drug1
drug name: SUNITINIB
rxNorm: 357977
atc: L01XE04
drug2
class name: THYROID HORMONES
class code: H03AA
Risk of reduction of the effectiveness of the thyroid hormones
severity: Take into account
495-SUXAMETHONIUM.html


***interaction***
drug1
drug name: SUXAMETHONIUM
rxNorm: 10154
atc: M03AB01
drug2
class name: ACETYLCHOLINESTERASE INHIBITORS
class code: ACETCHO
Risk of lengthening of the motor block, increased in the case of partial deficit of pseudo-cholinesterase 
severity: Take into account
496-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html


***interaction***
drug1
class name: ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)
class code: R01AA
drug2
class name: DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE
class code: G02CB-001
Risk of constriction of blood vessels and/or rapid elevation of blood pressure
severity: Not recommended

***interaction***
drug1
class name: ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)
class code: R01AA
drug2
class name: VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE
class code: N02CA0-001
Risk of constriction of blood vessels and/or of rapid elevation of blood pressure
severity: Not recommended

***interaction***
drug1
class name: ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)
class code: R01AA
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped
severity: Not recommended

***interaction***
drug1
class name: ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)
class code: R01AA
drug2
class name: INDIRECT SYMPATHOMIMETICS
class code: C01CA-R01BA
Risk of constriction of blood vessels and/or of rapid elevation of blood pressure
severity: CONTRAINDICATION
497-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES).html


***interaction***
drug1
class name: ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)
class code: C01CA
drug2
class name: HALOGENATED HYDROCARBON ANESTHETICS
class code: N01AB0-001
Serious ventricular arrhythmias due to increase of cardiac sensitization
severity: Not recommended

***interaction***
drug1
class name: ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)
class code: C01CA
drug2
class name: TRICYCLIC ANTIDEPRESSANTS
class code: N06AA-001
Paroxysmal hypertension with the possibility of arrhythmias (inhibition of the entry of the sympathomimetic into the sympathic fiber)
severity: Not recommended

***interaction***
drug1
class name: ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)
class code: C01CA
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Increase of the pressor action of the sympathomimetic, most often moderate. 
severity: Precaution for use
Only use under strict medical monitoring.

***interaction***
drug1
class name: ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)
class code: C01CA
drug2
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
By extrapolation from the non selective MAOIs: risk of increase of the pressor action 
severity: Precaution for use
To be used only under strict medical monitoring.

***interaction***
drug1
class name: ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)
class code: C01CA
drug2
class name: MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS
class code: N06A
Paroxysmal hypertension with possibility of arrhythmias (inhibition of the entry of the sympathomimetic into the sympathic fiber)
severity: Not recommended
498-INDIRECT-SYMPATHOMIMETICS.html


***interaction***
drug1
class name: INDIRECT SYMPATHOMIMETICS
class code: C01CA-R01BA
drug2
class name: OTHER INDIRECT SYMPATHOMIMETICS
class code: C01CA-R01BA
Risk of constriction of blood vessels and/or of hypertensive crises.
severity: CONTRAINDICATION

***interaction***
drug1
class name: INDIRECT SYMPATHOMIMETICS
class code: C01CA-R01BA
drug2
class name: DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE
class code: G02CB-001
Risk of constriction of blood vessels and/or of rapid elevation of blood pressure
severity: Not recommended

***interaction***
drug1
class name: INDIRECT SYMPATHOMIMETICS
class code: C01CA-R01BA
drug2
class name: VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE
class code: N02CA0-001
Risk of constriction of blood vessels and/or of rapid elevation of blood pressure


severity: Not recommended

***interaction***
drug1
class name: INDIRECT SYMPATHOMIMETICS
class code: C01CA-R01BA
drug2
class name: HALOGENATED HYDROCARBON ANESTHETICS
class code: N01AB0-001
Perioperative hypertension
severity: Precaution for use
In the case of scheduled surgery, it is preferable to stop the treatment several days before surgery.

***interaction***
drug1
class name: INDIRECT SYMPATHOMIMETICS
class code: C01CA-R01BA
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Paroxystic hypertension, hyperthermia that can be fatal. Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI has been stopped
severity: CONTRAINDICATION

***interaction***
drug1
class name: INDIRECT SYMPATHOMIMETICS
class code: C01CA-R01BA
drug2
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
Risk of constriction of blood vessels and/or rapid elevation of blood pressure
severity: Contraindication:
with bupropion

***interaction***
drug1
class name: INDIRECT SYMPATHOMIMETICS
class code: C01CA-R01BA
drug2
class name: ALPHA-SYMPATHOMIMETICS (ORAL AND/OR NASAL)
class code: R01AA
Risk of constriction of blood vessels and/or rapid elevation of blood pressure
severity: CONTRAINDICATION
499-TACROLIMUS.html


***interaction***
drug1
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
drug2
class name: AMINOGLYCOSIDES
class code: J01GB-001
Greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)
severity: Take into account

***interaction***
drug1
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Increase of the blood concentrations of tacrolimus due to inhibition of its metabolism by the amiodarone
severity: Precaution for use
Blood concentration dosage of tacrolimus, testing of the renal function, and adjustment of the dosage of tacrolimus during its administration with the amiodarone and when the amiodarone is stopped.

***interaction***
drug1
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
drug2
drug name: AMPHOTERICIN B 
rxNorm: 732
more atc: A01AB04
more atc: A07AA07
more atc: G01AA03
more atc: J02AA01
With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)
severity: Take into account

***interaction***
drug1
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Risk of addition of the nephrotoxic effects, especially with older patients
severity: Precaution for use
Monitor renal function at the beginning of treatment with the NSAI.

***interaction***
drug1
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
drug2
drug name: CLINDAMYCIN
rxNorm: 2582
more atc: D10AF01
more atc: G01AA10
more atc: J01FF01
Decrease of the blood concentrations of the immunosuppressant, with risk of loss of immunosuppressive activity. 
severity: Precaution for use
Reinforced testing of the blood dosages of tacrolimus and possible increase of its dosage. 

***interaction***
drug1
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
drug2
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
Risk of increase of the plasma concentrations of dabigatran
severity: Not recommended

***interaction***
drug1
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
drug2
drug name: DANAZOL
rxNorm: 3102
atc: G03XA01
Increase of the blood concentrations of the tacrolimus due to inhibition of its hepatic metabolism
severity: Precaution for use
Blood concentration dosage of the tacrolimus and adjustment of its dosage during the administration with the danazol and after it is stopped, with testing of the renal function.

***interaction***
drug1
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
drug2
class name: POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)
class code: C0E-004
Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)
severity: Not recommended

***interaction***
drug1
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
drug2
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
Increase of the blood concentrations of tacrolimus and of the creatinemia, due to inhibition of the hepatic metabolism of the tacrolimus by the josamycin
severity: Not recommended

***interaction***
drug1
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
drug2
drug name: LANSOPRAZOLE
rxNorm: 17128
more atc: A02BC03
more atc: A02BD07
more atc: A02BD03
more atc: A02BD02
Increase of the blood concentrations of the tacrolimus
severity: Precaution for use
Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after it is stopped. 

***interaction***
drug1
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
drug2
drug name: OMEPRAZOLE
rxNorm: 7646
more atc: A02BC01
more atc: A02BD05
more atc: A02BD01
Increase of the blood concentrations of the tacrolimus
severity: Precaution for use
Blood concentration dosage of the tacrolimus, testing of the renal function, and adjustment of the dosage during the administration of the substances together and after it is stopped.

***interaction***
drug1
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
drug2
drug name: POTASSIUM
rxNorm: 8588
atc: A12BA
Essentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)
severity: Not recommended 
Avoid administering these substances together unless there is preexisting hypokalemia.

***interaction***
drug1
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 
49-CLASS-I-ANTIARRHYTHMICS-(EXCEPT-LIDOCAINE).html


***interaction***
drug1
class name: CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)
class code: C01B-003
drug2
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)
class code: C07AB-001
Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)
severity: Precaution for use
Clinical monitoring and EKG

***interaction***
drug1
class name: CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)
class code: C01B-003
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
Negative inotropic effect with risk of acute decompensated heart failure 


severity: CONTRAINDICATION
4-ACETOHYDROXAMIC-ACID.html


***interaction***
drug1
drug name: ACETOHYDROXAMIC ACID
rxNorm: 16728
atc: G04BX03
drug2
drug name: IRON
rxNorm: 1431589
atc: B03A
Decrease of the digestive absorption of these two medications due to chelation of the iron
severity: Take into account
500-TAMOXIFEN.html


***interaction***
drug1
drug name: TAMOXIFEN
rxNorm: 10324
atc: L02BA01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist.

***interaction***
drug1
drug name: TAMOXIFEN
rxNorm: 10324
atc: L02BA01
drug2
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine [sic] 
severity: Not recommended

***interaction***
drug1
drug name: TAMOXIFEN
rxNorm: 10324
atc: L02BA01
drug2
drug name: DULOXETINE
rxNorm: 72625
atc: N06AX21
Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the duloxetine
severity: Not recommended

***interaction***
drug1
drug name: TAMOXIFEN
rxNorm: 10324
atc: L02BA01
drug2
drug name: FLUOXETINE
rxNorm: 4493
more atc: N06AB03
more atc: N06CA03
Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the fluoxetine
severity: Not recommended

***interaction***
drug1
drug name: TAMOXIFEN
rxNorm: 10324
atc: L02BA01
drug2
drug name: PAROXETINE
rxNorm: 32937
atc: N06AB05
Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the paroxetine
severity: Not recommended

***interaction***
drug1
drug name: TAMOXIFEN
rxNorm: 10324
atc: L02BA01
drug2
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the quinidine
severity: Not recommended

***interaction***
drug1
drug name: TAMOXIFEN
rxNorm: 10324
atc: L02BA01
drug2
drug name: TERBINAFINE
rxNorm: 37801
more atc: D01AE15
more atc: D01BA02
Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine
severity: Not recommended
501-TAMSULOSIN.html


***interaction***
drug1
drug name: TAMSULOSIN
rxNorm: 77492
atc: G04CA02
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism
severity: Precaution for use 
Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzyme inhibitor and after it is stopped, if the situation requires. 

***interaction***
drug1
drug name: TAMSULOSIN
rxNorm: 77492
atc: G04CA02
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzyme inhibitor and after it is stopped, if the situation requires.

***interaction***
drug1
drug name: TAMSULOSIN
rxNorm: 77492
atc: G04CA02
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism
severity: Not recommended

***interaction***
drug1
drug name: TAMSULOSIN
rxNorm: 77492
atc: G04CA02
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzyme inhibitor and after it is stopped, if the situation requires. 
502-TELAPREVIR.html


***interaction***
drug1
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia
severity: CONTRAINDICATION

***interaction***
drug1
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Risk of very large decrease of the concentrations of telaprevir.
severity: CONTRAINDICATION

***interaction***
drug1
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the atorvastatin)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Increase of the digoxinemia
severity: Precaution for use
Clinical and biological monitoring, and adjustment, if needed, of the dosage of the digoxin during the treatment with the telaprevir and after it is stopped. 

***interaction***
drug1
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
drug2
class name: NON-CONTRACEPTIVE ESTROGENS
class code: G03C-001
Decrease of the effectiveness of the estrogen
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the telaprevir and after it is stopped. 

***interaction***
drug1
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
drug2
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the telaprevir
severity: Precaution for use
Use a reliable contraceptive method, additional or alternative, during the administration of the substances together and two cycles after. 

***interaction***
drug1
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Increase of the plasma concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the telaprevir
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of its dosage during the administration of the substances together and after it is stopped.

***interaction***
drug1
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Decrease of the concentrations of the telaprevir and of the darunavir or of the fosamprenavir, with risk of therapeutic failure
severity: Not recommended

***interaction***
drug1
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Risk of increase of the plasma concentrations of telaprevir and of the itraconazole
severity: Precaution for use
Clinical monitoring. Avoid large doses of itraconaole (>200 mg per day).

***interaction***
drug1
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of very large decrease of the concentrations of telaprevir
severity: CONTRAINDICATION

***interaction***
drug1
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
drug2
drug name: RIFAMPICIN
rxNorm: 9384
more atc: J04AB02
more atc: J04AM02
more atc: J04AM05
more atc: J04AM06
Very large decrease of the concentrations of telaprevir
severity: CONTRAINDICATION

***interaction***
drug1
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
drug2
drug name: TENOFOVIR ALAFENAMIDE
rxNorm: 1721603
Risk of decrease of the effectiveness of the tenofovir alafenamide due to decrease of its intracellular activity by the telaprevir
severity: Not recommended
503-TELBIVUDINE.html


***interaction***
drug1
drug name: TELBIVUDINE
rxNorm: 474128
atc: J05AF11
drug2
drug name: PEG-INTERFERON ALFA-2A
rxNorm: 120608
atc: L03AB11
Increased risk of peripheral neuropathy
severity: CONTRAINDICATION
504-TELITHROMYCIN.html


***interaction***
drug1
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of its hepatic metabolism by the inducer
severity: Not recommended

***interaction***
drug1
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication
severity: CONTRAINDICATION

***interaction***
drug1
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
drug2
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome
severity: Take into account

***interaction***
drug1
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Increase of the digoxinemia due to increase of its absorption
severity: Precaution for use
Clinical monitoring and possibly monitoring of the dogoxinemia during the treatment with the telithromycin and after it is stopped.

***interaction***
drug1
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism
severity: Not recommended
When these are taken together, strict testing of the renal function, blood concentration dosage of the immunosuppressant and possible adjustment of the dosage.

***interaction***
drug1
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the undesirable effects, especially of the cardiac arrhythmia type
severity: CONTRAINDICATION 
with the patient having severe renal or hepatic insufficiency

***interaction***
drug1
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the St Johns wort
severity: Not recommended

***interaction***
drug1
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
drug2
drug name: MIZOLASTINE
rxNorm: 61455
atc: R06AX25
Increased risk of ventricular arrhythmia, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
drug2
drug name: RIFAMPICIN
rxNorm: 9384
more atc: J04AB02
more atc: J04AM02
more atc: J04AM05
more atc: J04AM06
Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the rifampicin
severity: Not recommended

***interaction***
drug1
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering drug). 
severity: CONTRAINDICATION

***interaction***
drug1
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
drug2
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
Increase of the concentrations of venlafaxine with risk of overdose
severity: Take into account

***interaction***
drug1
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
drug2
class name: VINCA ALKALOIDS
class code: L01CA
Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the telithromycin
severity: Precaution for use
Strict clinical and biological monitoring. Possibly, use another antibiotic.
505-TENOFOVIR-ALAFENAMIDE.html


***interaction***
drug1
drug name: TENOFOVIR ALAFENAMIDE
rxNorm: 1721603
drug2
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
Risk of lower effectiveness of the tenofovir alafenamide due to decrease of its intracellular activity by the boceprevir
severity: Not recommended

***interaction***
drug1
drug name: TENOFOVIR ALAFENAMIDE
rxNorm: 1721603
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption
severity: Precaution for use
In case of co-administration with the ciclosporine, the dose of tenofovir alafenamide must be limited to 10 mg per day.

***interaction***
drug1
drug name: TENOFOVIR ALAFENAMIDE
rxNorm: 1721603
drug2
drug name: COBICISTAT
rxNorm: 1306284
atc: VO3AX03
With the atazanavir, the darunavir or the lopinavir boosted with cobicistat, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption
severity: Precaution for use
In case of co-administration, the dose of tenofovir alafenamide must be limited to 10 mg per day. The administration with the other protease inhibitors of HIV has not been studied. 

***interaction***
drug1
drug name: TENOFOVIR ALAFENAMIDE
rxNorm: 1721603
drug2
class name: ENZYME INDUCERS
class code: N03-J05-001
Decrease of the plasma concentrations of the tenofovir alafenamide due to decrease of its absorption by the inducer
severity: Not recommended
If the administration of these medications together cannot be avoided, clinical monitoring during the administration and 1 to2 weeks after the inducer is stopped.

***interaction***
drug1
drug name: TENOFOVIR ALAFENAMIDE
rxNorm: 1721603
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
With the atazanavir, the darunavir or the lopinavir, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption
severity: Precaution for use
If these are administered together, the dose of tenofovir alafenamide must be limited to 10 mg per day. Administration with the other protease inhibitors of HIV has not been studied.

***interaction***
drug1
drug name: TENOFOVIR ALAFENAMIDE
rxNorm: 1721603
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption
severity: Precaution for use
In case of co-administration with the itraconazole, the dose of tenofovir alafenamide must be limited to 10 mg per day.

***interaction***
drug1
drug name: TENOFOVIR ALAFENAMIDE
rxNorm: 1721603
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption
severity: Precaution for use
In case of co-administration with the ketoconazole, the dose of tenofovir alafenamide must be limited to 10 mg per day.

***interaction***
drug1
drug name: TENOFOVIR ALAFENAMIDE
rxNorm: 1721603
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of tenofovir alafenamide due to decrease of its absorption by the rifampicin
severity: Not recommended
Clinical monitoring during the administration of these medications together and 1 to 2 weeks after the rifampicin is stopped.

***interaction***
drug1
drug name: TENOFOVIR ALAFENAMIDE
rxNorm: 1721603
drug2
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
Risk of reduction of the effectiveness of the tenofovir alafenamide due to decrease of its intracellular activity by the telaprevir
severity: Not recommended

***interaction***
drug1
drug name: TENOFOVIR ALAFENAMIDE
rxNorm: 1721603
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption
severity: Precaution for use
In case of co-administration with the verapamil, the dose of tenofovir alafenamide must be limited to 10 mg per day
506-TENOFOVIR-DISOPROXIL.html


***interaction***
drug1
drug name: TENOFOVIR DISOPROXIL
rxNorm: 300195
atc: J05AF07
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Risk of increase of the nephrotoxicity of the tenofovir, especially with large doses of the anti-inflammatory or in the presence of factors of risk of renal insufficiency. 
severity: Precaution for use
When these are administered together, monitor renal function.

***interaction***
drug1
drug name: TENOFOVIR DISOPROXIL
rxNorm: 300195
atc: J05AF07
drug2
drug name: ATAZANAVIR
rxNorm: 343047
atc: J05AE08
Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same substances together
severity: Take into account
Do not administer the atazanavir with the tenofovir without ritonavir. 

***interaction***
drug1
drug name: TENOFOVIR DISOPROXIL
rxNorm: 300195
atc: J05AF07
drug2
drug name: DIDANOSINE
rxNorm: 3364
atc: J05AF02
Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitochondrial toxicity of the didanosine
severity: Not recommended

***interaction***
drug1
drug name: TENOFOVIR DISOPROXIL
rxNorm: 300195
atc: J05AF07
drug2
drug name: LEDIPASVIR
rxNorm: 1591922
When co-administered with a protease inhibitor, increase of the plasma concentrations of the tenofovir by the ledipasvir
severity: Precaution for use
Clinical and biological monitoring, especially of the renal function.
507-TERBINAFINE.html


***interaction***
drug1
drug name: TERBINAFINE
rxNorm: 37801
more atc: D01AE15
more atc: D01BA02
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Decrease of the blood concentrations of ciclosporin
severity: Precaution for use
Testing of the blood concentrations of ciclosporin and possible adjustment of its dosage during the treatment with terbinafine and after it is stopped. 

***interaction***
drug1
drug name: TERBINAFINE
rxNorm: 37801
more atc: D01AE15
more atc: D01BA02
drug2
drug name: FLECAINIDE
rxNorm: 4441
atc: C01BC04
Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the terbinafine
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the flecaidine during the treatment with the terbinafine. 

***interaction***
drug1
drug name: TERBINAFINE
rxNorm: 37801
more atc: D01AE15
more atc: D01BA02
drug2
drug name: MEQUITAZINE
rxNorm: 29528
atc: R06AD07
Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor
severity: Not recommended

***interaction***
drug1
drug name: TERBINAFINE
rxNorm: 37801
more atc: D01AE15
more atc: D01BA02
drug2
drug name: METOPROLOL
rxNorm: 6918
atc: C07AB02
With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the metoprolol during the treatment with the terbinafine. 

***interaction***
drug1
drug name: TERBINAFINE
rxNorm: 37801
more atc: D01AE15
more atc: D01BA02
drug2
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the terbinafine
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the propafenone during the treatment with the terbinafine. 

***interaction***
drug1
drug name: TERBINAFINE
rxNorm: 37801
more atc: D01AE15
more atc: D01BA02
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin.
severity: Precaution for use
Clinical monitoring. If needed, adjustment of the dosage of the terbinafine during the treatment with the rifampicin.

***interaction***
drug1
drug name: TERBINAFINE
rxNorm: 37801
more atc: D01AE15
more atc: D01BA02
drug2
drug name: TAMOXIFEN
rxNorm: 10324
atc: L02BA01
Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine. 
severity: Nor recommended

***interaction***
drug1
drug name: TERBINAFINE
rxNorm: 37801
more atc: D01AE15
more atc: D01BA02
drug2
drug name: VORTIOXETINE
rxNorm: 1455099
atc: N06AX26
Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the terbinafine and after it is stopped.
508-TERIFLUNOMIDE.html


***interaction***
drug1
drug name: TERIFLUNOMIDE
rxNorm: 1310520
atc: L04AA31
drug2
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
Risk of general vaccine disease, possibly fatal 
severity: Not recommended
509-TETRABENAZINE.html


***interaction***
drug1
drug name: TETRABENAZINE
rxNorm: 10390
atc: N07XX06
drug2
class name: DOPAMINERGICS
class code: N04B-002
Reciprocal antagonism between the dopaminergic and the tetrabenazine
severity: Not recommended

***interaction***
drug1
drug name: TETRABENAZINE
rxNorm: 10390
atc: N07XX06
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Risk of hypertensive crises. Because of the duration of the action of the MAOI, this interaction is still theoretically possible two weeks after the MAOI is stopped
severity: CONTRAINDICATION

***interaction***
drug1
drug name:  TETRABENAZINE
rxNorm: 10390
atc: N07XX06
drug2
drug name: LEVODOPA
rxNorm: 6375
atc: N04BA01
Reciprocal antagonism between the levodopa and the tetrabenazine
severity: Not recommended
50-CLASS-IA-ANTIARRHYTHMICS.html


***interaction***
drug1
class name: CLASS IA ANTIARRHYTHMICS
class code: C01B-002
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic, due to increase of its hepatic metabolism by the inducer


severity: Precaution for use
Clinical monitoring, EKG, and testing of the plasma concentrations; if needed, adjustment of the dosage of the antiarrhythmic during the treatment with the inducer and after it is stopped. 

***interaction***
drug1
class name: CLASS IA ANTIARRHYTHMICS
class code: C01B-002
drug2
drug name: ESMOLOL
rxNorm: 49737
atc: C07AB09
Disorders of contractility, auto- regulation, and conduction (suppression of the compensatory sympathetic mechanisms)
severity: Precaution for use
Clinical monitoring and EKG

***interaction***
drug1
class name: CLASS IA ANTIARRHYTHMICS
class code: C01B-002
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic (increase of its hepatic metabolism). 


severity: Precaution for use
Clinical monitoring, EKG, and possibly monitoring of the plasma concentrations of the antiarrhythmic. If needed, adjustment of the dosage of the antiarrhythmic during the treatment with the rifampicin and after it is stopped (risk of overdose of the antiarrhythmic)
510-THALIDOMIDE.html


***interaction***
drug1
drug name: THALIDOMIDE
rxNorm: 10432
atc: L04AX02
drug2
drug name: DIDANOSINE
rxNorm: 3364
atc: J05AF02
Increased risk of onset of peripheral neuropathy due to addition of undesirable effects
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. 

***interaction***
drug1
drug name: THALIDOMIDE
rxNorm: 10432
atc: L04AX02
drug2
drug name: STAVUDINE
rxNorm: 59763
atc: J05AF04
Increased risk of onset of peripheral neuropathy due to addition of undesirable effects
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.

***interaction***
drug1
drug name: THALIDOMIDE
rxNorm: 10432
atc: L04AX02
drug2
drug name: ZALCITABINE
rxNorm: 3363
atc: J05AF03
Increased risk of onset of peripheral neuropathy due to addition of undesirable effects
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.
511-THEOPHYLLINE.html


***interaction***
drug1
drug name: THEOPHYLLINE 
rxNorm: 10438
atc: R03DA04
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Decrease of the the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness 
severity: Precaution for use
Strict monitoring of the the plasma concentrations of lithium and possible adjustment of the dosage of the lithium.

***interaction***
drug1
drug name: THEOPHYLLINE 
rxNorm: 10438
atc: R03DA04
drug2
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia.

***interaction***
drug1
drug name: THEOPHYLLINE 
rxNorm: 10438
atc: R03DA04
drug2
drug name: VEMURAFENIB
rxNorm: 1147220
atc: L01XE1
Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects.
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the theophylline during the treatment with vemurafenib and after it is stopped. 
512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html


***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Decrease of the plasma concentrations and of the effectiveness of the theophylline due to increase of its hepatic metabolism by the inducer
severity:  Precaution for use
Clinical monitoring and, if needed, monitoring of the theophyllinemia. Possible adjustment of the dosage of the theophylline during the treatment with the inducer and after it is stopped. 

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia. If there is reason for it, adjustment of the theophylline during the treatment with the cimetidine and after it is stopped. 

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: CIPROFLOXACIN
rxNorm: 2551
more atc: J01MA02
more atc: S01AE03
more atc: S02AA15
more atc: S03AA07
Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin.
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia.

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Risk of increase of the theophyllinemia, particularly with children
severity: Take into account

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: DIPYRIDAMOLE
rxNorm: 3521
atc: B01AC07
With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the theophylline
severity: Precaution for use
Interrupt a treatment with theophylline at least 5 days before myocardial perfusion imaging with the dipyridamole.

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: ENOXACIN
rxNorm: 3925
atc: J01MA04
Overdose of theophylline due to substantial decrease of its metabolism
severity: CONTRAINDICATION

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous with children
severity: Not recommended

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
Increase of the theophyllinemia with risk of overdose (decrease of the clearance of the theophylline)
severity: Precaution for use
Clinical monitoring and, possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the fluconazole and after it is stopped. 

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: FLUVOXAMINE
rxNorm: 42355
atc: N06AB08
Increase of the theophyllinemia with signs of overdose (decrease of the hepatic metabolism of the theophylline)
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia; if needed, adjustment of the dosage of the theophylline during the treatment with the fluvoxamine and after it is stopped. 

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: HALOTHANE
rxNorm: 5095
atc: N01AB01
Serious ventricular arrhythmias due to increase of cardiac sensitization
severity: Not recommended

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
class name: XANTHINE OXYDASE INHIBITORS
class code: M04AA0
In case of large doses of the inhibitor, increase of the plasma concentrations of theophylline due to inhibition of its metabolism
severity: Precaution for use
Clinical monitoring and testing of the theophyllinemia up to two or three weeks after the beginning of the treatment with the inhibitor; if there is reason for it, adjustment of the dosage during the treatment with these substances together. 

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Decrease of the plasma concentrations of the theophylline, due to increase of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the protease inhibitor and after it is stopped. 

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: JOSAMYCIN
rxNorm: 6084
atc: J01FA07
Risk of increase of the theophyllinemia, particularly with children
severity: Take into account

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: MEXILETINE
rxNorm: 6926
atc: C01BB02
Increase of the theophyllinemia with risk of overdose (decrease of the hepatic metabolism of the theophylline)
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the mexiletine and after it is stopped. 

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Decrease of the plasma concentrations of the theophylline, by reason of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (onset of an obstructive pulmonary syndrome)
severity: CONTRAINDICATION 
In case of accidental use of the substances together, do not stop the St Johns wort abruptly but test the plasma concentrations (or the effectiveness) of the substance taken with it before and then after stopping the St Johns wort.

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: NORFLOXACIN
rxNorm: 7517
more atc: J01MA06
more atc: S01AE02
Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)
severity: Precaution for use
Clinical monitoring, and possibly monitoring of the theophyllinemia. 

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: PEFLOXACIN
rxNorm: 7960
atc: J01MA03
Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)
severity: Precaution for use
Clinical monitoring and, possibly monitoring of the theophyllinemia.

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: PENTOXIFYLLINE
rxNorm: 8013
atc: C04AD03
Increase of the theophyllinemia with risk of overdose (competition at the level of the hepatic metabolism of the theophylline) 
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the pentoxifylline and after it is stopped. 

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction) 
severity: Precaution for use
Clinical monitoring, and, if needed, monitoring of the theophyllinemia. Adjust, if there is reason to, the dosage of the theophylline during the treatment with the rifampicin and after it is stopped. 

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: ROXITHROMYCIN
rxNorm: 9478
atc: J01FA06
Risk of increase of the theophyllinemia, particularly with children.
severity: Take into account

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
Possible increase of the theophyllinemia, with risk of overdose, due to inhibition of its hepatic metabolism
severity: Precaution for use
Clinical monitoring, plasma dosage, and possible adjustment of the dosage of theophylline. 

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: TIABENDAZOLE
rxNorm: 10450
more atc: D01AC06
more atc: P02CA02
Increase of the theophyllinemia with risk of overdose, due to decrease of the hepatic metabolism of the theophylline
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment (and after it is stopped, in the case where the anthelmintic is prescribed for a period exceeding 48 hours).

***interaction***
drug1
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
drug2
drug name: TICLOPIDINE
rxNorm: 10594
atc: B01AC05
Increase of the theophyllinemia with risk of overdose (decrease of the plasma clearance of the theophylline)
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the ticlopidine and after it is stopped. 
513-THROMBOLYTICS.html


***interaction***
drug1
class name: THROMBOLYTICS
class code: B01AD
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
Increase of the risk of hemorrhage
severity: Take into account

***interaction***
drug1
class name: THROMBOLYTICS
class code: B01AD
drug2
class name: PLATELET AGGREGATION INHIBITORS
class code: B01AC-001
Increase of the risk of hemorrhage
severity: Take into account

***interaction***
drug1
class name: THROMBOLYTICS
class code: B01AD
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the risk of hemorrhage
severity: Take into account

***interaction***
drug1
class name: THROMBOLYTICS
class code: B01AD
drug2
drug name: DEFIBROTIDE
rxNorm: 1311089
atc: B01AX01
Accrued risk of hemorrhage
severity: CONTRAINDICATION

***interaction***
drug1
class name: THROMBOLYTICS
class code: B01AD
drug2
class name: LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)
class code: B01AB-001
Increase of the risk of hemorrhage
severity: Take into account

***interaction***
drug1
class name: THROMBOLYTICS
class code: B01AD
drug2
class name: UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)
class code: B01AB-003
Increase of the risk of hemorrhage
severity: Take into account
514-TIABENDAZOLE.html


***interaction***
drug1
drug name: TIABENDAZOLE
rxNorm: 10450
more atc: D01AC06
more atc: P02CA02
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Increase of the theophyllinemia with risk of overdose, due to decrease of the hepatic metabolism of the theophylline
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment (and after it is stopped, in the case where the anthelmintic is prescribed for a period exceeding 48 hours).
515-TIAGABINE.html


***interaction***
drug1
drug name: TIAGABINE
rxNorm: 31914
atc: N03AG06
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism by the inducer
severity: Precaution for use
An increase of the dosage of the tiagabine can prove necessary in cases when it is administered with an anticonvulsant enzyme inducer.

***interaction***
drug1
drug name: TIAGABINE
rxNorm: 31914
atc: N03AG06
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism
severity: Precaution for use
An increase of the dosage of the tiagabine can prove necessary in cases when it is administered with the rifampicin.
516-TIANEPTINE.html


***interaction***
drug1
drug name: TIANEPTINE
rxNorm: 38252
atc: N06AX14
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Risk of drop in blood pressure, paroxystic hypertension, hyperthermia, convulsions, death
severity: Not recommended
517-TIBOLONE.html


***interaction***
drug1
drug name: TIBOLONE
rxNorm: 38260
atc: G03CX01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tibolone and after it is stopped. 
518-TICAGRELOR.html


***interaction***
drug1
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
Increase of the risk of hemorrhage due to addition of the platelet aggregation activities
severity: Not recommended
--except for validated indications for this combination in acute coronary syndromes.

***interaction***
drug1
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the anticonvulsant enzyme inducer, with risk of decrease of the therapeutic effect
severity: Not recommended

***interaction***
drug1
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
drug2
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding
severity: Take into account

***interaction***
drug1
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism
severity: Take into account

***interaction***
drug1
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism by the inhibitor
severity: CONTRAINDICATION

***interaction***
drug1
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the St Johns wort, with decrease of its therapeutic effect.
severity: CONTRAINDICATION

***interaction***
drug1
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
drug2
class name: OMBITASVIR + PARITAPRVIR
class code: OMPA
Increase of the plasma concentrations of the ticagrelor due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir
severity: CONTRAINDICATION

***interaction***
drug1
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
drug2
Drug with no codes: GRAPEFRUIT (JUICE AND FRUIT)
Doubling of the plasma concentrations of the antiagregant, with risk of increase of its undesirable effects, especially hemorrhagic ones
severity: Not recommended

***interaction***
drug1
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect.
severity: Not recommended

***interaction***
drug1
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism
severity: Take into account
519-TICLOPIDINE.html


***interaction***
drug1
drug name: TICLOPIDINE
rxNorm: 10594
atc: B01AC05
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
Increase of the risk of hemorrhage due to addition of the platelet antiagregation action
severity: Not recommended
If the administration of the substances together cannot be avoided, strict clinical monitoring.

***interaction***
drug1
drug name: TICLOPIDINE
rxNorm: 10594
atc: B01AC05
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Decrease of the blood concentrations of ciclosporin
severity: Precaution for use
Increase of the dosage of the ciclosporin according to testing of the blood concentrations. Reduction of the dosage if the ticlopidine is stopped. 

***interaction***
drug1
drug name: TICLOPIDINE
rxNorm: 10594
atc: B01AC05
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)
severity: Precaution for use
Clinical monitoring and testing of the plasma concentrations of phenytoin.

***interaction***
drug1
drug name: TICLOPIDINE
rxNorm: 10594
atc: B01AC05
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Increase of the theophyllinemia with risk of overdose (decrease of the plasma clearance of the theophylline). 
severity: Precaution for use
Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the ticlopidine and after it is stopped. 
51-ACETYLCHOLINESTERASE-INHIBITORS.html


***interaction***
drug1
class name: ACETYL-CHOLINESTERASE INHIBITORS
class code: ACETCHO
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
Risk of excessive bradycardia (addition of the bradycardia inducing effects)


severity: Precaution for use
Regular clinical monitoring, especially at the beginning of the administration of the substances together 

***interaction***
drug1
class name: ACETYL-CHOLINESTERASE INHIBITORS
class code: ACETCHO
drug2
drug name: PILOCARPINE
rxNorm: 8328
more atc: N07AX01
more atc: S01EB01
more atc: S01EB51
Risk of addition of the undesirable cholinergic effects, especially digestive ones
severity: Take into account

***interaction***
drug1
class name: ACETYL-CHOLINESTERASE INHIBITORS
class code: ACETCHO
drug2
drug name: SUXAMETHONIUM
rxNorm: 10154
atc: M03AB01
Risk of lengthening of the motor block, increased in the case of partial deficit of pseudocholinesterase
severity: Take into account
520-GASTROINTESTINAL-TARGETED-MEDICATIONS,-ANTACIDS,-AND-ABSORBANTS.html


***interaction***
drug1
class name: GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS
class code: A07BC-A02AD
drug2
Drug with no codes: MEDICATIONS ADMINISTERED BY ORAL ROUTE
Decrease of the absorption of certain other medications ingested simultaneously
severity: Precaution for use
As a precaution, it is preferable to take these gastrointestinal targeted medications, antacids, and absorbent medications at a different time from any other medication (more than 2 hours apart, if possible).

***interaction***
drug1
class name: GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS
class code: A07BC-A02AD
drug2
class name: SUBSTANCES WITH ABSORPTION REDUCED BY GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS 
class code: RBGI
Decrease of the absorption of these substances
severity: Precaution for use
Take the medications, antacids, or absorbants at a different time from these substances (more than 2 hours apart, if possible).
521-TOPIRAMATE.html


***interaction***
drug1
drug name: TOPIRAMATE
rxNorm: 38404
atc: N03AX11
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the carbamazepine
severity: Precaution for use
Clinical monitoring, and if needed, adjustment of the dosage of the toprimate during the treatment with the carbamazepine and after it is stopped.

***interaction***
drug1
drug name: TOPIRAMATE
rxNorm: 38404
atc: N03AX11
drug2
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
For doses of topiramate >= 200 mg/day: Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of estrogen
severity: Not recommended
Another method of contraception, in particular a barrier type, should be used. 

***interaction***
drug1
drug name: TOPIRAMATE
rxNorm: 38404
atc: N03AX11
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
For doses of topiramate >=200mg/day: increase of the the plasma concentrations of lithium that can reach toxic levels, with signs of overdose of lithium
severity: Precaution for use
Clinical and biological monitoring. Adjustment of the dosage of lithium. 

***interaction***
drug1
drug name: TOPIRAMATE
rxNorm: 38404
atc: N03AX11
drug2
drug name: OXCARBAZEPINE
rxNorm: 32624
atc: N03AF02
Risk of decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine
severity: Precaution for use
Clinical monitoring, and if needed, adjustment of the dosage of the topiramate during the treatment with the oxcarbazepine and after it is stopped. 

***interaction***
drug1
drug name: TOPIRAMATE
rxNorm: 38404
atc: N03AX11
drug2
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
Increase of the hyperammonemia, with increased risk of encephalopathy 
severity: Precaution for use
Regular clinical and biological monitoring. 
522-TORSADES-DE-POINTES-INDUCING-MEDICATIONS-(EXCEPT-ANTIPARASITICS,-NEUROLEPTICS,-METHADONE).html


***interaction***
drug1
class name: TORSADES DE POINTES INDUCING MEDICATIONS (EXCEPT ANTIPARASITICS, NEUROLEPTICS, METHADONE)
class code: C01B
drug2
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Contraindication
--for erythromycin and vincamine, only the forms administered by IV route are affected by this interaction. 
523-TRABECTEDINE.html


***interaction***
drug1
drug name: TRABECTEDINE
rxNorm: 397736
atc: L01CX0
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Risk of increase of the plasma concentrations of the trabectedine by the itraconazole
severity: Not recommended
If administering these medications together is necessary, clinical monitoring and possible adjustment of the dosage of the trabectedine during the length of the treatment with the itraconazole
524-NICOTINE-SUBSTITUTION-TREATMENT.html


***interaction***
drug1
class name: NICOTINE SUBSTITUION TREATMENT
class code: N07BA
drug2
class name: MEDICATIONS AT RISK WHEN WITHDRAWING FROM TOBACCO
class code: N0-R0-002
Risk of overdose when replacing tobacco by the substitution treatment
severity: Take into account
525-TRAMADOL.html


***interaction***
drug1
drug name: TRAMADOL
rxNorm: 10689
atc: N02AX02
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tramadol and after it is stopped. 

***interaction***
drug1
drug name: TRAMADOL
rxNorm: 10689
atc: N02AX02
drug2
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
Increase of the plasma concentrations of the tramadol due to decrease of its hepatic metabolism by the bupropion. In addition, risk of convulsions due to addition of the effects of the two medications
severity: Take into account

***interaction***
drug1
drug name: TRAMADOL
rxNorm: 10689
atc: N02AX02
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma
severity: CONTRAINDICATION

***interaction***
drug1
drug name: TRAMADOL
rxNorm: 10689
atc: N02AX02
drug2
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma
severity: Not recommended

***interaction***
drug1
drug name: TRAMADOL
rxNorm: 10689
atc: N02AX02
drug2
class name: MAOI-B 
class code: N04BD0-001
Risk of appearance of a serotonin syndrome
severity: Take into account

***interaction***
drug1
drug name: TRAMADOL
rxNorm: 10689
atc: N02AX02
drug2
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
class code: N06AB
Risk of appearance of convulsions and/or a serotonin syndrome
severity: Take into account

***interaction***
drug1
drug name: TRAMADOL
rxNorm: 10689
atc: N02AX02
drug2
drug name: ONDANSETRON
rxNorm: 26225
atc: A04AA01
Decrease of the intensity and of the duration of the analgesic effect of the tramadol and risk of decrease of the antiemitic effect of the ondansetron
severity: Take into account

***interaction***
drug1
drug name: TRAMADOL
rxNorm: 10689
atc: N02AX02
drug2
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
Risk of appearance of convulsions and/or of a serotonin syndrome
severity: Take into account
526-TRASTUZUMAB-EMTANSINE.html


***interaction***
drug1
drug name: TRASTUZUMAB EMTANSINE
rxNorm: 
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of the DM1, a component of the trastuzumab emtansine, due to inhibition of its metabolism by the inhibitor
severity: Not recommended
527-TRICLABENDAZOLE.html


***interaction***
drug1
drug name: TRICLABENDAZOLE
rxNorm: 38608
atc: P02BX04
drug2
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)
severity: CONTRAINDICATION
Wait 24 hours between stopping the triclabendazole and the dose of the medication derived from ergot of rye, and the reverse.

***interaction***
drug1
drug name: TRICLABENDAZOLE
rxNorm: 38608
atc: P02BX04
drug2
drug name: ERGOTAMINE
rxNorm: 4025
atc: N02CA02
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)
severity: CONTRAINDICATION
Wait 24 hours between stopping the thiclabendazole and the ergotamine, and the reverse.

***interaction***
drug1
drug name: TRICLABENDAZOLE
rxNorm: 38608
atc: P02BX04
drug2
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)
severity: CONTRAINDICATION
Wait 24 hours between stopping the triclabendazole and the dose of the torsade inducing medication, and the reverse. 

***interaction***
drug1
drug name: TRICLABENDAZOLE
rxNorm: 38608
atc: P02BX04
drug2
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)
severity: CONTRAINDICATION
Wait 24 hours between stopping the triclabendazole and the dose of the torsade inducing medication, and the reverse.
528-TRIMETHOPRIM.html


***interaction***
drug1
drug name: TRIMETHOPRIM
rxNorm: 10829
atc: J01EA01
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporin

With trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity
severity: Take into account

***interaction***
drug1
drug name: TRIMETHOPRIM
rxNorm: 10829
atc: J01EA01
drug2
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).
severity: CONTRAINDICATION

***interaction***
drug1
drug name: TRIMETHOPRIM
rxNorm: 10829
atc: J01EA01
drug2
drug name: PYRIMETHAMINE
rxNorm: 9010
more atc: P01BD01
more atc: P01BF04
Megaloblastic anemia, more particularly with strong doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines)
severity: Precaution for use
Regular CBC and addition of a treatment with folic acid (regular IM injections). 

***interaction***
drug1
drug name: TRIMETHOPRIM
rxNorm: 10829
atc: J01EA01
drug2
drug name: REPAGLINIDE
rxNorm: 73044
atc: A10BX02
Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim
severity: Not recommended
If administering these medications together cannot be avoided, strict clinical and biological monitoring. 
529-TRIPTANS.html


***interaction***
drug1
class name: TRIPTANS
class code: N02CC-001
drug2
class name: VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE
class code: N02CA0-001
Risk of arterial hypertension, of constriction of coronary arteries


severity: CONTRAINDICATION
Wait 6 to 24 hours, depending on the triptan, between taking it and the ergot alkaloid.

***interaction***
drug1
class name: TRIPTANS
class code: N02CC-001
drug2
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
class code: N06AB
Risk of appearance of a serotonin syndrome
severity: Take into account
52-ORAL-ANTICOAGULANTS.html


***interaction***
drug1
class name: ORAL ANTICOAGULANTS
class code: B01A-001
drug2
class name: OTHER ORAL ANTICOAGULANTS
class code: B01A-001
Risk of increase of hemorrhagic events when one oral anticoagulant is replaced with another.
severity: Take into account
Take into account the half-life of the oral anticoagulant and observe, if the situation requires, a delay for clearance before the start of treatment with another. Be sure to inform the patient. 

***interaction***
drug1
class name: ORAL ANTICOAGULANTS
class code: B01A-001
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
Increase of the risk of hemorrhage, especially in cases with a previous gastroduodenal ulcer


severity: Contraindication with:
- anti--inflammatory does of acetylsalicylic acid (>=1g per dose and/or >=3g per day)

***interaction***
drug1
class name: ORAL ANTICOAGULANTS
class code: B01A-001
drug2
class name: PLATELET AGGREGATION INHIBITORS
class code: B01AC-001
Increase of the risk of hemorrhage


severity: Take into account

***interaction***
drug1
class name: ORAL ANTICOAGULANTS
class code: B01A-001
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Increase of the oral anticoagulant's risk of hemorrhage (irritation of the gastroduodenal mucosa by the non-steroidal anti-inflammatories)


severity: Not recommended
If administering these medications together cannot be avoided, strict clinical monitoring, possibly biological monitoring. 

***interaction***
drug1
class name: ORAL ANTICOAGULANTS
class code: B01A-001
drug2
drug name: DEFIBROTIDE
rxNorm: 1311089
atc: B01AX01
Increased risk of hemorrhage
severity: Not recommended

***interaction***
drug1
class name: ORAL ANTICOAGULANTS
class code: B01A-001
drug2
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
Glucocorticoids (general and rectal routes): possible impact of the corticotherapy on the metabolism of the vitamin K antagonist and on that of the factors of coagulation. Risk of hemorrhage specific to the corticotherapy (digestive mucosa, vascular fragility) with large doses or in treatment prolonged beyond 10 days. 
severity: Precaution for use
When administering substances from these groups together is justified, strengthen monitoring: if the situation requires, with the vitamin K antagonists, biological monitoring on the 8th day, then every two weeks after that during the corticotherapy and after it is stopped. 

***interaction***
drug1
class name: ORAL ANTICOAGULANTS
class code: B01A-001
drug2
class name: LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)
class code: B01AB-001
Increase of the risk of hemorrhage


severity: Precaution for use
If administering these together cannot be avoided, reinforce clinical monitoring and, if the situation requires, biological monitoring. 

***interaction***
drug1
class name: ORAL ANTICOAGULANTS
class code: B01A-001
drug2
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
class code: N06AB
Increase of the risk of hemorrhage


severity: Precaution for use
Clinical monitoring and, if the situation requires, more frequent testing of the INR. Possible adjustment of the dosage of the oral anticoagulant during the administration with the SSRI and when it is stopped. 

***interaction***
drug1
class name: ORAL ANTICOAGULANTS
class code: B01A-001
drug2
drug name: IPILIMUMAB 
rxNorm: 1094833
atc: L01XC11
Increase of the risk of digestive system hemorrhage
severity: Precaution for use
Strict clinical monitoring.

***interaction***
drug1
class name: ORAL ANTICOAGULANTS
class code: B01A-001
drug2
class name: MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS
class code: N06A
Increase of the risk of hermorrhage.
severity: Precaution for use 
Clinical monitoring and, if the situation requires, more frequent testing of the INR. Possible adjustment of the dosage of the oral anticoagulant during the administration of these medications together and when it is stopped.
530-TRIPTANS-METABOLIZED-BY-THE-MAO.html


***interaction***
drug1
class name: TRIPTANS METABOLIZED BY THE MAO
class code: N02CC-002
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Risk of arterial hypertension, of constriction of the coronary arteries 
severity: CONTRAINDICATION

***interaction***
drug1
class name: TRIPTANS METABOLIZED BY THE MAO
class code: N02CC-002
drug2
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
Risk of arterial hypertension, of constriction of the coronary arteries 
severity: CONTRAINDICATION

***interaction***
drug1
class name: TRIPTANS METABOLIZED BY THE MAO
class code: N02CC-002
drug2
class name: MAOI-B 
class code: N04BD0-001
Risk of arterial hypertension, of constriction of the coronary arteries
severity: CONTRAINDICATION
531-TRIPTANS-NOT-METABOLIZED-BY-THE-MAO.html


***interaction***
drug1
class name: TRIPTANS NOT METABOLIZED BY THE MAO
class code: NO2CC-003
drug2
class name: IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)
class code: N06AF0
Risk of arterial hypertension, of constriction of the coronary arteries
severity: Not recommended

***interaction***
drug1
class name: TRIPTANS NOT METABOLIZED BY THE MAO
class code: NO2CC-003
drug2
class name: REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE
class code: NO6AG-001
Risk of arterial hypertension, of constriction of the coronary arteries
severity: Not recommended

***interaction***
drug1
class name: TRIPTANS NOT METABOLIZED BY THE MAO
class code: NO2CC-003
drug2
class name: MAOI-B 
class code: N04BD0-001
Risk of arterial hypertension, of constriction of the coronary arteries
severity: Not recommended
532-ULIPRISTAL.html


***interaction***
drug1
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer
severity: Not recommended
Choose a therapeutic alternative that is little or not at all metabolized. 

***interaction***
drug1
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
drug2
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
Risk of decrease of the effect of the ulipristal, due to decrease of its absorption
severity: Take into account

***interaction***
drug1
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
drug2
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
Risk of decrease of the effect of the ulipristal, due to decrease of its absorption
severity: Take into account

***interaction***
drug1
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
drug2
drug name: CYPROTERONE
rxNorm: 3014
more atc: G03HA01
more atc: G03HB01
Risk of antagonism of the effects of the progestin
severity: Not recommended
Do not take a progestin treatment fewer than 12 hours after stopping the ulipristal.

***interaction***
drug1
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
drug2
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
Risk of antagonism of the effects of the estrogen-progestin contraceptive
severity: Not recommended
Use an additional contraceptive method of the barrier type for several days after the ulipristal is stopped

***interaction***
drug1
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the ritonavir
severity: Not recommended
Choose a therapeutic alternative that is little or not at all metabolised. 

***interaction***
drug1
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer
severity: Not recommended
Choose a therapeutic alternative that is little or not at all metabolized. 

***interaction***
drug1
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
drug2
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
Risk of antagonism of the effects of the progestin contraceptive
severity: Not recommended
Use an additional contraceptive method of the barrier type for several days after the ulipristal is stopped

***interaction***
drug1
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
drug2
class name: NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT
class code: G03-003
Risk of antagonism of the effects of the progestin contraceptive
severity: Not recommended
Use an additional contraceptive method of the barrier type for several days after the ulipristal is stopped 

***interaction***
drug1
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer
severity: Not recommended
Chose a therapeutic alternative that is little or not at all metabolized.
533-ATTENUATED-LIVE-VIRUS-VACCINES.html


***interaction***
drug1
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
drug2
drug name: ABATACEPT 
rxNorm: 614391
atc: L04AA24
Risk of general vaccine disease, possibly fatal
severity: Not recommended
as well as during the 3 months following the end of the treatment

***interaction***
drug1
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
drug2
class name: MONOCLONAL ANTIBODIES (EXCEPT ANTI-TNF ALPHA)
class code: MONANT
Risk of general vaccine disease, possibly fatal. 
severity: Not recommended with
-- belimumab, blinatumomab, canakinumab, obinutuzumab,ofatumumab, rituximab, tocilizumab, ustekinumab

***interaction***
drug1
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
drug2
class name: ANTI-TNF ALPHA
class code: LO4AB
Risk of possibly fatal general vaccine disease 
severity: CONTRAINDICATION
And during the 3 months following the end of the treatment

***interaction***
drug1
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
drug2
drug name: BELATACEPT
rxNorm: 1112973
atc: L04AA28
Risk of general vaccine disease, possibly fatal
severity: Not recommended

***interaction***
drug1
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
drug2
class name: CYTOTOXICS
class code: L01
Risk of possibly fatal general vaccine disease
severity: CONTRAINDICATION
--And during the 6 months following the end of the chemotherapy

***interaction***
drug1
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
drug2
drug name: DIMETHYL (FUMERATE OF)
rxNorm: 1373478
atc: N07XX09
Possible increase of the risk of infection
severity: Take into account

***interaction***
drug1
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
drug2
class name: ANTI-LYMPHOCYTE GLOBULINS
class code: L04AA0-001
Risk of possibly fatal general vaccine disease. This risk is increased in older patients already immunodepressed by the underlying disease.
severity: Take into account
In particular, use an inactive vaccine when one exists (poliomyelitis).

***interaction***
drug1
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
drug2
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
With the exception of inhaled and local routes and for dosages greater than 10mg/day of prednisone equivalent (or >2mg/kg/day with children or >20 mg/day for children weighing more than 10 kg) for more than two weeks and for administration in "bolus" of the corticoids:

risk of possibly fatal general vaccine disease.
severity: CONTRAINDICATION
And during the 3 months following the end of the corticotherapy

***interaction***
drug1
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
drug2
drug name: HYDROXYCARBAMIDE 
rxNorm: 5552
atc: L01XX05
In its indication for the patient with drepanocytosis, theoretic risk of general fatal vaccine disease.
severity: Not recommended
Administering these medications together should only be considered if the benefits are estimated to be superior to this risk.

***interaction***
drug1
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Risk of possibly fatal general vaccine disease.
severity: CONTRAINDICATION
And during the 3 months following the treatment

***interaction***
drug1
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
drug2
Drug with no codes: MYCOPHENOLATE MOFETIL
more atc: MYCOPHEN
more atc: OLIC
more atc: ACID
more atc: MYCOPHEN
more atc: OLATE
more atc: MOFETIL
more atc: MYCOPHEN
more atc: OLIC
more atc: ACID
more atc: MYCOPHEN
more atc: OLIC
more atc: ACID
more atc: 7145
more atc: L04AA06
Risk of possibly fatal general vaccine disease.
severity: CONTRAINDICATION
And during the 3 months following the end of the treatment.

***interaction***
drug1
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
drug2
drug name: MYCOPHENOLATE SODIUM 
rxNorm: 408142
Risk of possibly fatal general vaccine disease 
severity: CONTRAINDICATION
And during the 3 months after the end of the treatment.

***interaction***
drug1
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
drug2
drug name: TERIFLUNOMIDE
rxNorm: 1310520
atc: L04AA31
Risk of general vaccine disease, possibly fatal
severity: Not recommended
534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html


***interaction***
drug1
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
drug2
drug name: ACETAZOLAMIDE
rxNorm: 167
atc: S01EC01
Increase of the hyperammonemia, with accrued risk of encephalopathy
severity: Precaution for use
Regular clinical and biological monitoring.

***interaction***
drug1
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
drug2
drug name: AZTREONAM
rxNorm: 1272
atc: J01DF01
Risk of onset of convulsive crises, due to decrease of the plasma concentrations of the valproic acid
severity: Precaution for use
Clinical monitoring, plasma dosages, and possible adjustment of the dosage of the anticonvulsant during the treatment with the antibiotic and after it is stopped.

***interaction***
drug1
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
drug2
drug name: CARBAMAZEPINE
rxNorm: 2002
atc: N03AF01
Increase of the plasma concentrations of the active metabolite of the carbamazepine with signs of overdose. In addition, decrease of the plasma concentrations of valproic acid due to increase of its hepatic metabolism by the carbamazepine
severity: Precaution for use
Clinical monitoring, plasma dosages and adjustment of the dosage of the two anticonvulsants.

***interaction***
drug1
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
drug2
drug name: FELBAMATE
rxNorm: 24812
atc: N03AX10
Increase of the plasma concentrations of the valproic acid, with risk of overdose. 
severity: Precaution for use
Clinical and biological monitoring, and possible adjustment of the dosage of the valproic acid or of the valpromide during the treatment with the felbamate and after it is stopped. 

***interaction***
drug1
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
drug2
drug name: LAMOTRIGINE
rxNorm: 28439
atc: N03AX09
Increased risk of serious cutaneous reactions (Lyell's syndorme). In addition, increase of the plasma concentrations of lamotrigine (decrease of its hepatic metabolism by the sodium valproate)
severity: Not recommended
If this combination of medications is judged necessary, strict clinical monitoring.

***interaction***
drug1
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
drug2
drug name: NIMODIPINE
rxNorm: 7426
atc: C08CA06
With the nimodipine by oral route, and by extrapolation, by injection: risk of increase of the hypotensive effect of the nimodipine due to increase of its plasma concentrations (decrease of its metabolism by the valproic acid)
severity: Take into account

***interaction***
drug1
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
drug2
class name: PENEMS
class code: J01DH
Risk of onset of convulsive crises, due to rapid decrease of the plasma concentrations of the valproic acid, that can become undetectable
severity: Not recommended

***interaction***
drug1
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
drug2
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
Increase of the hyperammonemia, with accrued risk of encephalopathy
severity: Precaution for use
Regular clinical and biological monitoring

***interaction***
drug1
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
drug2
class name: PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)
class code: N03AB
Increase of the hyperammonemia, with accrued risk of encephalopathy
severity: Precaution for use
Regular clinical and biological monitoring

***interaction***
drug1
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin
severity: Precaution for use
Clinical and biological monitoring and possible adjustment of the dosage of the anticonvulsant during the treatment with the rifampicin and after it is stopped.

***interaction***
drug1
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
drug2
drug name: RUFINAMIDE
rxNorm: 69036
atc: N03AF03
Possible increase of the concentrations of rufinamide, especially with children who weigh less than 30 kg
severity: Precaution for use
With children weighing less than 30kg: do not exceed the total dose of 600 mg/day after the period of titration.

***interaction***
drug1
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
drug2
drug name: TOPIRAMATE
rxNorm: 38404
atc: 38404
Increase of the hyperammonemia with accrued risk of encephalopathy
severity: Precaution for use
Regular clinical and biological monitoring.

***interaction***
drug1
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
drug2
drug name: ZIDOVUDINE (AZT)
rxNorm: 11413
more atc: J05AF01
more atc: J05AR01
more atc: J05AR04
more atc: J05AR05
Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid.
severity: Precaution for use
Regular clinical and biological monitoring. A CBC checking for anemia should be done during the course of the first two months of the administration of these substances together.

***interaction***
drug1
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
drug2
drug name: ZONISAMIDE 
rxNorm: 
more atc: N03AX15
Increase of the hyperammonemia, with accrued risk of encephalopathy
severity: Precaution for use
Regular clinical and biological monitoring 
535-VARDENAFIL.html


***interaction***
drug1
drug name: VARDENAFIL
rxNorm: 306674
atc: G04BE0
drug2
Drug with no codes: GRAPEFRUIT (JUICE AND FRUIT)
Increase of the plasma concentrations of the vardenafil, with risk of hypotension.
severity: Not recommended
536-VEMURAFENIB.html


***interaction***
drug1
drug name: VEMURAFENIB
rxNorm: 1147220
atc: L01XE15
drug2
drug name: BUPROPION
rxNorm: 42347
more atc: N06AX12
Risk of decrease of the concentrations of the bupropion, with increase of its active metabolite and increased toxicity
severity: Take into account

***interaction***
drug1
drug name: VEMURAFENIB
rxNorm: 1147220
atc: L01XE15
drug2
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
Risk of decrease of the concentrations of the combined estrogen-progestin contraceptive with the consequence of a risk of ineffectiveness
severity: Not recommended

***interaction***
drug1
drug name: VEMURAFENIB
rxNorm: 1147220
atc: L01XE15
drug2
drug name: IFOSFAMIDE
rxNorm: 5657
atc: L01AA06
Risk of decrease of the concentrations of the ifosfamide, with increase of its active metabolite and increased toxicity
severity: Take into account

***interaction***
drug1
drug name: VEMURAFENIB
rxNorm: 1147220
atc: L01XE15
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Risk of decrease of the concentrations of the immunosuppressants, with the consequence of a risk of ineffectiveness
severity: Not recommended

***interaction***
drug1
drug name: VEMURAFENIB
rxNorm: 1147220
atc: L01XE15
drug2
class name: ENZYME INDUCERS
class code: N03-J05-001
Risk of decrease of the concentrations of the vemurafenib, with lower effectiveness
severity: Not recommended

***interaction***
drug1
drug name: VEMURAFENIB
rxNorm: 1147220
atc: L01XE15
drug2
drug name: THEOPHYLLINE 
rxNorm: 10438
atc: R03DA04
Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the theophylline during the treatment with vemurafenib and after it is stopped. 
537-VENLAFAXINE.html


***interaction***
drug1
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Increase of the concentrations of venlafaxine with risk of overdose
severity: Take into account

***interaction***
drug1
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
Increase of the concentrations of venlafaxine with risk of overdose
severity: Take into account

***interaction***
drug1
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Increase of the concentrations of venlafaxine with risk of overdose. 
severity: Take into account

***interaction***
drug1
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increase of the concentrations of venlafaxine with risk of overdose
severity: Take into account

***interaction***
drug1
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Increase of the concentrations of venlafaxine with risk of overdose
severity: Take into account

***interaction***
drug1
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
drug2
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
Increase of the concentrations of venlafaxine with risk of overdose
severity: Take into account

***interaction***
drug1
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
drug2
drug name: TRAMADOL
rxNorm: 10689
atc: N02AX02
Risk of appearance of convulsions and/or of a serotonin syndrome
severity: Take into account

***interaction***
drug1
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
Increase of the concentrations of venlafaxine with risk of overdose
severity: Take into account
538-VERAPAMIL.html


***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
Increase of the plasma concentrations of afatinib due to increase of its absorption by the verapamil
severity: Precaution for use
It is recommended that the verapamil be administered as far as possible from the afatinib, preferably at an interval of 6 to 12 hours distant from the dose of afatinib.

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: ALISKIREN
rxNorm: 325646
more atc: C09XA02
more atc: C09DX02
Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects
severity: Precaution for use
Clinical monitoring.

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
For verapamil by injection:

--risk of bradycardia or of atrioventricular block

For verapamil by mouth:

--risk of bradycardia or of atrioventricular block, especially with older persons
severity: Not recommended with
--the verapamil via IV

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering medication
severity: Precaution for use
Use weaker doses of the cholesterol lowering medication. If the therapeutic objective is not reached, use another statin not affected by this type of interaction.

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure 
severity: Not recommended
The administration of these medications together should only be undertaken under strict clinical monitoring and EKG, in particular with older patients or at the beginning of treatment. 

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction
severity: CONTRAINDICATION

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: BUSPIRONE
rxNorm: 1827
atc: N05BE01
Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the verapamil, with increase of its undesirable effects
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the buspirone if necessary.

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders. 
severity: Precaution for use
Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: CLONIDINE
rxNorm: 2599
more atc: C02AC01
more atc: N02CX02
more atc: S01EA04
Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)
severity: Take into account

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
Risk of increase of the undesirable effects of the colchicine, due to increase of its plasma concentrations by the verapamil
severity: Not recommended

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding
severity: Precaution for use
In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose, or even 75 mg/day in case of moderate renal insufficiency

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: DANTROLENE
rxNorm: 3105
atc: M03CA01
With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident.
severity: CONTRAINDICATION

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Excessive bradycardia and atrioventricular block due to increase of the effects of the digoxin on autoregulation and conduction and due to decrease of the renal and extrarenal elimination of the digoxin
severity: Precaution for use
Clinical monitoring, EKG and, possibly, testing of the digoxinemia. If there is reason for it, adjustment of the dosage of the digoxin during the treatment with the verapamil and after it is stopped. 

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: DOXORUBICIN
rxNorm: 3639
atc: L01DB01
Risk of increase of the toxicity of the doxorubicin due to increase of its plasma concentrations
severity: Take into account

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker
severity: Precaution for use
Start the treatment by the calcium channel blocker with the lowest recommended dosages, and adjust the doses according to the EKG.

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: ERIBULINE
rxNorm: 1045453
atc: L01XX41
Increase of the plasma concentrations of eribuline by the verapamil.
severity: Not recommended

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin
severity: Precaution for use
Clinical monitoring and EKG, if there is reason for it, adjustment of the dosage of the verapamil during the treatment with the erythromycin and after it is stopped. 

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: ESMOLOL
rxNorm: 49737
atc: C07AB09
Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure
severity: Not recommended
-in case of alteration of the left ventricular function.

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: EVEROLIMUS
rxNorm: 141704
more atc: L01XE10
more atc: L04AA18
Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function and adjustment of the dosage during the administration of the two medications together and after it is stopped.

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: FIDAXOMICIN
rxNorm: 1111103
atc: A07AA12
Increase of the plasma concentrations of the fidaxomicin
severity: Not recommended

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: IBRUTINIB
rxNorm: 1442981
atc: L01XE27
Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the verapamil
severity: Precaution for use
Strict clinical monitoring and reduction of the dose of ibrutinib to 140 mg per day during the length of the administration of the two medications together.

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the inhibitor
severity: Precaution for use
Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the verapamil during the treatment with the inhibitor, and after it is stopped, as the situation requires.

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules.
severity: CONTRAINDICATION 

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
Increase of the plasma concentrations of midazolam (decrease of its hepatic metabolism with increase of sedation). 
severity: Precaution for use
Clinical monitoring and reduction of the dosage of midazolam during the treatment with the verapamil.

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Large reduction of the concentrations of verapamil, with risk of loss of its therapeutic effect.
severity: CONTRAINDICATION

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: NINTEDANIB
rxNorm: 1592737
more atc: L01XE31
Increase of the plasma concentrations of the nintedanib due to increase of it absorption by the verapamil
severity: Precaution for use
Clinical monitoring during the administration of these substances together

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: OLAPARIB
rxNorm: 1597582
atc: L01XX46
Increase of the plasma concentrations of olaparib by the verapamil
severity: Not recommended
If administering these together cannot be avoided, limit the dose of olaparib to 200 mg twice a day. 

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
Drug with no codes: GRAPEFRUIT (JUICE AND FRUIT)
Increase of the plasma concentrations of verapamil, with risk of the appearance of undesirable effects
severity: Take into account

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia
severity: Not recommended

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent
severity: Precaution for use
Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction.

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: SIROLIMUS
rxNorm: 35302
atc: L04AA10
Increase of the blood concentrations of the sirolimus (decrease of its hepatic metabolism by the verapamil).
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped. 

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of the renal function, and adjustment of the dosage during the administration of the medications together and after it is stopped.

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: TAMSULOSIN
rxNorm: 77492
atc: G04CA02
Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the tamsulosin during the treatment with the enzyme inhibitor and after it is stopped, if the situation requires. 

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: TENOFOVIR ALAFENAMIDE
rxNorm: 1721603
Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption
severity: Precaution for use
In case of co-administration with the verapamil, the dose of tenofovir alafenamide must be limited to 10mg per day.

***interaction***
drug1
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
drug2
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism
severity: Take into account
539-VIDARABINE.html


***interaction***
drug1
drug name: VIDARABINE
rxNorm: 11194
more atc: J05AB03
more atc: S01AD06
drug2
drug name: ALLOPURINOL
rxNorm: 519
atc: M04AA01
Increased risk of neurological disorders (trembling, confusion) due to partial inhibition of the metabolism of the antiviral
severity: Not recommended
53-ANTICONVULSANT-ENZYME-INDUCERS.html


***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: ABIRATERONE
rxNorm: 1100072
atc: L02BX03
Significant decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness
severity: Not recommended

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: AFATINIB
rxNorm: 1430438
atc: L01XE13
Decrease of the plasma concentrations of afatinib due to increase of its metabolism by these substances
severity: Precaution for use
Clinical monitoring during the administration of these substances together and 1 to 2 weeks after they are stopped. 

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: ALBENDAZOLE
rxNorm: 430
atc: P02CA03
Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of reduction of its effectiveness. 


severity: Precaution for use
Clinical monitoring of the therapeutic response and possible adjustment of the dosage of the albendazole during the treatment with the enzyme inducer and after it is stopped. 

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
class name: CALCIUM CHANNEL BLOCKERS
class code: CO8CA-001
Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism 


severity: Not recommended 
with the nimodipine

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
class name: CLASS IA ANTIARRHYTHMICS
class code: C01B-002
Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic, due to increase of its hepatic metabolism by the inducer. 


severity: Precaution for use
Clinical monitoring, EKG, and testing of the plasma concentrations; if needed, adjustment of the dosage of the antiarrhythmic during the treatment with the inducer and after it is stopped. 

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Decrease (or, infrequently, increase with the phenytoin) of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the anticonvulsant inducer


severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the anticonvulsant inducer and a week after it is stopped. 

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: APIXABAN
rxNorm: 1364430
atc: B01AF02
Decreased of the plasma concentrations of the apixaban by the anticonvulsant enzyme inducer, with risk of lower therapeutic effect.
severity: Not recommended

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
Risk of very large decrease of the concentrations of aprepitant
severity: Not recommended

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
Risk of decrease of the plasma concentrations of boceprevir


severity: Not recommended
If administering these substances together cannot be avoided, regular clinical and biological monitoring, especially at the beginning of the administration of the substances together

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
Risk of decrease of the plasma concentrations of bosentan
severity: Not recommended

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: COBICISTAT
rxNorm: 1306284
atc: VO3AX03
Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer
severity: CONTRAINDICATION

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: DABIGATRAN
rxNorm: 
more atc: 1037042
Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect
severity: Not recommended

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
Risk of decrease of the plasma concentrations of deferasirox


severity: Precaution for use
Monitor the ferritinemia during and after the treatment with the enzyme inducer. If needed, adjustment of the dosage of deferasirox.

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: DELAMANID
rxNorm: 1344662
atc: J04AK06
Decrease of the plasma concentratioins of delamanid due to increase of its hepatic metabolism by the inducer. 
severity: CONTRAINDICATION

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: DOXYCYCLINE
rxNorm: 3640
more atc: A01AB22
more atc: J01AA02
Decrease of the plasma concentrations of the doxycycline due to increase of its hepatic metabolism by the inducer
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the doxycycline

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
Large decrease of the concentrations of dronedarone due to increase of its metabolism, without notable modification of the active metabolite
severity: Not recommended

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
class name: NON-CONTRACEPTIVE ESTROGENS
class code: G03C-001
Decrease of the effectiveness of the estrogen 

.
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the anticonvulsant inducer and after it is stopped. 

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: FENTANYL
rxNorm: 4337
more atc: N01AH01
more atc: N02AB03
Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the anticonvulsant
severity: Not recommended
Choose another opioid.

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great with patients who have Addisons disease treated with hydrocortisone and in cases of organ transplants
severity: Precaution for use
Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped. 

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: HALOPERIDOL
rxNorm: 5093
atc: N05AD01
Clinical monitoring and, if needed, dosage adjustment during the treatment with carbamazepine and after it is stopped. 
severity: Precaution for use
Clinical monitoring and, if needed, dosage adjustment during the treatment with the carbamazepine and after it is stopped. 

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
class name: THYROID HORMONES
class code: H03AA
Risk of clinically low thyroid in patients with hypothyroidism, due to increase of the metabolism of the T3 and of the T4


severity: Precaution for use
Monitoring of the serum concentrations of T3 and T4 and adjustment, if needed, of the dosage of the thyroid hormones during the treatment with the inducer and after it is stopped. 

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: IDELALISIB
rxNorm: 1544460
atc: L01XX47
Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the anticonvulsant enzyme inducer
severity: Not recommended

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Risk of reduction of the effectiveness of the protease inhibitor due to increase of its hepatic metabolism by the inducer


severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
class name: METABOLIZED TYROSINE-KINASE INHIBITORS
class code: L01XE
Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer
severity: Not recommended

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the inducer


severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the ivabradine during the administration of these substances together and after the inducer is stopped. 

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: LEDIPASVIR
rxNorm: 1591922
Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the anticonvulsant enzyme inducer.
severity: CONTRAINDICATION

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: METRONIDAZOLE
rxNorm: 6922
more atc: A01AB17
more atc: D06BX01
more atc: G01AF01
more atc: J01XD01
more atc: P01AB01
Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer


severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of metronidazole during the treatment with the inducer and after it is stopped. 

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: MIDAZOLAM
rxNorm: 6960
atc: N05CD08
Risk of decrease of the plasma concentration of the midazolam by the anticonvulsant
severity: Take into account

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
class name: MINERALOCORTICOIDS
class code: H02AA0
Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great in patients with Addisons disease treated with the hydrocortisone and in the case of transplants.
severity: Precaution for use
Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped. 

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: MONTELUKAST
rxNorm: 88249
atc: R03DC03
Risk of reduction of the effectiveness of the montelukast due to increase of its hepatic metabolism by the inducer


severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the antiasthmatic during the treatment with the inducer and after it is stopped. 

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: NIMODIPINE
rxNorm: 7426
atc: C08CA06
Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism by the inducer
severity: Not recommended
Clinical monitoring and possible adjustment of the dosage of the calcium channel blocker during the treatment with the inducer and after it is stopped. 

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: PERAMPANEL
rxNorm: 1356552
atc: N03AX22
Large decrease (up to two thirds) of the concentrations of perampanel
severity: Take into account

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
Decrease of the plasma concentrations and of the effectiveness of the posaconazole


severity: Precaution for use
Clinical monitoring. If possible, plasma dosages of the posaconazole and possible adjustment of its dosage.

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: PRAZIQUANTEL
rxNorm: 8628
atc: P02BA01
Very large decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment due to increase of its hepatic metabolism by the inducer
severity: Not recommended

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: PROCARBAZINE
rxNorm: 8702
atc: L01XB01
Increase of the hypersensitivity reactions (hypereosinophilia, rash), due to increase of the metabolism of the procarbazine by the inducer
severity: Take into account

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the inducer
severity: Precaution of use
Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during its administration with the inducer and after the inducer is stopped.

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: QUETIAPINE
rxNorm: 51272
atc: N05AH04
Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.
severity: Not recommended

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: QUININE
rxNorm: 
more atc: P01BC01
Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer. 
severity: Precaution for use
Clinical monitoring and adjustment of the dosage of the quinine during the treatment with the inducer and after it is stopped

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: RANOLAZINE
rxNorm: 35829
atc: C01EB18
Risk of large decrease of the concentrations of ranolazine
severity: Not recommended

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: RIVAROXABAN
rxNorm: 1114195
atc: B01AF01
Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect.
severity: Not recommended

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
Increase of the plasma concentrations of the anticonvulsant, with risk of overdose, due to inhibition of its hepatic metabolism by the stiripentol.
severity: Precaution for use
Clinical monitoring and plasma dosage, when that is possible, of the anticonvulsant taken with the stiripentol and possible adjustment of its dosage. 

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
Risk of very large decrease of the concentrations of telaprevir
severity: CONTRAINDICATION

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment due to increase of its hepatic metabolism by the inducer
severity: Not recommended

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
class name: THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)
class code: R03DA
Decrease of the plasma concentrations and of the effectiveness of the theophylline due to increase of its hepatic metabolism by the inducer


severity: Precaution for use
Clinical monitoring and, if needed, monitoring of the theophyllinemia. Possible adjustment of the dosage of the theophylline during the treatment with the inducer and after it is stopped

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: TIAGABINE
rxNorm: 31914
atc: N03AG06
Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism by the inducer
severity: Precaution for use
An increase of the dosage of tiagabine can prove necessary when it is administered with an anticonvulsant enzyme inducer

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolsim by the anticonvulsant enzyme inducer, with risk of decrease of the therapeutic effect.
severity: Not recommended

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03XB02
Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer
severity: Not recommended
Choose a therapeutic alternative that is little or not at all metabolized. 

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
class name: VITAMIN D
class code: A11CC
Decrease of the concentrations of vitamin D more marked than in the absence of the inducer.
severity: Precaution for use
Concentration dosage of vitamin D and supplementation if necessary

***interaction***
drug1
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
-for carbamazipine, phenobarbital, primidone: Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the inducer

For phenytoin, fosphenytoin: 

Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the phenytoin, for one thing; and increase of the plasma concentrations of the phenytoin due to decrease of its hepatic metabolism by the voriconazole for another thing
severity: Contraindication
 -for carbamazepine, phenobarbital, primidone
540-VINCA-ALKALOIDS.html


***interaction***
drug1
class name: VINCA ALKALOIDS
class code: L01CA
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
more atc: J01FA09
more atc: A02BD04
more atc: A02BD05
more atc: A02BD06
more atc: A02BD07
Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin
severity: Precaution for use
Strict clinical and biological monitoring. Possibly, use another antibiotic. 

***interaction***
drug1
class name: VINCA ALKALOIDS
class code: L01CA
drug2
drug name: COBICISTAT
rxNorm: 1306284
atc: V03AX03
Increase of the neurotoxicity of the antimitotic due to decrease of its hepatic metabolism by the cobicistat
severity: Precaution for use
Strict clinical monitoring and possible adjustment of the dosage of the antimitotic. 

***interaction***
drug1
class name: VINCA ALKALOIDS
class code: L01CA
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin
severity: Precaution for use
Strict clinical and biological monitoring. Possibly, use another antibiotic.

***interaction***
drug1
class name: VINCA ALKALOIDS
class code: L01CA
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Increase of the toxicity of the antimitotic, due to decrease of its hepatic metabolism by the protease inhibitor. 
severity: Precaution for use
Strict clinical monitoring and possible adjustment of the dosage of the antimitotic.

***interaction***
drug1
class name: VINCA ALKALOIDS
class code: L01CA
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the itraconazole
severity: Not recommended

***interaction***
drug1
class name: VINCA ALKALOIDS
class code: L01CA
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the ketoconazole
severity: Not recommended

***interaction***
drug1
class name: VINCA ALKALOIDS
class code: L01CA
drug2
drug name: MITOMYCIN C
rxNorm: 632
atc: L01DC03
Risk of increase of the pulmonary toxicity of the mitomycin and of the vinca alkaloids
severity: Take into account

***interaction***
drug1
class name: VINCA ALKALOIDS
class code: L01CA
drug2
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the posaconazole
severity: Not recommended

***interaction***
drug1
class name: VINCA ALKALOIDS
class code: L01CA
drug2
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the telithromycin
severity: Precaution for use
Strict clinical and biological monitoring. Possibly, use another antibiotic. 
541-VISMODEGIB.html


***interaction***
drug1
drug name: VISMODEGIB
rxNorm: 1242987
atc: L01XX43
drug2
class name: ENZYME INDUCERS
class code: N03-J05-001
Risk of decrease of the plasma concentrations of vismodegib due to increase of its hepatic metabolism by the inducer
severity: Not recommended

***interaction***
drug1
drug name: VISMODEGIB
rxNorm: 1242987
atc: L01XX43
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the plasma concentrations of vismodegib
severity: CONTRAINDICATION
542-VITAMIN-A.html


***interaction***
drug1
drug name: VITAMIN A
rxNorm: 11246
more atc: A11C
more atc: A11CA
more atc: A11CA01
more atc: A11CA02
more atc: A11CB
more atc: V04CB01
drug2
class name: TETRACYCLINE ANTIBIOTICS
class code: J01AA
In case of intake of 10,000 IU/day and more: risk of intracranial hypertension
severity: CONTRAINDICATION

***interaction***
drug1
drug name: VITAMIN A
rxNorm: 11246
more atc: A11C
more atc: A11CA
more atc: A11CA01
more atc: A11CA02
more atc: A11CB
more atc: V04CB01
drug2
class name: RETINOIDS
class code: D05-D10
Risk of symptoms evocative of hypervitaminosis A
severity: CONTRAINDICATION
543-VITAMIN-D.html


***interaction***
drug1
class name: VITAMIN D
class code: A11CC
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Decrease of the concentrations of vitamin D more noticeable than in the absence of the inducer
severity: Precaution for use
Concentration dosage of vitamin D and supplementation if necessary.

***interaction***
drug1
class name: VITAMIN D
class code: A11CC
drug2
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
Decrease of the absorption of the vitamin D
severity: Take into account

***interaction***
drug1
class name: VITAMIN D
class code: A11CC
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the concentrations of vitamin D more noticeable than in the absence of treatment with the rifampacin 
severity: Precaution for use
Concentration dosage of vitamin D and supplementation if necessary.
544-VORICONAZOLE.html


***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Increased risk of ventricular arrhythmias, especially of torsades de pointes, due to possible decrease of the metabolism of the amiodarone. 
severity: Precaution for use
Clinical monitoring and EKG, and possible adjustment of the dosage of the amiodarone. 

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
--for carbamazepine, phenobarbital, primidone: 

Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the inducer

--for phenytoin, fosphenytoin: 

Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the phenytoin, for one thing; and increase of the plasma concentrations of the phenytoin due to decrease of its hepatic metabolism by the voriconazole, for another. 
severity: Contraindication
--for carbamazepine, phenobarbital, primidone

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage due to decrease of its hepatic metabolism
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with voriconazole and a week after it is stopped. 

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
class name: OTHER CORTICOIDES, ESPECIALLY INHALED ONES 
class code: D07AC-001
In case of prolonged use by oral or inhaled route:

increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the voriconazole, with risk of appearance of Cushings syndrome even of adrenal insufficiency
severity: Take into account

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
drug name: DEXAMETHASONE
rxNorm: 3264
more atc: A01AC02
more atc: C05AA09
more atc: D07AB19
more atc: D07XB05
more atc: D10AA03
more atc: H02AB02
more atc: R01AD03
more atc: S01BA01
more atc: S01CB01
more atc: S02BA06
more atc: S03BA01
Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome
severity: Take into account

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
drug name: DIHYDROERGOTAMINE
rxNorm: 3418
atc: N02CA01
Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
drug name: EFAVIRENZ
rxNorm: 195085
atc: J05AR06
Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the efavirenz
severity: Not recommended
If administering these substances together cannot be avoided, strict clinical monitoring and adjustment of the dosage of the voriconazole and of the efavirenz during the administration of the two together.

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
drug name: GLIPIZIDE
rxNorm: 4821
atc: A10BB07
Risk of increase of the plasma concentrations of the glipizide at the origin of potentially severe hypoglycemia
severity: Precaution for use
Inform the patient, reinforce self-monitoring of blood glucose and possibly adjust the dosage of the blood glucose lowering sulfonamide during and after the treatment with voriconazole.

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the voriconazole. 
severity: Not recommended 
--with the everolimus, the sirolimus, and the temsirolimus

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Very large reduction of the concentrations of the antifungal due to increase of its metabolism by the ritonavir, with risk of failure of the treatment
severity: Not recommended

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Significant reduction of the concentrations of voriconazole, with risk of loss of its therapeutic effect
severity: CONTRAINDICATION

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
drug name: NEVIRAPINE
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the nevirapine
severity: Not recommended
If the administration of the substances together cannot be avoided, strict clinical monitoring and possible adjustment of the dosage of the voriconazole during the administration of the substances together. 

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
Decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifabutin for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin for another. 
severity: Not recommended
If the administration of the substances together is judged necessary, clinical monitoring and adjustment of the dosage of the voriconazole (generally doubled) during the treatment with the rifabutin. 

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type due to decrease of the hepatic metabolism of the simvastatin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
drug2
drug name: VENLAFAXINE
rxNorm: 39786
atc: N06AX16
Increase of the concentrations of venlafaxine with risk of overdose. 
severity: Take into account
545-VORTIOXETINE.html


***interaction***
drug1
drug name: VORTIOXETINE
rxNorm: 1455099
atc: N06AX26
drug2
drug name: CINACALCET
rxNorm: 407990
atc: H05BX01
Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with cinacalcet and after it is stopped. 

***interaction***
drug1
drug name: VORTIOXETINE
rxNorm: 1455099
atc: N06AX26
drug2
drug name: FLUOXETINE
rxNorm: 4493
more atc: N06AB03
more atc: N06CA03
Risk of increase of the undesirable effects of the vortioxetine by decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the fluoxetine and after it is stopped.

***interaction***
drug1
drug name: VORTIOXETINE
rxNorm: 1455099
atc: N06AX26
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Reduction of the plasma concentrations of the vortioxetine
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the administration with the inducer and 1 to 2 weeks after it is stopped.

***interaction***
drug1
drug name: VORTIOXETINE
rxNorm: 1455099
atc: N06AX26
drug2
drug name: PAROXETINE
rxNorm: 32937
more atc: N06AB05
Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the viortioxetine during the treatment with the paroxetine and after it is stopped.

***interaction***
drug1
drug name: VORTIOXETINE
rxNorm: 1455099
atc: N06AX26
drug2
drug name: QUINIDINE
rxNorm: 9068
atc: C01BA01
Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the quinidine and after it is stopped.

***interaction***
drug1
drug name: VORTIOXETINE
rxNorm: 1455099
atc: N06AX26
drug2
drug name: TERBINAFINE
rxNorm: 37801
more atc: D01AE15
more atc: D01BA02
Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the terbinafine and after it is stopped
546-YOHIMBINE.html


***interaction***
drug1
drug name: YOHIMBINE
rxNorm: 220982
atc: G04BE04
drug2
drug name: CLONIDINE
rxNorm: 2599
more atc: C02AC01
more atc: N02CX02
more atc: S01EA04
Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors
severity: Not recommended
547-ZALCITABINE.html


***interaction***
drug1
drug name: ZALCITABINE
rxNorm: 3363
atc: J05AF03
drug2
drug name: DIDANOSINE
rxNorm: 3364
atc: J05AF02
Increased risk of onset of pancreatitis and of peripheral neuropathy due to addition of undesirable effects
severity: Precaution for use
Regular clinical monitoring and monitoring of the amylasemia. Do not administer these substances together if the amylasemia is at the high range of normal. 

***interaction***
drug1
drug name: ZALCITABINE
rxNorm: 3363
atc: J05AF03
drug2
drug name: GANCICLOVIR
rxNorm: 4678
more atc: J05AB06
more atc: S01AD09
Increased risk of onset of peripheral neuropathy due to addition of undesirable effects
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the two medications together. 

***interaction***
drug1
drug name: ZALCITABINE
rxNorm: 3363
atc: J05AF03
drug2
drug name: LAMIVUDINE
rxNorm: 68244
atc: J05AF05
Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites
severity: Not recommended

***interaction***
drug1
drug name: ZALCITABINE
rxNorm: 3363
atc: J05AF03
drug2
drug name: PENTAMIDINE
rxNorm: 7994
atc: P01CX01
Increased risk of peripheral neuropathy due to addition of undesirable effects
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. 

***interaction***
drug1
drug name: ZALCITABINE
rxNorm: 3363
atc: J05AF03
drug2
drug name: STAVUDINE
rxNorm: 59763
atc: J05AF04
Risk of decrease of the effectiveness of each antiviral, due to inhibition of the phosphorylation reaction at the origin of the active metabolites 
severity: Not recommended

***interaction***
drug1
drug name: ZALCITABINE
rxNorm: 3363
atc: J05AF03
drug2
drug name: THALIDOMIDE
rxNorm: 10432
atc: L04AX02
Increased risk of onset of peripheral neuropathy due to addition of undesirable effects
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. 
548-ZIDOVUDINE.html


***interaction***
drug1
drug name: ZIDOVUDINE 
rxNorm: 11413
atc: J05AF01
drug2
drug name: AMPHOTERICIN B 
rxNorm: 732
more atc: A01AB04
more atc: A07AA07
more atc: G01AA03
more atc: J02AA01
With the amphotericin B administered intravenously:

increase of the hematological toxicity (addition of effects of bone marrow toxicity)
severity: Precaution for use
More frequent CBC.

***interaction***
drug1
drug name: ZIDOVUDINE 
rxNorm: 11413
atc: J05AF01
drug2
drug name: DAPSONE
rxNorm: 3108
more atc: D10AX05
more atc: J04BA02
Increase of the hematological toxicity (addition of effects of bone marrow toxicity)
severity: Precaution for use
More frequent CBC

***interaction***
drug1
drug name: ZIDOVUDINE 
rxNorm: 11413
atc: J05AF01
drug2
drug name: FLUCYTOSINE
rxNorm: 4451
more atc: D01AE21
more atc: J02AX01
Increase of the hematological toxicity (addition of effects of bone marrow toxicity)
severity: Precaution for use
More frequent CBC

***interaction***
drug1
drug name: ZIDOVUDINE 
rxNorm: 11413
atc: J05AF01
drug2
drug name: GANCICLOVIR
rxNorm: 4678
more atc: J05AB06
more atc: S01AD09
Increase of the hematological toxicity (addition of effects of bone marrow toxicity)
severity: Precaution for use
Stop the zidovudine temporarily; CBC, and reintroduce, if possible, the zidovudine in weak doses.

***interaction***
drug1
drug name: ZIDOVUDINE 
rxNorm: 11413
atc: J05AF01
drug2
drug name: RIBAVIRIN
rxNorm: 9344
atc: J05AB04
Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of the medications together.

***interaction***
drug1
drug name: ZIDOVUDINE 
rxNorm: 11413
atc: J05AF01
drug2
drug name: STAVUDINE
rxNorm: 59763
atc: J05AF04
Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites
severity: Not recommended

***interaction***
drug1
drug name: ZIDOVUDINE 
rxNorm: 11413
atc: J05AF01
drug2
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid
severity: Precaution for use
Regular clinical and biological monitoring. A CBC checking for anemia should be done during the course of the first two months of the administration of these substances together. 
549-ZINC.html


***interaction***
drug1
drug name: ZINC
rxNorm: 1431163
atc: A12CB
drug2
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
Decrease of the digestive absorption of the zinc by the calcium 
severity: Precaution for use
Take the calcium salts at a different time from the zinc (more than 2 hours apart if possible).

***interaction***
drug1
drug name: ZINC
rxNorm: 1431163
atc: A12CB
drug2
class name: TETRACYCLINE ANTIBIOTICS
class code: J01AA
Decrease of the digestive absorption of the tetracycline antibiotics
severity: Precaution for use
Take the zinc salts at a different time from the tetracycline antibiotics (more than two hours apart if possible).

***interaction***
drug1
drug name: ZINC
rxNorm: 1431163
atc: A12CB
drug2
drug name: IRON
rxNorm: 1431589
atc: B03A
Decrease of the digestive absorption of the zinc by the iron
severity: Precaution for use
Take the iron salts at a different time from the zinc (more than 2 hours apart if possible).

***interaction***
drug1
drug name: ZINC
rxNorm: 1431163
atc: A12CB
drug2
class name: FLUOROQUINOLONES
class code: J01MA-001
Decrease of the digestive absorption of the fluoroquinolones
severity: Precaution for use
Take the zinc salts at a different time from the fluoroquinlones (more than 2 hours apart if possible).

***interaction***
drug1
drug name: ZINC
rxNorm: 1431163
atc: A12CB
drug2
drug name: STRONTIUM
rxNorm: 81638
atc: M05BX03
Decease of the digestive absorption of the strontium
severity: Precaution for use
Take the strontium at a different time from the zinc salts (more than two hours apart if possible).
54-METABOLIZED-ANTICONVULSANTS.html


***interaction***
drug1
class name: METABOLIZED ANTICONVULSANTS
class code: N03A-002
drug2
Drug with no codes: ST JOHNS WORT
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
more atc: 258326
Risk of decrease of the plasma concentrations and of the effectiveness of the anticonvulsant

.
severity: CONTRAINDICATION
550-ZOLPIDEM.html


***interaction***
drug1
drug name: ZOLPIDEM
rxNorm: 39993
more atc: N05CF02
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Slight increase of the sedative effect of the zolpidem
severity: Take into account

***interaction***
drug1
drug name: ZOLPIDEM
rxNorm: 39993
more atc: N05CF02
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring. Possibly use another hypnotic.
551-ZONISAMIDE.html


***interaction***
drug1
drug name: ZONISAMIDE
rxNorm: 
more atc: N03AX15
drug2
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
Increase of the hyperammonemia, with increased risk of encephalopathy
severity: Precaution for use
Regular clinical and biological monitoring.
552-ZOPICLONE.html


***interaction***
drug1
drug name: ZOPICLONE
rxNorm: 40001
atc: N05CF01
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Slight increase of the sedative effect of the zopiclone
severity: Take into account

***interaction***
drug1
drug name: ZOPICLONE
rxNorm: 40001
atc: N05CF01
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin
severity: Precaution for use
Clinical monitoring.Possibly use another hypnotic.
55-MONOCLONAL-ANTIBODIES-(EXCEPT-ANTI-TNF-ALPHA).html


***interaction***
drug1
class name: MONOCLONAL ANTIBODIES (EXCEPT ANTI-TNF ALPHA)
class code: MONANT
drug2
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
Risk of general vaccine disease, possibly fatal. 
severity: Not recommended with:
--belimumab, blinatumomab, canakinumab, obinutuzumab, ofatumumab, rituximab, tocilizumab, ustekinumab
56-TRICYCLIC-ANTIDEPRESSANTS.html


***interaction***
drug1
class name: TRICYCLIC ANTIDEPRESSANTS
class code: N06AA-001
drug2
class name: ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)
class code: A01AD
Serious ventricular arrhythmias due to increased cardiac sensitization

.
severity: Precaution for use
Limit the amount of adrenaline, for example: less than 0.1 mg of adrenalin in 10 minutes or 0.3 mg in an hour for an adult 

***interaction***
drug1
class name: TRICYCLIC ANTIDEPRESSANTS
class code: N06AA-001
drug2
drug name: BACLOFEN
rxNorm: 1292
atc: M03BX01
Risk of increase of the muscular hypotonia. 
severity: Take into account

***interaction***
drug1
class name: TRICYCLIC ANTIDEPRESSANTS
class code: N06AA-001
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)
severity: Take into account

***interaction***
drug1
class name: TRICYCLIC ANTIDEPRESSANTS
class code: N06AA-001
drug2
drug name: CLONIDINE
rxNorm: 2599
more atc: C02AC01
more atc: N02CX02
more atc: S01EA04
Described for desipramine, imipramine:

inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)
severity: Not recommended

***interaction***
drug1
class name: TRICYCLIC ANTIDEPRESSANTS
class code: N06AA-001
drug2
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
class code: N06AB
Increase of the plasma concentrations of the tricyclic antidepressant with risk of convulsions and increase of the undesirable effects
severity: Precaution for use
Increased clinical monitoring and, if necessary, adjustment of the dosage

***interaction***
drug1
class name: TRICYCLIC ANTIDEPRESSANTS
class code: N06AA-001
drug2
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
Risk of therapeutic failure in cases of concomitant treatment with orlistat
severity: Take into account

***interaction***
drug1
class name: TRICYCLIC ANTIDEPRESSANTS
class code: N06AA-001
drug2
class name: ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)
class code: C01CA
Paroxysmal hypertension with the possibility of arrhythmia (inhibition of the entry of the sympathomimetic into the sympathic fiber)
severity: Not recommended
57-ANTIHYPERTENSIVE-ALPHA-BLOCKERS.html


***interaction***
drug1
class name: ANTIHYPERTENSIVE ALPHA BLOCKERS
class code: C02CA0-001
drug2
class name: ALPHA BLOCKERS FOR UROLOGICAL USE
class code: G04CA-001
Increase of the hypotensive effect. Risk of severe orthostatic hypotension


severity: Not recommended

***interaction***
drug1
class name: ANTIHYPERTENSIVE ALPHA BLOCKERS
class code: C02CA0-001
drug2
class name: ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS
class code: C0-001
Increase of the hypotensive effect. Greater risk of orthostatic hypotension. 


severity: Take into account

***interaction***
drug1
class name: ANTIHYPERTENSIVE ALPHA BLOCKERS
class code: C02CA0-001
drug2
class name: TYPE 5 PHOSPHODIESTERASE INHIBITORS
class code: G04BE
Risk of orthostatic hypotension, especially with older patients
severity: Not recommended 
-with the doxazosine
58-CENTRAL-ANTIHYPERTENSIVES.html


***interaction***
drug1
class name: CENTRAL ANTIHYPERTENSIVES
class code: C02AC-001
drug2
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
Large increase of blood pressure in cases of sudden termination of the treatment with the central antihypertensive
severity: Precaution for use
Avoid ending treatment with the central antihypertensive abruptly. Clinical monitoring.

***interaction***
drug1
class name: CENTRAL ANTIHYPERTENSIVES
class code: C02AC-001
drug2
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
Central decrease of the sympathetic tone and vasodilator effect of the central antihypertensives, dangerous in case of heart failure treated with a beta-blocking agent and vasodilator
severity: Not recommended
59-ANTIHYPERTENSIVES-EXCEPT-ALPHA-BLOCKERS.html


***interaction***
drug1
class name: ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS
class code: C0-001
drug2
class name: ALPHA BLOCKERS FOR UROLOGICAL USE
class code: G04CA-001
Increase of the hypotensive effect. Greater risk of orthostatic hypotension
severity: Take into account

***interaction***
drug1
class name: ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS
class code: C0-001
drug2
class name: ANTIHYPERTENSIVE ALPHA BLOCKERS
class code: C02CA0-001
Increase of the hypotensive effect. Greater risk of orthostatic hypotension
severity: Take into account
5-ACETYLSALICYLIC-ACID.html


***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
drug name: ACETAZOLAMIDE
rxNorm: 167
atc: S01EC01
Increase of the undesirable effects, and especially of metabolic acidosis, of the acetylsalicylic acid in large doses and of the acetazolamide, due to decrease of the elimination of the acetylsalicylic acid by the acetazolamide
severity: Not recommended

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
drug name: ANAGRELIDE
rxNorm: 596724
atc: L01XX35
Increase of hemorrhagic events 


severity: Not recommended

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
For anti-inflammatory dosages of acetylsalicylic acid (>=1g per dose and/or >=3g per day) or for analgesic or antipyretic doses (>=500mg by dose and/or <3g per day):

Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect. 
severity: Precaution for use
Hydrate the patient and monitor renal function at the beginning of treatment.

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
class name: ORAL ANTICOAGULANTS 
class code: B01A-001
Increase of the risk of hemorrhage, especially in cases with a previous gastro duodenal ulcer. 


severity: Contraindication with:
- anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3g per day)

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Increase of the risk of digestive system ulceration and hemorrhage.
severity: Not recommended 
-with anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3g per day)

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
drug name: CLOPIDOGREL
rxNorm: 32968
atc: B01AC04
Increase of the risk of hemorrhage due to addition of the platelet aggregation activities. 


severity: Not recommended
-except in validated indications for this combination of drugs in acute coronary syndromes. 

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
With anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3g per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 g per day):

increase of the risk of digestive ulceration and hemorrhage
severity: Take into account

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
class name: DIURETICS
class code: C0E-001
For anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3g per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 g per day):

Acute renal insufficiency in dehydrated patients, due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.
severity: Precaution for use
Hydrate the patient and monitor renal function at the start of treatment.

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
class name: GLUCOCORTICODS (EXCEPT FOR HYDROCORTISONE) 
class code: A0-H0-001
Increase of the risk of hemorrhage
severity: Not recommended
-with anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >3 g per day)

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
class name: LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)
class code: B01AB-001
Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastro duodenal mucosa by the acetylsalicylic acid)
severity: Not recommended
-with anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3 g per day)

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
class name: LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES) 
class code: B01AB-002
The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding heparin in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.
severity: Take into account

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
drug name: UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)
rxNorm: 
Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastro duodenal mucosa by the acetylsalicylic acid)
severity: Not recommended 
-with anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3 g per day)

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
drug name: UNFRACTIONATED HEPARIN (PREVENTIVE DOSES)
rxNorm: 
The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring 
severity: Take into account

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
For anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3g per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 g per day):

Acute renal insufficiency in dehydrated patients, due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.
severity: Precaution for use
Hydrate the patient and monitor renal function at the start of treatment.

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
class code: N06AB
Increase of the risk of hemorrhage 


severity: Take into account

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
Increase of the toxicity, especially hematological, of the methotrexate (decrease of its renal clearance by the acetylsalicylic acid)
severity: With doses of methotrexate > 20 mg/week
-Contraindication 

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
drug name: PEMETREXED
rxNorm: 68446
atc: L01BA04
Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).
severity: Not Recommended
-in case of weak to moderate renal function

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
drug name: PROBENECID
rxNorm: 8698
atc: M04AB01
Decrease of the uricosuric effect due to competition of the elimination of the uric acid at the level of the renal tubules
severity: Not recommended

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
class name: THROMBOLYTICS
class code: B01AD
Increase of the risk of hemorrhage


severity: Take into account

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
drug name: TICAGRELOR
rxNorm: 1116632
atc: B01AC24
Increase of the risk of hemorrhage due to addition of the platelet antiagregation actions


severity: Not recommended
--except for validated indications for this combination in acute coronary syndromes

***interaction***
drug1
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
drug2
drug name: TICLOPIDINE
rxNorm: 10594
atc: B01AC05
Increase of the risk of hemorrhage due to addition of the platelet antiagregation actions


severity: Not recommended
If administering the substances together cannot be avoided, strict clinical monitoring.
60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html


***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
class name: OTHER NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
With the other non steroidal anti-inflammatory drugs: increase of the risk of causing ulcers and digestive hemorrhage 
severity: Not recommended

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
drug name: ACETYLSALICYLIC ACID
rxNorm: 1191
more atc: A01AD05
more atc: B01AC06
more atc: N02BA01
Increase of the risk of digestive system ulceration and hemorrhage
severity: Not recommended with
-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day)

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
class name: ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)
class code: C09CA0-001
Acute renal insufficiency with patients at risk (older patient, dehydration, treatment with diuretics, changes in renal function), due to decrease of the glomerular filtration (inhibition of the vasodilator prostaglandins due to the non-steroidal anti-inflammatories). These effects are generally reversible. In addition, reduction of the antihypertensive effect. 
severity: Precaution for use
Hydrate the patient and monitor renal function at the beginning of treatment and regularly while these substances are administered together.

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
class name: ORAL ANTICOAGULANTS
class code: B01A-001
Increase of the oral anticoagulants risk of hemorrhage (irritation of the gastroduodenal mucosa by the non-steroidal anti-inflammatories)


severity: Not recommended
If the administration of these substances together cannot be avoided, strict clinical monitoring and possibly biological monitoring. 

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
Reduction of the antihypertensive effect (inhibition of the vasodilating prostaglandins by the non steroidal anti-inflammatories
severity: Take into account

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Risk of addition of the nephrotoxic effects, especially with older patients.


severity: Precaution for use
Monitor renal function at the beginning of the treatment with the NSAI

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
Increase of the risk of causing ulcers and digestive hemorrhage
severity: Take into account

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
class name: DIURETICS
class code: C0E-001
Acute renal insufficiency with the patient at risk (older patient and/or dehydrated one) due to decrease of the glomerular filtration (inhibition of the vasodilator prostaglandins due to the NSAIs). Furthermore, reduction of the antihypertensive effect
severity: Precaution for use
Hydrate the patient and monitor renal function at the start of treatment

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
class name: GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)
class code: A0-H0-001
Increase of the risk of ulceration and of gastrointestinal hemorrhage
severity: Take into account

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
class name: LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)
class code: B01AB-001
Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)


severity: Not recommended
If administering the substances together cannot be avoided, strict clinical monitoring

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
class name: LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)
class code: B01AB-002
Increase of the risk of hemorrhage 
severity: Take into account

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
class name: UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)
class code: B01AB-003
Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)


severity: Not recommended
If administering the substances together cannot be avoided, strict clinical monitoring

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
class name: UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)
class code: B01AB-004
Increase of the risk of hemorrhage
severity: Take into account

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
class name: ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
class code: C09AA
Acute renal insufficiency with patients at risk (older patients, dehydrated ones, those taking diuretics, those with altered renal function) due to decrease of the glomerular filtration (inhibition of the vasodilating prostaglandins due to the NSAIs). These effects are generally reversible. Furthermore, reduction of the antihypertensive effect.
severity: Precaution for use
Hydrate the patient and monitor renal function at the beginning of treatment and regularly during the administration of the substances together.

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
class name: SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSR1s)
class code: NO6AB
Increase of the risk of hemorrhage
severity: Take into account

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
drug name: LITHIUM
rxNorm: 6448
atc: D11AX04
Increase of the plasma concentrations of lithium that can reach toxic values (decrease of the renal excretion of the lithium)
severity: Not recommended
If administering the substances together cannot be avoided, monitor the plasma concentrations of lithium strictly and adjust the dosage of the lithium during the treatment with the substances together and after the NSAI is stopped 

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
drug name: METHOTREXATE
rxNorm: 6851
more atc: L01BA01
more atc: L04AX03
Increase of the hematological toxicity of the methotrexate (decrease of the renal clearance of the methotrexate by the NSAIs).
severity: Not recommended
-for doses of methotrexate higher than 20 mg per week

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
drug name: PEMETREXED
rxNorm: 68446
atc: L01BA04
Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the NSAIs)
severity: Not recommended
-in case of weak to moderate renal function

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
drug name: PENTOXIFYLLINE
rxNorm: 8013
atc: C04AD03
Increase of the risk of hemorrage
severity: Take into account

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
drug name: TACROLIMUS
rxNorm: 42316
more atc: D11AH01
more atc: L04AD02
Risk of addition of the nephrotoxic effects, especially with older patients
severity: Precaution for use
Monitor the renal function at the beginning of treatment with the NSAI

***interaction***
drug1
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
drug2
drug name: TENOFOVIR DISOPROXIL
rxNorm: 300195
atc: J05AF07
Risk of increase of the nephrotoxicity of the tenofovir, especially with large doses of the anti-inflammatory or in the presence of factors of risk of renal insufficiency
severity: Precaution for use
When these are administered together, monitor renal function.
61-ANTIPARASITICS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html


***interaction***
drug1
class name: ANTIPARASITICS THAT TEND TO INDUCE TORSADES DE POINTES
class code: P01B-001
drug2
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: Contraindication
with citalopram, domperidone, escitalopram, hydroxyzine and piperaquine
62-ANTIPARKINSONIAN-ANTICHOLINERGICS.html


***interaction***
drug1
class name: ANTIPARKINSONIAN ANTICHOLINERGICS
class code: N04AA-001
drug2
class name: DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE
class code: G02CB-001
Risk of increase of neuropsychological disorders.


severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these substances together. 
63-ANTIPARKINSONIAN-DOPAMINERGICS.html


***interaction***
drug1
class name: ANTIPARKINSONIAN DOPAMINERGICS
class code: N04B-001
drug2
class name: ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)
class code: N05A-001
Reciprocal antagonism of the dopaminergic and the neuroleptics. The dopaminergic can cause or aggravate the psychotic disorders. When a treatment with neuroleptics is necessary for a Parkinsons patient treated with dopaminergics, these latter must be decreased progressively until they are stopped (their abrupt discontinuation exposes the patient to a risk of "neuroleptic malignant syndrome" (NMS)).
severity: Not recommended
64-ANTIPURINES.html


***interaction***
drug1
class name: ANTIPURINES
class code: ANTIPUR
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Decrease of the effect of the Vitamin K antagonist due to increase of its hepatic metabolism
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist at the beginning of the treatment with the immuno-inhibitor and after it is stopped

***interaction***
drug1
class name: ANTIPURINES
class code: ANTIPUR
drug2
class name: DERIVATIVES OF AMINOSALICYLIC ACID (ASA)
class code: A07EC-001
Risk of increase of the myelotoxicity of the immunoinhibitor, by inhibition of its hepatic metabolism by the ASA derivative, especially with patients presenting a partial deficit of thiopurine methyltransferase (TPMT)
severity: Take into account

***interaction***
drug1
class name: ANTIPURINES
class code: ANTIPUR
drug2
class name: XANTHINE OXYDASE INHIBITORS
class code: M04AA0
Possibly serious medullary insufficiency
severity: CONTRAINDICATION

***interaction***
drug1
class name: ANTIPURINES
class code: ANTIPUR
drug2
drug name: RIBAVIRIN
rxNorm: 9344
atc: J05AB04
Increased risks of serious undesirable effects, due to inhibition of the metabolism of the immunoinhibitor by the ribavirin
severity: Not recommended
65-H2-RECEPTOR-ANTAGONISTS.html


***interaction***
drug1
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
drug2
drug name: ATAZANAVIR
rxNorm: 343047
atc: J05AE08
Risk of decrease of the plasma concentrations of the atazanavir
severity: Take into account

***interaction***
drug1
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
drug2
drug name: CYANOCOBALAMIN
rxNorm: 11248
more atc: B03BA01
more atc: B03BA02
more atc: B03BA51
Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of vitamin B12
severity: Take into account

***interaction***
drug1
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
drug2
class name: METABOLIZED TYROSINE-KINASE INHIBITORS 
class code: L01XE
Risk of decrease of the bioavailabilty of the tyrosine kinase inhibitor, by reason of its pH-dependent absorption
severity: Take into account
-except with the vandetanib

***interaction***
drug1
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory
severity: Take into account

***interaction***
drug1
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory
severity: Take into account

***interaction***
drug1
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
drug2
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory
severity: Not recommended
-only with the oral suspension form of posaconazole

***interaction***
drug1
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
drug2
drug name: RILPIVIRINE
rxNorm: 1102270
atc: J05AG05
Risk of decrease of the plasma concentrations of the rilpivirine
severity: Take into account
If necessary, use an active H2 antihistmine in one dose per day, to be taken at least 12 hours before, or at least 4 hours after. 

***interaction***
drug1
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
drug2
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
Risk of decrease of the effect of the ulipristal due to decrease of its absorption 
severity: Take into account
66-PROTON-PUMP-INHIBITORS.html


***interaction***
drug1
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
drug2
drug name: ATAZANAVIR
rxNorm: 343047
atc: J05AE08
Very large decrease of the plasma concentrations of the atazanavir, with risk of therapeutic failure
severity: Not recommended

***interaction***
drug1
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
drug2
drug name: CYANOCOBALAMIN
rxNorm: 11248
more atc: B03BA01
more atc: B03BA02
more atc: B03BA51
Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12.
severity: Take into account

***interaction***
drug1
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
drug2
class name: METABLOIZED TYROSINE-KINASE INHIBITORS
class code: L01XE
Risk of decrease of the bioavailability of the tyrosine kinase inhibitor, by reason of its pH-dependent absorption
severity: Take into account
-except with the imatinib and the vandetanib

***interaction***
drug1
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory
severity: Take into account

***interaction***
drug1
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
Decrease of the absorption of the azole antifungal due to increase of the intragastric pH by the antisecretory 
severity: Take into account

***interaction***
drug1
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
drug2
drug name: LEDIPASVIR
rxNorm: 1591922
Decrease of the concentrations of ledipasvir when the proton pump inhibitor is administered before the ledipasvir
severity: Precaution for use
It is recommended that the proton pump inhibitor and the ledipasvir be taken simultaneously.

***interaction***
drug1
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
drug2
drug name: METHOTREXATE
rxNorm: 6851
more atc: BA01
more atc: L04AX03
Risk of increase of the toxicity of the methotrexate due to decrease of its elimination
severity: Not recommended
-with the methotrexate in doses > 20mg /week

***interaction***
drug1
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
drug2
drug name: ST JOHN'S WORT
rxNorm: 258326
Risk of ineffectiveness of the treatment by the antisecretory due to increase of its metabolism by the St Johns wort
severity: Take into account

***interaction***
drug1
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
drug2
Drug with no codes: MYCOPHENOLATE MOFETIL
more atc: MYCOPHEN
more atc: OLIC
more atc: ACID
more atc: MYCOPHEN
more atc: OLATE
more atc: MOFETIL
more atc: MYCOPHEN
more atc: OLIC
more atc: ACID
more atc: MYCOPHEN
more atc: OLIC
more atc: ACID
more atc: 7145
more atc: L04AA06
Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness
severity: Take into account

***interaction***
drug1
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
drug2
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
Decrease of the absorption of the azole antifungal, due to increase of the intragastric pH by the antisecretory 
severity: Not recommended
Not recommended

***interaction***
drug1
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
drug2
drug name: RILPIVIRINE
rxNorm: 1102270
atc: J05AG05
Decrease of the plasma concentrations of rilpivirine by the proton pump inhibitor (decreased absorption due to the increase of the gastric pH). 
severity: CONTRAINDICATION

***interaction***
drug1
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
drug2
drug name: ULIPRISTAL
rxNorm: 1005921
atc: G03AD02
Risk of decrease of the effect of the ulipristal, due to decrease of its absorption
severity: Take into account
67-MERCURIAL-ANTISEPTICS.html


***interaction***
drug1
class name: MERCURIAL ANTISEPTICS
class code: D08AK0
drug2
drug name: POVIDONE-IODINE
rxNorm: 8611
more atc: D08AG02
more atc: D09AA09
more atc: D11AC06
more atc: G01AX11
more atc: R02AA15
more atc: S01AX18
Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.
severity: Not recommended
68-URINARY-ANTISPASMODICS.html


***interaction***
drug1
class name: URINARY ANTISPASMODICS
class code: DFST
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of undesirable effects


severity: Contraindication
-with the darifenacin
69-ANTI-TNF-ALPHA.html


***interaction***
drug1
class name: ANTI-TNF ALPHA
class code: LO4AB
drug2
drug name: ABATACEPT 
rxNorm: 614391
atc: L04AA24
Increase of the immunodepression 
severity: Not recommended

***interaction***
drug1
class name: ANTI-TNF ALPHA
class code: LO4AB
drug2
drug name: ANAKINRA
rxNorm: 72435
atc: L04AC03
Increased risk of serious infections and neutropenia
severity: Not recommended

***interaction***
drug1
class name: ANTI-TNF ALPHA
class code: LO4AB
drug2
drug name: CANAKINUMAB
rxNorm: 853491
atc: L04AC08
Risk of increase of serious infections
severity: Not recommended

***interaction***
drug1
class name: ANTI-TNF ALPHA
class code: LO4AB
drug2
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
Risk of general vaccine disease possibly fatal
severity: CONTRAINDICATION
And during the 3 months following the end of the treatment.
6-ASCORBIC-ACID.html


***interaction***
drug1
drug name: ASCORBIC ACID
rxNorm: 1151
more atc: A11GA
more atc: 11GA01
more atc: A11GA01
more atc: A11GB
more atc: A11GB01
more atc: G01AD03
more atc: S01XA15
drug2
drug name: DEFEROXAMINE
rxNorm: 3131
atc: V03AC01
With large doses of ascorbic acid and by intravenous route: 

cardiac function anomalies, even acute heart failure (generally reversible by ending the administration of the Vitamin C).
severity: Precaution for use
In the case of hemochromatosis, only give Vitamin C after having started the treatment with the deferoxamine. Monitor cardiac function when these substances are administered together.
70-MORPHINE-LIKE-ANTITUSSIVES.html


***interaction***
drug1
class name: MORPHINE LIKE ANTITUSSIVES
class code: R05DA0-001
drug2
class name: AGONIST OPIOID ANALGESICS
class code: N01A-N02A
Increased risk of respiratory depression, which can be fatal in cases of overdose
severity: Take into account

***interaction***
drug1
class name: MORPHINE LIKE ANTITUSSIVES
class code: R05DA0-001
drug2
drug name: METHADONE
rxNorm: 6813
more atc: N02AC52
more atc: N07BC02
Increased risk of respiratory depression, which can be fatal in cases of overdose
severity: Take into account
71-TRUE-MORPHINE-ANTITUSSIVES.html


***interaction***
drug1
class name: TRUE MORPHINE ANTITUSSIVES
class code: R0GDA0-002
drug2
class name: AGONIST OPIOID ANALGESICS
class code: N01A-N02A
Increased risk of respiratory depression which can be fatal in cases of overdose
severity: Take into account

***interaction***
drug1
class name: TRUE MORPHINE ANTITUSSIVES
class code: R0GDA0-002
drug2
drug name: METHADONE
rxNorm: 6813
more atc: N02AC52
more atc: N07BC02
Increased risk of respiratory depression which can be fatal in case of overdose
severity: Take into account

***interaction***
drug1
class name: TRUE MORPHINE ANTITUSSIVES
class code: R0GDA0-002
drug2
class name: AGONIST-ANTAGONIST OPIOIDS 
class code: NO2A-001
Decrease of the antalgic or antitussive effect of the opioid, due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome
severity: Not recommended
72-VITAMIN-K-ANTAGONISTS.html


***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
Drug with no codes: ALCOHOL (DRINK OR INGREDIENT)
Possible variations of the anticoagulating effect, with increase in case of acute intoxication or decrease in case of chronic alcoholism (increased metabolism)
severity: Take into account

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: ALLOPURINOL
rxNorm: 519
atc: M04AA01
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the allopurinol and a week after it is stopped. 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: ALPHA-TOCOPHEROL
rxNorm: 11256
more atc: A11HA03
With the vitamin E used in doses greater than or equal to 500 mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with vitamin E and after it is stopped.

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: AMINOGLUTETHIMIDE
rxNorm: 677
atc: L02BG01
Described for warfarin and acenocoumarol.

Decrease of the effect of the vitamin K antagonist, due to increase of its hepatic metabolism by the aminoglutethimide
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with aminoglutethimide and two weeks after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the amiodorone and a week after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
class name: ANDROGENS
class code: A14AA0
Increase of the risk of hemorrhage due to direct effect on the coagulation and/or the fibrinolytic systems
severity: Precaution for use
More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the androgen and after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
class name: ANTICONVULSANT ENZYME INDUCERS
class code: N03A-001
Decrease (or, infrequently, increase with the phenytoin) of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the anticonvulsant inducer
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the anticonvulsant inducer and a week after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
class name: ANTIPURINES
class code: ANTIPUR
Decrease of the effect of the Vitamin K antagonist due to increase of its hepatic metabolism
severity: Precaution for use
More frequesnt testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist at the beginning of the treatment by the immunomodulator and after it is stopped. 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
Risk of decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the aprepitant
severity: Precaution for use
More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during and after the administration of the medications together. 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism
severity: Precaution for use 
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: CEFAMANDOLE
rxNorm: 2178
atc: J01DC03
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: CEFOPERAZONE
rxNorm: 2184
atc: J01DD12
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during treatment with the cephalosporin and after it is stopped 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: CEFOTETAN
rxNorm: 2184
atc: J01DC05
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution of use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it stopped. 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: CEFTRIAXONE
rxNorm: 2193
atc: J01DD04
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: CIMETIDINE
rxNorm: 2541
atc: A02BA01
With the cimetidine used in doses greater than or equal to 800mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cimetidine and a week after it is stopped. 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: CLINDAMYCIN
rxNorm: 2582
more atc: D10AF01
more atc: G01AA10
more atc: J01FF01
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin Kantagonist during the treatment with clindamycin and after it is stopped.

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: COLCHICINE
rxNorm: 2683
atc: M04AC01
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the colchicine and a week after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
class name: TETRACYCLINE ANTIBIOTICS
class code: D06AA-J01AA
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tetracycline antibiotic and after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
class name: CYTOTOXICS
class code: L01
Increase of the risk of thrombosis and hemorrhage accompanying tumors. In addition, possible interaction between the vitamin K antagonist and the chemotherapy
severity: Precaution for use
More frequent testing of the INR

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: DANAZOL
rxNorm: 3102
atc: G03XA01
Increase of the risk of hemorrhage due to direct effect on coagulation and/or the fibrinolytic systems.
severity: Precaution for use
More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the danazol and after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: DEFERASIROX
rxNorm: 614373
atc: V03AC03
Increase of the risk of causing ulcers and digestive hemorrhage
severity: Take into account

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: DISULFIRAM
rxNorm: 3554
atc: N07BB01
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the disulfiram and a week after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: DRONEDARONE
rxNorm: 233698
atc: C01BD07
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the dronedarone and a week after it is stopped. 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: ECONAZOLE
rxNorm: 3743
atc: G01AF05
Regardless of the route of administration of the econazole:

increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with econazole and after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: EFAVIRENZ
rxNorm: 195085
atc: J05AR06
Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
class name: FIBRATES
class code: C01AB-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fibrate and a week after it is stopped. 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
atc: J02AC01
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluconazole and a week after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
class name: FLUOROQUINOLONES
class code: J01MA-001
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
class name: FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)
class code: L01BC-001
Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Not recommended
If it is not possible to avoid administering these together, more frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the cytotoxic and a week after it is stopped.

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: GLUCOSAMINE
rxNorm: 4845
atc: M01AX05
Increase of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: GRISEOFULVINE
rxNorm: 5021
atc: D01BA01
Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the griseofulvine
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the griseofulvine and a week after it is stopped 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
class name: UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENT)
class code: B01AB-003
Increase of the risk of hemorrhage
severity: Precaution for use
When the heparin alternates with the vitamin K antagonist, strengthen clinical monitoring. 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: IMATINIB
rxNorm: 282388
atc: L01XE01
Increase of the risk of hemorrhage
severity: Not recommended
If administering these together cannot be avoided, strict clinical monitoring and more frequent monitoring of the INR

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
class name: HMG-COA REDUCTASE INHIBITORS (STATINS)
class code: C10AA
Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist.

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Variation of the effect of the vitamin K antagonist, most often by decreasing it
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the length of the treatment

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the itraconazole and a week after it is stopped.

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: LEVOCARNITINE
rxNorm: 42955
atc: A16AA01
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequenttesting of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with levocarnitine and a week after it is stopped.

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
class name: MACROLIDES (EXCEPT SPIRAMYCIN)
class code: J01FA
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage the vitamin K antagonist during the treatment with the macrolide and after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: METHYLPREDNISOLONE 
rxNorm: 
For doses of 0.5g to 1g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
Testing of the INR 2 to 4 days after the bolus of mythylprednisolone or in the presence of any signs of hemorrhage

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: MICONAZOLE 
rxNorm: 6932
more atc: A01AB09
more atc: A07AC01
more atc: D01AC02
more atc: G01AF04
more atc: J02AB01
more atc: S02AA13
Unpredictable hemorrhage, possibly serious
severity: CONTRAINDICATION

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: ST JOHN'S WORT
rxNorm: 258326
Decrease of the plasma concentrations of the vitamin K antagonist, by reason of its enzyme inducer effect, with risk of reduction of effectiveness, even complete loss of the effect, which could have serious consequences (thrombolitic event)
severity: CONTRAINDICATION
In case of an accidental use of the two substances together, do not stop the St Johns Wort suddenly, but test the INR before and then after the St Johns Wort is stopped. 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: NEVIRAPINE 
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism
severity: Precaution for use
More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: NOSCAPINE
rxNorm: 7533
atc: R05DA07
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Not recommended

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: ORLISTAT
rxNorm: 37925
atc: A08AB01
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the orlistat and after it is stopped 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: PARACETAMOL
rxNorm: 161
atc: N02BE01
Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage when taking paracetamol in maximal doses (4g/day) for at least 4 days
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during treatment with the paracetamol and after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: PENTOXIFYLLINE
rxNorm: 8013
atc: C04AD03
Increase of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pentoxifylline and a week after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: PRISTINAMYCIN
rxNorm: 66958
atc: J01FG01
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pristinamycin and after it is stopped. 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: PROGUANIL
rxNorm: 2382
atc: P01BB01
Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the proguanil and after it is stopped. 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
Increase of the anticoagulant effect and of the risk of hemorrhage. Mecanism proposed: inhibition of the metabolism of the vitamin K antagonist
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the propafenone and after it is stopped. 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin. 
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the rifampicin and a week after it is stopped. 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: ROPINIROLE
rxNorm: 72302
atc: N04BC04
Increase of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with ropinirole and after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: SUCRALFATE
rxNorm: 10156
atc: A02BX02
Decrease of the digestive absorption of the vitamin K antagonist
severity: Precaution for use
Take the sucralfate at a different time from the vitamin K antagonist (more than 2 hours apart, if possible)

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: SULFAFURAZOLE
rxNorm: 10207
atc: S01AB02
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the antibiotic and a week after it is stopped.

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: SULFAMETHIZOLE
rxNorm: 10179
more atc: B05CA04
more atc: D06BA04
more atc: J01EB02
more atc: S01AB01
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the antibiotic treatment and a week after it is stopped. 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: SULFAMETHOXAZOLE
rxNorm: 10180
atc: J01EC01
Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage 
severity: Not recommended
If administering the substances together cannot be avoided, more frequent testing of the INR and adjustment of the dosage of the vitamin K antagonist during the treatment with cotrimoxazole and after it is stopped. 

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: TAMOXIFEN
rxNorm: 10324
atc: L02BA01
Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
class name: THROMBOLYTICS
class code: B01AD
Increase of the risk of hemorrhage
severity: Take into account

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: TIBOLONE
rxNorm: 38260
atc: G03CX01
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tibolone and after it is stopped

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: TRAMADOL
rxNorm: 10689
atc: N02AX02
Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tramadol and after it is stopped.

***interaction***
drug1
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage due to decrease of its hepatic metabolism
severity: Precaution for use
More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with voriconazole and a week after it is stopped. 
73-APIXABAN.html


***interaction***
drug1
drug name: APIXABAN
rxNorm: 1364430
atc: B01AF02
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Decrease of the plasma concentrations of the apixaban by the anticonvulsant enzymatic inducer, with risk of decrease of the therapeutic effect.
severity: Not recommended

***interaction***
drug1
drug name: APIXABAN
rxNorm: 1364430
atc: B01AF02
drug2
drug name: FLUCONAZOLE
rxNorm: 4450
more atc: D01AC15
more atc: J02AC01
Increase of the plasma concentrations of the apixiban by the fluconazole, with increase of the risk of bleeding
severity: Not recommended

***interaction***
drug1
drug name: APIXABAN
rxNorm: 1364430
atc: B01AF02
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of the apixaban by the inhibitor, with increase of the risk of bleeding. 
severity: Not recommended

***interaction***
drug1
drug name: APIXABAN
rxNorm: 1364430
atc: B01AF02
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect. 
severity: Not recommended
74-APOMORPHINE.html


***interaction***
drug1
drug name: APOMORPHINE
rxNorm: 1043
more atc: G04BE07
more atc: N04BC0
drug2
drug name: ONDANSETRON
rxNorm: 26225
atc: A04AA01
Severe hypotension and loss of consciousness have been reported when ondansetron and apomorphine were taken together. 
severity: CONTRAINDICATION
75-APREPITANT.html


***interaction***
drug1
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Risk of very large decrease of the concentrations of aprepitant
severity: Not recommended

***interaction***
drug1
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Risk of decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the aprepitant
severity: Precaution for use
More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during and after the administration of the medications together. 

***interaction***
drug1
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
drug2
drug name: CYPROTERONE
rxNorm: 3014
more atc: G03HA01
more atc: G03HB01
Risk of decrease of the concentrations of the cyproterone with risk of lower contraceptive effectiveness
severity: Precaution for use
--In its use as a hormonal contraceptive: 

***interaction***
drug1
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
drug2
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
Decrease of the concentrations of the estrogen-progestin or of the progestin, with risk of lower contraceptive effectiveness. 
severity: Precaution for use
Chose another contraceptive method, in particular a barrier type, during the time these medications are taken together and a cycle following. 

***interaction***
drug1
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
drug2
drug name: IFOSFAMIDE
rxNorm: 5657
atc: L01AA06
Risk of increase of the neurotoxicity of the ifosfamide
severity: Take into account 

***interaction***
drug1
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increase of the concentrations of aprepitant due to decrease of its hepatic metabolism by the itraconazole. 
severity: Take into account

***interaction***
drug1
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
drug2
drug name: PIMOZIDE
rxNorm: 8331
atc: N05AG02
Increased risk of ventricular arrhythmias, especially of torsades de pointes
severity: CONTRAINDICATION

***interaction***
drug1
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
drug2
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
(Except for IUD), decrease of the concentrations of progestin, with risk of lower contraceptive effectiveness.
severity: Precaution for use
Choose another method of contraception, in particular a barrier type, during the administration of these medications together and a cycle after. 

***interaction***
drug1
drug name: APREPITANT
rxNorm: 358255
atc: A04AD12
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Very large decrease of the concentrations of aprepitant
severity: Not recommended
76-ARIPIPRAZOLE.html


***interaction***
drug1
drug name: ARIPIPRAZOLE
rxNorm: 89013
atc: N05AX12
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Decrease of the plasma concentrations of the aripiprazole
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the aripiprazole during the administration of these medications together and 1 to 2 weeks after the inducer is stopped. 
77-ATALUREN.html


***interaction***
drug1
drug name: ATALUREN
rxNorm: 
more atc: M09AX03
drug2
class name: AMINOGLYCOSIDES
class code: J01GB-001
Risk of increase of the renal toxicity of the aminoglycoside
severity: CONTRAINDICATIOIN
78-ATAZANAVIR.html


***interaction***
drug1
drug name: ATAZANAVIR
rxNorm: 343047
atc: J05AE08
drug2
class name: H2 RECEPTOR ANTAGONISTS
class code: A02BA-001
Risk of decrease of the plasma concentrations of the atazanavir
severity: Take into account

***interaction***
drug1
drug name: ATAZANAVIR
rxNorm: 343047
atc: J05AE08
drug2
class name: PROTON PUMP INHIBITORS
class code: A02BC-001
Very large decrease of the plasma concentrations of the atazanavir, with risk of therapeutic failure
severity: Not recommended

***interaction***
drug1
drug name: ATAZANAVIR
rxNorm: 343047
atc: J05AE08
drug2
drug name: BUPRENORPHINE
rxNorm: 1819
more atc: N02AE01
more atc: N07BC01
Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor
severity: Take into account

***interaction***
drug1
drug name: ATAZANAVIR
rxNorm: 343047
atc: J05AE08
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Increase of the plasma concentrations of clarithromycin and inhibition of the formation of its active metabolite
severity: Precaution for use
Regular clinical and biological monitoring, especially at the beginning of the administration of these drugs together

***interaction***
drug1
drug name: ATAZANAVIR
rxNorm: 343047
atc: J05AE08
drug2
drug name: EFAVIRENZ
rxNorm: 195085
more atc: J05AG03
more atc: J05AR06
Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism
severity: Not recommended
If the administration of the two substances together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together

***interaction***
drug1
drug name: ATAZANAVIR
rxNorm: 343047
atc: J05AE08
drug2
drug name: NEVIRAPINE 
rxNorm: 53654
more atc: J05AG01
more atc: J05AR07
more atc: J05AR05
Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism
severity: Not recommended
If the administration of these medications together proves necessary, adjustment of the dosage of the atazanavir with regular clinical and biological monitoring, especially at the beginning of the administration of the two substances together

***interaction***
drug1
drug name: ATAZANAVIR
rxNorm: 343047
atc: J05AE08
drug2
drug name: TENOFOVIR DISOPROXIL
rxNorm: 300195
more atc: J05AF07
more atc: J05AR06
more atc: J05AR08
more atc: J05AR09
more atc: J05AR03
Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same two substances together [sic]
severity: Take into account
Do not administer atazanavir with the tenofovir without ritonavir
79-ATORVASTATIN.html


***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: AZITHROMYCIN
rxNorm: 18631
atc: J01FA10
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol-lowering medication
severity: Precaution for use
Use weaker doses of the cholesterol-lowering medication or another statin not affected by this type of interaction

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type, due to decrease of the hepatic metabolism of the atorvastatin
severity: Precaution for use
Do not exceed the dosage of 20 mg/day of atorvastatin. If the therapeutic objective is not attained with this dosage, use another statin not affected by this type of interaction.

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the metabolism of the cholesterol-lowering medication)
severity: Precaution for use
Do not exceed the dosage of 10mg/day of atorvastatin. If the therapeutic objective is not reached at that dosage, use another statin not affected by this type of interaction.

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: CLARITHROMYCIN
rxNorm: 21212
atc: J01FA09
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering drug
severity: Precaution for use
Administer weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering agent
severity: Precaution for use
Use weaker doses of cholesterol-lowering agent or another statin not affected by this type of interaction

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: ERYTHROMYCIN
rxNorm: 4053
more atc: D10AF02
more atc: J01FA01
more atc: S01AA17
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering agent
severity: Precaution for use
Use weaker doses of cholesterol-lowering medication. If the therapeutic objective is not reached, use another statin not affected by this type of interaction

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)
severity: Not recommended
Use weaker doses of atorvastatin. If the therapeutic objective is not reached, use another statin not affected by this type of interaction

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: KETOCONAZOLE
rxNorm: 
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
class name: OMBITASVIR + PARITAPRVIR
class code: OMPA
Increase of the plasma concentrations of the atorvastatin due to decrease of its hepatic metabolism by the therapy with the two drug combination
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
Drug with no codes: GRAPEFRUIT (JUICE AND FRUIT)
Increase of the plasma concentrations of the hypokaliemiant, with risk of undesirable effects, especially muscular ones
severity: Take into account

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: POSACONAZOLE
rxNorm: 282446
atc: J02AC04
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: RANOLAZINE
rxNorm: 35829
atc: C01EB18
Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to inhibition of the metabolism of the atorvastatin by the ranolazine
severity: Precaution for use
Use weaker doses of cholesterol-lowering agent or another statin not affected by this type of interaction

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin
severity: Not recommended

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: ROXITHROMYCIN
rxNorm: 9478
atc: J01FA06
Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type
severity: Precaution for use
Use weaker doses of cholesterol lowering agent

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: STIRIPENTOL
rxNorm: 37119
atc: N03AX17
Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol-lowering medication)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: TELAPREVIR
rxNorm: 1102261
atc: J05AE11
Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the atorvastatin)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: TELITHROMYCIN
rxNorm: 274786
atc: J01FA15
Increased risk of undesirable effects (dose-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol-lowering medication)
severity: CONTRAINDICATION

***interaction***
drug1
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol-lowering medication
severity: Precaution for use
Use weaker doses of cholesterol-lowering agent. If the therapeutic objective is not reached, use another statin not affected by this type of interaction
7-CHOLIC-ACID.html


***interaction***
drug1
drug name: CHOLIC ACID
rxNorm: 1440856
atc: A05AA03
drug2
class name: PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)
class code: N03AA-001
Antagonist effect of the barbiturate
severity: CONTRAINDICATION
80-ATOVAQUONE.html


***interaction***
drug1
drug name: ATOVAQUONE
rxNorm: 60212
atc: P01AX06
drug2
drug name: EFAVIRENZ
rxNorm: 195085
atc: J05AR06
Decrease of the plasma concentrations of atovaquone by the enzyme inducer
severity: Not recommended

***interaction***
drug1
drug name: ATOVAQUONE
rxNorm: 60212
atc: P01AX06
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Decrease, possibly very large, of the plasma concentrations of the atovaquone due to increase of its metabolism
severity: Not recommended

***interaction***
drug1
drug name: ATOVAQUONE
rxNorm: 60212
atc: P01AX06
drug2
drug name: RIFABUTIN
rxNorm: 55672
atc: J04AB04
Moderate decrease of the plasma concentrations of atovaquone by the enzyme inducer
severity: Take into account

***interaction***
drug1
drug name: ATOVAQUONE
rxNorm: 60212
atc: P01AX06
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Decrease of the plasma concentrations of atovaquone by the enzyme inducer
severity: Not recommended
81-OTHER-CORTICOIDES,-ESPECIALLY-INHALED-ONES.html


***interaction***
drug1
class name: OTHER CORTICOIDES, ESPECIALLY INHALED ONES
class code: D07AC-001
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome, even of adrenal insufficiency
severity: Take into account

***interaction***
drug1
class name: OTHER CORTICOIDES, ESPECIALLY INHALED ONES
class code: D07AC-001
drug2
drug name: ITRACONAZOLE
rxNorm: 28031
atc: J02AC02
In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the itraconazole, with risk of appearance of Cushing's syndrome, even of adrenal insufficiency
severity: Take into account

***interaction***
drug1
class name: OTHER CORTICOIDES, ESPECIALLY INHALED ONES
class code: D07AC-001
drug2
drug name: KETOCONAZOLE
rxNorm: 6135
more atc: D01AC08
more atc: G01AF11
more atc: J02AB02
In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the ketoconazole, with risk of appearance of Cushing's syndrome, even of adrenal insufficiency
severity: Take into account

***interaction***
drug1
class name: OTHER CORTICOIDES, ESPECIALLY INHALED ONES
class code: D07AC-001
drug2
drug name: VORICONAZOLE
rxNorm: 121243
atc: J02AC03
In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the voriconazole, with risk of appearance of Cushing's syndrome, even of adrenal insufficiency
severity: Take into account
82-AVANAFIL.html


***interaction***
drug1
drug name: AVANAFIL
rxNorm: 1291301
atc: G04BE10
drug2
Drug with no codes: GRAPEFRUIT (JUICE AND FRUIT)
Increase of the plasma concentrations of the avanafil, with risk of hypotension
severity: Not recommended
83-AZITHROMYCIN.html


***interaction***
drug1
drug name: AZITHROMYCIN 
rxNorm: 18631
atc: J01FA10
drug2
drug name: ATORVASTATIN
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering medication
severity: Precaution for use
Use weaker doses of the cholesterol lowering medication or another statin not affected by this type of interaction.

***interaction***
drug1
drug name: AZITHROMYCIN 
rxNorm: 18631
atc: J01FA10
drug2
drug name: CICLOSPORIN
rxNorm: 3008
atc: S01XA18
Risk of increase of the blood concentrations of ciclosporin and of the creatinemia
severity: Precaution for use
Blood concentration dosage of the ciclosporin, testing of the renal function, and adjustment of the dosage during the administration of the two substances together and after the macrolide is stopped.

***interaction***
drug1
drug name: AZITHROMYCIN 
rxNorm: 18631
atc: J01FA10
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Increase of the digoxinemia due to increase of its absorption
severity: Precaution for use
Clinical monitoring and possibly monitoring of the digoxinemia during the treatment with the azithromycin and after it is stopped. 

***interaction***
drug1
drug name: AZITHROMYCIN 
rxNorm: 18631
atc: J01FA10
drug2
drug name: IVABRADINE
rxNorm: 77417
atc: C01EB17
Increased risk of problems with ventricular rhythm, especially of torsades de pointes. In addition, increase of the plasm concentrations of the ivabradine due to decrease of its metabolism by the azithromycin.
severity: Precaution for use
Clinical monitoring and EKG during the administration of these together.

***interaction***
drug1
drug name: AZITHROMYCIN 
rxNorm: 18631
atc: J01FA10
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolosis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent
severity: Precaution for use
Use weaker doses of the cholesterol lowering agent or chose another statin not affected by this type of interaction.

***interaction***
drug1
drug name: AZITHROMYCIN 
rxNorm: 18631
atc: J01FA10
drug2
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrhythmias, especially torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG during the administration of these substances together. 
84-AZTREONAM.html


***interaction***
drug1
drug name: AZTREONAM
rxNorm: 1272
atc: J01DF01
drug2
class name: VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE
class code: N03AG0
Risk of onset of convulsive crises, due to decrease of the plasma concentrations of the valproic acid
severity: Precaution for use
Clinical monitoring, plasma dosages, and possible adjustment of the dosage of the anticonvulsant during the treatment with the antibiotic and after it is stopped.
85-BACLOFEN.html


***interaction***
drug1
drug name: BACLOFEN
rxNorm: 1292
atc: M03BX01
drug2
class name: TRICYCLIC ANTIDEPRESSANTS
class code: N06AA-001
Risk of increase of hypotonia
severity: Take into account

***interaction***
drug1
drug name: BACLOFEN
rxNorm: 1292
atc: M03BX01
drug2
drug name: LEVODOPA
rxNorm: 6375
atc: N04BA01
Risk of aggravation of the Parkinsons syndrome or of undesirable central effects (visual hallucinations, confusion, headaches)
severity: Take into account
86-BARBITURATES.html


***interaction***
drug1
class name: BARBITURATES
class code: N05CA-001
drug2
class name: BENZODIAZEPINES AND RELATED
class code: N05-001
Increased risk of respiratory depression, which can be fatal in case of overdose
severity: Take into account

***interaction***
drug1
class name: BARBITURATES
class code: N05CA-001
drug2
class name: OPIOIDS
class code: N0-R0
Increased risk of respiratory depression, which can be fatal in case of overdose
severity: Take into account
87-BEDAQUILINE.html


***interaction***
drug1
drug name: BEDAQUILINE
rxNorm: 1364504
atc: J04AK05
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer
severity: Not recommended

***interaction***
drug1
drug name: BEDAQUILINE
rxNorm: 1364504
atc: J04AK05
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor
severity: Not recommended
If administering these drugs together is necessary, more frequent EKG and monitoring of transaminase levels are recommended.

***interaction***
drug1
drug name: BEDAQUILINE
rxNorm: 1364504
atc: J04AK05
drug2
drug name: ST JOHNS WORT
rxNorm: 258326
Risk of decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer
severity: Not recommended
88-BELATACEPT.html


***interaction***
drug1
drug name: BELATACEPT
rxNorm: 1112973
atc: L04AA28
drug2
class name: ATTENUATED LIVE VIRUS VACCINES
class code: J07B-001
Risk of general vaccine disease, possibly fatal. 
severity: Not recommended
89-BENZODIAZEPINES-AND-RELATED.html


***interaction***
drug1
class name: BENZODIAZEPINES AND RELATED
class code: N05-001
drug2
class name: BARBITURATES
class code: N05CA-001
Increased risk of respiratory depression, which can be fatal in case of overdose
severity: Take into account

***interaction***
drug1
class name: BENZODIAZEPINES AND RELATED
class code: N05-001
drug2
drug name: BUPRENORPHINE
rxNorm: 1819
more atc: N02AE01
more atc: N07BC01
With the buprenorphine used in replacement therapy: increased risk of respiratory depression, which can be fatal. 
severity: Take into account
Evaluate carefully the risk /benefit relationship of administering these substances together. Inform the patient of the necessity of adhering to the prescribed doses. 

***interaction***
drug1
class name: BENZODIAZEPINES AND RELATED
class code: N05-001
drug2
drug name: CLOZAPINE
rxNorm: 2626
atc: N05AH02
Accrued risk of drop in blood pressure with respiratory and/or cardiac arrest.
severity: Take into account

***interaction***
drug1
class name: BENZODIAZEPINES AND RELATED
class code: N05-001
drug2
class name: OPIOIDS
class code: N0-R0
Increased risk of respiratory depression, which can be fatal in case of overdose
severity: Take into account
8-CLODRONIC-ACID.html


***interaction***
drug1
drug name: CLODRONIC ACID
rxNorm: 3350
atc: M05BA02
drug2
drug name: ESTRAMUSTINE
rxNorm: 4089
atc: L01XX11
Risk of increase of the plasma concentrations of estrasmustine by the clodronate
severity: Precaution for use
Clinical monitoring during the administration of these substances together. 
90-BETA-2-MIMETICS-or-BETA2-ADRENERGIC-AGONISTS.html


***interaction***
drug1
class name: BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS
class code: R03C-001
drug2
drug name: HALOTHANE
rxNorm: 5095
atc: N01AB01
In cases of obstetrical surgery, increased uterine inertia with risk of hemorrhage; furthermore serious ventricular arrhythmias, due to increase of the cardiac reactivity
severity: Not recommended
Interrupt treatment with the beta-2 agonist if the anesthesia must be done with halothane

***interaction***
drug1
class name: BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS
class code: R03C-001
drug2
drug name: INSULIN
rxNorm: 5856
more atc: A10AC01
more atc: A10AC02
more atc: A10AC03
more atc: A10AC04
more atc: A10AD01
more atc: A10AD02
more atc: A10AD03
more atc: A10AD04
more atc: A10AD05
more atc: A10AE01
more atc: A10AE02
more atc: A10AE03
more atc: A10AE04
more atc: A10AE05
more atc: A10AF01
Elevation of the glycemia by the beta-2 mimetic
severity: Precaution for use
Reinforce blood and urine monitoring

***interaction***
drug1
class name: BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS
class code: R03C-001
drug2
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
Elevation of the glycemia by the beta-2 mimetic
severity: Precaution for use
Reinforce blood and urine monitoring. Possibly change to insulin, if the situation requires. 
91-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL-AND-SOTALOL).html


***interaction***
drug1
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)
class code: C07AB-001
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Disorders of autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)
severity: Precaution for use
Clinical monitoring and EKG

***interaction***
drug1
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)
class code: C07AB-001
drug2
class name: CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)
class code: C01B-003
Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)
severity: Precaution for use
Clinical monitoring and EKG
92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html


***interaction***
drug1
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
drug2
class name: HALOGENATED HYDROCARBON ANESTHETICS
class code: N01AB0-001
Reduction of the compensatory cardiovascular reactions by the beta-blocking agents. The beta-adrenergic inhibition can be elevated during the surgical procedure by the beta-mimetics
severity: Precaution for use
As a general rule, do not stop the treatment with the beta-blocking agent and, in any case, avoid stopping it abruptly. Inform the anesthesiologist of this treatment.

***interaction***
drug1
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
drug2
class name: CENTRAL ANTIHYPERTENSIVES
class code: C02AC-001
Large increase of blood pressure in cases of sudden discontinuation of the treatment with the central hypertensive
severity: Precaution for use
Avoid stopping the treatment with the central antihypertensive abruptly. Clinical monitoring

***interaction***
drug1
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
drug2
class name: NON STEROIDAL ANTI-INFLAMMATORY DRUGS
class code: M01A-002
Reduction of the antihypertensive effect (inhibition of the vasodilator prostaglandins by the non steroidal anti-inflammatories)
severity: Take into account

***interaction***
drug1
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
drug2
class name: DIHYDROPYRIDINES
class code: C08CA-002
Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (addition of the negative inotropic effects). The beta-blocking agent can furthermore minimize the sympathetic reflex reaction brought into play in the case of excessive hemodynamic repercussion 
severity: Take into account

***interaction***
drug1
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and heart failure
severity: Not recommended
The administration of these medications together should only be done under clinical monitoring and strict EKG, in particular with older patients or at the beginning of treatment.

***interaction***
drug1
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
drug2
drug name: DIPYRIDAMOLE
rxNorm: 3521
atc: B01AC07
With the dipyridamole by injection: increase of the antihypertensive effect


severity: Take into account 

***interaction***
drug1
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
drug2
class name: GLINIDES
class code: A10BX-001
All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia
severity: Precaution for use
Inform the patient, and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose

***interaction***
drug1
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
drug2
class name: GLIPTINS
class code: A10B-001
All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia
severity: Precaution for use
Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose

***interaction***
drug1
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
drug2
drug name: INSULIN 
rxNorm: 5856
more atc: A10AC01
more atc: A10AC02
more atc: A10AC03
more atc: A10AC04
more atc: A10AD01
more atc: A10AD02
more atc: A10AD03
more atc: A10AD04
more atc: A10AD05
more atc: A10AE01
more atc: A10AE02
more atc: A10AE03
more atc: A10AE04
more atc: A10AE05
more atc: A10AF01
All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia
severity: Precaution for use
Inform the patient and, especially at the beginning of treatment, reinforce self-monitoring of blood glucose.

***interaction***
drug1
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
drug2
drug name: LIDOCAINE
rxNorm: 6387
more atc: C01BB01
more atc: C05AD01
more atc: D04AB01
more atc: N01BB02
more atc: R02AD02
more atc: S01HA07
more atc: S02DA01
more atc: N01BB52
With lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)
severity: Precaution for use
Clinical monitoring, EKG, and, possibly testing of the plasma concentrations of lidocaine during the administration of the substances together and after the beta-blocking agent is stopped. Adjustment, if needed, of the dosage of the lidocaine

***interaction***
drug1
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
drug2
drug name: PROPAFENONE
rxNorm: 8754
atc: C01BC03
Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)
severity: Precaution for use
Clinical monitoring and EKG.

***interaction***
drug1
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
drug2
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia
severity: Precaution for use
Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of treatment. 

***interaction***
drug1
class name: BETA BLOCKING AGENTS (EXCEPT ESMOLOL)
class code: C07AB-002
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and heart failure
severity: Not recommended
The administration of these medications together should only be undertaken under strict clinical monitoring and EKG, in particular with older patients or at the beginning of treatment. 
93-BETA-BLOCKING-AGENTS-IN-HEART-FAILURE.html


***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
drug name: AMIODARONE
rxNorm: 703
atc: C01BD01
Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia.
severity: Precaution for use
Regular clinical monitoring and EKG

***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
class name: HALOGENATED HYDROCARBON ANESTHETICS
class code: N01AB0-001
Reduction of the compensatory cardiovascular reactions by the beta-blocking agents. The beta-adrenergic inhibition can be elevated by the beta-stimulants during the surgery 
severity: Precaution for use
As a general rule, do not stop the treatment with the beta blocking agent and, in any case, avoid stopping it abruptly. Inform the anesthesiologist of this treatment.

***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
class name: CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)
class code: C01B-003
Negative inotropic effect with risk of acute decompensated heart failure
severity: CONTRAINDICATION

***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
class name: ACETYLCHOLINESTERASE INHIBITORS
class code: ACETCHO
Risk of excessive bradycardia (addition of the bradycardia inducing effects)
severity: Precaution for use
Regular clinical monitoring, especially at the beginning of the administration of the substances together 

***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
class name: TRICYCLIC ANTIDEPRESSANTS
class code: N06AA-001
Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)
severity: Take into account

***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
class name: CENTRAL ANTIHYPERTENSIVES
class code: C02AC-001
Central decrease of the sympathetic tone and vasodilator effect of the central antihypertensives, dangerous in cases of heart failure treated with a beta-blocking agent and vasodilator 
severity: Not recommended

***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
drug name: DIGOXIN 
rxNorm: 3407
atc: C01AA05
Difficulties of autoregulation (bradycardia, sinus arrest) and of sinoatrial and atrioventricular conduction 
severity: Take into account

***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
class name: DIHYDROPYRIDINES
class code: C08CA-002
Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (negative iotropic effect of the dihydropyridines in vitro more or less marked and susceptible of adding to the negative inotropic effects of the beta-blocking agents). The presence of a beta-blocking treatment can furthermore minimize the sympathetic reflex reaction put into play in cases of excessive hemodynamic repercussion
severity: Take into account

***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
drug name: DILTIAZEM
rxNorm: 3443
atc: C08DB01
Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest), and disorders of sinoatrial and atrioventricular conduction
severity: CONTRAINDICATION

***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
class name: GLINIDES
class code: A10BX-001
All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia
severity: Precaution for use
Inform the patient and, especially at the beginning of treatment, strengthen self-monitoring of blood glucose.

***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
drug name: INSULIN 
rxNorm: 5856
more atc: A10AC01
more atc: A10AC02
more atc: A10AC03
more atc: A10AC04
more atc: A10AD01
more atc: A10AD02
more atc: A10AD03
more atc: A10AD04
more atc: A10AD05
more atc: A10AE01
more atc: A10AE02
more atc: A10AE03
more atc: A10AE04
more atc: A10AE05
more atc: A10AF01
All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia
severity: Precaution for use
Inform the patient and, especially at the start of treatment, reinforce self-monitoring of blood glucose

***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
drug name: LIDOCAINE
rxNorm: 6387
more atc: C01BB01
more atc: C05AD01
more atc: D04AB01
more atc: N01BB02
more atc: R02AD02
more atc: S01HA07
more atc: S02DA01
more atc: N01BB52
Negative inotropic effect with risk of acute decompensated heart failure
severity: Take into account

***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
class name: NEUROLEPTICS
class code: N05AA-003
Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)
severity: Take into account

***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
class name: SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES
class code: C01-N05
Increased risk of ventricular arrythmias, especially of torsades de pointes
severity: Precaution for use
Clinical monitoring and EKG.

***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
class name: BLOOD GLUCOSE LOWERING SULFONAMIDES
class code: A10BB
All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia
severity: Precaution for use
Inform the patient and reinforce self-monitoring of blood glucose, especially at the beginning of treatment. 

***interaction***
drug1
class name: BETA-BLOCKING AGENTS IN HEART FAILURE
class code: C07AB-003
drug2
drug name: VERAPAMIL
rxNorm: 11170
atc: C08DA01
Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction 
severity: CONTRAINDICATION
94-BISPHOSPHONATES.html


***interaction***
drug1
class name: BISPHOSPHONATES
class code: M05B-001
drug2
drug name: CALCIUM
rxNorm: 1428011
atc: A12AA
For calcium salts administered via oral route: decrease of the digestive absorption of the bisphosphonates
severity: Precaution for use
Take the calcium salts and antacids at a different time from the bisphosphonates (from 30 minutes minimum to more than 2 hours apart, if possible, depending on the bisphosphonate).

***interaction***
drug1
class name: BISPHOSPHONATES
class code: M05B-001
drug2
drug name: IRON
rxNorm: 1431589
atc: B03A
For the iron salts administered via oral route: decrease of the digestive absorption of the bisphosphonates
severity: Precaution for use
Take the iron salts at a different time from the bisphosphonates (from 30 minutes minimum to more than 2 hours apart, if possible, depending on the bisphosphonate).
95-BLEOMYCIN.html


***interaction***
drug1
drug name: BLEOMYCIN 
rxNorm: 1622
atc: L01DC01
drug2
drug name: BRENTUXIMAB 
rxNorm: 1147320
more atc: L01XC12
Risk of increase of pulmonary toxicity
severity: CONTRAINDICATION
96-BOCEPREVIR.html


***interaction***
drug1
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Risk of decrease of the plasma concentrations of boceprevir
severity: Not recommended
If administering these substances together cannot be avoided, regular clinical and biological monitoring, especially at the beginning of the administration of them together.

***interaction***
drug1
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
drug2
drug name: ATORVASTATIN 
rxNorm: 83367
atc: C10AA05
Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the atorvastatin
severity: Precaution for use
Do not exceed the dosage of 20mg/day of atorvastatin. If the therapeutic objective is not reached with this dosage, use another statin not affected by this type of interaction.

***interaction***
drug1
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
drug2
drug name: DROSPIRENONE
rxNorm: 840781
atc: G03AA12
Increase by more than double of the concentrations of drosperinone when taken with the boceprevir
severity: Nor recommended
Choose a contraceptive with another progestin, especially in cases of hyperkalemia

***interaction***
drug1
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
drug2
class name: NON-CONTRACEPTIVE ESTROGENS
class code: G03C-001
Decrease of the effectiveness of the estrogen.
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration with the boceprevir.

***interaction***
drug1
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
drug2
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
Aside from the combination with ethinylestradiol (0.035mg)/noresthisterone (1mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir
severity: Precaution for use
Use a reliable contraceptive method, additional or alternative, during the time these medications are taken together. 

***interaction***
drug1
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
drug2
class name: IMMUNOSUPPRESSANTS
class code: L04A
Increase of the blood concentrations of the immunosuppressant (substantial for the ciclosporin, extremely large for the tacrolimus)
severity: Precaution for use
Blood concentration dosage of the immunosuppressant, testing of renal function, and adjustment of its dosage during the administration of the medications together and after it is stopped.

***interaction***
drug1
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
drug2
class name: RITONAVIR BOOSTED PROTEASE INHIBITORS
class code: J05AE-002
Decrease of the concentrations of the boceprevir and of the lopinavir (or darunavir or fosamprenavir), with risk of therapeutic failure
severity: Not recommended

***interaction***
drug1
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
drug2
drug name: METHADONE 
rxNorm: 6813
atc: N07BC02
Decrease of the plasma concentrations of methadone, with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism by the boceprevir
severity: Precaution for use
Regular clinical monitoring and possible adjustment of the dosage of methadone.

***interaction***
drug1
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
drug2
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
Aside from the combination with ethinylestradiol (0.035mg)/noresthisterone (1mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir
severity: Precaution for use
Use a reliable contraceptive method, additional or alternative, during the time these medications are taken together. 

***interaction***
drug1
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of decrease of the plasma concentrations of boceprevir
severity: Not recommended
If administering these together cannot be avoided, regular clinical and biological monitoring, especially at the beginning of treatment with the two medications together.

***interaction***
drug1
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
drug2
drug name: SIMVASTATIN
rxNorm: 36567
atc: C10AA01
Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin
severity: CONTRAINDICATION

***interaction***
drug1
drug name: BOCEPREVIR
rxNorm: 1102129
atc: J05AE12
drug2
drug name: TENEFOVIR ALAFENAMIDE
rxNorm: 1721603
Risk of decrease of the effectiveness of the tenefovir alafenamide by decrease of its intracellular activity by the boceprevir
severity: Not recommended
97-BORTEZOMIB.html


***interaction***
drug1
drug name: BORTEZOMIB
rxNorm: 358258
atc: L01XX32
drug2
class name: ENZYMATIC INDUCERS
class code: N03-J05-001
Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness
severity: Take into account

***interaction***
drug1
drug name: BORTEZOMIB
rxNorm: 358258
atc: L01XX32
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Risk of increase of the undesirable effects, especially neurological, of the bortezomib due to decrease of its metabolism.
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the bortezomib during the length of the treatment with the enzymatic inhibitor.
98-BOSENTAN.html


***interaction***
drug1
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
drug2
class name: ANTICONVULSANT ENZYMATIC INDUCERS
class code: N03A-001
Risk of decrease of the plasma concentrations of bosentan
severity: Not recommended

***interaction***
drug1
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
drug2
class name: VITAMIN K ANTAGONISTS
class code: B01AA-001
Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism
severity: Precaution for use
More frequent testing of INR. Possible adjustment of the dosage of the vitamin K antagonist. 

***interaction***
drug1
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
drug2
drug name: CICLOSPORIN
rxNorm: 3008
more atc: L04AD01
more atc: S01XA18
Large decrease of the blood concentrations of the ciclosporin and increase of the plasma concentrations of bosentan
severity: CONTRAINDICATION

***interaction***
drug1
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
drug2
drug name: CYPROTERONE
rxNorm: 3014
more atc: G03HA01
more atc: G03HB01
Risk of decrease of the effectiveness of the cyproterone
severity: Precaution for use
In its indications such as anti-androgen, clinical monitoring and if possible adjustment of the dosage of the cyproterone during the administration with the bosentan and after it is stopped.

***interaction***
drug1
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
drug2
class name: COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES
class code: G03AB-001
Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive
severity: Precaution for use
Use a reliable contraceptive method, additional or alternative, during the length of time the two substances are administered together and for a cycle after. 

***interaction***
drug1
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
drug2
drug name: GLIBENCLAMIDE
rxNorm: 4815
atc: A10BB01
Risk of reduced effectiveness of the glibenclamide due to decrease of its plasma concentrations, because of the inducer effect of the bosentan. Furthermore, cases of hepotoxicity have been reported with these two substances administered together. 
severity: Precaution for use
Monitoring of the glycemia, adjustment of the treatment if needed, and monitoring of the hepatic biological constants. 

***interaction***
drug1
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
drug2
class name: STRONG INHIBITORS OF CYP3A4
class code: J02-J05
Increased risk of the undesirable effects of the bosantan, especially hepatic attacks, due to decrease of its metabolism by the inhibitor
severity: Precaution for use
Clinical and biological monitoring during the administration of these together.

***interaction***
drug1
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
drug2
class name: PROGESTIN CONTRACEPTIVES
class code: G03-001
Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism. 
severity: Precaution for use
Use an additional or alternative reliable method of contraception during the time these substances are administered together and one cycle following

***interaction***
drug1
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
drug2
class name: NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT
class code: G03-003
Risk of decrease of the effectiveness of the progestogen
severity: Precaution for use
Clinical monitoring and possible adjustment of the dosage of the hormonal treatment during the administration of the bosentan and after it is stopped.

***interaction***
drug1
drug name: BOSENTAN
rxNorm: 75207
atc: C02KX01
drug2
drug name: RIFAMPICIN
rxNorm: 9384
atc: J04AB02
Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan
severity: Not recommended
99-BOTULINUM-TOXIN.html


***interaction***
drug1
drug name: BOTULINUM TOXIN
rxNorm: 1716
atc: M03AX01
drug2
class name: AMINOGLYCOSIDES
class code: J01GB-001
Risk of increase of the effects of the botulinum toxin with the aminoglycosides (by extrapolation from the effects observed during the course of the botulism)
severity: Not recommended
Use another antibiotic.
9-FOLINIC-ACID.html

***interaction***
drug1
drug name: FOLINIC ACID
rxNorm: 6313
more atc: B03BB
more atc: B03BB01
more atc: B03BB51
drug2
class name: FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)
class code: L01BC-001
Strengthening of the effects, both cytostatic and undesirable, of the fluorouracil. 
severity: Take into account
2886 Interactions Processed
***** Only 0 Errors!
